Copies may be obtained from:

The Directorate: Pharmaceutical Programmes and Planning
Private Bag X828
Pretoria
0001

OR

Department of Health Website: www.doh.gov.za

First printed 1996
Second edition 1998
Third edition 2003
Fourth edition 2008

ISBN: 978-1-920031-48-0

NOTE:
The information presented in these guidelines conforms to the current medical, nursing and pharmaceutical practice. It is provided in good faith. Contributors and editors cannot be held responsible for errors, individual responses to medicines and other consequences.

Any part of this material may be reproduced, copied or adapted to meet local needs, without permission from the committee or the Department of Health, provided that the parts reproduced are distributed free of charge or at no cost – not for profit.

Published by:
The National Department of Health, Pretoria, South Africa
FOREWORD

“In science the important thing is to modify and change one’s ideas as science advances”

Herbert Spencer

It is our pleasure to introduce the fourth edition of the Standard Treatment Guidelines and Essential Medicines List for Primary Health Care. In keeping with the goals of the National Drug Policy, the review was done to keep pace with the advances in the field of medicine. Changes in this edition are a reflection of current epidemiology norms and recent developments in medicine.

The challenges facing the health sector are numerous but not insurmountable. The effective and efficient use of medicines will go a long way towards meeting these challenges.

Our goal of evidence based medicine selection has been strengthened in this edition. Affordability, without compromising quality, has been taken into account.

The numerous comments received and involvement from stakeholders is heartening and has contributed enormously to the excellence of this edition. We are indebted to all experts, opinion leaders and users of this book for their contribution.

The Standard Treatment Guidelines and Essential Drugs List is a living document and comments are invited in order to ensure appropriateness and responsiveness to emerging needs.

I would like to congratulate the committee on completing the reviews and to thank them for their continued commitment to the process over the years despite their busy schedules.

It is our sincere hope that the healthcare workers will continue to utilise the Standard Treatment Guidelines and Essential Medicine List in their efforts to providing quality care which we ourselves expect to receive.

MS B HOGAN
MINISTER OF HEALTH
INTRODUCTION

Medicines consume a significant portion of the total health care budget. Equitable access to affordable medicines remains a challenge. In accordance with the National Drug Policy, the Standard Treatment Guidelines and Essential Medicines List ensure that cost-effective treatment options are available to citizens of the country, and seeks to build capacity in health care workers at the Primary Health Care Level.

Emerging developments in medicine and scientific advances provided the basis for the review of the Standard Treatment Guidelines and Essential Medicine List. During this process consideration was given to factors such as evidence based therapeutics, prevailing medicine cost and practical experience. Where necessary, expert opinion was solicited.

Consultation with wider stakeholders is an integral part of the review process. I am pleased to note that as a result of the productive feedback of users, this new edition has been completely updated and substantially improved.

Efforts have been made to ensure that Guidelines of priority programmes such as HIV and AIDS, TB, Chronic diseases, IMCI, etc are harmonised with the Standard Treatment Guidelines and Essential Medicine List.

An appeal is being made to all users to follow the recommended guidelines at the back of the book when submitting comments or requesting additions or deletions of medicines from the list. Users are also encouraged to use the Adverse Drug Reaction Report Forms in the book. This will ensure that the quality of service is enhanced and will guide selection of appropriate medicine in future.

I would like to take this opportunity to thank the National Essential Drugs List Committee, the Primary Health Care Level Expert Review Committee, the Chairpersons and all who contributed to the review.

Their dedication and commitment to realising our vision of an accessible, caring and high quality health system is appreciated.

MR TD MSELEKU
DIRECTOR-GENERAL: HEALTH
ACKNOWLEDGEMENTS

We wish to convey our sincere gratitude to all those who participated in the review of this edition. The advice, comments, criticisms and contributions from the various stakeholders including professional societies, expert committees and individuals, has gone a long way toward producing a hugely improved edition of the Standard Treatment Guidelines and Essential Medicines List for Primary Health Care. Without the willingness to participate in this consultative process, this edition would not be have been possible.

In particular, we would like to thank:

» The Chair of the Primary Health Care Level Expert Review Committee, Prof B W van de Wal, for his loyalty, continued commitment and tireless efforts.

» The members of the Committee themselves, for sacrificing their time and for their dedication and willingness to share and learn.

» Prof Pudifin for his technical and editorial support.

NATIONAL ESSENTIAL DRUGS LIST COMMITTEE
Ms M Hela (Chairperson) Prof L Bamford
Prof M Blockman Dr GPG Boon
Dr H Brits Prof BB Hoek
Prof PM Jeena Ms Y Johnson
Ms CC Kotzenberg Prof G Maartens
Prof B Maharaj Ms HM Marais
Ms L Mahlangu Prof J Moodley
Mr HT Mphaka Ms MNM Ntshangase
Dr AG Parrish Dr L Pein
Dr T Pillay Dr H Saeed
Mr P Setsiba Mr C Shabalala
Mr GS Steel Ms N Thipa
Mr CJL van de Merwe Prof BW van de Wal
Dr N Xundu

PRIMARY HEALTH CARE LEVEL EXPERT REVIEW COMMITTEE
Prof BW van de Wal (Chairman) Prof L Bamford
Dr GPG Boon Dr E Bera
Dr H Brits Prof I Katz
Prof G Maartens Prof B Maharaj
Dr M Mashabane Sr G Mdleleni
Sr MM Ntshangase Dr K Parbhoo
Dr L Pein Dr H Saeed
Dr PZ Sinxadi Mr G Steel
CONSULTANTS

Prof J Aboobaker
Prof P Commerford
Prof D Labadarios
Prof Y Osman
Prof John Rodda

Dr I van Biljon
Prof J Hofmeyr
Prof D Lewis
Prof B Rayner
Prof C Szabo

COMMENTS AND CONTRIBUTIONS

Dr SE Abizu
Prof M Adhikari
Dr M Archary
Ms L Baker
Prof E Bateman
Dr MO Bello
Ms L Botham
Prof A Bryer
Prof J Carr
Ms M Cassimjee
Dr B Cheyip
Prof M Connor
Dr A Coovadia
Prof M Cotton
Prof K Dheda
Dr W Duim
Dr L Fairall
Dr J Goosen
Dr H Gous
Dr P Haug
Dr L Jenkins
Dr G Jordaan
Prof B Kies
Dr K Klusmann
Prof S Levin
Prof R Mash
Ms H Moeng
Dr ME Moss
Dr DD Munsamy
Prof KA Newton
Dr S Oliver
Prof W Pienaar
Dr P Potter
Dr H W Prozesky
Prof R Raine
Prof GA Richards
Dr H Sammons
Prof S Schaaf
Dr G Sherman

Mr Z Achmat
Prof G Ainslie
Dr TJ Avenant
Dr P Barrow
Dr M Bateman
Dr V Black
Ms S Brits
Prof TR Carmichael
Dr JM Carter
Ms L Channing
Prof NO Chabikuli
Prof P Cooper
Dr R Cornick
Dr N R Dlamini
Dr MW du Toit
Prof V Fritz
Dr T Gould
Dr Robin Green
Prof D Hellenberg
Dr L Jones
Dr S Kalula
Dr H J Kirby
Dr K Lecuona
Prof AD Marais
Dr R Mathiba
Ms DB Mofukeng
Prof G Muller
Dr C Nel
Dr J Nuttall
Dr G Paget
Dr V Pinkney-Atkinson
Dr R Pretorius
Prof F J Raal
Dr AS Ramdass
Prof H Saloojee
Mrs B Sayed
Dr A Schlemmer
Ms JN Shongwe
Dr A Smith  Dr FJ Smit
Dr H Staub  Ms L Terblanche
Dr D Theron  Dr V Tihon
Dr B Tipping  Dr C van Deventer
Dr K van der Merwe  Dr C van Deventer
Ms T van Greunen  Dr DJH Veale
Dr F Venter  Dr CC Visser
Dr S Wadee  Prof LA Wallis
Prof D Whitelaw  Prof J Wilmshurst
Dr T Winstanley  Prof G Wing
Prof E Zöllner

EDITORIAL
Prof D Pudi
Dr G Boon
Dr PZ Sinxadi
Ms K Jamaloodien

SECRETARIAT
Ms K Jamaloodien
Ms JP Ludick
Ms H Zeeman

LOGISTICS
Ms N Fürst  Mr M Molewa
Ms P Ngobese  Mr S Sello

Ms M Hela
Acting Cluster Manager: Pharmaceutical Policy and Planning
Ms H Zeeman
Manager: Affordable Medicines
TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foreword</td>
<td>iii</td>
</tr>
<tr>
<td>Introduction</td>
<td>iv</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>v</td>
</tr>
<tr>
<td>How to use the book</td>
<td>xvi</td>
</tr>
<tr>
<td>The Essential Medicines Concept</td>
<td>xx</td>
</tr>
<tr>
<td>A guide to patient adherence in chronic conditions</td>
<td>xxiii</td>
</tr>
<tr>
<td>Ideal Body weight</td>
<td>xxix</td>
</tr>
<tr>
<td>Peak expiratory flow rates</td>
<td>xxx</td>
</tr>
<tr>
<td>Disease notification procedures</td>
<td>xxxii</td>
</tr>
<tr>
<td>Chapter 1: Dental and oral conditions</td>
<td>1</td>
</tr>
<tr>
<td>1.1 Abscess and caries, dental</td>
<td>2</td>
</tr>
<tr>
<td>1.1.1 Abscess, dental</td>
<td>2</td>
</tr>
<tr>
<td>1.1.2 Caries, dental</td>
<td>3</td>
</tr>
<tr>
<td>1.2 Candidiasis, oral (thrush)</td>
<td>4</td>
</tr>
<tr>
<td>1.3 Gingivitis and periodontitis</td>
<td>5</td>
</tr>
<tr>
<td>1.3.1 Gingivitis, uncomplicated</td>
<td>5</td>
</tr>
<tr>
<td>1.3.2 Peridontitis</td>
<td>6</td>
</tr>
<tr>
<td>1.3.3 Necrotising periodontitis</td>
<td>6</td>
</tr>
<tr>
<td>1.4 Herpes stomatitis</td>
<td>8</td>
</tr>
<tr>
<td>1.5 Aphthous ulcers</td>
<td>9</td>
</tr>
<tr>
<td>Chapter 2: Gastro-intestinal conditions</td>
<td>10</td>
</tr>
<tr>
<td>2.1 Abdominal pain</td>
<td>11</td>
</tr>
<tr>
<td>2.2 Dyspepsia, heartburn and indigestion</td>
<td>12</td>
</tr>
<tr>
<td>2.3 Nausea and vomiting, non-specific</td>
<td>13</td>
</tr>
<tr>
<td>2.4 Anal conditions</td>
<td>14</td>
</tr>
<tr>
<td>2.4.1 Anal fissures</td>
<td>14</td>
</tr>
<tr>
<td>2.4.2 Haemorrhoids</td>
<td>14</td>
</tr>
<tr>
<td>2.5 Appendicitis</td>
<td>15</td>
</tr>
<tr>
<td>2.6 Cholera</td>
<td>16</td>
</tr>
<tr>
<td>2.7 Constipation</td>
<td>17</td>
</tr>
<tr>
<td>2.8 Diarrhoea</td>
<td>19</td>
</tr>
<tr>
<td>2.8.1 Diarrhoea, acute in children</td>
<td>19</td>
</tr>
<tr>
<td>2.8.2 Diarrhoea, persistent in children</td>
<td>22</td>
</tr>
<tr>
<td>2.8.3 Diarrhoea, acute, without blood in adults</td>
<td>23</td>
</tr>
<tr>
<td>2.8.4 Diarrhoea, chronic in adults</td>
<td>24</td>
</tr>
<tr>
<td>2.9 Dysentery</td>
<td>24</td>
</tr>
<tr>
<td>2.9.1 Dysentery, bacillary</td>
<td>25</td>
</tr>
<tr>
<td>2.9.2 Dysentery, amoebic</td>
<td>27</td>
</tr>
<tr>
<td>2.10 Helminthic infestation</td>
<td>30</td>
</tr>
<tr>
<td>2.10.1 Helminthic infestation, tapeworm</td>
<td>30</td>
</tr>
<tr>
<td>2.10.2 Helminthic infestation, excluding tapeworm</td>
<td>31</td>
</tr>
<tr>
<td>2.11 Irritable bowel syndrome</td>
<td>32</td>
</tr>
<tr>
<td>2.12 Typhoid fever</td>
<td>33</td>
</tr>
</tbody>
</table>
Chapter 3: Nutritional and blood conditions

3.1 Anaemia
   3.1.1 Anaemia, iron deficiency
   3.1.2 Anaemia, macrocytic or megaloblastic

3.2 Childhood malnutrition, including failure to thrive (FTT)
   3.2.1 Severe malnutrition
   3.2.2 Failure to thrive or not growing well

3.3 Vitamin A deficiency

3.4 Vitamin B deficiencies
   3.4.1 Pellagra (nicotinic acid deficiency)
   3.4.2 Pyridoxine (Vitamin B₆ deficiency)
   3.4.3 Thiamine deficiency (Wernicke’s encephalopathy and beriberi)

Chapter 4: Cardiovascular conditions

4.1 Prevention of ischaemic heart disease and atherosclerosis
4.2 Angina pectoris, unstable
4.3 Angina pectoris, stable
4.4 Cardiac arrest, cardiopulmonary resuscitation
4.5 Cardiac failure, congestive (CCF)
   4.5.1 Cardiac failure, congestive (CCF), adults
   4.5.2 Cardiac failure, congestive (CCF), children
4.6 Myocardial infarction, acute (AMI)
4.7 Hypertension
   4.7.1 Hypertension in adults
   4.7.2 Hypertension in children
4.8 Pulmonary oedema, acute
4.9 Rheumatic fever, acute
4.10 Valvular heart disease and congenital structural heart disease

Chapter 5: Skin Conditions

5.1 Dry skin
5.2 Itching (pruritus)
5.3 Acne vulgaris
5.4 Bacterial infections of the skin
   5.4.1 Boil, abscess
   5.4.2 Impetigo
   5.4.3 Cellulitis
5.5 Fungal infections of the skin
   5.5.1 Athlete’s foot – tinea pedis
   5.5.2 Candidiasis, skin
   5.5.3 Ringworm and other tineas
5.6 Parasitic infections of the skin
   5.6.1 Lice (pediculosis)
   5.6.2 Scabies
5.7 Eczema
5.7.1 Eczema, atopic 85
5.7.2 Eczema, acute, moist or weeping 88
5.7.3 Dermatitis, seborrhoeic 89
5.8 Nappy rash 90
5.9 Sandworm 91
5.10 Urticaria 91
5.11 Pityriasis rosea 92
5.12 Molluscum contagiosum 93
5.13 Herpes simplex 94
5.14 Herpes Zoster 95
5.15 Warts 95
5.15.1 Common warts 95
5.15.2 Plane warts 95
5.15.3 Plantar warts 95
5.15.4 Filiform warts 96
5.15.5 Genital warts: Condylomata accuminata 96

Chapter 6: Obstetrics and gynaecology 97

Obstetrics 98

6.1 Bleeding in pregnancy 98
6.1.1 Miscarriage 98
6.1.2 Antepartum haemorrhage 99
6.2 Antenatal care 100
6.2.1 Care of HIV positive pregnant woman 100
6.2.2 Hypertensive disorders of pregnancy 101
6.2.3 Anaemia in pregnancy 103
6.2.4 Syphilis in pregnancy 104
6.3 Preterm labour (PTL) and preterm prelabour rupture of membranes (PPROM) 106
6.3.1 Preterm labour (PTL) 106
6.3.2 Preterm prelabour rupture of membranes (PPROM) 106
6.4 Intrapartum Care 107
6.5 Care of the neonate 110
6.5.1 Sick neonate and neonatal emergencies 110
6.5.2 Neonatal resuscitation 112
6.6 Postpartum care 115
6.6.1 Feeding options for HIV positive mothers 115
6.6.2 Cracked nipples during breastfeeding 115

Gynaecology 116

6.7 Pregnancy, ectopic 116
6.8 Vaginal bleeding 116
6.8.1 Abnormal vaginal bleeding during fertile years 116
6.8.2 Bleeding, post-menopausal 117
6.9 Dysmenorrhoea 118
6.10 Hormone replacement therapy 118
6.11 Ulcers, vaginal 119
6.12 Vaginal discharge/lower abdominal pain in women 119
<table>
<thead>
<tr>
<th>Chapter 10: Infectious Diseases</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.6 Dysentery, biliary</td>
<td>168</td>
</tr>
<tr>
<td>10.7 Giardiasis</td>
<td>168</td>
</tr>
<tr>
<td>10.8 Malaria</td>
<td>169</td>
</tr>
<tr>
<td>10.8.1 Falciparum malaria, severe</td>
<td>171</td>
</tr>
<tr>
<td>10.8.2 Malaria, prophylaxis (Self provided care)</td>
<td>172</td>
</tr>
<tr>
<td>10.9 Measles</td>
<td>172</td>
</tr>
<tr>
<td>10.10 Meningitis</td>
<td>175</td>
</tr>
<tr>
<td>10.11 Mumps</td>
<td>176</td>
</tr>
<tr>
<td>10.12 Rubella (German measles)</td>
<td>177</td>
</tr>
<tr>
<td>10.13 Schistosomiasis</td>
<td>178</td>
</tr>
<tr>
<td>10.14 Typhoid fever</td>
<td>179</td>
</tr>
<tr>
<td>10.14 Tuberculosis</td>
<td>179</td>
</tr>
</tbody>
</table>

Chapter 11: Human immunodeficiency virus and acquired immunodeficiency syndrome (HIV AND AIDS)  

Human immunodeficiency virus infection in adults  

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.1 Antiretroviral therapy, adults</td>
<td>184</td>
</tr>
<tr>
<td>11.2 Opportunistic infections, prophylaxis in adults</td>
<td>185</td>
</tr>
<tr>
<td>11.2.1 TB chemoprophylaxis</td>
<td>186</td>
</tr>
<tr>
<td>11.3 Opportunistic infections, treatment in adults</td>
<td>187</td>
</tr>
<tr>
<td>11.3.1 Aphthous ulcers in HIV infection</td>
<td>187</td>
</tr>
<tr>
<td>11.3.2 Candidiasis, oral</td>
<td>187</td>
</tr>
<tr>
<td>11.3.3 Candida oesophagitis</td>
<td>187</td>
</tr>
<tr>
<td>11.3.4 Diarrhoea, HIV associated</td>
<td>188</td>
</tr>
<tr>
<td>11.3.5 Eczema, seborrhoeic</td>
<td>188</td>
</tr>
<tr>
<td>11.3.6 Fungal nail infections</td>
<td>188</td>
</tr>
<tr>
<td>11.3.7 Fungal skin infections</td>
<td>189</td>
</tr>
<tr>
<td>11.3.8 Gingivitis, acute, necrotising, ulcerative</td>
<td>189</td>
</tr>
<tr>
<td>11.3.9 Herpes simplex ulcers, chronic</td>
<td>189</td>
</tr>
<tr>
<td>11.3.10 Herpes zoster (Shingles)</td>
<td>189</td>
</tr>
<tr>
<td>11.3.11 Meningitis, cryptococcal</td>
<td>190</td>
</tr>
<tr>
<td>11.3.12 Papular pruritic eruption</td>
<td>191</td>
</tr>
<tr>
<td>11.3.13 Pneumonia, bacterial</td>
<td>191</td>
</tr>
<tr>
<td>11.3.14 Pneumonia, pneumocystis</td>
<td>191</td>
</tr>
<tr>
<td>11.3.15 Toxoplasmosis</td>
<td>192</td>
</tr>
<tr>
<td>11.3.16 Tuberculosis (TB)</td>
<td>192</td>
</tr>
</tbody>
</table>

Human immunodeficiency virus infection in children  

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.4 Antiretroviral therapy, children</td>
<td>196</td>
</tr>
<tr>
<td>11.5 Opportunistic infections, prophylaxis in children</td>
<td>200</td>
</tr>
<tr>
<td>11.5.1 Immunisation</td>
<td>201</td>
</tr>
<tr>
<td>11.5.2 TB chemoprophylaxis</td>
<td>201</td>
</tr>
<tr>
<td>11.6 Opportunistic infections, treatment in children</td>
<td>201</td>
</tr>
<tr>
<td>11.6.1 Candidiasis, oral (thrush), recurrent</td>
<td>201</td>
</tr>
<tr>
<td>11.6.2 Candida oesophageal</td>
<td>202</td>
</tr>
<tr>
<td>11.6.3 Diarrhoea</td>
<td>202</td>
</tr>
<tr>
<td>11.6.4 Pneumonia</td>
<td>202</td>
</tr>
<tr>
<td>11.6.5 Measles and chickenpox</td>
<td>202</td>
</tr>
</tbody>
</table>
11.6.6 Skin conditions 202
11.6.7 Tuberculosis (TB) 203
11.7 Developmental delay or deterioration 203
11.8 Anaemia 203
11.9 Supportive care 203
11.10 HIV and kidney disease 204

Chapter 12: Sexually transmitted infections 206
12.1 Lower abdominal pain (LAP) 207
12.2 Vaginal discharge syndrome (VDS) 208
12.3 Male urethritis syndrome (MUS) 210
12.4 Scrotal swelling (SSW) 211
12.5 Genital ulcer syndrome (GUS) 212
12.6 Bubo 213
12.7 Balanitis/balanoposthitis (BAL) 214
12.8 Syphilis serology and treatment 215
12.9 Treatment of more than one STI syndrome 218
12.10 Genital molluscum contagiosum (MC) 220
12.11 Genital warts (GW) Condylomata Accuminata 220
12.12 Pubic lice (PL) 221

Chapter 13: Immunisation 222
13.1 Immunisation schedule 223
13.2 Dosage and administration 224
13.3 Vaccines for routine administration 225
13.4 The cold chain 228
13.5 The revised opened multi-dose vial policy 230

Chapter 14: Musculoskeletal conditions 231
14.1 Arthralgia 232
14.2 Arthritis, rheumatoid 233
14.3 Arthritis, septic 233
14.4 Gout 234
14.4.1 Gout, acute 234
14.4.2 Gout, chronic 236
14.5 Osteoarthrosis (osteoarthritis) 237

Chapter 15: Central nervous system conditions 239
15.1 Stroke 240
15.2 Seizures (convulsions/fits) 241
15.3 Febrile convulsions 242
15.4 Epilepsy 244
15.5 Meningitis 248
15.5.1 Meningitis, acute bacterial 248
15.5.2 Meningitis, meningococcal, prophylaxis 250
15.6 Status epilepticus 251
15.7 Headache, mild, non-specific 251
## Chapter 16: Mental health conditions

<table>
<thead>
<tr>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.1</td>
</tr>
<tr>
<td>16.2</td>
</tr>
<tr>
<td>16.3</td>
</tr>
<tr>
<td>16.4</td>
</tr>
<tr>
<td>16.5</td>
</tr>
</tbody>
</table>

## Chapter 17 - Respiratory conditions

<table>
<thead>
<tr>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>17.1</td>
</tr>
<tr>
<td>17.1.1</td>
</tr>
<tr>
<td>17.1.2</td>
</tr>
<tr>
<td>17.1.3</td>
</tr>
<tr>
<td>17.1.4</td>
</tr>
<tr>
<td>17.2</td>
</tr>
<tr>
<td>17.2.1</td>
</tr>
<tr>
<td>17.3</td>
</tr>
<tr>
<td>17.3.1</td>
</tr>
<tr>
<td>17.3.2</td>
</tr>
<tr>
<td>17.3.3</td>
</tr>
<tr>
<td>17.3.4</td>
</tr>
<tr>
<td>17.3.5</td>
</tr>
<tr>
<td>17.3.6</td>
</tr>
<tr>
<td>17.3.7</td>
</tr>
<tr>
<td>17.3.8</td>
</tr>
<tr>
<td>17.3.9</td>
</tr>
</tbody>
</table>

## Chapter 18: Eye conditions

<table>
<thead>
<tr>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>18.1</td>
</tr>
<tr>
<td>18.1.1</td>
</tr>
<tr>
<td>18.1.2</td>
</tr>
<tr>
<td>18.1.3</td>
</tr>
<tr>
<td>18.1.4</td>
</tr>
<tr>
<td>18.2</td>
</tr>
<tr>
<td>18.2.1</td>
</tr>
<tr>
<td>18.2.2</td>
</tr>
<tr>
<td>18.3</td>
</tr>
<tr>
<td>18.4</td>
</tr>
<tr>
<td>18.5</td>
</tr>
<tr>
<td>18.6</td>
</tr>
</tbody>
</table>

## Chapter 19: Ear, nose and throat conditions

<table>
<thead>
<tr>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>19.1</td>
</tr>
<tr>
<td>19.2</td>
</tr>
<tr>
<td>19.3</td>
</tr>
</tbody>
</table>
19.3.1 Otitis externa 310
19.3.2 Otitis media, acute 312
19.3.3 Otitis media, chronic, suppurative 314
19.4 Sinusitis, acute, bacterial 314
19.5 Tonsillitis and pharyngitis 316

Chapter 20: Pain 319
20.1 Pain control 320
20.2 Chronic non-cancer pain 323
20.3 Chronic cancer pain 325

Chapter 21: Trauma and emergencies 331
21.1 Angina pectoris, unstable 332
21.2 Bites and stings 332
  21.2.1 Animal and human bites 332
  21.2.2 Insect stings and spider bites 336
  21.2.3 Snakebites 338
21.3 Burns 341
21.4 Cardiac arrest – cardiopulmonary resuscitation 346
  21.4.1 Cardiac arrest, adults 346
  21.4.2 Cardiopulmonary arrest, children 348
  21.4.3 Management of suspected choking/foreign body aspiration in children. 353
21.5 Delirium with acute confusion and aggression in adults 355
21.6 Exposure to poisonous substances 357
21.7 Eye, chemical burn 361
21.8 Eye injury, foreign body 361
21.9 HIV prophylaxis, post exposure (PEP) 361
  21.9.1 Penetrative sexual abuse or sexual assault 361
  21.9.2 Occupational post-exposure HIV prophylaxis for healthcare workers (HCW) 366
21.10 Hyperglycaemia and ketoacidosis 368
21.11 Hypoglycaemia and hypoglycaemic coma 368
21.12 Injuries 371
21.13 Myocardial infarction, acute (AMI) 372
21.14 Nose bleeds (epistaxis) 373
21.15 Pulmonary oedema, acute 373
21.16 Shock 375
21.17 Shock, anaphylactic 377
21.18 Sprains and strains 379
21.19 Status epilepticus 380

Guidelines for the motivation of a new medicine on the National Essential Medicine List 383
Guidelines for adverse drug reaction reporting 387
Index of drugs/medicines 394
Index of Conditions 399
Abbreviations 405
The Primary Health Care Standard Treatment Guidelines and Essential Medicines List should be used by doctors and nurses providing care at clinics, community health centres and gateway clinics at hospitals to provide access to pharmaceuticals to manage common conditions at this level. It is the responsibility of the PTCs to ensure availability of medicines.

All the medicines in this book should also be available at higher levels of care.

Provincial PTCs have the authority to facilitate and control access to additional hospital level EDL medicines at specified PHC facilities.

It is the responsibility of the province to facilitate access of medicines with referral from a higher level to a lower level.

Provincial PTCs have the authority to reasonably adapt the STG/EDL to local conditions and circumstances.

It is important that you become familiar with the contents and layout of the book in order to use the standard treatment guidelines effectively.

Where relevant this book is consistent with the Standard Treatment Guidelines for Hospital Level, Adults and Paediatrics, Integrated Management of Childhood Illness Strategy (IMCI) and other National Programme treatment guidelines.

The ICD-10 number, included with the conditions, refers to an international classification method used when describing certain diseases and conditions. A brief description and diagnostic clinical, radiological and laboratory tests are included to assist the medical officer to make a diagnosis. These guidelines also make provision for referral of patients with more complex and uncommon conditions to facilities with the resources for further investigation and management.

It is important to remember that the recommended treatments provided in this book are guidelines only and are based on the assumption that prescribers are competent to handle patients’ health conditions presented at their facilities. Where the professional expertise at certain PHC centres exceeds that of an average clinic, PTCs are encouraged to tailor the availability of medicines at these centres by using their initiative and creative insight. Adopting a more flexible approach means that available staff at each site are better utilised and a more convenient service can be provided for patients.

The treatment guidelines are presented in chapters according to the organ systems of the body. In order to find the relevant sections in the book easily, use the indices at the back of the book. These have been divided into indices of disease conditions.
and medicines. Some of the medicines listed are only examples of a therapeutic class. In such cases the Provincial Pharmacy and Therapeutics Committees (PTCs) will decide on their medicine of choice within that therapeutic class.

All suspected adverse medicine reactions must be reported. In this book, only the common adverse effects have been mentioned. Information on the reporting of adverse medicine reactions is provided in the section Guidelines for Adverse Drug Reaction Reporting. The purpose of ADR reporting is to reduce the risks associated with the use of medicines and ultimately improve patient care.

The section on Patient Adherence in Chronic Conditions aims to provide support to health workers to assist patients in achieving their health goals.

Comments that aim to improve these treatment guidelines will be appreciated. The submission form and guidelines for completing the form are included in the book. Motivations will only be accepted from the Provincial PTC.

Comments from persons and institutions outside the public service should be sent to:

The Essential Drugs Programme
Pharmaceutical Programmes and Planning
Department of Health
Private Bag X828
Pretoria
0001

DOSE CALCULATION
Many of the medicines are presented in the text in the form of tables. Doses are indicated as mg/kg. In addition, doses are also presented in terms of weight bands and according to age.

It is recommended that doses be calculated by weight. If this is not possible choose dose from weight band. Only use the dose according to age as a last resort. In particular, do not use age bands if child looks small for age or malnourished.

The mg/kg/dose dose can be used in 2 ways:
1. To check a dose, here the prescribed dose is divided by the weight and compared to the published mg/kg/dose.

2. Where greater accuracy is needed in establishing a suitable dose the patient’s weight is multiplied by the mg/kg/dose and rounded up or down to the most practical dose to administer. When dispensing the dose should be check as per 1.
PRESCRIPTION WRITING
Medicines should be prescribed only when they are necessary for treatments following clear diagnosis. Not all patients or conditions need prescriptions for medicines. In certain conditions simple advice and other general measures may be more suitable.

In all cases carefully consider the expected benefit of a prescribed medication against potential risks. This is important during pregnancy where the risk to both mother and foetus must be considered.

All prescriptions should:
» be written legibly in ink by the prescriber with the full name and address of the patient, and signed with the date on the prescription form.
» specify the age and weight of the patient in the case of children.
» have contact details of the prescriber e.g. name and telephone number.

In all prescription writing, note the following:
» The name of the medicine or preparation should be written in full using the generic name and
» No abbreviations should be used due to the risk of misinterpretation. Avoid the Greek mu (µ): write mcg as an abbreviation for micrograms.
» Avoid unnecessary use of decimal points and only use where decimal points are unavoidable. A zero should be written in front of the decimal point where there is no other figure, e.g. 2 mg not 2.0 mg or 0.5 mL and not .5 mL.
» Frequency. Avoid Greek and Roman frequency abbreviations that cause considerable confusion – qid, qod, tds, tid, etc. Instead either state the frequency in terms of hours (e.g. 8 hourly) or times per day in numerals (e.g. 3x/d).
» State the treatment regimen in full:
  − medicine name and strength
  − dose or dosage
  − dose frequency
  − duration of treatment

Example
Amoxicillin 250 mg 8 hourly for 5 days

» In the case of “as required”, a minimum dose interval should be specified, e.g. every 4 hours as required.
» Most monthly outpatient prescriptions for chronic medication are for 28 days; check that the patient will be able to access a repeat before the 28 days are up.
» After writing a prescription, check that you have stated dose, dose units, route, frequency, and duration for each item. Consider whether the number of items is too great to be practical for the patient, and check that there are no redundant items or potentially important medicine interactions. Ensure that
the prescription is dated and that the patient’s name and folder number are on the prescription card. Only then sign the script, and in addition, provide some other way for the pharmacy staff to identify you if there are problems (print your name, use a stamp, or use a prescriber number from your institution’s pharmacy.)
THE ESSENTIAL MEDICINES CONCEPT

The WHO describes Essential medicines as those that satisfy the priority health care needs of the population. Essential medicines are intended to be available within the context of functioning health systems at all times in adequate quantities, in the appropriate dosage forms, with assured quality and adequate information, and at a price the individual and the community can afford.

The concept of essential medicines is forward-looking. It incorporates the need to regularly update medicines selections to:

» reflect new therapeutic options and changing therapeutic needs;
» the need to ensure medicine quality; and
» the need for continued development of better medicines, medicines for emerging diseases, and medicines to meet changing resistance patterns.

Effective health care requires a judicious balance between preventive and curative services. A crucial and often deficient element in curative services is an adequate supply of appropriate medicines. In the health objectives of the National Drug Policy, the government of South Africa clearly outlines its commitment to ensuring availability and accessibility of medicines for all people. These are as follows:

» To ensure the availability and accessibility of essential medicines to all citizens.
» To ensure the safety, efficacy and quality of drugs.
» To ensure good prescribing and dispensing practices.
» To promote the rational use of drugs by prescribers, dispensers and patients through provision of the necessary training, education and information.
» To promote the concept of individual responsibility for health, preventive care and informed decision-making.

Achieving these objectives requires a comprehensive strategy that not only includes improved supply and distribution, but also appropriate and extensive human resource development. The implementation of an Essential Drugs Programme (EDP) forms an integral part of this strategy, with continued rationalisation of the variety of medicines available in the public sector as a first priority. The private sector is encouraged to use these guidelines and drug list wherever appropriate.

The criteria for the selection of essential drugs for Primary Health Care in South Africa were based on the WHO guidelines for drawing up a national EDL. Essential medicines are selected with due regard to disease prevalence, evidence on efficacy and safety, and comparative cost.

The implementation of the concept of essential medicines is intended to be flexible and adaptable to many different situations. It remains a national responsibility to determine which medicines are regarded as essential.

It should be noted that the Primary Health Care Essential Medicines List (EML) reflects only the minimum requirements for Primary Health Care level facilities. In keeping with the objectives of the National Drug Policy, provincial and local Pharmacy and Therapeutics Committees should provide additional drugs from the Hospital level EDL based on the services offered and the competency of the staff at each facility.
A GUIDE TO PATIENT ADHERENCE IN CHRONIC CONDITIONS

Achieving health goals for chronic conditions such as asthma, diabetes, HIV and AIDS, epilepsy, hypertension, mental health disorders and TB requires attention to:

- Adherence to long term pharmacotherapy – incomplete or non-adherence can lead to failure of an otherwise sound pharmacotherapeutic regimen.
- Organisation of health care services, which includes consideration of access to medicines and continuity of care.

Patient Adherence

Adherence is the extent to which a person’s behaviour – taking medication, following a diet and/or executing lifestyle changes, corresponds with agreed recommendations from a health care provider.

Poor adherence results in less than optimal management and control of the illness and is often the primary reason for suboptimal clinical benefit. It can result in medical and psychosocial complications of disease, reduced quality of life of patients, and wasted health care resources.

Poor adherence can fall into one of the following patterns where the patient:

- Takes the medication very rarely (once a week or once a month);
- Alternates between long periods of taking and not taking their medication e.g. after a seizure or BP reading;
- Skips entire days of medication;
- Skips doses of the medication;
- Skips one type of medication;
- Takes the medication several hours late;
- Does not stick to the eating or drinking requirements of the medication;
- Adheres to a purposely modified regimen; and
- Adheres to an unknowingly incorrect regimen.

Adherence should be assessed on a regular basis. Although there is no gold standard, the current consensus is that a multi method approach that includes self report be adopted such as that below.

Barriers that contribute toward poor adherence

<table>
<thead>
<tr>
<th>BARRIER</th>
<th>RECOMMENDED SUPPORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Life style</td>
<td></td>
</tr>
<tr>
<td>It is often difficult to take multiple medications</td>
<td>Create a treatment plan with information on how and when to take the medications.</td>
</tr>
<tr>
<td>A busy schedule makes it difficult to remember to take the medication.</td>
<td>Use reminders such as cues that form part of the daily routine.</td>
</tr>
<tr>
<td>BARRIER</td>
<td>RECOMMENDED SUPPORT</td>
</tr>
<tr>
<td>---------</td>
<td>---------------------</td>
</tr>
<tr>
<td><strong>Attitudes and beliefs</strong></td>
<td></td>
</tr>
<tr>
<td>» The condition is misunderstood or denied.</td>
<td>» Remind patients that they have a long term illness that requires their involvement.</td>
</tr>
<tr>
<td>» Treatment may not seem to be necessary.</td>
<td>» Use change techniques such as motivational interviewing.</td>
</tr>
<tr>
<td>» May have low expectations about treatment.</td>
<td>» Identify goals to demonstrate improvement/stabilisation.</td>
</tr>
<tr>
<td><strong>Social and economic</strong></td>
<td></td>
</tr>
<tr>
<td>» May lack support at home or in the community</td>
<td>» Encourage participation in treatment support programs.</td>
</tr>
<tr>
<td>» May not have the economic resources to attend appointments.</td>
<td>» Consider down referral or reschedule appointment to fit in with other commitments.</td>
</tr>
<tr>
<td><strong>Healthcare team related</strong></td>
<td></td>
</tr>
<tr>
<td>» Little or no time during the visit to provide information.</td>
<td>» Encourage patient to ask questions.</td>
</tr>
<tr>
<td>» Information may be provided in a way that is not understood.</td>
<td>» Use patient literacy materials in the patient’s language of choice.</td>
</tr>
<tr>
<td>» Relationship with the patient may not promote understanding and self management.</td>
<td>» Engage active listening.</td>
</tr>
<tr>
<td><strong>Treatment related</strong></td>
<td></td>
</tr>
<tr>
<td>» Complex medication regimens (multiple medications and doses) can be hard to follow.</td>
<td>» If possible reduce treatment complexity</td>
</tr>
<tr>
<td>» May be discouraged if they don’t feel better right away.</td>
<td>» Help the patient understand the condition and the role of their medication</td>
</tr>
<tr>
<td>» May be concerned about adverse effects.</td>
<td>» Discuss treatment goals in relation to potential adverse effects.</td>
</tr>
</tbody>
</table>

Although many of these recommendations require longer consultation time, this investment is rewarded many times over during the subsequent years of management.

For a patient to consistently adhere to long term pharmacotherapy requires integration of the regimen into his or her daily life style. The successful integration of the regimen is informed by the extent to which the regimen differs from his or her established daily routine. Where the pharmacological proprieties of the medication permits it, the pharmacotherapy dosing regimen should be adapted to the patient’s daily routine. For example, a shift worker may need to take a sedating medicine in the morning when working night shifts, and at night, when working day shifts. If the intrusion into life style is too great alternative agents should be considered if they
are available. This would include situations such as a lunchtime dose in a school-going child who remains at school for extramural activity and is unlikely to adhere to a three times a regimen but may very well succeed with a twice daily regimen.

Towards concordance when prescribing
Establish the patient's:
» occupation
» daily routine
» recreational activities;
» past experiences with other medicines
» expectations of therapeutic outcome
Balance these against the therapeutic alternatives identified based on clinical findings. Any clashes between the established routine and life style with the chosen therapy should be discussed with the patient in such a manner that the patient will be motivated to a change their lifestyle.

Note:
Education that focuses on these identified problems is more likely to be successful than a generic approach toward the condition/medicine.

Education points to consider
» Focus on the positive aspects of therapy whilst being encouraging regarding the impact of the negative aspects and offer support to deal with them if they occur.
» Provide realistic expectations regarding:
  – normal progression of the illness - especially important in those diseases where therapy merely controls the progression and those that are asymptomatic.
  – the improvement that therapy and non-drug treatment can add to the quality of life.
» Establish therapeutic goals and discuss them openly with the patient.
» Any action to be taken with loss of control or when side effects develop.
» In conditions that are asymptomatic or where symptoms have been controlled, reassure the patient that this reflects therapeutic success, and not that the condition has resolved.
» Where a patient raises concern regarding anticipated side effects, attempt to place this in the correct context with respect to incidence, the risks vs. the benefits, and whether or not the side effects will disappear after continued use.

Note:
Some patient's lifestyles make certain adverse responses acceptable which others may find intolerable. Sedation is unlikely to be acceptable to a student but an older patient with insomnia may welcome this side effect. This is where concordance plays a vital role.

Notes on prescribing in chronic conditions.
» Don’t change doses without good reason.
» Never blame anyone or anything for non-adherence before fully investigating
the cause
» If the clinical outcome is unsatisfactory - investigate adherence (remember side effects may be a problem here).
» Always think about side effects and screen for them from time to time.
» When prescribing a new medicine for an additional health related problem ask yourself whether or not this medicine is being used to manage a side effect.
» Adherence with a once daily dose is best. Twice daily regimens show agreeable adherence. However once the interval is decreased to 3 times a day there is a sharp drop in adherence with poor adherence to 4 times a day regimens.
» Keep the total number of tablets to an absolute minimum as too many may lead to medication dosing errors and may influence adherence

Improving Continuity of Therapy
» Make clear and concise records.
» Involvement the patient in the care plan.
» Every patient on chronic therapy should know:
  – his/her diagnosis
  – the name of every medicine
  – the dose and interval of the regimen
  – his/her BP or other readings

Note: The prescriber should reinforce this only once management of the condition has been established.
» When the patient seeks medical attention for any other complaints such as a cold or headache he/she must inform that person about any other condition/disease and its management
» If a patient indicates that he/she is unable to comply with a prescribed regimen, consider an alternative - not to treat might be one option, but be aware of the consequences e.g. ethical
Patient Adherence Record

Folder No. __________________________ Date (dd/mm/yyyy) __/__/___

Self-Reporting

Question | Yes | No
---|---|---
Do you sometimes find it difficult to remember to take your medicine? | | |
When you feel better, do you sometimes stop taking your medication? | | |
Thinking back over the past four days, have you missed any of your doses? | | |
Sometimes if you feel worse when you take the medicine, do you stop talking it? | | |

Visual Analogue Scale (VAS)

Score ______%  

Pill Identification Test (PIT)

<table>
<thead>
<tr>
<th>Medication</th>
<th>Knows the name (Y/N)</th>
<th>Knows the number of pills per dose (Y/N)</th>
<th>Time the medication is taken</th>
<th>Knows any additional instruction</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Morning (hour)</td>
<td>Evening (hour)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

xxvii
**Pill Count**

Did the client return the medication containers?  

| Yes* | No |
---|---|

*If yes, check that the client only used medication from this container since the date of their last visit. If leftover medication had been used or an emergency prescription obtained, then the calculation will be invalid – skip to adherence assessment.

\[
\% \text{ Adherence} = \frac{\text{Dispensed} - \text{Returned}}{\text{Expected to be taken}} \times 100
\]

Adherence Assessment

| Self-reporting | Answered ‘No’ to all questions | Answered ‘Yes’ to 1 question | Answered ‘Yes’ to 2 or more questions |
---|---|---|---|
**VAS** | > 95% | 75–94% | Less than 75% |
**PIT—Client knows the…** | Dose, Time, and Instructions | Dose and Time | Dose only or confused |
**Pill count** | > 95% | 75–94% | Less than 75% |
**Overall Adherence** | High | Moderate | Low |
IDEAL BODY WEIGHT

Male

![Graph showing the relationship between height and ideal body weight for males.]

Female

![Graph showing the relationship between height and ideal body weight for females.]

xxix
PEAK EXPIRATORY FLOW RATES

Normal peak flow readings for children aged 5 to 18 years

Normogram redrawn from original data, Godfrey S et al, Br J Dis Chest 1970;64:15
Peak expiratory flow in normal subjects

---

**MEN**

- 6'3" 190
- 6'0" 183
- 5'9" 175
- 5'8" 167
- 5'3" 160

**WOMEN**

- 5'9" 175
- 5'6" 169
- 5'3" 160
- 5'0" 152
- 4'9" 145

**Note:**

- In men, values of PEF up to 100 litres/min. less than predicted and in women less than 85 litres/min. less than predicted are within normal limits.

---

**Standard deviation. men** = 48 litres/min

**Standard deviation. women** = 42 litres/min

---

CALCULATING % PREDICTED PEAK FLOW RATE

- Take the best of 3 of the patient's observed peak flow rate:
  e.g. 200, 180, 190 performed, so take 200
- Find the patient's sex, age and height predicted value from nomogram or sheet:
  e.g. 480 for a woman of age 25 years and height 167cm
- Divide patient's observed peak flow rate over their predicted peak flow rate
  e.g.: 200/480 = 0.42
- Multiply by 100:
  e.g. 0.42X100 = 42%

So, in this example, patient's peak observed flow rate is 42% of predicted

CALCULATING PEAK FLOW VARIABILITY

There are a number of methods for calculating PEF variability.

The one we use is as follows:

- Subtract the lowest from the highest reading:
  e.g.: 400 – 300 = 100
- Divide by the highest reading:
  e.g.: 100/400 = 0.25
- Multiply by 100:
  e.g.: 0.25X100 = 25%

So, in this example, where a patient has readings of 300 to 400, the variability is 25% and asthma is diagnosed (i.e. ≥ 15%)
DISEASE NOTIFICATION PROCEDURES

The disease reporting system in South Africa is based on government law (Health Act, Act 63 of 1977) and regulations where specific infectious diseases (see list of notifiable medical conditions below) must be reported to the Provincial Health Departments, who then report to the National Department of Health (see flow chart of data below). Disease surveillance comprises mainly four types: Notifiable disease-reporting system, Laboratory-based surveillance, Hospital-based surveillance and Population based surveillance.

Notifiable Disease reporting
A notification serves as the first step in a surveillance cycle, namely for data-capturing or data collection. Notification can be done via the mail, fax or telephone to the local authority concerned. Any person (not necessarily a health worker) can notify a notifiable medical condition (see the Health Act regulations - legal obligations). The list of notifiable medical conditions at the moment determines that 40 different diseases are notifiable (see list below).

Process
Forms involved
   GW17/5: initial diagnosis (complete immediately)
   GW17/3: line list of cases (complete weekly)
   GW17/4: line list of deaths (complete weekly)

The initial diagnosis of a notifiable medical condition are done on a case-based form with the relevant address and fine details on it, to make tracing of the case as easy as possible, since a disease notification demands action (follow-up) at the lowest level (GW17/5 - for cases and deaths).

In South Africa it is required by law that completed weekly disease notification forms are submitted for all notifiable diseases from each local authority or district office to the provincial office. These should be completed and sent by all reporting units e.g. hospitals, health centres, health posts, clinics, private practitioners, private nurses, to the district public health office. The initial diagnosis forms are summarised weekly on separate line list forms for cases (GW17/3) and for deaths (GW17/4).

To ensure complete reporting of all EPI diseases, a zero report should be sent if no cases of a notifiable disease were seen for the reporting period.

Reporting
   from reporting units to district office within 9 days
   reporting week is Sunday to Saturday

All the reporting units should submit their disease notifications to reach the district no later than 9 days after the end of the reporting week. A reporting week
is normally taken from Sunday to Saturday. Thus, the weekly notifications are normally expected by the following Monday.

All reports received within that period are considered to be on time. After that period has passed, any reports received is considered late. Some diseases can be monitored more accurately through the laboratory because of the nonspecificity of the clinical syndrome e.g. most types of food poisoning. For other diseases, laboratory data acts only as a confirmation of the clinical diagnosis. These include Rabies, Cholera and Crimean Congo Haemorrhagic fever.

**Hospital-based surveillance**
Hospital discharge information as well as mortality data can be used to monitor disease trends and disease burden in a particular area served by the hospital.

**Population-based surveillance**
A population-based surveillance system collects and analyses medical information in a well-defined population.

Complete reporting is needed when doing surveillance on rarely occurring diseases as well as for the elimination of diseases (e.g. polio eradication in SA by 2000 - surveillance of Acute Flaccid Paralysis).
FLOW CHART

Procedure to follow with notifiable medical conditions

**Diagnosis**
can be any health worker, not necessarily a Doctor

↓
GW 17/5
immediately

↓
**Local authority / Hospital / District**
whoever is responsible for disease containment

↓
GW17/3 (cases)
GW 17/4 (deaths)
weekly

↓
**Regional office**
Health Information Unit
if data entry is done at regional level -
province specific

↓
Computer disks
e-mail
weekly

↓
**Provincial office**
Health Information Unit
if data entry is done at provincial level -
province specific

↓
computer disks
e-mail
weekly

↓
**National Department**
Directorate HSR & Epidemiology
Private Bag X828, Pretoria 0001
Notifiable Medical Conditions

Acute flaccid paralysis
Anthrax
Brucellosis
Cholera
Congenital syphilis
Crimean-Congo haemorrhagic fever
Other haemorrhagic fevers of Africa
Diphtheria
Food poisoning
Haemophilus Influenza type B
Lead poisoning
Legionellosis
Leprosy
Malaria
Measles
Meningococcal infection
Paratyphoid fever
Plague
Poisoning agricultural stock remedies
Poliomyelitis
Rabies
Rheumatic fever
Tetanus
Tetanus neonatorum
Trachoma
Tuberculosis primary
Tuberculosis pulmonary
Tuberculosis of other respiratory organs
Tuberculosis of meninges
Tuberculosis of intestines, peritoneum
Tuberculosis of bones and joints
Tuberculosis of genito-urinary system
Tuberculosis of other organs
Tuberculosis miliary
Tuberculosis total
Typhoid fever
Typhus fever (lice-borne)
Typhus fever (rat flea-borne)
Viral hepatitis type A
Viral hepatitis type B
Viral hepatitis non-A non-B
Viral hepatitis unspecified
Viral hepatitis total
Whooping cough
Yellow fever
Chapter 1: Dental and oral conditions

1.1 Abscess and caries, dental
   1.1.1 Abscess, dental
   1.1.2 Caries, dental

1.2 Candidiasis, oral (thrush)

1.3 Gingivitis and periodontitis
   1.3.1 Gingivitis, uncomplicated
   1.3.2 Periodontitis
   1.3.3 Necrotising periodontitis

1.4 Herpes stomatitis

1.5 Aphthous ulcers
### Abscess and caries, dental

#### 1.1.1 Abscess, dental

K04.7

**Description**

Acute or chronic suppuration related to teeth, due to infection. It is characterised by:

- acute, severe, throbbing pain
- swelling adjacent to the tooth, or on the face
- pain worsened by tapping on affected teeth
- restriction in mouth opening or difficulty in swallowing
- pus collection and drainage either intra-orally or on the face

**Drug treatment**

Initiate treatment before referral.

- **Amoxicillin, oral, 10–20 mg/kg 8 hourly for 5 days**

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 11–20 kg</td>
<td>250 mg</td>
<td>Syrup</td>
<td>Capsule 250 mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>125 mg/5 mL</td>
<td>250 mg/5 mL</td>
</tr>
<tr>
<td>≥ 20 kg and above</td>
<td>500 mg</td>
<td>–</td>
<td>2 capsules</td>
</tr>
</tbody>
</table>

**Penicillin–allergic patients:**

- **Erythromycin, oral, 10–15 mg/kg/dose 6 hourly for 5 days**

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 11–14 kg</td>
<td>150 mg</td>
<td>Syrup</td>
<td>Tablets 250 mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>125 mg/5 mL</td>
<td>1 tablet</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>200 mg</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>250 mg</td>
<td>8 mL</td>
<td>1 tablet</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>375 mg</td>
<td>10 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 35 kg and above</td>
<td>500 mg</td>
<td>–</td>
<td>2 tablets</td>
</tr>
</tbody>
</table>
## Chapter 1 Dental and oral conditions

- **Metronidazole, oral, 7.5 mg/kg/dose** 8 hourly for 5 days

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th><strong>Use one of the following:</strong></th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>[Syrup 200mg / 5mL]</td>
<td>Tablets 200mg</td>
</tr>
<tr>
<td>≥9–11 kg</td>
<td>80 mg</td>
<td>2 mL – –</td>
<td>–</td>
</tr>
<tr>
<td>≥11–14 kg</td>
<td>100 mg</td>
<td>2.5 mL ½ tablet – –</td>
<td>≥18 months–3 years</td>
</tr>
<tr>
<td>≥14–17.5 kg</td>
<td>120 mg</td>
<td>3 mL – –</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥17.5–25 kg</td>
<td>160 mg</td>
<td>4 mL – –</td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td>≥25–35 kg</td>
<td>200 mg</td>
<td>5 mL 1 tablet ½ tablet</td>
<td>≥7–11 years</td>
</tr>
<tr>
<td>≥35–55 kg</td>
<td>300 mg</td>
<td>7.5 mL 1½ tablets –</td>
<td>≥11–15 years</td>
</tr>
<tr>
<td>≥55 kg and above</td>
<td>400 mg</td>
<td>– 2 tablets 1 tablet</td>
<td>≥ 15 years and adult</td>
</tr>
</tbody>
</table>

- **Paracetamol, oral, 15 mg/kg/dose** 4–6 hourly when required to a maximum of 4 doses per 24 hours.

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th><strong>Use one of the following:</strong></th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>[Syrup 120 mg/5mL]</td>
<td>Tablet 500 mg</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>120 mg</td>
<td>5 mL –</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>180 mg</td>
<td>7.5 mL –</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–35 kg</td>
<td>240 mg</td>
<td>10 mL ½ tablet –</td>
<td>≥ 5–11 years</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>500 mg</td>
<td>– 1 tablet</td>
<td>≥11–15 years</td>
</tr>
<tr>
<td>≥55 kg and above</td>
<td>Up to 1000 mg</td>
<td>–</td>
<td>Up to 2 tablets</td>
</tr>
</tbody>
</table>

**Referral**

- All cases on diagnosis

### 1.1.2 Caries, dental K02

To be managed by a dentist.

For local anaesthesia for dental procedures:
- **Xylocaine** (Dentist only)
- **Xylocaine with adrenaline** (Dentist only)
1.2 Candidiasis, oral (thrush)

**Description**
An infection of the mouth and sometimes of the pharynx caused by species of the Candida fungus. Presents as painful creamy white patches that can be scratched off the tongue and buccal mucosae. Often occurs in otherwise healthy babies up to one month of age.

Risk factors for candida include:
- poor oral hygiene
- immunosuppression (severe cases are common)
- prolonged use of broad spectrum antibiotics or corticosteroids (also inhaled)
- certain chronic diseases, e.g. diabetes mellitus
- trauma e.g. poorly fitting dentures

**General measures**
- Identify underlying diseases (e.g. diabetes or HIV) or medication (such as steroid inhaler or long-term antibiotics)
- Improve oral hygiene
- Cup feeding in preference to bottle feeding
- Ensure proper fitting dentures

**Drug treatment**

**Infants**
- Nystatin suspension, oral, 100 000 IU/mL, 1 mL after each feed for 7 days
  - or
  - Gentian violet, 0.5%, topical aqueous solution, applied to the inside of the mouth three times daily
  - Continue for 48 hours after cure.

**Adults**
- Antifungal lozenges (troches), e.g. amphotericin B, oral, one lozenge (troche) sucked 6 hourly for 5 days.
  - Treatment may need to be repeated.

**Note:**
HIV infected patients with oral candidiasis and painful or difficult swallowing have oesophageal involvement and need fluconazole – See section 11.3.3: Candida oesophagitis.

**Referral**
- No improvement
- Uncertain diagnosis
- Pharyngeal spread
1.3 Gingivitis and peridontitis
K05

1.3.1 Gingivitis, uncomplicated
K05.0

Description
Inflammation of the gum margin causing the gums to separate from the teeth. Pockets form between the gums and the teeth. Pus and bacteria can collect in these pockets, eventually causing periodontitis, a disease in the tissue that surround and supports the teeth – See section 1.3.2: Peridontitis.

Characteristics of uncomplicated gingivitis:
» change in the normal gum contour » may be painful
» redness » swollen gums
» watery exudate/bleeding » gum recession may occur
» may be recurrent

Prophylaxis and general measures
Oral hygiene is usually adequate to prevent superficial mouth and gum infection:
» Oral hygiene after each meal to remove plaque and food debris.
» Frequent thorough brushing of teeth, at least twice daily.
» Dental flossing at least once a day.
» Homemade salt mouthwash may help, e.g. ½ medicine measure of table salt in a glass of lukewarm water. Rinse mouth for one minute twice daily.

Drug treatment
- Paracetamol, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum of 4 doses per 24 hours

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 11–14 kg</td>
<td>120 mg</td>
<td>Syrup 120 mg/5mL</td>
<td>5 mL</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>180 mg</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>≥ 17.5–35 kg</td>
<td>240 mg</td>
<td>Tablett 500 mg</td>
<td>7.5 mL</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>500 mg</td>
<td>10 mL</td>
<td>½ tablet</td>
</tr>
<tr>
<td>≥55 kg and above</td>
<td>Up to 1 000 mg</td>
<td>–</td>
<td>1 tablet</td>
</tr>
</tbody>
</table>

- Chlorhexidine 0.2%, 15 mL as a mouthwash, 2–4 times daily for 5 days after brushing and flossing
1.3.2 Periodontitis

**Description**
Progressive gingivitis to the point where the underlying bone is eroded and is characterised by loose teeth in their sockets. It is a cause of tooth loss in adults. See section 1.3.1: Gingivitis, uncomplicated.

**General measures**
- Advice on improving and maintaining oral hygiene.
- Frequent thorough brushing of teeth (at least twice daily).

**Drug treatment**
- Chlorhexidine 0.2%, 15 mL as a mouthwash, 2–4 times daily for 5 days after brushing

**Referral**
- All cases

1.3.3 Necrotising periodontitis

**Description**
An acute very painful infection of the gingival margin characterised by:
- Foul smelling breath
- Loss of gingiva and supporting bone around teeth
- Presence of underlying disease, e.g. HIV
May lead to loss of surrounding lips and cheeks if not adequately treated.

**Management**
- Relieve pain
- Improve oral hygiene
**Drug treatment**

- Metronidazole, oral, 7.5 mg/kg/dose 8 hourly for 5 days

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 9–11 kg</td>
<td>80 mg</td>
<td>2 mL – –</td>
<td>≥ 12–18 months</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>100 mg</td>
<td>2.5 mL – –</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>≥14–17.5 kg</td>
<td>120 mg</td>
<td>3 mL – –</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥17.5–25 kg</td>
<td>160 mg</td>
<td>4 mL – –</td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td>≥25–35 kg</td>
<td>200 mg</td>
<td>5 mL 1 tablet ½ tablet</td>
<td>≥7–11 years</td>
</tr>
<tr>
<td>≥35–55 kg</td>
<td>300 mg</td>
<td>7.5mL 1½ tablets –</td>
<td>≥11–15 years</td>
</tr>
<tr>
<td>≥55 kg and above</td>
<td>400 mg</td>
<td>– 2 tablets 1 tablet</td>
<td>≥ 15 years and adult</td>
</tr>
</tbody>
</table>

- Chlorhexidine 0.2%, 15 mL as a mouthwash, 2–4 times daily 30 minutes after brushing.
  - Continue for 5 days

- Paracetamol, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum of 4 doses per 24 hours

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 11–14 kg</td>
<td>120 mg</td>
<td>5 mL –</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>180 mg</td>
<td>7.5 mL –</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–35 kg</td>
<td>240 mg</td>
<td>10 mL ½ tablet</td>
<td>≥ 5–11 years</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>500 mg</td>
<td>– 1 tablet</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>Up to 1 000 mg</td>
<td>– Up to 2 tablets</td>
<td>≥ 15 years and adults</td>
</tr>
</tbody>
</table>

**Referral**

For dental treatment:

» No improvement within 5 days
1.4 Herpes stomatitis

Description
Acute, painful vesicular eruptions of the lips and mouth caused by Herpes simplex virus characterised by:

- Shallow painful ulcers on the lips, gingiva and tongue
- Pain exacerbated on eating
- It is a self-limiting infection with symptoms subsiding within 10 days

General measures
- Homemade salt mouthwash may help, e.g. ½ medicine measure of table salt in a glass of lukewarm water. Rinse mouth for one minute twice daily
- Improve nutrition
- Ensure adequate hydration
- Fluid diet for children
- Avoid acidic drinks, e.g. orange juice or soft drinks as they may cause pain
- Cover lesions on the lips with petroleum jelly

Drug treatment
- Paracetamol, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum of 4 doses per 24 hours
  - In children under six months calculate dose by weight

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 3.5–5 kg</td>
<td>48 mg</td>
<td>Syrup 120 mg/5mL</td>
<td>≥ 1–3 months</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>60 mg</td>
<td>2.5 mL</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>96 mg</td>
<td>4 mL</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥ 9 – 14 kg</td>
<td>120 mg</td>
<td>5 mL</td>
<td>≥ 12 months–3 years</td>
</tr>
<tr>
<td>≥ 14 – 17.5 kg</td>
<td>180 mg</td>
<td>7.5 mL</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5 – 35 kg</td>
<td>240 mg</td>
<td>10 mL</td>
<td>≥ 5–11 years</td>
</tr>
<tr>
<td>≥ 35 – 55 kg</td>
<td>500 mg</td>
<td>½ tablet</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>Up to 1000 mg</td>
<td>Up to 2 tablets</td>
<td>Adults</td>
</tr>
</tbody>
</table>

Extensive oral herpes:
- Tetracaine 1 %, oral, topical, applied every 3 to 4 hours.
  - Apply a thin layer on the affected areas only.

Note:
Children with extensive oral herpes should be treated with aciclovir if this can be started within 72 hours of onset of symptoms.
HIV infected patients with Herpes stomatitis:
- Aciclovir, oral, 8 hourly for 7 days. (Doctor initiated)
  - Paediatric dose: 250 mg/m²/dose

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Susp 200 mg/5mL</td>
<td>Tablet 200 mg</td>
</tr>
<tr>
<td>≥ 3.5–7 kg</td>
<td>80 mg</td>
<td>2 mL – –</td>
<td>≥ 1–6 months</td>
</tr>
<tr>
<td>≥ 7–11 kg</td>
<td>100 mg</td>
<td>2.5 mL – –</td>
<td>≥ 6–18 months</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>120 mg</td>
<td>3 mL – –</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>≥ 14–25 kg</td>
<td>160 mg</td>
<td>4 mL –</td>
<td>≥ 3–7 years</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>200 mg</td>
<td>5 mL 1 tablet ½ tablet</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>300 mg</td>
<td>7.5 mL 1½ tablets –</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>400 mg</td>
<td>– 2 tablets 1 tablet</td>
<td>≥ 15 years and adults</td>
</tr>
</tbody>
</table>

Referral
- Severe condition with complications
- Dehydrated patients
- No improvement after 1 week of treatment

1.5 Aphthous ulcers

Description
Painful ulcers in the oropharynx. Minor ulcers (<1 cm diameter) usually heal within 2 weeks. Major ulcers (>1 cm diameter) are very painful, often very deep and persist.

Drug treatment
Minor aphthous ulcers:
- Choline salicylate/cetalkonium chloride 8.7/0.01% oral gel, applied 6 hourly until healed

Referral
- Major aphthous ulcers for further diagnostic evaluation
Chapter 2: Gastro-intestinal conditions

2.1 Abdominal pain
2.2 Dyspepsia, heartburn and indigestion
2.3 Nausea and vomiting, non-specific
2.4 Anal conditions
  2.4.1 Anal fissures
  2.4.2 Haemorrhoids
2.5 Appendicitis
2.6 Cholera
2.7 Constipation
2.8 Diarrhoea
  2.8.1 Diarrhoea, acute in children
  2.8.2 Diarrhoea, persistent in children
  2.8.3 Diarrhoea, acute, without blood in adults
  2.8.4 Diarrhoea, chronic in adults
2.9 Dysentery
  2.9.1 Dysentery, bacillary
  2.9.2 Dysentery, amoebic
2.10 Helminthic infestation
  2.10.1 Helminthic infestation, tapeworm
  2.10.2 Helminthic infestation, excluding tapeworm
2.11 Irritable bowel syndrome
2.12 Typhoid fever
Chapter 2  Gastro-intestinal conditions

2.1 Abdominal pain
R10.4

**Description**
Abdominal pain is a common symptom, which may be non-specific. It is frequently benign, but may indicate a serious acute pathology. A thorough evaluation is necessary to exclude a surgical abdomen or other serious condition.

The history should include:
- duration, location, type, radiation and severity of pain
- relieving or aggravating factors e.g. food, antacids, exertion
- associated symptoms e.g. fever or chills, weight loss or gain, nausea, vomiting, diarrhoea, cramps fresh blood per rectum, melaena stools, jaundice, change in stool or urine colour
- past medical and surgical history
- medication history
- alcohol intake
- family history of bowel disorders
- menstrual and contraceptive history in women
- associated vaginal discharge in women with lower abdominal pain

Examination should emphasise detection of:
- tachycardia
- fever
- jaundice
- abdominal masses, distension, tenderness
- signs of peritonitis (rebound tenderness and guarding)

**Drug treatment**
Symptomatic treatment if no specific cause or indication for referral is found.

**Urinary tract infection**
See chapter 8: Kidney and urological disorders

**Dyspepsia**
See section 2.2: Dyspepsia, heartburn and indigestion

**For pain relief (adults)**
Analgesia as appropriate.

**Renal and biliary colic, or acute surgical abdomen**
- Morphine, IM/IV, 10–15 mg as a single dose and refer
  For IV morphine:
  - Dilute in 10 mL sodium chloride 0.9%
  - Administer slowly over 4–5 minutes
Chapter 2  Gastro-intestinal conditions

Abdominal pain with cramp-like pains  
- Hyoscine butylbromide, oral, 10–20 mg 6–8 hourly for a maximum of 3 days

Cancer pain e.g. pancreatic, gastric cancer  
See section 20.3: Chronic cancer pain.

Referral  
- Severe pain with no confirmed cause treatable at primary healthcare level
- Signs of acute abdomen
- Associated bloody non-diarrhoeal stools
- Associated abdominal mass

2.2 Dyspepsia, heartburn and indigestion  
K30/R12

Description  
Dyspepsia, heartburn and indigestion are common conditions, which often present with epigastric discomfort and minimal change in bowel habits. Intermittent indigestion, heartburn or dyspepsia may be associated with:
- use of NSAIDs, e.g. aspirin, ibuprofen, pain powders
- spicy food, alcohol, carbonated drinks
- smoking
Consider the possibility that dyspeptic symptoms may be due to acute coronary syndrome.

General measures  
- Stop smoking.
- Limit alcohol intake.
- Eat small frequent meals.
- Check haemoglobin.
- Check for a drug cause likely to be associated with dyspeptic symptoms.

Drug treatment  
Initiate drug therapy only after full assessment.
- Aluminium hydroxide 250 mg/magnesium trisilicate 500 mg, oral, 1–2 tablets to be chewed 1 hour before and 3 hours after meals and at night when needed.
  - Maximum of 16 tablets daily or continuous treatment for 7 days

If there is no response  
- Cimetidine, oral, 400 mg at bedtime for 14 days

! CAUTION !  
Cimetidine has a high potential for drug interactions when used concomitantly with other drugs.

Referral  
- Presence of warning signs:  
  - weight loss
Chapter 2  
**Gastro-intestinal conditions**

- persistent vomiting
- dysphagia
- anaemia
- haematemesis
- palpable abdominal mass

» No response within 7 days of starting cimetidine treatment

» Recurrence of symptoms:
- especially in age over 50 years
- family history of gastric carcinoma
- previous gastric surgery

### 2.3 Nausea and vomiting, non-specific

**R11**

**Description**

There are many possible causes of nausea and vomiting. Some important causes to **exclude** are:

» gastro-intestinal disease

» liver disease

» renal failure

» alcohol abuse

» early pregnancy

» medicines

Establish if the vomiting is associated with:

» abdominal pain

» diarrhoea

» headache

» constipation

**General measures**

» Maintain adequate hydration with clear fluids

  See section 2.8: Diarrhoea

» In children in whom feeds are stopped, this should not be for more than 1 hour and restart feeding in smaller more frequent amounts

**Drug treatment**

Do not use anti-emetics in children.

**Adults**

- Metoclopramide, IV/oral, 10 mg 6–8 hourly

**Referral**

**Urgent**

» Severe dehydration

» Shock

» Diabetes
2.4 Anal conditions

2.4.1 Anal fissures

K60.2

Description
Painful small cracks just inside the anal margin. It is often seen together with a sentinel pile or external haemorrhoids and may cause spasm of the anal sphincter.

General measures
» Dietary advice to promote soft stools.

Drug treatment
- Bismuth subgallate compound, ointment, topical, applied 2–4 times daily
  or
- Lignocaine 2%, cream, topical, applied after each bowel action
- Lactulose, oral, 0.5 mL/kg/dose once daily
  o If poor response, increase frequency to 12 hourly

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Syrup 3.3 g/5 mL</th>
<th>Age years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 5–9 kg</td>
<td>2.5 mL</td>
<td>≥ 3 months–1 year</td>
</tr>
<tr>
<td>≥ 9–17.5 kg</td>
<td>5 mL</td>
<td>≥ 1–5 years</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>7.5 mL</td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>10 mL</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>10 – 20 mL</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>10 – 20 mL</td>
<td>≥ 15 years and adult</td>
</tr>
</tbody>
</table>

Referral
» Severe pain
» Recurrent episodes
» Poor response to symptomatic treatment

2.4.2 Haemorrhoids

I84.9

Description
Varicose veins of the ano-rectal area, usually accompanied by a history of constipation.
Chapter 2  
Gastro-intestinal conditions

In older patients consider a diagnosis of underlying carcinoma.

**General measures**

» High-fibre diet.
» Counsel against chronic use of laxatives.
» Avoid straining at stool.

**Drug treatment**

Symptomatic treatment for painful haemorrhoids

- Bismuth subgallate compound, ointment, topical, applied 2–4 times daily
  - Lignocaine 2%, cream, topical, applied after each bowel action

**Constipation**

See section 2.7: Constipation

**Referral**

» For surgical intervention if necessary
  - if the haemorrhoid cannot be reduced
  - if the haemorrhoid is thrombosed
» Children

2.5 Appendicitis

K35.9

**Referral**

» All patients with suspected appendicitis:
  - right iliac fossa tenderness
  - right iliac fossa rebound pain
  - severe persistent abdominal pain

2.6 Cholera

A00.9

**Note:** notifiable condition.

**Description**

Very acute severe watery diarrhoea due to infection with the micro-organism *Vibrio cholerae.*

Clinical features include:

» rice water appearance of stools:
  - no blood in stools
  - no pus in stools
  - no faecal odour
  - possible vomiting
  - rapid severe dehydration
Chapter 2  Gastro-intestinal conditions

Note:
The prime objective is to prevent and treat dehydration.

General measures
» Rehydrate aggressively with ORS.

Drug treatment
Dehydration
Children
Treat dehydration – See Section 2.8.1: Diarrhoea, acute in children

Adults
Oral treatment
• Oral rehydration solution (ORS)
  or
  Homemade sugar and salt solution (see section 2.8: Diarrhoea)
  The volume of fluid required for oral rehydration depends on the severity of
  the dehydration.

Oral rehydration is preferable to IV. In stuporose patients administer ORS by
nasogastric tube.
IV treatment
• Sodium chloride 0.9%, IV and refer

For the management of severe dehydration during cholera outbreaks, replace
sodium chloride 0.9% with:
• Ringer–Lactate, IV and refer

Do not administer ceftriaxone to patients receiving Ringer–Lactate, or who
have received Ringer–Lactate intravenously in the previous 48 hours.

Ringer–Lactate should only be available at PHC level during cholera outbreaks.

Cholera epidemics or where cholera is confirmed on culture
Antibiotics may vary according to sensitivities in epidemics. Consult the NICD for
the latest recommendations. Current recommendations are:
Chapter 2 Gastro-intestinal conditions

- Doxycycline, oral, as a single dose
  - Adults (including pregnant women)
  - Children: 4 mg/kg/dose

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months / years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Capsules 50 mg</td>
<td>Capsules 100 mg</td>
</tr>
<tr>
<td>≥ 7–14 kg</td>
<td>50 mg</td>
<td>1 capsule</td>
<td>–</td>
</tr>
<tr>
<td>≥ 14–25 kg</td>
<td>100 mg</td>
<td>2 capsules</td>
<td>1 capsule</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>150 mg</td>
<td>3 capsules</td>
<td>–</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>200 mg</td>
<td>–</td>
<td>2 capsules</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>300 mg</td>
<td>–</td>
<td>3 capsules</td>
</tr>
</tbody>
</table>

- Contra--indicated in children less than 8 years. However, in confirmed cases or during epidemics, where the organism is not sensitive to other antibiotics, a single dose may be administered.

Referral

» Severely ill patients
» According to provincial and local policy
» Children under 6 months of age

2.7 Constipation

K59.0

Description

A condition characterised by a change in usual bowel habits and dry, hard stools. There is a decreased frequency of bowel action and patients should be assessed individually.

Constipation may have many causes, including:

» incorrect diet (fibre and fluid) » lack of exercise
» pregnancy » old age
» drugs, e.g. opiates and anticholinergics » ignoring the urge
» hypothyroidism » neurogenic
» lower bowel abnormalities » psychogenic disorders
» chronic use of enemas and laxatives » cancer of the bowel
» behavioural problems in children
CAUTION!
In adults be especially suspicious of a change in bowel habits, as there is a possibility of cancer of the large bowel.

**General measures**

» Encourage exercise.
» Increase intake of fibre-rich food, e.g. vegetables, coarse maize meal, bran and cooked dried prunes.
» Ensure adequate hydration.
» Encourage regular bowel habits.
» Discourage continuous use of laxatives.

**Drug treatment**

**Children over 12 months**
- Lactulose, oral, 0.5 mL/kg/dose once daily
  - If poor response, increase frequency to 12 hourly

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Syrup (3.3 g/5 mL)</th>
<th>Age (years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 5–9 kg</td>
<td>2.5 mL</td>
<td>≥ 3 months–1 year</td>
</tr>
<tr>
<td>≥ 9–17.5 kg</td>
<td>5 mL</td>
<td>≥ 1–5 years</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>7.5 mL</td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>10 mL</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>10–20 mL</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>10–20 mL</td>
<td>≥ 15 years and adult</td>
</tr>
</tbody>
</table>

**Adults**
- Sennosides A and B, oral, 7.5 mg, 2 tablets at night.
  - In resistant cases increase to 4 tablets.
  - or
    - Lactulose 10–20 mL once or twice daily

CAUTION!
Prolonged severe constipation may present with overflow “diarrhoea”. Rectal examination should be done in all cases.

**Referral**

» Recent change in bowel habits
» Faecal impaction
» Poor response to treatment
» Uncertain cause of constipation
Chapter 2  

Gastro-intestinal conditions

2.8 Diarrhoea

CAUTION!
There is no place for antidiarrhoeal preparations in the treatment of acute diarrhoea in children or dysentery.

2.8.1 Diarrhoea, acute in children

Description
A sudden onset of change in consistency and frequency of stools with or without vomiting in children. It is commonly caused by a virus but may be caused by bacteria or parasites. The cause of these conditions cannot be diagnosed without laboratory investigation. It may be an epidemic if many patients are infected at the same time.

Special risk situations
Diarrhoea in infants less than 2 weeks, malnourished babies, and babies with other danger signs such as:
- convulsions
- altered level of consciousness
- persistent vomiting
- respiratory distress
- persistent diarrhoea
- hypothermia
- surgical abdomen

Refer these babies urgently for treatment. Before referral, administer:
- Ceftriaxone, IM, 50–80 mg/kg/dose immediately as a single dose

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following injections mixed with water for injection (WFI):</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>250 mg WFI 2 mL</td>
</tr>
<tr>
<td>≥ 2–2.5 kg</td>
<td>125 mg</td>
<td>1 mL</td>
</tr>
<tr>
<td>≥ 2.5–3.5 kg</td>
<td>200 mg</td>
<td>1.6 mL</td>
</tr>
<tr>
<td>≥ 3.5–5.5 kg</td>
<td>250 mg</td>
<td>2 mL</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>375 mg</td>
<td>3 mL</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>500 mg</td>
<td>4 mL</td>
</tr>
<tr>
<td>≥ 9–11 kg</td>
<td>625 mg</td>
<td>5 mL</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>750 mg</td>
<td>6 mL</td>
</tr>
<tr>
<td>≥ 14–17.5 kg and above</td>
<td>1 000 mg</td>
<td>–</td>
</tr>
<tr>
<td>≥ 17.5 kg and above</td>
<td>1 000 mg</td>
<td>–</td>
</tr>
</tbody>
</table>

Age
Months/years

≥ 2–2.5 kg
≥ 2.5–3.5 kg
≥ 3.5–5.5 kg
≥ 5–7 kg
≥ 7–9 kg
≥ 9–11 kg
≥ 11–14 kg
≥ 14–17.5 kg and above
≥ 17.5 kg and above

Birth–1 month
≥ 1–3 months
≥ 3–6 months
≥ 6–12 months
≥ 12–18 months
≥ 18 months–3 years
≥ 3–5 years
≥ 5 years and adults
Chapter 2  
Gastro-intestinal conditions

! CAUTION!

Do not administer calcium containing fluids, e.g. Ringer-Lactate, within 48 hours of administering ceftriaxone.
Contra-indicated in neonatal jaundice.
Annotate the dosage and route of administration in the referral letter.

Special types of diarrhoea

» Bloody diarrhoea
  – consider dysentery – See section 2.9: Dysentery

» Diarrhoea with high fever or very ill
  – consider typhoid – See section 2.12: Typhoid fever

» Persistent diarrhoea, more than 14 days
  – refer patient

» Diarrhoea in children in the context of an adult epidemic
  – consider cholera – See section 2.6: Cholera

Treatment according to hydration classification

Assess hydration
Identify signs present to classify dehydration as (beginning from the left column):
- 2 of the signs below but not severe dehydration
- None of the signs of dehydration

<table>
<thead>
<tr>
<th>Signs of classification</th>
<th>C Severe dehydration</th>
<th>B Some dehydration</th>
<th>A No visible dehydration</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2 of the signs below</td>
<td>2 of the signs below but not severe dehydration</td>
<td>None of the signs of dehydration</td>
</tr>
<tr>
<td>Level of consciousness</td>
<td>lethargic or unconscious</td>
<td>restless or irritable</td>
<td>well alert</td>
</tr>
<tr>
<td>Sunken eyes</td>
<td>eyes sunken</td>
<td>eyes sunken</td>
<td>eyes not sunken</td>
</tr>
<tr>
<td>Ability to drink</td>
<td>drinks poorly or not able to drink</td>
<td>thirsty, drinks eagerly</td>
<td>drinks normally, not excessive thirst</td>
</tr>
<tr>
<td>Skin pinch (Turgor)</td>
<td>severe decrease in skin turgor</td>
<td>skin pinch returning over 2 seconds or more</td>
<td>skin pinch goes back immediately</td>
</tr>
</tbody>
</table>
## Gastro-intestinal conditions

<table>
<thead>
<tr>
<th>C</th>
<th>Severe dehydration</th>
<th>B</th>
<th>Some dehydration</th>
<th>A</th>
<th>No visible dehydration</th>
</tr>
</thead>
</table>
| Give rapidly:  
  - Sodium chloride 0.9%, IV, 20 mL/kg  
  Repeat up to twice if radial pulse is weak or undetectable.  
  Continue with 20 mL/kg every hour for the next 5 hours.  

Then:  
Refer urgently for continued management continuing with 20 mL/kg every hour for the next 5 hours during urgent referral unless the child is reclassified as B: Some dehydration.  
  - Reassess every 2 hours while awaiting transfer.  
  - If hydration status does not improve, give IV fluids more rapidly.  
  
As soon as the child can drink, usually after 3–4 hours in infants and 1–2 hours in children, also give:  
  - ORS, oral, 5 mL/kg/hour  

If IV administration is not possible, insert a nasogastric tube and while awaiting and during urgent transfer give:  
  - ORS, 20 mL/kg/hour over the next 6 hours via the nasogastric tube  
If only oral administration is possible, or the condition is not improving, transfer the child urgently giving ORS during transfer.  

Reassess every 4 hours for classification – if improves to classification B: Some dehydration – treat as such |
| Give:  
  - ORS, oral, 80 mL/kg over 4 hours, e.g. 5 mL/kg every 15 minutes  
  
Give more if the child wants more.  

Show the caregiver how to give ORS with a cup and spoon using frequent small sips.  
If child vomits wait 10 minutes and then continue more slowly.  

Encourage the caregiver to continue feeding the child especially breastfeeding.  
If after 4 hours there are:  
  - no signs of dehydration – treat as A: No visible dehydration  
  - still some dehydration signs – continue as above  
  - signs of severe dehydration – treat as C: Severe dehydration  

Show the caregiver how to give ORS with a cup and spoon using frequent small sips.  
Encourage caregiver to give 10 mL/kg after each diarrhoeal stool until diarrhoea stops, i.e.  
  - child age up to 2 years, 50–100 mL  
  - child age 2 years or more, 100–200 mL after each loose stool.  
Continue at home.  
Encourage the caregiver to continue feeding the child, especially breastfeeding.  
Instruct the caregiver how to make ORS/SSS at home and to continue treatment.  

---

**Chapter 2**
Child should return immediately if:
» no improvement
» condition deteriorates
» poor drinking or feeding
» blood in stool
» fever develops
» sunken eyes
» slow skin pinch

In all children who are able to take oral medication
- Zinc (elemental), oral for 14 days:
  - If < 10 kg give 10 mg/day
  - If > 10 kg give 20 mg/day

Homemade sugar and salt solution may be used if oral rehydration formula is not available and is promoted for home use pending primary health care consultation:

### Homemade sugar and salt solution (SSS)

½ level medicine measure of table salt

plus

8 level medicine measures of sugar
dissolved in 1 litre of boiled (if possible) then cooled water

(1 level medicine measure = approximately 1 level 5 mL teaspoon)

**Referral**

» Severe dehydration with other complications
» Dysentery in children under 12 months of age
» Malnourished children
» Children with general danger signs, e.g. altered level of consciousness, convulsions, inability to feed or drink, intractable vomiting.
» Suspected acute surgical abdomen

**2.8.2 Diarrhoea, persistent in children**

**Description**

Diarrhoea for 7–14 days.

**General measures**

» Assess for possible HIV infection, and manage appropriately.
» Prevent dehydration using Homemade sugar and salt solution (See Section 2.8.1: Diarrhoea, acute in children – Plan A)
Chapter 2  Gastro-intestinal conditions

» Counsel mother regarding feeding.
  − If breastfeeding, give more frequent, longer feeds.
  − If replacement feeding replace milk with breast milk or with fermented milk products such as amasi (maas) or yoghurt, if available.
  − Continue with solids - give small, frequent meals at least 6 times a day.
» Follow-up 5 days. If diarrhoea persists, refer to doctor for investigation.

**Drug treatment**

Give an additional dose of Vitamin A:

- Vitamin A (retinol), oral

<table>
<thead>
<tr>
<th>Age range</th>
<th>Dose units</th>
<th>Capsule 100 000 u</th>
<th>Capsule 200 000 u</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infants 6–11 months old</td>
<td>100 000</td>
<td>1 capsule</td>
<td>–</td>
</tr>
<tr>
<td>Children 12 months to 5 years</td>
<td>200 000</td>
<td>2 capsules</td>
<td>1 capsule</td>
</tr>
</tbody>
</table>

- Zinc (elemental), oral for 14 days:
  o If < 10 kg give 10 mg/day
  o If > 10 kg give 20 mg/day

**Referral**

» Child younger than two months of age
» Signs of dehydration – See Section 2.8.1: Diarrhoea, acute in children
» Malnutrition or weight loss
» Diarrhoea that persists for more than 5 days with treatment, refer to doctor for investigation
» Diarrhoea present for more than 14 days

**2.8.3 Diarrhoea, acute, without blood, in adults**

**K52.9**

**Description**

Acute diarrhoea is usually self-limiting and is managed by fluid replacement.

**Drug treatment**

Treat vigorously.

- Oral rehydration solution (ORS)
  or
  Homemade sugar and salt solution (SSS)

- Loperamide, oral, 4 mg immediately and 2 mg as required after each loose stool up to 6 hourly.
  o Not more than 12 mg daily.
Chapter 2  Gastro-intestinal conditions

Referral
» Suspected acute surgical abdomen
» Diarrhoea with complications

2.8.4 Diarrhoea, chronic, in adults
K52.9

Description
Diarrhoea lasting more than 2 weeks.
The majority of cases may be HIV related. Encourage HIV testing.

A stool sample should be requested for microscopy for ova, cysts and parasites
Note: Culture and sensitivity should not be requested on the form.

Giardiasis is a common cause of chronic diarrhoea in adults, and may be difficult
to diagnose on stools. Therefore empiric treatment for giardiasis is recommended
before referring such patients.

Drug treatment
Giardiasis
• Metronidazole, oral, 2 g daily for 3 days

Chronic diarrhoea in HIV/AIDS
See section 11.3.4: Diarrhoea, HIV associated

Referral
» All HIV negative cases with no pathogen identified and significant diarrhoea

2.9 Dysentery
A03.0

Dysentery or diarrhoeal stool with blood or mucus is usually due to bacteria and
should be treated as bacillary dysentery. If there is no clinical response within three
days consider managing as amoebic dysentery or refer for formal assessment.
It is important to exclude surgical conditions, e.g. intussusception in children.
Commonly encountered infectious conditions include Shigella, Salmonella, E. Coli, and Campylobacter.

Referral
» No response to treatment
**Chapter 2  Gastro-intestinal conditions**

**2.9.1 Dysentery, bacillary**

*Description*

Acute infection of the bowel usually caused by *Shigella, Salmonella* or *Campylobacter*.

There is sudden onset diarrhoea with:

» blood (not due to haemorrhoids or anal fissure) or mucus in the stools
» convulsions (in children)
» fever
» tenesmus

**General measures**

» Prevent spread of micro-organism by:
  - preventing contamination of food and water through good sanitation
  - washing hands thoroughly before handling food
  - washing soiled garments and bed clothes

**Drug treatment**

Treat hydration vigorously.

**Children**

Treat dehydration according to Section 2.8.1: Diarrhoea, acute in children

**Adults**

**Oral treatment**

- Oral rehydration solution
  - Homemade sugar and salt solution

  **Homemade sugar and salt solution (SSS)**

  \[
  \text{\(\frac{1}{2}\) level medicine measure of table salt} \quad \text{plus} \quad \text{8 level medicine measures of sugar}
  \]

  dissolved in 1 litre of boiled (if possible) then cooled water

  (1 level medicine measure = approximately 1 level 5 mL teaspoon)

The amount of fluid required for oral rehydration depends on the severity of the dehydration.
Chapter 2  
Gastro-intestinal conditions

IV treatment
- Sodium chloride 0.9%, IV

Antibiotic therapy
Indicated for:
- children over 1 year old and adults with blood in the stools
- HIV infected patients

- Ciprofloxacin, oral, 15 mg/kg/dose 12 hourly for 3 days

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months / years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 9–11 kg</td>
<td>150 mg</td>
<td>3 mL – –</td>
<td>≥ 12–18 months</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>200 mg</td>
<td>4 mL – –</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>250 mg</td>
<td>5 mL 1 tablet –</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>300 mg</td>
<td>6 mL – –</td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>375 mg</td>
<td>7.5 mL – –</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>≥ 35 kg and above</td>
<td>500 mg</td>
<td>– 2 tablets 1 tablet</td>
<td>≥ 11 years and adults</td>
</tr>
</tbody>
</table>

Note:
Check for complications such as intestinal perforation or peritonitis and ensure adequate urine output to exclude haemolytic uraemic syndrome.

Referral
- Malnutrition in children
- Severe illness
- Dehydration in children
- Persistent blood in urine on dipstick or macroscopically
- Acute abdominal signs (severe pain, acute tenderness, persistent or bilious vomiting),
- Bloody mucus passed in absence of diarrhoea.
Chapter 2  Gastro-intestinal conditions

» Children less than 12 months of age. In these children, before referral give:
  • Ceftriaxone, IM, 50–80 mg/kg/dose immediately as a single dose

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following injections mixed with water for injection (WFI):</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>250 mg WFI 2 mL</td>
</tr>
<tr>
<td>≥ 2–2.5 kg</td>
<td>125 mg</td>
<td>1 mL</td>
</tr>
<tr>
<td>≥ 2.5–3.5 kg</td>
<td>200 mg</td>
<td>1.6 mL</td>
</tr>
<tr>
<td>≥ 3.5–5.5 kg</td>
<td>250 mg</td>
<td>2 mL</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>375 mg</td>
<td>3 mL</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>500 mg</td>
<td>4 mL</td>
</tr>
<tr>
<td>≥ 9–11 kg</td>
<td>625 mg</td>
<td>5 mL</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>750 mg</td>
<td>6 mL</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>1 000 mg</td>
<td>–</td>
</tr>
<tr>
<td>≥ 17.5 kg and above</td>
<td>1 000 mg</td>
<td>–</td>
</tr>
</tbody>
</table>

! CAUTION !
Do not administer calcium containing fluids, e.g. Ringer-Lactate, within 48 hours of administering ceftriaxone.
Contra-indicated in neonatal jaundice.
Annotate the dosage and route of administration in the referral letter.

2.9.2 Dysentery, amoebic
A06.0

Description
A condition characterised by loose stools or rarely diarrhoea, caused by the parasite Entamoeba histolytica, with:
» blood
» mucus
» possible constipation, in the alternative
» usually without fever
The presentation is usually subacute.

Drug treatment
For dehydration
» Treat vigorously.
Children
Treat dehydration according to Section 2.8.1: Diarrhoea, acute in children

Adults
Oral treatment
- Oral rehydration solution
  or
  Homemade sugar and salt solution

<table>
<thead>
<tr>
<th>Homemade sugar and salt solution (SSS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>½ level medicine measure of table salt</td>
</tr>
<tr>
<td>plus</td>
</tr>
<tr>
<td>8 level medicine measures of sugar</td>
</tr>
<tr>
<td>dissolved in 1 litre of boiled (if possible) then cooled water</td>
</tr>
<tr>
<td>(1 level medicine measure = approximately 1 level 5 mL teaspoon)</td>
</tr>
</tbody>
</table>

The amount of fluid required for oral rehydration depends on the severity of the dehydration.

IV treatment
- Sodium chloride 0.9%, IV

If case confirmed by identification of organisms on wet stools or if dysentery treated with antibiotics has not improved within 3 days:
- Metronidazole, oral, 8 hourly for 5 days
  - Paediatric dose: 12–17 mg/kg/dose

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥9–11 kg</td>
<td>160 mg</td>
<td>4 mL</td>
<td>≥ 12–18 months</td>
</tr>
<tr>
<td>≥11–14 kg</td>
<td>200 mg</td>
<td>5 mL</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>≥14–17.5 kg</td>
<td>240 mg</td>
<td>6 mL</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥17.5–25 kg</td>
<td>300 mg</td>
<td>7.5 mL 1½ tablets</td>
<td>≥ 5 – 7 years</td>
</tr>
<tr>
<td>≥25–35 kg</td>
<td>400 mg</td>
<td>10 mL 2 tablets 1 tablet</td>
<td>≥7–11 years</td>
</tr>
<tr>
<td>≥35–55 kg</td>
<td>600 mg</td>
<td>15 mL 3 tablets 1½ tablets</td>
<td>≥11–15 years</td>
</tr>
<tr>
<td>≥55 kg and above</td>
<td>800 mg</td>
<td>4 tablets 2 tablets</td>
<td>≥ 15 years and adult</td>
</tr>
</tbody>
</table>

Referral
» Malnutrition in children
» Severe illness
» Dehydration
» Persistent blood in urine on dipstix or macroscopically
» Acute abdominal signs (severe pain, acute tenderness, persistent or bilious
vomiting),

» Bloody mucous passed in absence of diarrhoea.
» No improvement after 3 days treatment
» Children less than 12 months of age. In these children, before referral give:
  - Ceftriaxone, IM, 50–80 mg/kg/dose immediately as a single dose

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following injections mixed with water for injection (WFI):</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 2–2.5 kg</td>
<td>125 mg</td>
<td>250 mg WFI 1 mL 0.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 2.5–3.5 kg</td>
<td>200 mg</td>
<td>500 mg WFI 2 mL 1 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 3.5–5.5 kg</td>
<td>250 mg</td>
<td>250 mg WFI 3 mL 1.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>375 mg</td>
<td>≥ 1–3 months</td>
<td></td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>500 mg</td>
<td>625 mg WFI 5 mL 2.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 9–11 kg</td>
<td>625 mg</td>
<td>≥ 12–18 months</td>
<td></td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>750 mg</td>
<td>≥ 18 months–3 years</td>
<td></td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>1 000 mg</td>
<td>≥ 3–5 years</td>
<td></td>
</tr>
<tr>
<td>≥ 17.5 kg and above</td>
<td>1 000 mg</td>
<td>≥ 5 years and adults</td>
<td></td>
</tr>
</tbody>
</table>

! CAUTION!

Do not administer calcium containing fluids, e.g. Ringer-lactate, within 48 hours of administering ceftriaxone.
Contra-indicated in neonatal jaundice.
Annotate the dosage and route of administration in the referral letter.
2.10 Helminthic infestation

2.10.1 Helminthic infestation, tapeworm

**Description**
Infestation with tapeworm occurs after eating infected, undercooked or raw meat like beef or pork.
Infestation may be caused by:
- beef tapeworm – *Taenia saginata*
- pork tapeworm – *Taenia solium*

**Signs and symptoms include:**
- vague abdominal pain
- diarrhoea
- weight loss
- flat white worm segments seen in the stool (blunt ended)
- anal (nocturnal) itch

**General measures**
- Health education on adequate preparation of potentially infected meat.

**Drug treatment**
- If the patient has diarrhoea, wait for it to settle.
  - Albendazole, oral, daily for three days
    - Children under 2 years: 200 mg
    - Children over 2 years and adults: 400 mg

**Referral**
- Abdominal tenderness or pain
- Abdominal masses
- Vomiting
Chapter 2  
Gastro-intestinal conditions

2.10.2 Helminthic infestation, excluding tapeworm

B82.0

Description

Types of worm infestation and the characteristics are shown in the table below. Check for anaemia and failure to thrive. The infestations are often asymptomatic.

<table>
<thead>
<tr>
<th>Type of worm</th>
<th>Description</th>
<th>Signs and symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Roundworm</td>
<td>Ascaris lumbricoides</td>
<td></td>
</tr>
<tr>
<td></td>
<td>» Long pink/white worms with sharp ends</td>
<td>» Cough</td>
</tr>
<tr>
<td></td>
<td>» Up to 25–30 cm long</td>
<td>» If there is vomiting consider intestinal obstruction</td>
</tr>
<tr>
<td></td>
<td>» Often seen in the stools and vomitus</td>
<td></td>
</tr>
<tr>
<td>Pinworm</td>
<td>Enterobius vermicularis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>» White and thread-like</td>
<td>» Anal itching – worse at night</td>
</tr>
<tr>
<td></td>
<td>» Up to 10 mm long</td>
<td>» Sleeplessness</td>
</tr>
<tr>
<td></td>
<td>» Often seen in the stools</td>
<td></td>
</tr>
<tr>
<td></td>
<td>» Self-infection common</td>
<td></td>
</tr>
<tr>
<td>Hookworm</td>
<td>Necator americanus</td>
<td></td>
</tr>
<tr>
<td></td>
<td>» Up to 8 mm long</td>
<td>» No symptoms or pain</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» Anaemia</td>
</tr>
<tr>
<td>Threadworm</td>
<td>Strongyloides stercoralis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>» Very small, up to 4 mm long</td>
<td>» No obvious symptoms</td>
</tr>
<tr>
<td></td>
<td>» Very rare</td>
<td></td>
</tr>
<tr>
<td>Whipworm</td>
<td>Trichuris trichiura</td>
<td></td>
</tr>
<tr>
<td></td>
<td>» Up to 5 cm long</td>
<td>» No symptoms</td>
</tr>
<tr>
<td></td>
<td>» Anterior half thinner than posterior half</td>
<td>» Abdominal pain</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» Diarrhoea</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» Possible anaemia and rectal prolapse</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» Abdominal discomfort</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» Weight loss</td>
</tr>
</tbody>
</table>

General measures

» Patient counseling and education.
» Wash hands with soap and water, particularly:
   – after passing a stool
   – before working with food or eating
» Keep fingernails short.
» Wash fruit and vegetables well or cook.
» Keep toilet seats clean.
» Teach children to use toilets and wash hands.
» Do not pollute the soil with sewage or sludge.
» Dispose of faeces properly.
Chapter 2  Gastro-intestinal conditions

Drug treatment

- Mebendazole, oral,
  - Children 1–2 years: 100 mg 12 hourly for three days
  - Children > 2 years and adults: 500 mg as a single dose

For *Strongyloides stercoralis* refer for specific therapy.

Referral

» Signs of intestinal obstruction
» Abdominal tenderness
» Pain
» Persistent vomiting

2.11 Irritable bowel syndrome (IBS)

K58
(Synonyms: spastic colon, irritable colon)

Description

Functional bowel disorder: Motility disturbance of the entire GIT resulting in recurrent symptoms of pain, constipation and/or diarrhoea and bloating.

General measures

For patients with an established diagnosis:

» Reassure patient that there is no serious organic disorder.
» High fibre/bran diets may be tried for patients with constipation.
  - warn about temporary increased flatus and abdominal distension.
  - high fibre/bran diets are not effective for GLOBAL IBS (i.e. all symptoms).
» Dietary advice by dietician.

Drug treatment

» Not specifically indicated.
» Based on patients predominant symptoms
» Short-term symptomatic treatment for diarrhoea and/or constipation.

Laxatives only for constipation specific, see Section 2.7: Constipation
Antidiarrhoeals only for diarrhoea specific, see Section 2.8: Diarrhoea
2.12 Typhoid fever

**A01.0**

Note: notifiable condition.

**Description**

A septicaemic illness with fever caused by the micro-organism *Salmonella typhi*. The cause of the fever is difficult to diagnose except in an epidemic. It may present with:

- acute abdomen – See section 2.1: Abdominal pain
- prolonged or high fever in a previously healthy individual
- fever with a slower pulse rate than expected
- headache and convulsions
- constipation during the first week
- diarrhoea may occur later in the illness and may be accompanied by frank bleeding
- confirmation is only by stool culture or blood tests

**Drug treatment**

Treat dehydration if present and refer.

**Referral**

Urgent

- All cases or suspected cases
Chapter 3: Nutritional and blood conditions

3.1 Anaemia
   3.1.1 Anaemia, iron deficiency
   3.1.2 Anaemia, macrocytic or megaloblastic

3.2 Childhood malnutrition, including failure to thrive
   3.2.1 Severe malnutrition
   3.2.2 Failure to thrive or not growing well

3.3 Vitamin A deficiency

3.4 Vitamin B deficiencies
   3.4.1 Pellagra (Nicotinic acid deficiency)
   3.4.2 Pyridoxine (Vitamin B₆ deficiency)
   3.4.3 Thiamine deficiency (Wernicke's encephalopathy and beriberi)
Chapter 3

Nutritional and blood conditions

3.1 Anaemia

E64.9

**Description**
A condition characterised by low haemoglobin, clinically recognised by pallor. It is commonly caused by:
- nutritional deficiency of iron or folate
- chronic systemic diseases
- blood loss (bleeding/haemorrhage) e.g. caused by parasites, ulcers, tumours, excessive menstruation

Other causes include:
- infiltration or replacement of the bone marrow
- abnormal haemoglobin or red cells
- haemolysis

**Diagnosis**

<table>
<thead>
<tr>
<th></th>
<th>Hb less than:</th>
</tr>
</thead>
<tbody>
<tr>
<td>non-pregnant women</td>
<td>11 g/dL</td>
</tr>
<tr>
<td>pregnant women</td>
<td>10 g/dL</td>
</tr>
<tr>
<td>males</td>
<td>12 g/dL</td>
</tr>
<tr>
<td>children 1–5 years</td>
<td>10 g/dL</td>
</tr>
<tr>
<td>children over 5 years</td>
<td>11 g/dL</td>
</tr>
</tbody>
</table>

**Children less than 5 years**
Anaemia is most often due to iron deficiency – See Section 3.1.1. Consider blood loss if the anaemia is severe (Hb less than 7 g/dL).

**In older children and adults**
Request a full blood count.
- If MCV is normal (normocytic):
  - then systemic disease is the likely cause
- If MCV is low (microcytic):
  - then iron deficiency is the likely cause
- If MCV is high (macrocytic):
  - then folate and/or vitamin B$_{12}$ deficiency is the likely cause

**Pregnant women**
See section 6.2.3: Anaemia in pregnancy.

**Referral**
- Unknown cause
- Symptoms of anaemia e.g. palpitations and shortness of breath
- Evidence of cardiac failure
- Signs of chronic disease (first investigate for HIV and TB)
Chapter 3  Nutritional and blood conditions

» Anaemia associated with enlargement of the liver, spleen or lymph nodes
» Signs and symptoms of acute blood loss or bleeding disorder
» Blood in stool or melaena
» Pregnant women over 34 weeks of gestation and a Hb less than 7 g/dL
» Children with Hb less than 6 g/dL (If Hb cannot be done, severe palmar pallor)
» No improvement despite correct treatment

3.1.1 Anaemia, iron deficiency
D50.9

Description
Iron deficiency is a common cause of anaemia in younger children and women of childbearing age.
In pregnancy and during the post-partum period, folate deficiency and/or combined iron or folate deficiency are common.
Diagnosis suggested on a full blood count. In children this is unnecessary unless referral criteria above are present.

Note:
Iron deficiency in adult males and non-menstruating women is generally due to occult blood loss and all cases should be referred.

General measures
» Identify and treat the cause.
» Exclude other causes – see referral criteria in 3.1 above.
» Lifestyle and dietary adjustment.
### Drug treatment

**Children**
- Iron, oral, 1–2 mg/kg/dose of elemental iron 8 hourly with meals

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Dose (mg of elemental iron)</th>
<th>Use one of the following:</th>
<th>Age (Months/years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 3.5–5.5 kg</td>
<td>6 mg</td>
<td>Gluconate syrup 350 mg/5 mL (40 mg elemental iron/5 mL)</td>
<td>0.8 mL</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>8 mg</td>
<td>Lactate drops (25 mg elemental iron/mL)</td>
<td>1 mL</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>16 mg</td>
<td>Sulphate compound tablets BPC 170 mg (± 65 mg elemental iron)</td>
<td>2 mL</td>
</tr>
<tr>
<td>≥ 9–25 kg</td>
<td>20 mg</td>
<td>–</td>
<td>2.5 mL</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>40 mg</td>
<td>–</td>
<td>5 mL</td>
</tr>
<tr>
<td>≥ 35 kg and above</td>
<td>65 mg</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Follow up Hb after 14 days.

» If Hb is lower than before – refer,

» If same or higher – continue treatment and repeat after another 14 days.

Continue treatment for 3 months after Hb is normal

**Empiric treatment for worms (this will not treat tapeworm):**
- Mebendazole, oral,
  - Children 1–2 years: 100 mg 12 hourly for three days
  - Children > 2 years and adults: 500 mg as a single dose

**Adults**
- Ferrous sulphate compound BPC, oral, 170 mg three times daily with food

Follow up at monthly intervals.
The expected response is an increase in Hb of 2 g/dL or more in 4 weeks.
Continue for 3–6 months after Hb is normal to replenish body iron stores

! **CAUTION!**
Iron is extremely toxic in overdose, particularly in children.
All medication should be stored out of reach of children.

**Prophylaxis**
Infants from 6 weeks of life:
If < 2.5 kg at birth:
- Ferrous lactate, oral, 0.3 mL daily until 6 months of age
3.1.2 Anaemia, macrocytic or megaloblastic

**Description**

Anaemia with large red blood cells may be due to folate or vitamin $B_{12}$ deficiency. Folate deficiency is common in pregnant women. Vitamin $B_{12}$ deficiency occurs mainly in older adults, and can cause neurological damage if not treated. Special investigations are required to confirm the diagnosis, except in pregnant women – See section 6.2.3: Anaemia in pregnancy.

**Investigations**

FBC will confirm macrocytic anaemia.

- MCV will be elevated
- Hb and/or white cell count and/or platelet count reduced

Serum vitamin $B_{12}$ and red cell folate must be done – low values will confirm the diagnosis.

**Note:**

The antiretrovirals, stavudine and zidovudine, both cause elevated MCV, and zidovudine often causes anaemia and/or decreased white cell count. It is not necessary to measure folate and $B_{12}$ if the patient is not anaemic.

**General measures**

- Ensure adequate intake of dietary folate (e.g. liver, eggs, fortified breakfast cereals, lentils, sugar beans and spinach), and vitamin $B_{12}$, (e.g. liver, fish and eggs).
- Reduce alcohol intake.

**Drug treatment**

Folic acid deficiency:

- Folic acid, oral, 5 mg daily until Hb is normal.
  - Check Hb monthly

**Referral**

- All patients with suspected macrocytic anaemia, for investigation and treatment, except in pregnancy and lactating women who should be treated for folate deficiency.
Chapter 3 Nutritional and blood conditions

» Patients with B₁₂ deficiency
» Chronic diarrhoea
» Poor response within a month of treatment

3.2 Childhood malnutrition, including failure to thrive (FTT) E46

In all children, check for malnutrition and anaemia:
» plot the weight on the Road to Health Chart
» look at the shape of the weight curve:
  Is the weight curve rising parallel to the reference lines?
  or
  is it flattening?
  or
  is there weight loss?
Look for visible wasting.
Look and feel for oedema of both feet.
Look for palmar pallor, and
Check haemoglobin if anaemia is suspected.

3.2.1 Severe malnutrition E42

Description
Severe malnutrition is defined as a weight-for-age less than 60% of the expected weight, marasmus, or nutritional oedema of both feet (kwashiorkor). According to IMCI classification, severe malnutrition is defined as very low weight.

Clinical presentation:
» Kwashiorkor
  – nutritional oedema associated with skin changes, hepatomegaly and weight usually less than the 3rd percentile for age.
» Marasmus
  – clinical (visible) severe wasting and weight less than 60% of the expected weight for age.
» Marasmic kwashiorkor
  – features of both

All children with severe malnutrition are at risk of complications or death.
Refer urgently!
Stabilise before referral.
Exception
Babies who were premature and are growing parallel to or better than the percentiles, would not be classified as severe malnutrition.

Danger signs in children with severe malnutrition:

» dehydration  »  shock
» lethargy »  weeping skin lesions
» hypothermia »  hypoglycaemia
» jaundice »  refusing feeds

All children with severe malnutrition need stabilisation, followed by urgent referral, as they are at risk of complications or death due to:

» hypothermia
» hypoglycaemia
» infection
» fluid overload leading to heart failure

Initiate treatment while waiting for transport to hospital.

General measures

Prevent or treat hypoglycaemia

» Begin feeding immediately if the child is stable and able to take oral feeds.
  Feed at 15 mL/kg 3 hourly.
  – If the child is hypothermic or hypoglycaemic, feed 10 mL/kg 2 hourly.
  – If oral feeds are refused or not finished, feed via a nasogastric tube
Use expressed breast milk if mother is breastfeeding or any available breast milk substitute.

» Check blood glucose with a finger prick glucose stix test on arrival and 3 hourly.
  If blood glucose under 3 mmol/L in asymptomatic child give whichever of the following is most quickly available:
  – immediate feed, or
  – dextrose 10% (50 mL) or
  – sucrose solution (1 rounded teaspoon of sugar in 3 and a half tablespoons of water)

» Recheck blood sugar in 30 minutes to confirm above 3 mmol/L.
  If hypoglycaemia symptomatic (fits/decreased consciousness) or severe hypoglycaemia (< 1.5 mmol/L) or unresponsive hypoglycaemia give:
  – dextrose water 10% 5 mL/kg IV (1 part 50% dextrose diluted with 4 parts sterile water) and immediately restart feeds.

Prevent or treat hypothermia:

» Measure under-arm temperature 3 hourly.
  Keep child warm using mother-child skin-to-skin contact (Kangaroo care), if mother is present.
  Keep the child dry and covered at all times, especially the head and avoid drafts.
Chapter 3  

Nutritional and blood conditions

If the axillary temperature is below 36°C, warm urgently (use skin to skin contact with mother and wrap both in blankets, if this is not possible clothe and wrap the child in dry warm clothes and blankets and keep near a heater in a warm area). Monitor temperature 2 hourly until more than 36.5°C then resume 3 hourly monitoring.

Drug treatment

![CAUTION!]

In malnutrition if IV fluids are given for severe dehydration/shock, give Sodium chloride 0.9% 10 mL/kg/hour and check for volume overload after each bolus – once stable continue with ORS orally or by nasogastric tube.

Infection

Note:

Signs of infection such as fever are usually absent. Treat for infection while awaiting transfer.

If there are no danger signs – 1st dose while arranging referral to hospital:

- Amoxicillin, oral, 20–30 mg/kg as a single dose

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following syrups</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 2–2.5 kg</td>
<td>62.5 mg</td>
<td>2.5 mL 1.25 mL</td>
<td>34–36 weeks</td>
</tr>
<tr>
<td>≥ 2.5–3.5 kg</td>
<td>100 mg</td>
<td>4 mL 2 mL</td>
<td>Birth–1 month</td>
</tr>
<tr>
<td>≥ 3.5–5.5 kg</td>
<td>125 mg</td>
<td>5 mL 2.5 mL</td>
<td>≥ 1–3 months</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>175 mg</td>
<td>7 mL 3.5 mL</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥ 7–11 kg</td>
<td>250 mg</td>
<td>10 mL 5 mL</td>
<td>≥ 6–18 months</td>
</tr>
<tr>
<td>≥ 11–17.5 kg</td>
<td>375 mg</td>
<td>15 mL 7.5 mL</td>
<td>≥ 18 months–5 years</td>
</tr>
</tbody>
</table>
If the child has any danger signs:

- Ceftriaxone, IM, 50–80 mg/kg/dose immediately as a single dose

### Use one of the following injections mixed with water for injection (WFI):

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>250 mg WFI 2 mL</th>
<th>500 mg WFI 2 mL</th>
<th>1 000 mg WFI 3.5 mL</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 2–2.5</td>
<td>125 mg</td>
<td>1 mL</td>
<td>0.5 mL</td>
<td>–</td>
<td>Birth–1 month</td>
</tr>
<tr>
<td>≥ 2.5–3.5</td>
<td>200 mg</td>
<td>1.6 mL</td>
<td>0.8 mL</td>
<td>–</td>
<td>≥ 1–3 months</td>
</tr>
<tr>
<td>≥ 3.5–5.5</td>
<td>250 mg</td>
<td>2 mL</td>
<td>1 mL</td>
<td>–</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥ 5–7</td>
<td>375 mg</td>
<td>3 mL</td>
<td>1.5 mL</td>
<td>–</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥ 7–9</td>
<td>500 mg</td>
<td>4 mL</td>
<td>2 mL</td>
<td>–</td>
<td>≥ 12–18 months</td>
</tr>
<tr>
<td>≥ 9–11</td>
<td>625 mg</td>
<td>5 mL</td>
<td>2.5 mL</td>
<td>–</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>≥ 11–14</td>
<td>750 mg</td>
<td>6 mL</td>
<td>3 mL</td>
<td>–</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 14–17.5</td>
<td>1 000 mg</td>
<td>–</td>
<td>4 mL</td>
<td>3.5 mL</td>
<td>≥ 5 years and adults</td>
</tr>
<tr>
<td>≥ 17.5 kg and above</td>
<td>1 000 mg</td>
<td>–</td>
<td>4 mL</td>
<td>3.5 mL</td>
<td></td>
</tr>
</tbody>
</table>

**CAUTION!**
Do not administer calcium containing fluids, e.g. Ringer-Lactate, within 48 hours of administering ceftriaxone.

Contra-indicated in neonatal jaundice.

Annotate the dosage and route of administration in the referral letter.

Give an additional dose of Vitamin A:

- Vitamin A (retinol), oral, every 6 months up to the age of 5 years
  - give to neonate at birth if not breast fed
  - if breast fed, give to mother

<table>
<thead>
<tr>
<th>Age range</th>
<th>Dose units</th>
<th>Capsule 50 000 u</th>
<th>Capsule 100 000 u</th>
<th>Capsule 200 000 u</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mother who will breast feed</td>
<td>200 000</td>
<td>–</td>
<td>2 capsule</td>
<td>1 capsule</td>
</tr>
<tr>
<td>Infants 6–11 months old</td>
<td>100 000</td>
<td>2 capsules</td>
<td>1 capsule</td>
<td>–</td>
</tr>
<tr>
<td>Children 12 months to 5 yrs</td>
<td>200 000</td>
<td>–</td>
<td>2 capsule</td>
<td>1 capsule</td>
</tr>
</tbody>
</table>
### 3.2.2 Failure to thrive or not growing well

**Description**

Children and infants who have either:

- unsatisfactory weight gain (growth curve flattening or weight loss) on the Road to Health Chart
- low weight for age, i.e. under the 3rd percentile weight for age but over the 60% expected weight for age

**Note:**

Babies who were premature and growing parallel to or better than the percentiles, should not be classified as failure to thrive or not growing well.

Failure to thrive (FTT) may be due to:

- insufficient food intake due to anorexia and illness or poor availability of food
- insufficient uptake of nutrients, e.g. malabsorption
- insufficient use of nutrients for growth due to chronic disease
- an increased demand for nutrients due to illness such as TB

Conduct a feeding and clinical assessment to determine the cause and exclude anaemia.

**General measures**

- Counselling on nutrition.
- Nutritional supplementation should be supplied unless there is a correctable cause.

**Drug treatment**

- Multivitamin, oral, daily

**Empiric treatment for worms (this will not treat tapeworm):**

- Mebendazole, oral,
  - Children 1–2 years: 100 mg 12 hourly for three days
  - Children > 2 years and adults: 500 mg as a single dose

- Vitamin A (retinol), oral, every 6 months up to the age of 5 years
  - give to neonate at birth if not breast fed
  - if breast fed, give to mother

<table>
<thead>
<tr>
<th>Age range</th>
<th>Dose units</th>
<th>Capsule 100 000 u</th>
<th>Capsule 200 000 u</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mother who will breast feed</td>
<td>200 000</td>
<td>2 capsules</td>
<td>1 capsule</td>
</tr>
<tr>
<td>Infants 6–11 months old</td>
<td>100 000</td>
<td>1 capsule</td>
<td>–</td>
</tr>
<tr>
<td>Children 12 months to 5 yrs</td>
<td>200 000</td>
<td>2 capsules</td>
<td>1 capsule</td>
</tr>
</tbody>
</table>
Chapter 3  

Nutritional and blood conditions

Anaemia
See section 3.1: Anaemia

Referral
- No response to treatment
- All children other than those with insufficient food intake
- Severe malnutrition

3.3 Vitamin A deficiency
E50.9

Description
A condition predominantly affecting the skin, mucous membranes and the eyes. It is most common in children of 1 to 5 years. If associated with measles and diarrhoea there is an increased risk of illness and death. If not identified and treated early, it can cause blindness.

Clinical features include:
- Night blindness or inability to see in the dark
- Bitot's spot or white foamy patches on the eye
- Conjunctival xerosis or the conjunctiva becomes dry
- Corneal xerosis or the cornea becomes dry
- Keratomalacia or wrinkling and cloudiness of cornea
- Corneal ulceration or the cornea becomes soft and bulges

General measures
Dietary supplementation with vitamin A rich food including:
- Fortified maize meal and/or bread
- Carrots, sweet potato, mangoes and pawpaw
- Dark green leafy vegetables e.g. morogo/imifino and spinach
- Liver, eggs, full cream milk and fish
**Drug treatment**

**Prophylaxis**
- Vitamin A (retinol), oral, every 6 months up to the age of 5 years
  - give to neonate at birth if not breast fed
  - if breast fed, give to mother

<table>
<thead>
<tr>
<th>Age range</th>
<th>Dose units</th>
<th>Capsule 100 000 u</th>
<th>Capsule 200 000 u</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mother who will breast feed</td>
<td>200 000</td>
<td>2 capsules</td>
<td>1 capsule</td>
</tr>
<tr>
<td>Infants 6–11 months old</td>
<td>100 000</td>
<td>1 capsule</td>
<td>–</td>
</tr>
<tr>
<td>Children 12 months to 5 yrs</td>
<td>200 000</td>
<td>2 capsules</td>
<td>1 capsule</td>
</tr>
</tbody>
</table>

**Note:**
A high-dose vitamin A capsule can be given to post-partum women up to 8 weeks after delivery if the mother is breastfeeding, or within 6 weeks if she is not breastfeeding.

**Treatment**

Children 0–5 years with:
- severe under nutrition
- persistent diarrhoea
- any of the clinical signs of vitamin A deficiency
- measles

Older children and adults with:
- any clinical signs of vitamin A deficiency
- measles

- Vitamin A (retinol), oral, every 6 months up to the age of 5 years
  - give to neonate at birth if not breast fed
  - if breast fed, give to mother

<table>
<thead>
<tr>
<th>Age range</th>
<th>Dose units</th>
<th>Capsule 50 000 u</th>
<th>Capsule 100 000 u</th>
<th>Capsule 200 000 u</th>
</tr>
</thead>
<tbody>
<tr>
<td>Newborn – not breast fed</td>
<td>50 000</td>
<td>1 capsule</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Newborn – breast fed</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Mother who will breast feed</td>
<td>200 000</td>
<td>–</td>
<td>2 capsules</td>
<td>1 capsule</td>
</tr>
<tr>
<td>Infants 6–11 months old</td>
<td>100 000</td>
<td>2 capsules</td>
<td>1 capsule</td>
<td>–</td>
</tr>
<tr>
<td>Children 12 months to 5 yrs</td>
<td>200 000</td>
<td>–</td>
<td>2 capsules</td>
<td>1 capsule</td>
</tr>
</tbody>
</table>

**Administration of a vitamin A capsule**
- Cut the narrow end of the capsule with scissors
- Open the child’s mouth by gently squeezing the cheeks
- Squeeze the drops from the capsule directly into the back of the child’s mouth. If a child spits up most of the vitamin A liquid immediately, give one more dose.
- Mothers can swallow the capsule with water
- Do **NOT** give the capsule to the mother or the caretaker to take home
Chapter 3  

Nutritional and blood conditions

Note:
» Children suffering from measles or clinical vitamin A deficiency should receive a repeat dose the following day.
» Children who received a prophylactic dose within the previous month should not receive the treatment dose of vitamin A.
» If a child is scheduled to receive a routine prophylactic dose of vitamin A and has received a treatment dose within the past month, postpone the routine dose for approximately one month.
» Wait at least one month between doses.
» Children receiving routine multivitamin syrup can still receive routine vitamin A supplements.

Referral
» All complicated cases

3.4 Vitamin B deficiencies

3.4.1 Pellagra (nicotinic acid deficiency)

Description
Pellagra is a condition associated with nicotinic acid deficiency. It is usually accompanied by other vitamin deficiencies.

Clinical features include:
» diarrhoea
» dementia
» dermatitis with darkening of sun-exposed skin
Chapter 3  Nutritional and blood conditions

**General measures**

» Lifestyle adjustment.
» Patient counselling.
» Discourage alcohol abuse.

**Drug treatment**

**Children**

- Nicotinamide, oral, 100 mg 8 hourly

**Adults**

- Nicotinamide, oral, 100 mg 8 hourly

**Referral**

» Failure to respond

### 3.4.2 Pyridoxine (Vitamin B₆) deficiency

**E53.1**

**Description**

Commonly presents assigns of peripheral neuropathy including:

» tingling sensation
» burning pain or numbness of the feet

Pyridoxine deficiency is related to:

» malnutrition
» alcoholism
» isoniazid or combination TB therapy

**Drug treatment**

**Children**

- Pyridoxine, oral, 50–200 mg daily for 3 weeks

**Adults**

- Pyridoxine, oral, 200 mg daily for 3 weeks

Then follow with:

- Pyridoxine, oral, 25 mg daily as a maintenance dose (for patients on TB therapy/isoniazid)

**Referral**

» Failure to respond
» Children
3.4.3 Thiamine deficiency (Wernicke’s encephalopathy and beriberi)

E53.9

Description
Clinical features include:
» confusion
» short term memory loss
» paralysis of one or more of the ocular muscles or ophthalmoplegia
» nystagmus
» ataxia
» peripheral neuropathy
» cardiac failure

Alcoholics may present with Wernicke’s encephalopathy, neuropathies or cardiac failure associated with multiple vitamin deficiencies.

General measures
» Lifestyle adjustment.

Drug treatment
Peripheral neuropathy and cardiac failure (wet beriberi):
• Thiamine, oral, 100 mg daily

In susceptible patients, administration of intravenous glucose precipitates Wernicke’s encephalopathy if administered before thiamine supplementation. Thiamine should be given first in all patients treated with intravenous glucose who are at risk of thiamine deficiency, e.g. alcoholics.

Patients presenting with encephalopathy or eye muscle paralysis
• Thiamine, IM, 100 mg
Followed by:
• Dextrose 5 %, IV

Referral
» All patients with encephalopathy, eye muscle paralysis or cardiac failure
Chapter 4: Cardiovascular conditions

4.1 Prevention of ischaemic heart disease and atherosclerosis
4.2 Angina pectoris, unstable
4.3 Angina pectoris, stable
4.4 Cardiac arrest, cardiopulmonary resuscitation
4.5 Cardiac failure, congestive (CCF)
  4.5.1 Cardiac failure, congestive (CCF), adults
  4.5.2 Cardiac failure, congestive (CCF), children
4.6 Myocardial infarction, acute (AMI)
4.7 Hypertension
  4.7.1 Hypertension in adults
  4.7.2 Hypertension in children
4.8 Pulmonary oedema, acute
4.9 Rheumatic fever, acute
4.10 Valvular heart disease and congenital structural heart disease
4.1 Prevention of ischaemic heart disease and atherosclerosis

Major risk factors for ischaemic cardio- and cerebrovascular disease

- diabetes mellitus
- hypertension
- central obesity: waist circumference ≥ 102 cm (men) and ≥ 88 cm (women)
- smoking
- dyslipidaemia:
  - total cholesterol > 6.5 mmol/L, or
  - LDL > 4 mmol/L, or
  - HDL < 1 mmol/L in men and < 1.2 mmol/L in women
- family history of premature cardiovascular disease in male relatives less than 55 years and in female relatives less than 65 years
- age: men > 55 years, women > 65 years

General measures

Lifestyle modification

All persons with risk factors for ischaemic heart disease should be encouraged to make the following lifestyle changes as appropriate:

- maintain ideal weight, i.e. BMI < 25
- weight reduction in the overweight patient, i.e. BMI > 25
- reduce alcohol intake to no more than 2 standard drinks/day
- follow a prudent eating plan i.e. low fat, high fibre and unrefined carbohydrates, with adequate fresh fruit and vegetables
- regular moderate aerobic exercise, e.g. 30 minutes brisk walking 3–5 times/week
- smoking cessation

Calculation of absolute risk of myocardial infarction over 10 years (in the absence of ischaemic heart disease and monogenetic dyslipidaemia)

To derive the absolute risk as percentage of subjects who will have a myocardial infarction over 10 years: Add the points for each risk category (men – section A; women – section B). The risk associated with the total points is then derived from section C (for men and women).
### Chapter 4 Cardiovascular conditions

#### Section A: Men

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–34</td>
<td>–1</td>
</tr>
<tr>
<td>35–39</td>
<td>0</td>
</tr>
<tr>
<td>40–44</td>
<td>1</td>
</tr>
<tr>
<td>45–49</td>
<td>2</td>
</tr>
<tr>
<td>50–54</td>
<td>3</td>
</tr>
<tr>
<td>55–59</td>
<td>4</td>
</tr>
<tr>
<td>60–64</td>
<td>5</td>
</tr>
<tr>
<td>65–69</td>
<td>6</td>
</tr>
<tr>
<td>70–74</td>
<td>7</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total cholesterol</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 4.1 mmol/L</td>
<td>–3</td>
</tr>
<tr>
<td>4.2–5.2</td>
<td>0</td>
</tr>
<tr>
<td>5.3–6.2</td>
<td>1</td>
</tr>
<tr>
<td>6.3–7.2</td>
<td>2</td>
</tr>
<tr>
<td>&gt; 7.2</td>
<td>3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HDL cholesterol</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 0.91 mmol/L</td>
<td>2</td>
</tr>
<tr>
<td>0.91–1.16</td>
<td>1</td>
</tr>
<tr>
<td>1.17–1.29</td>
<td>0</td>
</tr>
<tr>
<td>1.3–1.55</td>
<td>0</td>
</tr>
<tr>
<td>&gt; 1.55</td>
<td>–2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Blood pressure*</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 120 / &lt; 80</td>
<td>0</td>
</tr>
<tr>
<td>120–129 / 80–84</td>
<td>0</td>
</tr>
<tr>
<td>130–139 / 85–89</td>
<td>1</td>
</tr>
<tr>
<td>140–159 / 90–99</td>
<td>2</td>
</tr>
<tr>
<td>≥ 160 / ≥ 100</td>
<td>3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-smoker</td>
<td>0</td>
</tr>
<tr>
<td>Smoker</td>
<td>2</td>
</tr>
<tr>
<td>Not diabetic</td>
<td>0</td>
</tr>
<tr>
<td>Diabetic</td>
<td>2</td>
</tr>
</tbody>
</table>

#### Section B: Women

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–34</td>
<td>–9</td>
</tr>
<tr>
<td>35–39</td>
<td>–4</td>
</tr>
<tr>
<td>40–44</td>
<td>0</td>
</tr>
<tr>
<td>45–49</td>
<td>3</td>
</tr>
<tr>
<td>50–54</td>
<td>6</td>
</tr>
<tr>
<td>55–59</td>
<td>7</td>
</tr>
<tr>
<td>60–64</td>
<td>8</td>
</tr>
<tr>
<td>65–69</td>
<td>8</td>
</tr>
<tr>
<td>70–74</td>
<td>8</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total cholesterol</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 4.1 mmol/L</td>
<td>–2</td>
</tr>
<tr>
<td>4.2–5.2</td>
<td>0</td>
</tr>
<tr>
<td>5.3–6.2</td>
<td>1</td>
</tr>
<tr>
<td>6.3–7.2</td>
<td>1</td>
</tr>
<tr>
<td>&gt; 7.2</td>
<td>3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HDL cholesterol</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 0.91 mmol/L</td>
<td>5</td>
</tr>
<tr>
<td>0.91–1.16</td>
<td>2</td>
</tr>
<tr>
<td>1.17–1.29</td>
<td>1</td>
</tr>
<tr>
<td>1.3–1.55</td>
<td>0</td>
</tr>
<tr>
<td>&gt; 1.55</td>
<td>–3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Blood pressure*</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 120 / &lt; 80</td>
<td>–3</td>
</tr>
<tr>
<td>120–129 / 80–84</td>
<td>0</td>
</tr>
<tr>
<td>130–139 / 85–89</td>
<td>0</td>
</tr>
<tr>
<td>140–159 / 90–99</td>
<td>2</td>
</tr>
<tr>
<td>≥ 160 / ≥ 100</td>
<td>3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-smoker</td>
<td>0</td>
</tr>
<tr>
<td>Smoker</td>
<td>2</td>
</tr>
<tr>
<td>Not diabetic</td>
<td>0</td>
</tr>
<tr>
<td>Diabetic</td>
<td>4</td>
</tr>
</tbody>
</table>

* Use the highest reading of either diastolic or systolic pressure (mmHg).
**Section C: Risk** (% of cohort defined by the score who will have a myocardial infarction in 10 years)

| Total points | -2 | -1 | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 |
|--------------|----|----|---|---|---|---|---|---|---|---|---|---|----|----|----|----|----|----|----|
| Men (%)      | 2  | 3  | 3 | 4 | 5 | 7 | 8 | 10| 13| 16| 20| 25| 31| 37| 45| >53|    |    |    |    |
| Women (%)    | 1  | 2  | 2 | 3 | 3 | 4 | 4 | 5 | 6 | 7 | 8 | 10| 11| 13| 15| 18| 20| 24| >27|

The score is gender dependent: for example, 6 points for men and 10 for women both have a 10% risk.

**Drug treatment**

**Indication for Lipid Lowering Drug Therapy**

- Established atherosclerotic disease:
  - ischaemic heart disease
  - peripheral vascular disease
  - atherothrombotic stroke

**Note:**
Lipid lowering drugs should be administered in this setting even if the cholesterol is normal.

- Type 2 diabetics

**Note:**
Lipid lowering drugs should be administered in this setting even if the cholesterol is normal.

- A risk of MI of greater than 20% in 10 years (see table above)

**Note:**
Lipid lowering therapy should only be commenced in this group if the dyslipidaemia is not corrected with lifestyle modification.

- Such high-risk patients will benefit from lipid lowering (statin) therapy irrespective of their baseline LDL-C levels.

**Note:**
When lipid-lowering drugs are used, this is ALWAYS in conjunction with ongoing lifestyle modification.

HMGCoA reductase inhibitors (statins) that lower LDL by at least 25%, e.g.:
- Simvastatin, oral, 10 mg daily

**Referral**

- Random cholesterol >7.5 mmol/L
- Fasting triglycerides >10 mmol/L
4.2 Angina pectoris, unstable

Description

Unstable angina is a medical emergency and if untreated can progress to myocardial infarction.

Presents as chest pain or discomfort similar to stable angina but with the following additional characteristics:

- angina at rest or minimal effort
- angina occurring for the first time, particularly at rest
- prolonged angina lasting longer than 10 minutes and is not relieved by sublingual nitrates
- the pattern of angina accelerates and gets worse

Diagnosis

- made from good history
- ECG may show ST segment depression or transient ST segment elevation
- a normal ECG does not exclude the diagnosis

Drug treatment

- Oxygen 40% via facemask
- Aspirin soluble, oral, 150 mg immediately.
- Isosorbide dinitrate, sublingual, 5 mg immediately and then repeat once if necessary for pain relief
- Morphine, IV, 5–10 mg
  - Dilute IV morphine to 10 mL with water for injection or sodium chloride 0.9%.

This is a high-risk condition for CVD and is an indication for a statin for patients with proven lesions.

HMGCoA reductase inhibitors, e.g.:

- Simvastatin, oral, 10 mg/day.
  - This therapy requires good initial evaluation, ongoing support for patients and continuous evaluation to ensure compliance.
  - Random cholesterol should be measured at baseline.
  - If < 7.5 mmol/L – initiate therapy.
  - If > 7.5 mmol/L – initiate therapy and refer for further assessment.

Therapy should be initiated together with appropriate lifestyle modification and adherence monitoring.
Chapter 4  Cardiovascular conditions

Referral
Urgent
» All patients

4.3 Angina pectoris, stable

Description
Characteristic chest pain due to myocardial ischaemia usually occurring on exercise and relieved by rest.

General measures
» Life style modification.
» Intensive health education.
» Modify reversible risk factors.

Drug treatment
Long-term prophylaxis for thrombosis:
• Aspirin soluble, oral, 150 mg daily
plus
Nitrates, short acting e.g.:
• Isosorbide dinitrate, sublingual, 5 mg
  o May be repeated if required at 5-minute intervals for 3 or 4 doses.
plus
STEP 1
• Atenolol, oral, 50–100 mg daily
  o Titrate to resting heart rate of approximately 60 beats per minute.

If β-blocker cannot be tolerated or is contraindicated, consider long acting calcium channel blocker.

STEP 2
add
Long acting calcium channel blocker e.g.:
• Amlodipine, oral, 5 mg daily
  or
  Nifedipine, oral, slow release 30 mg daily

STEP 3
add
• Isosorbide mononitrate, oral, 10–20 mg 12 hourly
  or
  Isosorbide dinitrate, oral, 20–40 mg, 12 hourly
  o At 8:00 and 14:00 hours for both drugs in order to provide a nitrate free period to prevent tolerance.
Chapter 4  Cardiovascular conditions

- Modify for night shift workers.

This is a high-risk condition for CVD and is an indication for a statin for patients with proven lesions.
HMGCoA reductase inhibitors, e.g.:
- Simvastatin, oral, 10 mg/day.
  This therapy requires good initial evaluation, ongoing support for patients and continuous evaluation to ensure compliance.
Therapy should be initiated together with appropriate lifestyle modification and adherence monitoring.

Referral
» When diagnosis is in doubt
» Failed medical therapy

4.4 Cardiac arrest, cardio-pulmonary resuscitation
(See Chapter 21 – Trauma and emergencies)
I46.9

4.5 Cardiac failure, congestive (CCF)
I50.0

4.5.1 Cardiac failure, congestive (CCF), adults
I50.0

Description
CCF is a clinical syndrome and has several causes. The cause and immediate precipitating factor(s) of the CCF must be identified and treated to prevent further damage to the heart.

Signs and symptoms include:
» dyspnoea (breathlessness)
» tachypnoea (breathing rate more than 18 in men and more than 20 in women)
» inspiratory basal crackles or crepitations on auscultation of the lungs
» fatigue
» ankle swelling with pitting oedema
» raised jugular venous pressure
» tachycardia
» enlarged liver, often tender
Chapter 4  Cardiovascular conditions

General measures
» Monitor body weight to assess changes in fluid balance
» Salt (sodium chloride) restriction to less than 2–3 g per day
» Regular exercise within limits of symptoms

Drug treatment
All patients need to be assessed by a doctor for initiation or change of treatment.

Many of the drugs used can affect renal function and electrolytes. Monitor sodium, potassium and serum creatinine.

STEP 1: Diuretic plus ACE inhibitor
Mild volume overload (mild CCF) and normal renal function – thiazide diuretic
- Hydrochlorothiazide, oral, 25–50 mg daily
  - Contraindication:
    - gout
    - severely impaired liver function
    - severely impaired renal function

Significant volume overload or abnormal renal function – loop diuretic
- Furosemide, oral, daily. (Doctor initiated)
  - Initial dose: 40 mg
  - Maximum dose: 80 mg
  - Higher dosages may be needed if also renal failure
  - Once failure has improved, consider switching to hydrochlorothiazide
  - Monitor electrolytes and creatinine

Acute pulmonary oedema
- Furosemide, IV
See section 21.15: Pulmonary oedema, acute

Note:
» Reduce diuretic dose when ACE inhibitor is introduced
» Routine use of potassium supplements with diuretics is not recommended. They should only be used short term to correct documented low serum potassium level

All patients with CCF, unless contraindicated or poorly tolerated ACE inhibitor, e.g.:
- Enalapril up to maximum of 10 mg twice daily
  - Titrate dosages gradually upwards until an optimal dose is achieved
  - Absolute contraindications include: (also see package insert)
    - cardiogenic shock
    - bilateral renal artery stenosis or stenosis of an artery to a single
kidney, aortic valve stenosis and hypertrophic obstructive cardiomyopathy
- pregnancy
- angioedema with previous use of ACE inhibitors or angiotensin receptor blockers

STEP 2: Add spironolactone, only if serum potassium can be monitored

- Spironolactone, oral, 25 mg daily

<table>
<thead>
<tr>
<th>CAUTION!</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spironolactone can cause severe hyperkalemia and should only be used when serum potassium can be monitored.</td>
</tr>
<tr>
<td>Do not use together with potassium supplements.</td>
</tr>
<tr>
<td>Do not use in kidney failure.</td>
</tr>
</tbody>
</table>

STEP 3: Carvedilol (alpha 1 and non-selective beta blocker) unless contraindicated. (See package insert for full prescribing information)

- Carvedilol, oral
  - Starting dose: 3.125 mg twice daily.
  - Increase at two-weekly intervals by doubling the daily dose until maximum of 25 mg twice daily, if tolerated.
  - If not tolerated, i.e. worsening of cardiac failure manifestations, reduce the dose to the previously tolerated dose.
  - Up-titration can take several months.
  - Absolute contraindications include: (also see package insert)
    - patients with cardiogenic shock, bradycardia, various forms of heart block
    - severe fluid overload
    - hypotension
    - asthma

Note:
Do not use atenolol for cardiac failure.

STEP 4: Refer

Symptomatic CCF despite above therapy

- Digoxin, oral, 0.125 mg daily
  - Patients in whom plasma levels should be monitored:
    - the elderly
    - patients with poor renal function
    - low body weight

People with CCF on diuretics may become hypokalaemic.
Digoxin therapy should not be initiated if the patient is hypokalaemic.
Chapter 4  Cardiovascular conditions

Referral

Urgent
» Patients with prosthetic heart valve
» Suspected infective endocarditis
» Fainting spells

Referral
» Initial assessment and initiation of treatment
» Poor response to treatment and symptomatic

4.5.2 Cardiac failure, congestive (CCF), children

I50.0

Description
Congestion of the systemic or pulmonary venous systems due to cardiac dysfunction of various different causes and is often mistaken for respiratory infection.

Many conditions including congenital heart disease and acquired cardiac and lung conditions (such as cor-pulmonale due to bronchiectasis in HIV positive children) can cause cardiac failure in children.

Signs and symptoms

Infants
» rapid breathing
» chest indrawing
» crackles or crepitations in lungs
» rapid heart rate
» cardiomegaly
» active cardiac impulse
» enlarged tender liver

It often presents primarily with shortness of breath, difficulty in feeding and sweating during feeds. Oedema is usually not an obvious feature.

Children
» rapid breathing
» chest indrawing
» crackles or crepitation in lungs
» rapid heart rate
» active and displaced cardiac impulse
» enlarged tender liver
» oedema of the lower limbs or lower back
Chapter 4  Cardiovascular conditions

General measures
While arranging transfer:

- Oxygen, using nasal canula at 2–3 L per minute
  - or
- Oxygen 40%, using face mask at 2–3 L per minute
  » Semi-Fowlers position

Note:
If hypertensive, consider glomerulonephritis in children.

Drug treatment
While arranging transfer:
If CCF is strongly suspected
- Furosemide, IV, 1 mg/kg immediately. Do not put up a drip or run in any IV fluids

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Dose (mg)</th>
<th>Injection (10 mg/mL)</th>
<th>Age (Months/years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 3.5–5 kg</td>
<td>4 mg</td>
<td>0.4 mL</td>
<td>≥1–3 months</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>6 mg</td>
<td>0.6 mL</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>8 mg</td>
<td>0.8 mL</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥ 9–11 kg</td>
<td>10 mg</td>
<td>1 mL</td>
<td>≥12–18 months</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>12 mg</td>
<td>1.2 mL</td>
<td>≥18 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>15 mg</td>
<td>1.5 mL</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>20 mg</td>
<td>2 mL</td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>30 mg</td>
<td>3 mL</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>≥ 35 kg and above</td>
<td>40 mg</td>
<td>4 mL</td>
<td>≥ 11 years and adults</td>
</tr>
</tbody>
</table>

Referral
» All children with suspected congestive cardiac failure

4.6 Myocardial infarction, acute (AMI)
I21.9

Description
AMI is caused by the complete or partial occlusion of a coronary artery and requires prompt hospitalisation and intensive care management.
The major clinical feature is severe chest pain with the following characteristics:
» site – retrosternal or epigastric
» quality – crushing or burning pain or discomfort
» radiation – to the neck and/or down the inner part of the left arm
Chapter 4 Cardiovascular conditions

- duration – at least 20 minutes and often not responding to sublingual nitrates.
- occurs at rest

and may be associated with:

- pallor
- sweating
- arrhythmias
- pulmonary oedema
- a drop in blood pressure

Note:
Not all features have to be present.

Emergency treatment before transfer

- Cardiopulmonary resuscitation if necessary (See section 21.4: Cardiac arrest – cardiopulmonary resuscitation)
  - Oxygen, 40%, by facemask

  - Aspirin soluble, oral, 150 mg as a single dose as soon as possible
  - plus
    - Isosorbide dinitrate, sublingual, 5 mg, every 5–10 minutes as needed for relief of pain to a maximum of 5 tablets.
  - plus
    - Morphine 15 mg diluted with 14 ml of water for injection or normal saline, slow IV. (Doctor initiated.)
      - Start with 2–3 mg thereafter slowly increase by 1 mg/minute up to 10–15 mg.
      - Can be repeated after 4–6 hours if necessary, for pain relief.
      - Beware of hypotension
  - plus
    - Only for confirmed ST-elevation myocardial infarction or new LBBB and if patient presents within 6 hours of onset of pain:
      - Streptokinase, IV, 1.5 million IU diluted in 100 mL dextrose 5% or sodium chloride 0.9% and given over 30–60 minutes. (Doctor initiated.)
        - Start as soon as possible after diagnosis is made, preferably within the first 3 hours.

Contraindications
- known bleeding disorder
- stroke within last 6 months or any previous haemorrhagic stroke
- GIT bleeding within last 3 months or peptic ulcer
- recent major trauma, surgery or head injury.
- streptokinase given within past 1 year or known allergy to it.

! CAUTION!
Blood pressure may decrease and pulse rate may increase after administration of streptokinase.
Do not stop streptokinase when there is a drop in blood pressure. However, discontinue streptokinase if patient shows manifestations of impending shock.
Chapter 4  Cardiovascular conditions

Monitor continuously and also during transfer:
» pulse
» blood pressure
» respiration depth and rate (count for a full minute)

Aftercare
This is a high-risk condition for CVD and is an indication for a statin for patients with proven lesions.
HMG-CoA reductase inhibitors, e.g.:
• Simvastatin, oral, 10 mg daily.
This therapy requires good initial evaluation, ongoing support for patients and continuous evaluation to ensure compliance.
Random cholesterol should be measured at baseline.
If < 7.5 mmol/L – initiate therapy.
If > 7.5 mmol/L – initiate therapy and refer for further assessment.
Therapy should be initiated together with appropriate lifestyle modification and adherence monitoring.

Referral
Urgent
» All suspected or diagnosed cases

4.7 Hypertension

4.7.1 Hypertension in adults

Description
A condition characterised by a blood pressure (BP) elevated above normal measured on three separate occasions, a minimum of 2 days apart. However, when blood pressure is severely elevated (see table), a minimum of 3 blood pressure readings must be taken at the first visit to confirm hypertension. Ensure that the correct cuff size is used in obese patients.
» Systolic BP equal to or more than 140 mmHg.
   and/or
» Diastolic BP equal to or more than 90 mmHg
Chapter 4  Cardiovascular conditions

LEVELS OF HYPERTENSION IN ADULTS

<table>
<thead>
<tr>
<th>Level of hypertension</th>
<th>Systolic mmHg</th>
<th>Diastolic mmHg</th>
</tr>
</thead>
<tbody>
<tr>
<td>mild</td>
<td>140 – 159</td>
<td>90 - 99</td>
</tr>
<tr>
<td>moderate</td>
<td>160 – 179</td>
<td>100 – 109</td>
</tr>
<tr>
<td>severe</td>
<td>180 or more</td>
<td>110 or more</td>
</tr>
</tbody>
</table>

» Achieve and maintain the target BP
   – In most cases the target BP should be: systolic below 140 mmHg and diastolic below 90 mmHg.
» Achieve target BP in special cases as:
   – In diabetic patients and patients with cardiac or renal impairment, target BP should be below 130/80 mmHg

General measures
All patients with hypertension require lifestyle modification:
» weight loss if overweight
» regular physical exercise
» stop smoking
» moderate or no alcohol intake
» restrict salt intake
» restrict fat intake
» adequate dietary fibre intake (fruit, vegetable and unrefined carbohydrate)

Drug treatment
Initial drug choices in patients qualifying for treatment is dependent on presence of compelling indications.

Drug treatment choices without compelling indications

Mild hypertension
When there are no risk factors and there is poor response to lifestyle modification measures after 3 months, initiate drug therapy.

Moderate hypertension
Initiate drug therapy as well as lifestyle modification after confirmation of diagnosis.

Presence of risk factors
Drug therapy as well as lifestyle modification, should be initiated after confirmation of diagnosis
Chapter 4  Cardiovascular conditions

Special cases
Pregnancy-induced hypertension:
• Methyldopa, oral, 250–500 mg, 6–8 hourly, only during pregnancy

Hypertension urgency
Systolic BP above 240 mmHg, diastolic BP above 140 mmHg without symptoms of target organ damage:
» initiate treatment at step 3

Stroke
Blood pressure is normally elevated in acute stroke and should only be treated if it persists for more than two days or is severely elevated.
Diastolic BP above 130 mmHg.
Reduce gradually.

Elderly
In patients without co-existing disease, initiate drug treatment only when systolic BP above 160 and diastolic above 90 mmHg.

Note:
Check adherence to medication before escalating therapy.
Monitor patients monthly and adjust therapy if necessary until the BP is stable.
After target BP is achieved, patients may be seen at 3–6 monthly intervals.

! CAUTION !
Lower BP over a few days.
A sudden drop in BP can be dangerous, especially in the elderly.

Stepwise treatment without compelling indications

STEP 1

<table>
<thead>
<tr>
<th>Entry to Step 1</th>
<th>Treatment</th>
<th>Target</th>
</tr>
</thead>
</table>
| » Diastolic BP 90 – 99 mmHg and/or systolic BP 140 – 159 mmHg without any existing disease and
  » No major risk factors                                                        | » Lifestyle modification   | » BP control within 3 months to systolic BP below 140 and
diastolic below 90 mmHg                     |
## Chapter 4  Cardiovascular conditions

### STEP 2

<table>
<thead>
<tr>
<th>Entry to Step 2</th>
<th>Treatment</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diastolic BP 90 – 99 mmHg and systolic BP 140 – 159 mmHg without any existing disease and No major risk factors and Failure of lifestyle modification alone to reduce BP after 3 months or Mild hypertension with major risk factors or existing disease or Moderate hypertension at diagnosis</td>
<td>Lifestyle modification and Hydrochlorothiazide, oral, 12.5 mg daily</td>
<td>BP control within 1 month to systolic BP below 140 and diastolic below 90 mmHg</td>
</tr>
</tbody>
</table>

### STEP3

<table>
<thead>
<tr>
<th>Entry to Step 3</th>
<th>Treatment</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Failure to achieve targets in Step 2 after 1 month despite adherence to therapy or Severe hypertension (See table)</td>
<td>Lifestyle modification and Hydrochlorothiazide, oral, 12.5 mg daily and ACE-inhibitor, e.g.: enalapril, 10 mg daily add Long acting calcium channel blocker, e.g.: amlodipine, oral 5 mg daily</td>
<td>BP control within 1 month to systolic BP below 140 and diastolic below 90 mmHg</td>
</tr>
</tbody>
</table>
### Chapter 4  Cardiovascular conditions

#### STEP 4

<table>
<thead>
<tr>
<th>Entry to Step 4</th>
<th>Treatment</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>» Failure of step 3 after 1 month of compliance</td>
<td>» Lifestyle modification and • Hydrochlorothiazide, oral, 12.5 mg daily and • ACE-inhibitor, e.g.: enalapril, increase to 10–20 mg daily and • Long acting calcium channel blocker, e.g.: amlodipine, oral, 5 mg daily</td>
<td>» BP control within 1 month to systolic BP below 140 and diastolic below 90 mmHg with no side-effects</td>
</tr>
</tbody>
</table>

#### STEP 5

<table>
<thead>
<tr>
<th>Entry to Step 5</th>
<th>Treatment</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>» Failure of step 4 after 1 month of compliance</td>
<td>» Lifestyle modification and • Hydrochlorothiazide, oral, increase to 25 mg daily and • ACE-inhibitor, e.g. enalapril, 20 mg daily and • Long acting calcium channel blocker, e.g. amlodipine, oral 10 mg daily and add: • Atenolol, oral, 50 mg daily</td>
<td></td>
</tr>
</tbody>
</table>

If not controlled on step 5 – Refer to Chapter 4 Cardiovascular conditions
### Chapter 4  Cardiovascular conditions

<table>
<thead>
<tr>
<th>Compelling indications for specific drugs</th>
<th>Drug class</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angina</td>
<td>• ß-blocker or Long acting calcium channel blocker</td>
</tr>
<tr>
<td>Prior myocardial infarct</td>
<td>• ß-blocker and • ACE inhibitor</td>
</tr>
<tr>
<td>Heart failure</td>
<td>• ACE inhibitor and • Carvedilol For volume overload: • Loop diuretic</td>
</tr>
<tr>
<td>Left ventricular hypertrophy (confirmed by ECG)</td>
<td>• ACE inhibitor</td>
</tr>
<tr>
<td>Stroke: secondary prevention</td>
<td>• Hydrochlorothiazide and • ACE inhibitor</td>
</tr>
<tr>
<td>Diabetes type 1 and 2 with or without evidence of microalbuminuria or proteinuria</td>
<td>• ACE inhibitor, usually in combination with diuretic</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>• ACE inhibitor, usually in combination with diuretic</td>
</tr>
<tr>
<td>Isolated systolic hypertension</td>
<td>• Hydrochlorothiazide or Long acting calcium channel blocker</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>• Methyldopa</td>
</tr>
</tbody>
</table>

### Contraindications to individual drugs

**Hydrochlorothiazide**
- gout
- pregnancy
- severe liver failure
- renal failure

**Beta-adrenergic blocking agent e.g. atenolol**

**Absolute:**
- asthma
- chronic obstructive airways disease

**Relative:**
- heart failure (not carvedilol)
- diabetes mellitus
- peripheral vascular disease
- bradycardia: pulse rate less than 50 per minute
Chapter 4  Cardiovascular conditions

ACE inhibitors
» pregnancy
» bilateral renal artery stenosis
» aortic valve stenosis
» history of angioedema

! CAUTION !
Advise all patients receiving ACEI about the symptoms of angioedema

Calcium channel blockers
» heart failure

Referral
» Young adults (under 30 years)
» BP not controlled by four drugs and where there is no doctor available.
» Pregnancy
» Signs of target organ damage, such as oedema, dyspnoea, proteinuria, angina etc.
» If severe side effects develop

HYPERTENSIVE EMERGENCY

Description
A marked elevated blood pressure systolic BP ≥ 180 mmHg and/or a diastolic BP above 130 mmHg associated with one or more of the following:
» unstable angina/chest pain
» neurological signs, e.g. severe headache, visual disturbances, confusion, coma or seizures
» pulmonary oedema
» renal failure

Drug treatment
• Amlodipine, oral, 10 mg immediately as a single dose

If pulmonary oedema:
• Furosemide, IV, 40 mg as a single dose

! CAUTION !
A hypertensive emergency needs immediate referral to hospital.

Referral
Urgent
» All patients
4.7.2 Hypertension in children

Description

In children, the diagnosis of hypertension is based on weight or height. Hypertension is defined as systolic and/or diastolic blood pressure ≥ the 95th percentile for gender, age and height percentile on at least three consecutive occasions. See table below.

The choice of appropriate cuff size is important. Too small a cuff for the arm leads to falsely high BP. The cuff bladder must encircle at least 80% of the upper arm and should cover at least 75% of the distance between the acromion and the olecranon. It is better to use a cuff that is slightly too large than one that is too small. Large cuffs, if covered with linen-like material, can be folded to the appropriate size in smaller infants as long as the bladder encompasses the arm.

Infants and preschool-aged children are almost never diagnosed with essential hypertension and are most likely to have secondary forms of hypertension.

With age, the prevalence of essential hypertension increases, and after age 10 it becomes the leading cause of elevated BP. Obesity currently is emerging as a common comorbidity of essential hypertension in paediatric patients, often manifesting during early childhood.

Diagnosis

95th Percentile of Systolic and Diastolic BP relation to age of child

<table>
<thead>
<tr>
<th>Age of child</th>
<th>Systolic mmHg</th>
<th>Diastolic mmHg</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 weeks–6 years</td>
<td>115</td>
<td>80</td>
</tr>
<tr>
<td>8 years</td>
<td>120</td>
<td>82</td>
</tr>
<tr>
<td>9 years</td>
<td>125</td>
<td>84</td>
</tr>
<tr>
<td>10 years</td>
<td>130</td>
<td>86</td>
</tr>
<tr>
<td>12 years</td>
<td>135</td>
<td>88</td>
</tr>
<tr>
<td>14 years</td>
<td>140</td>
<td>90</td>
</tr>
</tbody>
</table>

or

95th Percentile of Systolic and Diastolic BP relation to height of child

<table>
<thead>
<tr>
<th>Height cm</th>
<th>Systolic mmHg</th>
<th>Diastolic mmHg</th>
</tr>
</thead>
<tbody>
<tr>
<td>100</td>
<td>114</td>
<td>70</td>
</tr>
<tr>
<td>110</td>
<td>116</td>
<td>72</td>
</tr>
<tr>
<td>120</td>
<td>118</td>
<td>74</td>
</tr>
<tr>
<td>130</td>
<td>120</td>
<td>74</td>
</tr>
<tr>
<td>140</td>
<td>125</td>
<td>75</td>
</tr>
<tr>
<td>150</td>
<td>130</td>
<td>75</td>
</tr>
<tr>
<td>160</td>
<td>135 (131)</td>
<td>77</td>
</tr>
<tr>
<td>170</td>
<td>140 (133)</td>
<td>80</td>
</tr>
<tr>
<td>180</td>
<td>145 (135)</td>
<td>83</td>
</tr>
</tbody>
</table>

(Girls 95th percentile given in brackets).
Chapter 4  Cardiovascular conditions

Referral

» All cases with BP above the 95th percentile

4.8 Pulmonary oedema, acute
(See Chapter 21 - Trauma and emergencies)
J81

4.9 Rheumatic fever, acute
I01.9

Note: notifiable condition.

Description
A condition in which the body develops antibodies against its own tissues following a streptococcal throat infection. Effective treatment of streptococcal pharyngitis can markedly reduce the occurrence of this disease. Commonly occurs in children between 3 and 15 years of age.

Clinical signs and symptoms include:
» arthralgia or arthritis that may shift from one joint to another
» carditis including cardiac failure
» heart murmurs
» subcutaneous nodules
» erythema marginatum
» chorea (involuntary movements of limbs or face)
» other complaints indicating a systemic illness e.g. fever

Drug treatment

Eradication of streptococci in throat
• Benzathine benzylpenicillin, IM, single dose
  o Children under 30 kg:  600 000 IU
  o Children over 30 kg and adults:  1.2 MU
or
Adults and children
• Phenoxyethylpenicillin, oral, 500 mg 12 hourly for 10 days

Penicillin–allergic patients:
• Erythromycin, oral, 6 hourly before meals for 10 days
  o Children 125 mg
  o Adults  250 mg

Prophylaxis for rheumatic fever
All patients with confirmed rheumatic fever and no rheumatic valvular disease
• Benzathine benzylpenicillin, IM, every 21–28 days (3–4 weeks) until the age of 21 years
Chapter 4  Cardiovascular conditions

All patients with confirmed rheumatic fever and rheumatic valvular disease
- Benzathine benzylpenicillin, IM, every 21–28 days (3–4 weeks) until the age of 35 years
  - Children under 30 kg: 600 000 IU
  - Children over 30 kg and adults: 1.2 MU

  !CAUTION!
  IM injections must be avoided if patients are on warfarin

or

Phenoxymethylpenicillin, oral, 12 hourly
  - Children 1–6 years: 125 mg
  - Children > 6 years and adults: 250 mg

Penicillin–allergic patients:
- Erythromycin, oral, 12 hourly before meals
  - Children: 125 mg
  - Adults: 250 mg

Referral
» All patients for diagnosis and management

4.10 Valvular heart disease and congenital structural heart disease
I09.9

Description
Damage to heart valves, chamber or vessel wall anomalies caused by rheumatic fever and by other causes, e.g. congenital heart defects and ischaemic heart disease.
It may be complicated by:
» heart failure
» infective endocarditis
» atrial fibrillation
» systemic embolism

General measures
» Advise all patients with a heart murmur with regard to the need for prophylaxis treatment prior to undergoing certain medical and dental procedures
» Advise patients to inform health care providers of the presence of the heart murmur when reporting for medical or dental treatment
Drug treatment

Prophylaxis antibiotic treatment for infective endocarditis
» should be given prior to certain invasive diagnostic and therapeutic procedures e.g. tooth extraction, to prevent infective endocarditis
» is essential for all children with congenital or rheumatic heart lesions needing dental extraction

Dental extraction if no anaesthetic is required
- Amoxicillin, oral, 50 mg/kg with a ceiling dose of 2 000 mg, 1 hour before the procedure
  - Repeat dose 6 hours later

<table>
<thead>
<tr>
<th>Age</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than 5 years</td>
<td>750 mg</td>
</tr>
<tr>
<td>5 to 10 years</td>
<td>1 500 mg</td>
</tr>
<tr>
<td>10 years and older</td>
<td>2 000 mg</td>
</tr>
</tbody>
</table>

If allergic to penicillin:
» Refer

If anaesthetic is required:
» Refer

Prophylaxis for rheumatic fever
See section 4.9: Rheumatic fever, acute

Referral
» All patients with heart murmurs for assessment
» All patients with heart murmurs not on a chronic management plan
» Development of cardiac signs and symptoms
» Worsening of clinical signs and symptoms of heart disease
» Any newly developing medical condition, e.g. fever
» All patients with valvular heart disease for advice on prophylactic antibiotic treatment prior to any invasive diagnostic or therapeutic procedure
Chapter 5: Skin Conditions

5.1 Dry skin
5.2 Itching (pruritus)
5.3 Acne vulgaris
5.4 Bacterial infections of the skin
   5.4.1 Boil, abscess
   5.4.2 Impetigo
   5.4.3 Cellulitis
5.5 Fungal infections of the skin
   5.5.1 Athlete's foot – tinea pedis
   5.5.2 Candidiasis, skin
   5.5.3 Ringworm and other tineas
5.6 Parasitic infections of the skin
   5.6.1 Lice (pediculosis)
   5.6.2 Scabies
5.7 Eczema
   5.7.1 Eczema, atopic
   5.7.2 Eczema, acute, moist or weeping
   5.7.3 Dermatitis, seborrhoeic
5.8 Nappy rash
5.9 Sandworm
5.10 Urticaria
5.11 Pityriasis rosea
5.12 Molluscum contagiosum
5.13 Herpes simplex
5.14 Herpes Zoster
5.15 Warts
   5.15.1: Common warts
   5.15.2: Plane warts
   5.15.3: Plantar warts
   5.15.4: Filiform warts
   5.15.5: Genital warts: Condylomata accuminata
5.1 Dry Skin

Description
The skin is dry and rough, together with varying degrees of scaling. Severe forms are mainly inherited, e.g. ichthyosis. Milder forms (xeroderma) are common in chronic conditions, e.g. HIV disease, malignancies and atopic eczema, and are seen as dryness with only slight scaling.

Drug treatment
- Emulsifying ointment (UE), to wash or bath.
- Aqueous cream (UEA), applied to dry areas as a moisturiser and for maintenance treatment.

5.2 Itching (pruritus)

Description
Itching may:
» be localised or generalised
» be accompanied by obvious skin lesions
» accompany many systemic diseases, e.g. hepatitis
» be caused by scabies and insect bites

General measures
» Lukewarm baths.
» Trim fingernails.

Drug treatment
- Calamine lotion, applied when needed.
or
In infants:
- Aqueous cream (UEA), applied when needed.
Chapter 5

Severe or refractory pruritus
- Chlorpheniramine, oral, 0.1 mg/kg/dose 6–8 hourly

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 9–11 kg</td>
<td>1 mg</td>
<td>2.5 mL</td>
<td>≥ 12–18 months</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>1.2 mg</td>
<td>3 mL</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>1.5 mg</td>
<td>4 mL</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>2 mg</td>
<td>5 mL</td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>3 mg</td>
<td>7.5 mL</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>4 mg</td>
<td>1 tablet</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>4 mg</td>
<td>1 tablet</td>
<td>≥ 15 years and adults</td>
</tr>
</tbody>
</table>

Note:
Chlorpheniramine is sedating and in mild cases may be used only at night.

For long term use in adults and school going children, e.g. for chronic pruritus
- Cetirizine, oral, once daily at night

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months / years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 14–25 kg</td>
<td>5 mg</td>
<td>5 mL</td>
<td>≥ 3–7 years</td>
</tr>
<tr>
<td>≥ 25–55 kg</td>
<td>10 mg</td>
<td>10 mL 1 tablet</td>
<td>≥ 7–15 years</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>10 mg</td>
<td>1 tablet</td>
<td>≥ 15 years and adults</td>
</tr>
</tbody>
</table>

! CAUTION !
Do not give an antihistamine to children under 6 months.

Referral
» No improvement after 2 weeks.

5.3 Acne vulgaris
L70.0

Description
A skin condition that is caused by hormones and sebum gland hypertrophy leading to a blocking and/or infection of the follicles with Propionibacterium acnes.
Occurs more commonly in adolescence but may also occur in adulthood.
It is distributed on face, chest and back.
It ranges in severity from mild, with a few blackheads, to severe with nodules and cysts. Severe forms are common in HIV disease and itching may be a feature.

**General measures**
- Do not squeeze lesions.
- Avoid greasy cosmetics and hair spray.

**Drug treatment**
**Many pustules**
- Benzoyl peroxide 5%, gel, apply at night.
- Doxycycline, oral, 100 mg daily for 3 months.

<table>
<thead>
<tr>
<th>!CAUTION!</th>
</tr>
</thead>
<tbody>
<tr>
<td>As doxycycline impairs the efficacy of oral contraceptives, barrier contraception should be used in addition.</td>
</tr>
</tbody>
</table>

**Referral**
- No improvement after 3 months
- Development of severe complications e.g. deep pustules
- Severe cases of nodular acne

### 5.4 Bacterial infections of the skin

#### 5.4.1 Boil, abscess

**L02.9**

**Description**
Localised bacterial skin infection of hair follicles or dermis, usually with *S. aureus*.
The surrounding skin becomes:
- swollen
- red
- hot
- tender to touch

**Note:**
Check blood glucose level if diabetes suspected or if the boils are recurrent. Boils in diabetic or immunocompromised patients require careful management.

**General measures**
- Encourage general hygiene.
Apply local hot compresses three times daily until the boil/abscess starts draining.

Drainage of abscess is the treatment of choice. Perform surgical incision only after the lesion is mature.

**Drug treatment**

*Systemic antibiotics are seldom necessary, except if there are:*

- swollen lymph nodes in the area
- fever
- extensive surrounding cellulitis

- **Flucloxacillin, oral, 12–25 mg/kg/dose 6 hourly for 5 days**

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Dose (mg)</th>
<th>Use one of the following:</th>
<th>Age (Months / years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 2.5–5 kg</td>
<td>62.5 mg</td>
<td>Syrup 125 mg/5 mL</td>
<td>Birth–3 months</td>
</tr>
<tr>
<td>≥ 5–11 kg</td>
<td>125 mg</td>
<td>Capsule 250 mg</td>
<td>≥ 3–18 months</td>
</tr>
<tr>
<td>≥ 11–25 kg</td>
<td>250 mg</td>
<td>10 mL</td>
<td>≥ 18 months–7 years</td>
</tr>
<tr>
<td>≥ 25 kg and above</td>
<td>500 mg</td>
<td>2 capsules</td>
<td>≥ 7 years and adults</td>
</tr>
</tbody>
</table>

*Penicillin–allergic patients*

- **Erythromycin, oral, 10–15 mg/kg/dose 6 hourly**

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Dose (mg)</th>
<th>Use one of the following:</th>
<th>Age (Months / years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 2.5–3.5 kg</td>
<td>35 mg</td>
<td>Syrup 125 mg/5 mL</td>
<td>Birth–1 month</td>
</tr>
<tr>
<td>≥ 3.5–5 kg</td>
<td>50 mg</td>
<td>Tablets 250 mg</td>
<td>≥ 1–3 months</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>75 mg</td>
<td>2 mL</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>100 mg</td>
<td>3 mL</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥ 9–11 kg</td>
<td>125 mg</td>
<td>4 mL</td>
<td>≥ 12–18 months</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>150 mg</td>
<td>5 mL</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>200 mg</td>
<td>6 mL</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>250 mg</td>
<td>8 mL</td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>375 mg</td>
<td>1 tablet</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>≥ 35 kg and above</td>
<td>500 mg</td>
<td>2 tablets</td>
<td>≥ 11 years and adults</td>
</tr>
</tbody>
</table>

**Referral**

- No response to treatment
- Progression of the condition
5.4.2 Impetigo

**Description**
A common skin infection due to streptococci or staphylococci that occurs mainly in children.
Clinical features include:
» purulent sores with crusts or scabs
» pain
» usually starts on the face
» spreading to neck, hands, arms and legs

**Note:**
Check urine for blood if the sores have been present for more than a week.

**General measures**
» Prevent infection by keeping breaks in the skin clean.
» Avoid insect bites.
» Trim finger nails.
» Wash and soak sores in soapy water to soften and remove crusts.
» Advise on the importance of washing daily.
» Continue with general measures until the sores are completely healed.

**Drug treatment**
- Povidone iodine 5%, cream, apply three times daily
- Amoxicillin, oral, 10–20 mg/kg 8 hourly for 5 days

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 2–2.5 kg</td>
<td>50 mg</td>
<td>2 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 2.5–3.5 kg</td>
<td>62.5 mg</td>
<td>2.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 3.5–5 kg</td>
<td>75 mg</td>
<td>3 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>125 mg</td>
<td>5 mL</td>
<td>2.5 mL</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>150 mg</td>
<td>6 mL</td>
<td>3 mL</td>
</tr>
<tr>
<td>≥ 9–11 kg</td>
<td>187.5 mg</td>
<td>7.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 11–17.5 kg</td>
<td>250 mg</td>
<td>10 mL</td>
<td>5 mL</td>
</tr>
<tr>
<td>≥ 17.5–20 kg</td>
<td>375 mg</td>
<td>15 mL</td>
<td>7.5 mL</td>
</tr>
<tr>
<td>≥ 20–55 kg</td>
<td>500 mg</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>&gt;55 kg and above</td>
<td>500 mg</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>
If no response:
- Flucloxacillin, oral, 12–25 mg/kg/dose 6 hourly for 5 days

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months / years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Syrup 125 mg/5 mL</td>
<td>Tablets 250 mg</td>
</tr>
<tr>
<td>≥ 2.5–5 kg</td>
<td>62.5 mg</td>
<td>2.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 5–11 kg</td>
<td>125 mg</td>
<td>5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 11–25 kg</td>
<td>250 mg</td>
<td>10 mL</td>
<td>–</td>
</tr>
<tr>
<td>&gt; 25–55 kg</td>
<td>500 mg</td>
<td>–</td>
<td>2 capsules</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>500 mg</td>
<td>–</td>
<td>2 capsules</td>
</tr>
</tbody>
</table>

Penicillin–allergic patients
- Erythromycin, oral, 10–15 mg/kg/dose 6 hourly

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months / years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Syrup 125 mg/5 mL</td>
<td>Tablets 250 mg</td>
</tr>
<tr>
<td>≥ 2.5–3.5 kg</td>
<td>35 mg</td>
<td>1.4 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 3.5–5 kg</td>
<td>50 mg</td>
<td>2 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>75 mg</td>
<td>3 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>100 mg</td>
<td>4 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 9–11 kg</td>
<td>125 mg</td>
<td>5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>150 mg</td>
<td>6 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 14–17.5</td>
<td>200 mg</td>
<td>8 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>250 mg</td>
<td>10 mL</td>
<td>1 tablet</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>375 mg</td>
<td>15 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 35 kg and above</td>
<td>500 mg</td>
<td>–</td>
<td>2 tablets</td>
</tr>
</tbody>
</table>

In patients with improvement but not complete cure, a further 5-day course of antibiotics should be given.

**Referral**

» No improvement in 10 days
» Presence of blood on urine test strip for longer than 5 – 7 days
» Clinical features of glomerulonephritis – See Section 8.3.1: Glomerular disease – Nephritic syndrome

**5.4.3 Cellulitis**

L03.9

**Description**

A skin infection that is usually caused by streptococci, but also staphylococci and occasionally other organisms.
Chapter 5  
Skin Conditions

A diffuse, spreading, acute infection within skin and soft tissues, characterised by:
  » oedema
  » increased local temperature
  » redness
  » no suppuration
Occurs commonly on the lower legs, but may occur elsewhere. May follow minor trauma. It is frequently associated with lymphangitis and regional lymph node involvement. There may be significant systemic manifestations of infection:
  » fever
  » chills
  » tachycardia
  » hypotension
  » delirium/altered mental state
May present as an acute fulminant or chronic condition.

Drug treatment

- Flucloxacillin, oral, 12–25 mg/kg/dose 6 hourly for 5 days
  - 10 days for more severe infection

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months / years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 2.5–5 kg</td>
<td>62.5 mg</td>
<td>Syrup 125 mg/5 mL</td>
<td>Capsules 250 mg</td>
</tr>
<tr>
<td>≥ 5–11 kg</td>
<td>125 mg</td>
<td>2.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 11–25 kg</td>
<td>250 mg</td>
<td>5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 25–55 kg</td>
<td>500 mg</td>
<td>10 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>500 mg</td>
<td>–</td>
<td>2 capsules</td>
</tr>
</tbody>
</table>

Penicillin–allergic patients

- Erythromycin, oral, 10–15 mg/kg/dose 6 hourly

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months / years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 2.5–3.5 kg</td>
<td>35 mg</td>
<td>Syrup 125 mg/5 mL</td>
<td>Tablets 250 mg</td>
</tr>
<tr>
<td>≥ 3.5–5 kg</td>
<td>50 mg</td>
<td>1.4 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>75 mg</td>
<td>2 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>100 mg</td>
<td>3 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 9–11 kg</td>
<td>125 mg</td>
<td>4 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>150 mg</td>
<td>5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>200 mg</td>
<td>6 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>250 mg</td>
<td>8 mL</td>
<td>1 tablet</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>375 mg</td>
<td>10 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 35 kg and above</td>
<td>500 mg</td>
<td>–</td>
<td>2 tablets</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>500 mg</td>
<td>–</td>
<td>2 tablets</td>
</tr>
</tbody>
</table>
Chapter 5  
Skin Conditions

Severe cases  
Refer for parenteral antibiotics

Referral  
» Children when associated with significant pain, swelling or loss of function - refer urgently to exclude osteomyelitis  
» Extensive cellulitis  
» Necrosis  
» Recurrent cellulitis associated with underlying conditions, e.g. lymphoedema  
» Cellulitis with systemic manifestations, e.g. confusion, hypotension  
» Inadequate response to initial antibiotic treatment  
» Poorly controlled diabetic patients

5.5 Fungal infections of the skin  
B35

5.5.1 Athlete’s foot – tinea pedis  
B35.3

Description  
A common contagious fungal infection (tinea) of the foot characterised by itching, burning and stinging between the toes spreading to the sole. Secondary eczema of the hands may be an associated condition. Vesicles may occur in inflammatory cases. Reinfection is common.

General measures  
» Discourage the use of shared bathing or swimming areas until healed.  
» Use own towels and toiletries.  
» Keep feet dry:  
  – wear open shoes or sandals  
  – do not wear socks of synthetic material  
  – dry between toes after washing the feet or walking in water  
  – wash and dry feet twice daily before applying treatment

Drug treatment  
• Imidazole cream, e.g. clotrimazole 2%, applied twice daily for 4 weeks.

Referral  
» Severe infection  
» Involvement of the nails  
» No improvement after 4 weeks
Chapter 5

5.5.2 Candidiasis, skin

Vaginal candidiasis: See section 12.2: Vaginal discharge syndrome

**Description**

A skin infection caused by *C. albicans*.

Most common sites for infection are skin folds such as:

» under the breasts
» perineum
» axilla
» nail folds
» groin

The skin lesions or sores:

» appear moist (weeping)
» may have peripheral white pustules and scales
» have clear edges
» are red raw-looking patches

**Note:**

Infection often occurs in immunocompromised patients.

Suspect HIV if the infection is severe or chronic.

Exclude diabetes.

**Drug treatment**

- Imidazole cream, e.g. clotrimazole 2% cream, applied three times daily for 14 days

**Referral**

» No response to topical treatment

5.5.3 Ringworm and other tineas

**Description**

A highly contagious fungal infection of the skin that can be found anywhere on the body.

Clinical features include:

» itchy ringlike patches
» raised borders
» patches slowly grow bigger

As the patch extends a clear area develops in the center which may become
hyperpigmented in dark skin.
Extensive disease is common in HIV.

**General measures**

» Prevent spreading the infection to others.
» Do not share:
  – clothes
  – towels
  – toiletries, especially combs and hair brushes
» Wash skin well and dry before applying treatment.

**Drug treatment**
Treat any secondary skin infection with antibiotics – See section 5.4.2: Impetigo

- Imidazole, e.g. clotrimazole 2% cream, topical, applied 3 times daily.
  - Continue using cream for at least 2 weeks after lesions have cleared.

**For scalp infections (Doctor initiated):**
- Fluconazole, oral, 5–8 mg/kg for 28 days

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 7–11 kg</td>
<td>50 mg</td>
<td>1 capsule</td>
<td>≥ 6–18 months</td>
</tr>
<tr>
<td>≥ 11–25 kg</td>
<td>100 mg</td>
<td>2 capsules</td>
<td>≥ 18 months–7 years</td>
</tr>
<tr>
<td>≥ 25–55 kg</td>
<td>150 mg</td>
<td>3 capsules</td>
<td>≥ 7–15 years</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>200 mg</td>
<td>– 1 capsule</td>
<td>≥ 15 years and adults</td>
</tr>
</tbody>
</table>

**Note:**
Do not give to women of child-bearing age unless they are using an effective contraceptive.

**Tinea versicolor**
Oral antifungal therapy is not indicated.
- Selenium sulphide shampoo
  - Apply daily to body for 3 days.
  - Leave on for 30 minutes then wash off.

**Referral**
» Infection is widespread
» No response to treatment for scalp lesions
5.6 Parasitic infections of the skin

5.6.1 Lice (pediculosis)  
B85.2

Description
An infestation of the hairy parts of the body with lice.  
Head lice are common in children. The eggs (nits) appear as fixed white specks on the hair.  
Body lice live in the seams of clothing and only come to the skin to feed.

Clinical features include:  
» itching  
» bite marks  
» presence of secondary eczema and secondary infection

Note:
Body lice may carry typhus fever.

General measures
Head lice
» Wash hair.  
» Use a fine comb to comb out the nits after washing hair.  
» Shave the head. This may not be necessary if permethrin rinse is used.  
» Prevent spread by treating other contacts.  
» Remove nits manually from eyelashes.

Body lice
» Do not shave the pubic area.  
» Prevent spread by treating other contacts.  
» Regularly wash bed linen and underclothes in hot water and expose to sunlight.

Drug treatment

<table>
<thead>
<tr>
<th>! CAUTION !</th>
</tr>
</thead>
</table>
| Do not use commercial insect sprays as they are toxic.  
Lotions used for the treatment of lice are toxic when swallowed. |

Head lice
- Permethrin 1% cream rinse, applied after washing hair with shampoo.  
  o Rinse off after 10 minutes.  

Note:  
  o Do not apply to broken skin or sores.  
  o Avoid contact with eyes.
Chapter 5  Skin Conditions

Body lice
Adults and adolescent children:

- Benzyl benzoate 25% lotion, undiluted, applied over the whole body.
  - Leave on overnight and wash off the next day.
  - Repeat once a week for up to 3 weeks.

  **Note:**
  - **Do not** apply to neck and face.
  - Avoid contact with eyes and broken skin or sores.
  - The lotion is toxic if swallowed.
  - Itching may continue for 2–3 weeks after treatment.
  - Do not continue if a rash or swelling develops.

Antibiotic treatment for secondary infection
See section 5.4.2: Impetigo

**Referral**
» Lice infestation of eyelashes in children to exclude inappropriate sexual contact (suspected sexual abuse)

5.6.2 Scabies

**Description**
An infestation with the parasite *Sarcoptes scabei*. Most commonly occurs in the skin folds. The infestation spreads easily and usually affects more than one person in the household.

Clinical features include:
» intense itching, which is more severe at night
» the presentation of small burrows between fingers, toes, elbow areas and skin folds where the parasite has burrowed under the skin
» secondary infection which may occur due to scratching with dirty nails

**General measures**
All close contacts must be treated simultaneously even if they are not itchy – see drug treatment below.
» Cut finger nails and keep them clean.
» Wash all linen and underclothes in hot water.
» Expose all bedding to direct sunlight.
» Put on clean, washed clothes after drug treatment.
Drug treatment

Adults and children over 6 years:
- Benzyl benzoate 25% lotion, applied undiluted to the whole body from the neck to the feet on two consecutive days.
  - Leave on overnight and wash off the next day.
  - Note:
    - Benzyl benzoate is toxic if swallowed.
    - Itching may continue for 2–3 weeks after treatment.
    - Do not continue if rash or swelling develops
    - Avoid contact with eyes and broken skin or sores

If benzyl benzoate is unsuccessful:
- Sulphur 5% ointment, applied daily for 3 days

Children under 6 years:
- Sulphur 5% ointment, applied daily for 3 days
  - Note:
    - Itching may continue for 2–3 weeks after treatment.
    - Do not continue if rash or swelling develops
    - Avoid contact with eyes and broken skin or sores

Treatment may need to be repeated after one week.

Antibiotic treatment for secondary infection
See section 5.4.2: Impetigo

5.7 Eczema

5.7.1 Eczema, atopic
L20.9/B00.0

Description
An itchy red rash or dry rough skin linked to allergy.
In babies it appears at approximately 3 months.
A family history of asthma, hay fever or atopic dermatitis is common.
Clinical features:
» occurs on the inner (flexural) surfaces of the elbows and knees, the face and creases of the neck
» can become chronic with thickened scaly skin (lichenification)
» secondary bacterial infection may occur with impetigo or pustules
» can be extensive in infants
» very itchy at night
Eczema is usually a chronic condition and requires long term care.
Sufferers of atopic eczema are particularly susceptible to herpes simplex infection
and may present with large areas of involvement with numerous vesicles and crusting surrounded by erythema (eczema herpeticum).

**General measures**

- Avoid wearing clothes made from wool.
- Avoid overheating by blankets at night.
- Cut nails short.
- Avoid scratching.
- Avoid perfumed soap.

**Drug treatment**

**STEP 1**
- Emulsifying ointment (UE), to wash or bath
- Aqueous cream (UEA), applied to dry areas as a moisturiser

**STEP 2**
If no response within seven days or more severe eczema:
- Hydrocortisone 1% cream, applied twice daily for 7 days
  - Apply sparingly to the face.
  - Do not apply around the eyes.

If there is a response:
Reduce the use of the hydrocortisone cream over a few days and maintain treatment with:
- Aqueous cream (UEA)
  - or
  - Emulsifying ointment (UE)

**STEP 3**
If no response within seven days or more severe eczema:
- Potent topical corticosteroids, e.g. betamethasone 0.1% ointment applied twice daily for 7 days (Doctor initiated)
  - Do not apply to face, neck and flexures

If there is a response:
Reduce the use of the hydrocortisone cream over a few days and maintain treatment with:
- Aqueous cream (UEA)
  - or
  - Emulsifying ointment (UE)
Chapter 5  

Skin Conditions

For itching not controlled with topical treatment:
- Chlorpheniramine, oral, 0.1 mg/kg/dose 6–8 hourly

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 9–11 kg</td>
<td>1 mg</td>
<td>Syrup 2 mg/5 mL</td>
<td>≥ 12–18 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tablet 4 mg</td>
<td></td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>1.2 mg</td>
<td>2.5 mL</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>1.5 mg</td>
<td>3 mL</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>2 mg</td>
<td>4 mL</td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>3 mg</td>
<td>5 mL</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>4 mg</td>
<td>7.5 mL</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>4 mg</td>
<td>–</td>
<td>≥ 15 years and adults</td>
</tr>
</tbody>
</table>

Note:
Chlorpheniramine is sedating and in mild cases may be used only at night.

For long term use in adults and school going children:
- Cetirizine, oral, once daily at night

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months / years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 14–25 kg</td>
<td>5 mg</td>
<td>Syrup 1 mg/L</td>
<td>≥ 3–7 years</td>
</tr>
<tr>
<td>≥ 25–55 kg</td>
<td>10 mg</td>
<td>10 mL</td>
<td>≥ 7–15 years</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>10 mg</td>
<td>–</td>
<td>Adults</td>
</tr>
</tbody>
</table>

For eczema herpeticum:
- Aciclovir, oral, 8 hourly for 10 days
  - Paediatric dose: 250 mg/m²/dose

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 3.5–7 kg</td>
<td>80 mg</td>
<td>Syrup 200 mg/5 mL</td>
<td>≥ 1–6 months</td>
</tr>
<tr>
<td>≥ 7–11 kg</td>
<td>100 mg</td>
<td>2.5 mL</td>
<td>≥ 6–18 months</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>120 mg</td>
<td>3 mL</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>≥ 14–25 kg</td>
<td>160 mg</td>
<td>4 mL</td>
<td>≥ 3–7 years</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>200 mg</td>
<td>5 mL</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>300 mg</td>
<td>7.5 mL</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>400 mg</td>
<td>–</td>
<td>≥ 15 years and adults</td>
</tr>
</tbody>
</table>
Chapter 5  

Skin Conditions

Referral
» No improvement in 2 weeks
» Infants requiring more than 1% hydrocortisone

5.7.2 Eczema, acute, moist or weeping
L21.9

Description
A form of eczema with microscopic or large vesicles, associated with oozing and eventual crusting and scaling.

General measures
» Sodium chloride 0.9% dressings, applied daily or twice daily
» Avoid use of soap on affected areas

Drug treatment
Antibiotic treatment for staphylococcal secondary infection:
• Flucloxacillin, oral, 12–25 mg/kg/dose 6 hourly for 5 days

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months / years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Syrup 125 mg/5mL</td>
<td>Capsule 250 mg</td>
</tr>
<tr>
<td>≥ 2.5–5 kg</td>
<td>62.5 mg</td>
<td>2.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 5–11 kg</td>
<td>125 mg</td>
<td>5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 11–25 kg</td>
<td>250 mg</td>
<td>10 mL</td>
<td>–</td>
</tr>
<tr>
<td>&gt; 25–55 kg</td>
<td>500 mg</td>
<td>–</td>
<td>2 capsules</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>500 mg</td>
<td>–</td>
<td>2 capsules</td>
</tr>
</tbody>
</table>

Penicillin–allergic patients
• Erythromycin, oral, 10–15 mg/kg/dose 6 hourly

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months / years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Syrup 125 mg/5mL</td>
<td>Capsule 250 mg</td>
</tr>
<tr>
<td>≥ 2.5–3.5 kg</td>
<td>35 mg</td>
<td>1.4 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 3.5–5 kg</td>
<td>50 mg</td>
<td>2 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>75 mg</td>
<td>3 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>100 mg</td>
<td>4 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 9–11 kg</td>
<td>125 mg</td>
<td>5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>150 mg</td>
<td>6 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>200 mg</td>
<td>8 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>250 mg</td>
<td>10 mL</td>
<td>1 tablet</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>375 mg</td>
<td>15 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 35 kg and above</td>
<td>500 mg</td>
<td>–</td>
<td>2 tablets</td>
</tr>
</tbody>
</table>
Chapter 5  Skin Conditions

For itching:
- Chlorpheniramine, oral, 0.1 mg/kg/dose 6–8 hourly

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt; 9–11 kg</td>
<td>1 mg</td>
<td>2.5 mL</td>
<td>&gt; 12–18 months</td>
</tr>
<tr>
<td>&gt; 11–14 kg</td>
<td>1.2 mg</td>
<td>3 mL</td>
<td>&gt; 18 months–3 years</td>
</tr>
<tr>
<td>&gt; 14–17.5 kg</td>
<td>1.5 mg</td>
<td>4 mL</td>
<td>&gt; 3–5 years</td>
</tr>
<tr>
<td>&gt; 17.5–25 kg</td>
<td>2 mg</td>
<td>5 mL</td>
<td>&gt; 5–7 years</td>
</tr>
<tr>
<td>&gt; 25–35 kg</td>
<td>3 mg</td>
<td>7.5 mL</td>
<td>&gt; 7–11 years</td>
</tr>
<tr>
<td>35 kg and above</td>
<td>4 mg</td>
<td>–</td>
<td>1 tablet</td>
</tr>
</tbody>
</table>

Topical steroids should only be considered after the infection has cleared.

Referral
» No improvement after a week
» Severe acute moist or weeping eczema

5.7.3 Dermatitis, seborrhoeic
L21.9

Description
In its simplest form it is dandruff, which tends to be rather oily. Pruritus may or may not be present. The scalp, ears and skin folds are commonly affected. It may become very extensive, particularly in infants and HIV infected patients.

General measures
» Cut nails short.
» Avoid scratching.
» Avoid perfumed soap.

Drug treatment
- Hydrocortisone 1% cream, applied 2–3 times daily until improved.
  o Then apply once or twice weekly for maintenance as needed.

For severe eczema:
- Betamethasone 0.1% ointment, applied twice daily for 5–7 days. (Doctor initiated)
  o Do not apply to face and skin folds.
For scalp itching, scaling and dandruff:
- Selenium sulphide 2% suspension
  - Apply weekly by lathering on the scalp
  - Rinse off after 10 minutes

Note:
Consider the possibility of HIV infection in patients with diffuse seborrhoeic eczema.

5.8 Nappy rash
L22

Description
A diffuse reddish eruption usually caused by irritation from:
- persistent moisture and irregular cleaning and drying or nappy in area,
- diarrhoeal stools, and
- underlying skin conditions in some cases, or
- improper rinsing of nappies to remove soap.

General measures
- Change nappies regularly.
- Do not use waterproof pants to cover nappy.
- Expose nappy area to air if possible especially with severe nappy dermatitis.
- Educate caregiver and give advice on:
  - washing, rinsing and drying of the nappy area when soiled
  - regular nappy changes
  - proper washing and rinsing of nappies

Drug treatment
- Zinc and castor oil ointment, applied after each nappy change

If no improvement within 3 days, suspect candida:
- Clotrimazole 2% cream followed by zinc and castor oil ointment applied after each nappy change

Referral
- No improvement after 3 days of clotrimazole treatment
5.9 Sandworm
B76.0

Description
Creeping eruption (cutaneous larva migrans) caused by *Ancylostoma braziliense*, a hookworm of dog or cat. Larvae of ova in soil penetrate skin through the feet, legs, buttocks or back and cause a winding thread-like trail of inflammation with itching, scratching dermatitis and bacterial infection.

Drug treatment
- Albendazole, oral, daily for three days
  - Children under 2 years: 200 mg
  - Children over 2 years and adults: 400 mg
- Chlorpheniramine, oral, 0.1 mg/kg/dose 6–8 hourly

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt; 9–11 kg</td>
<td>1 mg</td>
<td>2.5 mL Syrup 2 mg/5 mL</td>
<td>&gt; 12–18 months</td>
</tr>
<tr>
<td>&gt; 11–14 kg</td>
<td>1.2 mg</td>
<td>3 mL Syrup 2 mg/5 mL</td>
<td>&gt; 18 months–3 years</td>
</tr>
<tr>
<td>&gt; 14–17.5 kg</td>
<td>1.5 mg</td>
<td>4 mL Syrup 2 mg/5 mL</td>
<td>&gt; 3–5 years</td>
</tr>
<tr>
<td>&gt; 17.5–25 kg</td>
<td>2 mg</td>
<td>5 mL Syrup 2 mg/5 mL</td>
<td>&gt; 5–7 years</td>
</tr>
<tr>
<td>&gt; 25–35 kg</td>
<td>3 mg</td>
<td>7.5 mL Syrup 2 mg/5 mL</td>
<td>&gt; 7–11 years</td>
</tr>
<tr>
<td>35 kg and above</td>
<td>4 mg</td>
<td>1 tablet</td>
<td>&gt; 11 years and adults</td>
</tr>
</tbody>
</table>

5.10 Urticaria
L50.9

Description
Urticaria is a skin disorder characterised by itchy wheals (hives). There are many causes, including allergic, toxic or physical. Allergic urticaria may be caused by drugs, plant pollen, insect bites or foodstuffs, e.g. fish, eggs, fruit, milk and meat.

Note:
Aspirin is a common cause and is found in many medicines.

General measures
» Take detailed history to detect trigger factors.
» Lifestyle adjustment.
Chapter 5  Skin Conditions

Drug treatment

- Chlorpheniramine, oral, 0.1 mg/kg/dose 6–8 hourly

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt; 9–11 kg</td>
<td>1 mg</td>
<td>2.5 mL</td>
<td>&gt; 12–18 months</td>
</tr>
<tr>
<td>&gt; 11–14 kg</td>
<td>1.2 mg</td>
<td>3 mL</td>
<td>&gt; 18 months–3 years</td>
</tr>
<tr>
<td>&gt; 14–17.5 kg</td>
<td>1.5 mg</td>
<td>4 mL</td>
<td>&gt; 3–5 years</td>
</tr>
<tr>
<td>&gt; 17.5–25 kg</td>
<td>2 mg</td>
<td>5 mL</td>
<td>&gt; 5–7 years</td>
</tr>
<tr>
<td>&gt; 25–35 kg</td>
<td>3 mg</td>
<td>7.5 mL</td>
<td>&gt; 7–11 years</td>
</tr>
<tr>
<td>35 kg and above</td>
<td>4 mg</td>
<td>–</td>
<td>&gt; 11 years and adults</td>
</tr>
</tbody>
</table>

- Calamine lotion, applied on the skin

Referral

» No improvement or response after 24 hours
» Progressive illness

5.11 Pityriasis rosea

Description

A common disease of unknown cause, probably due to a viral infection as it occurs in minor epidemics. It is most common in young adults but any age may be affected. The rash involves the trunk, neck and mainly proximal parts of the limbs. Presents as pink papules, and macules which are oval and slightly scaly at the margins. The eruption is usually preceded by a few days by one larger, oval, slightly scaly area (“herald patch”), commonly found in the scapular area or abdomen. The macules on the thorax characteristically lie parallel to the long axis of the ribs (“Christmas tree” distribution). The itch is usually mild and there few or no constitutional symptoms. It is self-limiting within about 6–8 weeks.

General measures

» Explain about the benign but protracted nature of the condition.
Chapter 5

Skin Conditions

Drug treatment
- Chlorpheniramine, oral, 0.1 mg/kg/dose 6–8 hourly

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Syrup 2 mg/5 mL</td>
<td>Tablet 4 mg</td>
</tr>
<tr>
<td>&gt; 9–11 kg</td>
<td>1 mg</td>
<td>2.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>&gt; 11–14 kg</td>
<td>1.2 mg</td>
<td>3 mL</td>
<td>–</td>
</tr>
<tr>
<td>&gt; 14–17.5 kg</td>
<td>1.5 mg</td>
<td>4 mL</td>
<td>–</td>
</tr>
<tr>
<td>&gt; 17.5–25 kg</td>
<td>2 mg</td>
<td>5 mL</td>
<td>–</td>
</tr>
<tr>
<td>&gt; 25–35 kg</td>
<td>3 mg</td>
<td>7.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>35 kg and above</td>
<td>4 mg</td>
<td>–</td>
<td>1 tablet</td>
</tr>
</tbody>
</table>

- Aqueous cream, applied 3 times daily.

5.12 Molluscum contagiosum
B08.1

Description
Infectious disease caused by a poxvirus. Presents with a dome-shaped papules with a central depression (umbilication). Their number varies from occasional lesions to large crops of lesions particularly in those co-infected with HIV. Papules are commonly seen on the face in children but may be found at any dermal site except on the palms and soles. They may also occur on the genitalia as an STI.

General measures
In genital molluscum contagiosum:
» Counsel on risk reduction for transmission of STI and STI.
» Provide and promote use of condoms.
» Notify partner to be examined and treated.

In non-genital molluscum contagiosum:
» Allow to heal spontaneously if the lesions are few in number

Drug treatment
- Tincture of iodine BP, applied to the core of individual lesions using an applicator.

Referral
» Extensive lesions for cryotherapy with liquid nitrogen
Chapter 5  
Skin Conditions  

5.13 Herpes simplex  
B00.0  

**Description**  
Infection caused by herpes simplex virus type 1. The primary infection usually presents as a gingivostomatitis but may occur at other sites, e.g. the face. It is characterised by grouped crusted vesicles surrounded by erythema. The secondary infection usually presents with cold sores on the lips or nose often in association with upper or lower respiratory tract infection. Sufferers of atopic eczema are particularly susceptible to the virus and may present with large areas of involvement with numerous vesicles and crusting surrounded by erythema (eczema herpeticum). Mucocutaneous ulceration for more than 1 month (AIDS–defining illness). Ulcers occur commonly in the mouth genital or perianal regions See Section 11.3.9: Herpes simplex ulcers, chronic  

**General measures**  
» Keep the skin lesions clean and dry  

**Drug treatment**  
Extensive herpes or eczema herpeticum:  
- Aciclovir, oral, 8 hourly for 10 days  
  - Paediatric dose: 250 mg/m²/dose  

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 3.5–7</td>
<td>80 mg</td>
<td>2 mL 200 mg/5 mL</td>
<td>≥ 1–6 months</td>
</tr>
<tr>
<td>7–11</td>
<td>100 mg</td>
<td>2.5 mL 200 mg</td>
<td>≥ 6–18 months</td>
</tr>
<tr>
<td>11–14</td>
<td>120 mg</td>
<td>3 mL 200 mg</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>14–25</td>
<td>160 mg</td>
<td>4 mL 200 mg</td>
<td>≥ 3–7 years</td>
</tr>
<tr>
<td>25–35</td>
<td>200 mg</td>
<td>5 mL 1 tablets</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>35–55</td>
<td>300 mg</td>
<td>7.5 mL 1½ tablets</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td>≥55 kg and above</td>
<td>400 mg</td>
<td>2 tablets 1 tablet</td>
<td>≥ 15 years and adults</td>
</tr>
</tbody>
</table>
Chapter 5  

5.14 Herpes zoster  
(See Section 11.3.10)

5.15 Warts  
B07

Description  
A common, infectious, self-limiting condition of the skin or mucous membrane caused by papilloma virus.

5.15.1 Common Warts

Seen most often on the hands and fingers. 
Raised nodular type with a rough ‘warty’ surface.

General measures
» May be left alone to wait for improvement

Drug treatment
• Podophyllum resin 20% and salicylic acid 25% ointment, applied under plaster nightly.
  o Protect surrounding skin with petroleum jelly.
  o Repeat until the wart falls off.

Referral
» Extensive warts

5.15.2 Plane Warts

Very small warts which are just slightly raised. 
These present as smooth, flat, skin-coloured or slightly pigmented surface and occurs particularly on the face, backs of the hands and knees.

Referral
» Extensive cases involving the face

5.15.3 Plantar Warts

Appear commonly on the pressure-bearing areas of the soles and can be painful
and interfere with walking. Because pressure forces them deep into the dermis they are flat, almost circular lesions, with a rough surface and are often thick and hard due to increased keratin formation.

**Drug treatment**

- Podophyllum resin 20% and salicylic acid 25% ointment, applied under plaster nightly.
  - Protect surrounding skin with petroleum jelly.
  - Repeat until the wart falls off.

**Referral**

» No response to treatment

» Diabetic patients

### 5.15.4 Filiform Warts

Pedunculated warts found on the face, neck and occasionally on mucous membrane of the mouth. In the anogenital area they are known as condylomata accuminata.

See Section 12.11: Genital warts (GW): *condylomata accuminata*

**Referral**

» Extensive involvement

### 5.15.5 Genital Warts: Condylomata Accuminata

A63.0

See section 12.11: Genital warts (GW): *condylomata accuminata*
Chapter 6: Obstetrics and gynaecology

Obstetrics
6.1 Bleeding in pregnancy
   6.1.1 Miscarriage
   6.1.2 Antepartum haemorrhage
6.2 Antenatal care
   6.2.1 Care of HIV positive pregnant woman
   6.2.2 Hypertensive disorders of pregnancy
   6.2.3 Anaemia in pregnancy
   6.2.4 Syphilis in pregnancy
6.3 Preterm labour (PTL) and preterm prelabour rupture of membranes
   6.3.1 Preterm labour (PTL)
   6.3.2 Preterm prelabour rupture of membranes
6.4 Intrapartum Care
6.5 Care of the neonate
   6.5.1 Sick neonate and neonatal emergencies
   6.5.2 Neonatal resuscitation
6.6 Postpartum care
   6.6.1 Feeding options for HIV positive mothers
   6.6.2 Cracked nipples during breastfeeding

Gynaecology
6.7 Pregnancy, ectopic
6.8 Vaginal bleeding
   6.8.1 Abnormal vaginal bleeding during fertile years
   6.8.2 Bleeding, post-menopausal
6.9 Dysmenorrhoea
6.10 Hormone replacement therapy
6.11 Ulcers, vaginal
6.12 Vaginal discharge/lower abdominal pain in women
6.1 Bleeding in pregnancy

6.1.1 Miscarriage

Description

Bleeding from the genital tract prior to 24 weeks gestation, as determined either from last menstrual period (LMP) or ultrasound, which may or may not be associated with lower abdominal pain (LAP), and is classified as follows:

» Threatened miscarriage:
  – mild vaginal bleeding, usually no associated LAP
  – cervix closed on digital examination

» Inevitable miscarriage:
  – moderate vaginal bleeding associated LAP
  – cervical dilatation may be present

» Incomplete miscarriage:
  – vaginal bleeding with clots
  – passage of products of conception

» Complete miscarriage:
  – complete passage of all products of conception
  – usually still requires referral for confirmation

» Septic miscarriage:
  – any miscarriage with history of interference, pyrexia, tachycardia and/or offensive products of conception

(For perinatal mortality reporting, a stillbirth is considered a fetus > 1 000 g or > 28 weeks gestation.)

General measures

» Monitor vital parameters, e.g. Hb, pulse, BP, temperature.
» Treat for shock if indicated.
» Counselling and support.

Drug treatment

- Oxytocin 20 units, IV, diluted in 1 000 mL sodium chloride 0.9% and infused at 125 mL/hour in all cases, except where threatened miscarriage is suspected.

If septic miscarriage is suspected, before referral
- Ceftriaxone, IV, 1 g
Chapter 6  Obstetrics and gynaecology

| ! CAUTION ! |
| Do not administer calcium containing fluids, e.g. Ringer-lactate, within 48 hours of administering ceftriaxone. |
| Contra-indicated in neonatal jaundice. |

and
- Metronidazole, oral, 400 mg

In Rh-negative, non sensitised, women
- Anti-D immunoglobulin, IM, 100 mcg preferably within 72 hours but may be given up to 7 days following management of miscarriage.

**Referral**

**Urgent**
» All patients

### 6.1.2 Antepartum Haemorrhage

**O46.9**

**Description**
Vaginal bleeding in pregnancy after 24 weeks of gestation as determined either from LMP or ultrasound.
Important causes include the following:
» abruptio placentae,
» placenta praevia and
» uterine rupture (particularly when misoprostol was used).

**Drug treatment**
- Sodium chloride 0.9%, IV

» Treat for shock if necessary.
» Avoid vaginal examination.

**Referral**

**Urgent**
» All patients

| ! CAUTION ! |
| Avoid using prostaglandins, e.g. misoprostol together with oxytocin when the uterus is greater than 20 weeks size. |
6.2 Antenatal care

6.2.1 Care of HIV positive pregnant woman

Description
HIV is currently the commonest cause of maternal deaths in South Africa. Transmission of HIV from mother to infant may occur during pregnancy, delivery, and/or breast-feeding.
Without intervention, 25–40% of infants born to HIV positive women may become infected. With appropriate interventions, maternal mortality as well as perinatal transmission of HIV can be substantially reduced.

General measures
At first antenatal visit
» Offer counselling and voluntary HIV testing to all pregnant women, preferably at 1st visit.
  – If she is HIV positive, a CD4 count must be done at once.
  – The CD4 result must be obtained within 1 week.
» Assist HIV positive pregnant women with access to TOP services, when requested, i.e. unplanned, unwanted pregnancy less than 20 weeks.
» Identify HIV positive pregnant women who are eligible for life-long ART.
  – Refer to appropriate ARV unit.
» HIV positive pregnant women not yet eligible for ART should be counselled about the benefits of PMTCT.

Drug treatment
Mother
Refer all HIV positive pregnant women with indications for long term ART to ARV unit regardless of gestational age. These women should be fast tracked for access to ART.

HIV positive pregnant women without indication for ART
• Zidovudine, oral, 300 mg 12 hourly from 28 weeks of pregnancy until delivery.
  o Zidovudine is still of benefit even if started after 28 weeks of pregnancy.
plus
• Nevirapine, oral, 200 mg single dose as early as possible in labour, or 4 hours prior to elective Caesarean section.

» Check baseline Hb prior to starting zidovudine therapy.
  – If below 8 g/dL do not commence zidovudine and refer patient.
» Monitor Hb every 4 weeks while on therapy.
  – If Hb drops below 8 g/dL, refer patient.
Newborn
- Nevirapine, oral, 2 mg/kg single dose within 48 hours of birth.
  plus
- Zidovudine, oral, 4 mg/kg/dose 12 hourly for the first week of life.
  o If the mother received less than 4 weeks of zidovudine antenatally, give zidovudine to newborn for 4 weeks.
This regimen is applicable to all HIV-exposed newborns, regardless of which prophylaxis or treatment the mother received antenatally.

6.2.2 Hypertensive disorders of pregnancy
O13/O14

Description
Hypertension in pregnancy, pre-eclampsia and eclampsia may have very serious and fatal consequences for both the mother and the baby.
Hypertension at 20 weeks of gestation or more (gestational hypertension) characterised by:
  » BP equal or above 140/90 mmHg measured on two occasions 4 hours apart
  OR
  » diastolic BP above 110 mmHg measured on one occasion

Hypertensive disorders of pregnancy can be classified as:
  » Chronic hypertension:
    – hypertension without proteinuria diagnosed before pregnancy or before 20 weeks of pregnancy.
  » Chronic kidney disease:
    – proteinuria with/without hypertension prior to 20 weeks
  » Gestational hypertension:
    – hypertension without proteinuria, detected after 20 weeks of pregnancy.
  » Pre-eclampsia:
    – Hypertension with proteinuria after 20 weeks of pregnancy.
  » Eclampsia:
    – generalised tonic-clonic seizures in women with pre-eclampsia.

LEVELS OF SEVERITY

<table>
<thead>
<tr>
<th>Level of hypertension</th>
<th>BP Level mmHg</th>
<th>Proteinuria</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Systolic</td>
<td>Diastolic</td>
</tr>
<tr>
<td>mild</td>
<td>140–159</td>
<td>or</td>
</tr>
<tr>
<td>severe</td>
<td>above 160</td>
<td>and</td>
</tr>
</tbody>
</table>

PREVENTION
All antenatal patients to reduce the risk of pre-eclampsia:
- Calcium, oral, 1 g of elementel calcium daily
MILD HYPERTENSION

General measures
» May be managed without admission before 38 weeks of gestation.
» Review the following on a weekly basis:
  – BP
  – weight
  – urine analysis
  – height of fundus
  – fetal heart rate and movements
» Advise bed rest.
» Educate on signs requiring follow-up.
» Admit to hospital if proteinuria is present.
» Admit at 38 weeks for delivery.

Drug treatment
• Methyldopa, oral, 250 mg 8 hourly.
  o Maximum dose: 750 mg 8 hourly.

PREGNANCY IN PATIENTS WITH HYPERTENSION
» Stop ACE Inhibitors when pregnancy is planned or as soon as pregnancy is diagnosed.

Drug treatment
• Methyldopa, oral, 250mg 8 hourly.
  o Maximum dose: 750mg 8 hourly
  or
  Nifedipine, slow release, oral, 30 mg daily.

SEVERE HYPERTENSION

Drug treatment
» Aim to reduce diastolic BP to ± 100 mmHg.
Preload with:
• Sodium chloride 0.9%, IV, 300 mL unless in cardiac failure.
  plus
  • Nifedipine, oral, 10 mg (not sublingual) as a single dose.
    o May be repeated in 30 minutes if diastolic BP remains above 110 mmHg

ECLAMPSIA

General measures
» Ensure safe airway.
» Turn woman onto left lateral position.
» Administer oxygen.
» Stabilise prior to urgent referral.
» Insert a Foley’s catheter.
Drug treatment

- Magnesium sulphate, IV, 4 g as a loading dose diluted with 200 mL sodium chloride 0.9% and infused over 20 minutes.

and

- Magnesium sulphate, IM, 10 g given as 5 g in each buttock
  - Then IM, 5 g every 4 hours in alternate buttocks

If infusion pump is available, administration of a continuous infusion is preferred:

- Magnesium sulphate, IV, at 1 g/hour as a continuous infusion.
  - 10 g in 200 mL sodium chloride at over 20 mL/hour

Stop magnesium sulphate if:

- urine output is less than 100 mL in 4 hours, or
- respiratory rate is less than 16 breaths per minute, or
- if patellar reflexes are absent

If magnesium toxicity suspected (decreased tendon reflexes)

- Calcium gluconate 10%, IV, 10 mL administered over 2–3 minutes as antidote.

Referral

Urgent

- Severe pre-eclampsia and eclampsia
  - stabilise the patient
  - initiate magnesium sulphate loading dose and infusion before referral
  - monitor vital signs while awaiting transport
- Poor control in mild gestational hypertension
- Hypertension with proteinuria

6.2.3 Anaemia in pregnancy

Description

Anaemia in pregnancy is pallor plus a haemoglobin (Hb) of less than 11 g/dL, mostly due to either iron deficiency, folic acid deficiency or a combination of both. Women with iron deficiency often have ‘pica’, e.g. eating substances such as soil, charcoal, ice, etc.

General measures

- Reduce intake of tea.
- Do not drink tea within 2 hours of taking iron tablets.
Drug treatment

Prevention:
All antenatal patients, routine iron and folic acid supplementation.

Single pregnancy:
- Ferrous sulphate compound BPC, oral, 170 mg once daily with food
  and
- Folic acid, oral, 5 mg daily

Twin or multiple pregnancy:
- Ferrous sulphate compound BPC, oral, 170 mg 12 hourly with food.
  and
- Folic acid, oral, 5 mg daily.

Established anaemia with Hb less than 10 g/dL:
- Ferrous sulphate compound BPC, oral, 170 mg 8 hourly with food.
  
  o  Continue for three months after the Hb normalises in order to replenish
  body iron stores.
  and
- Folic acid, oral, 5 mg daily.

Referral
- Hb less than 7 g/dL at any stage
- Hb less than 10 g/dL and patients over 34 weeks of gestation
- Non-responding Hb
- A rise in the Hb of less than 1.5 g/dL over 2 weeks in early pregnancy
- Any low Hb with an obstetric complication
- Signs or symptoms of acute or chronic blood loss
- Pallor (anaemia) plus signs of chronic disease, e.g. suspicion of TB, or the
  presence of hepatosplenomegaly
- Evidence of cardiac failure
- Anaemia of sudden onset

6.2.4 Syphilis in pregnancy
O98.1

Description
A sexually transmitted infection with many manifestations that may be
asymptomatic in pregnant women. It is caused by the spirochaete, T pallidum.
Vertical transmission to the fetus occurs in up to 40% of cases in untreated
mothers. Untreated maternal syphilis may lead to miscarriage, stillbirth, non-
immune hydrops fetalis, or congenital syphilis in the newborn.
Diagnosis is made by positive serology (VDRL, RPR) confirmed with positive
TPHA or FTA.
Chapter 6 Obstetrics and gynaecology

All pregnant women should have a RPR test at the first visit.

General measures
» Encourage partner notification and treatment.
» Provide counselling and promote HIV testing.
» Educate on treatment adherence.
» Promote condom use.

Drug treatment
Pregnant woman
- Benzathine benzylpenicillin, IM, 2.4 MU weekly for 3 weeks
  - Follow up at 3 months after the last injection to confirm a fourfold (i.e. 2 dilution) reduction in VDRL/RPR titres

Penicillin allergy:
- Erythromycin, oral, 500 mg 6 hourly for 28 days.
- Mother, once she has stopped breast-feeding:
  - Doxycycline, oral, 100 mg 12 hourly for 28 days.

Note:
Erythromycin does not reliably cure syphilis in the woman. The mother must be followed up with repeated RPR after 3 months to confirm a four fold reduction in VDRL/RPR titres.

Newborn baby
Asymptomatic, well baby
- Benzathine benzylpenicillin (depot formulation), IM, 50 000 units/kg as a single dose into the lateral thigh

Symptomatic baby
- Procaine penicillin (depot formulation), IM, 50 000 units/kg daily for 10–14 days
  - Not for IV use
  - or
  - Benzylpenicillin (Penicillin G), IV, 50 000 units/kg, 12 hourly for 10–14 days

! CAUTION !
Procaine penicillin and benzathine benzylpenicillin (depot formulation) should not be given intravenously.
6.3 Preterm labour (PTL) and preterm prelabour rupture of membranes (PPROM)

6.3.1 Preterm labour (PTL)

Description
Regular painful contractions, three per 10 minutes, occurring before 37 weeks of gestation. Labour prior to 34 weeks is of clinical importance due to adverse neonatal outcomes.

General measures
Less than 26 weeks:
» refer without drugs to inhibit uterine contractions (tocolysis).

26 – 33+ weeks of gestation:
» refer with initial tocolysis and corticosteroids.

≥ 34 weeks gestation:
» allow labour to continue.

Drug treatment
26 – 33+ weeks gestation
• Betamethasone, IM, 12 mg two doses 24 hours apart.

Tocolysis:
Preload with:
• Sodium chloride 0.9%, IV, 300 mL
then
• Nifedipine, oral, 20 mg as a single dose
  o Follow with 10 mg after 30 minutes,
  o Then 10 mg every 4 hours until patient is transferred
  o Maximum duration: 24 hours

Referral
» All cases prior to 34 weeks

6.3.2 Preterm prelabour rupture of membranes (PPROM)

Description
Rupture of the membranes prior to 37 weeks of gestation. PPROM prior to 34
weeks is of clinical importance due to adverse neonatal outcomes. Confirmed with a sterile speculum examination demonstrating leakage of amniotic fluid. If there is clinical uncertainty, test for pH – liquor is alkaline. Avoid digital vaginal examination.

**Drug treatment**

26 – 33+ weeks gestation
- Betamethasone, IM, 12 mg two doses 24 hours apart.

**Referral**
- All cases

**6.4 Intrapartum care**

For the comprehensive management of women in labour, refer to the National Maternity Care Guidelines.

**Description**

Labour is divided into 4 stages:
- **First stage**
  - onset of regular uterine contractions at term to full dilatation of cervix
- **Second stage**
  - full dilatation to delivery of the baby
- **Third stage**
  - delivery of the baby to delivery of the placenta
- **Fourth stage**
  - 1 hour post delivery

**General measures**
- Encourage companion support.
- Ensure that the mother is adequately hydrated.
- Monitor progress of labour on partogram.

**Drug treatment**

First stage with cervical dilatation of less than 10 cm:
- Analgesia:
  - Pethidine, IM, 100 mg 4 hourly
  - Morphine, IM, 10–15 mg, 4 hourly (Doctor initiated)
  - Nitrous oxide 50% mixed with oxygen 50%, given by mask
and
For nausea and sedation, if needed:
• Promethazine, IM, 25 mg 4 hourly

Second stage
If episiotomy is needed, local anaesthetic:
• Lignocaine 1%.
  o Do not exceed 20 mL

Fetal distress during labour:
• Salbutamol 1 mg/mL, IV, 100–250 mcg administered slowly over 2 minutes and refer.
  Reconstitute the tocolytic as follows:
  o Salbutamol 1 ml added to 200 mL sodium chloride 0.9% to make a 5 mcg/mL solution.
  o Draw up 20 mL (100 mcg) in syringe. Monitor pulse.
  o Inject 20 mL (100 mcg) over at least 1 minute. Monitor pulse.
  o If pulse is not more than 120/minute, inject another 20 mL over at least 1 minute. Monitor pulse.
  o Maximum dose 250 mcg (50 mL) over at least 2 minutes.
  o Do not administer if mother has cardiac disease.
Place the mother in the left lateral position.

Inadequate or inco-ordinate uterine contractions:
Use only for primigravida and titrate to individual needs. Contraction frequency should never exceed 5 in 10 minutes.
• Oxytocin, IV, diluted with 1 000 mL sodium chloride 0.9%.
  o Infuse at a rate of 6 mL/hour (1 milliunit /minute)

<table>
<thead>
<tr>
<th>Time after starting minutes</th>
<th>Oxytocin dose milliunits/minute</th>
<th>Dilute 10 units in 1 000 mL sodium chloride 0.9% (mL/hour)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1</td>
<td>6</td>
</tr>
<tr>
<td>30</td>
<td>2</td>
<td>12</td>
</tr>
<tr>
<td>60</td>
<td>4</td>
<td>24</td>
</tr>
<tr>
<td>90</td>
<td>6</td>
<td>36</td>
</tr>
<tr>
<td>120</td>
<td>8</td>
<td>48</td>
</tr>
<tr>
<td>150</td>
<td>10</td>
<td>60</td>
</tr>
<tr>
<td>180</td>
<td>12</td>
<td>72</td>
</tr>
</tbody>
</table>

Precautions
» Use oxytocin for augmentation only, not for induction of labour.
» Do not administer oxytocin when the action line on the partogram has been crossed – refer to hospital.
Chapter 6  Obstetrics and gynaecology

Prevention of post-partum haemorrhage after delivery of the baby:
» Check for twin
• Oxytocin, IM, 10 units

Post-partum haemorrhage:
» Rub up the uterus to expel clots from vagina.
» Empty the bladder.
• Oxytocin, IV, 20 units in 1 000 mL Ringers-Lactate infused rapidly
As fluid replacement:
• Sodium chloride 0.9%, IV

If no response:
• Ergometrine, IM, 0.5 mg. (Doctor initiated)
  o Avoid ergometrine in hypertensive women unless haemorrhage is life threatening.
  o Repeat after 10–15 minutes if no response to first dose, while arranging referral.

If referral is delayed and if no response within 10–15 minutes after second dose of ergometrine:
• Misoprostol, sublingual, 400 mcg as a single dose. (Doctor initiated)

Rh negative mother
Administer to Rh-negative mother if baby is Rh-positive or baby’s Rh group is not known
• Anti-D immunoglobulin, IM, 100 mcg, preferably within 72 hours but can be given up to 7 days after delivery.

Baby
See section 6.5: Care of the neonate

Observe mother and neonate closely for 1–2 hours before transfer to the postnatal ward.

Note for HIV positive patients:
» Do not rupture the membranes unless it is essential.
» Provide PMTCT – See section 6.2.1: Care of HIV positive pregnant woman
» Avoid unnecessary episiotomy and other invasive procedures, to reduce the mother to child transmission of HIV.

Referral
» Prolonged labour according to charting on partogram
» Post-partum haemorrhage
» Incomplete delivery of the placenta
6.5 Care of the neonate

Drug treatment

Neonatal conjunctivitis prophylaxis:
- Chloramphenicol ophthalmic ointment 1%, applied routinely to each eye after birth.

Bleeding prophylaxis:
To prevent hypoprothrombinaemia
- Vitamin K, IM, 1 mg immediately after birth routinely

Neonate not breathing well:
After mother received morphine/pethidine up to 4 hours before birth:
- Naloxone, IM, 0.1 mg/kg

Routine immunisation EPI:
- BCG vaccination, intradermal, once neonate is stable.
- Polio vaccine, oral, once neonate is stable
No baby must be sent home without immunisation.

6.5.1 Sick neonate and neonatal emergencies

Description
Newborn infants can become ill very rapidly and signs of disease are often not readily appreciated unless specifically looked for. All of these conditions in newborns should be referred urgently.
The most common serious conditions are:
» septicaemia or infections
» respiratory conditions
» congenital abnormalities
» late effects of asphyxia

Possible serious bacterial infection or other severe abnormalities must be suspected when any of the following are found:
» convulsions
» fast breathing (more than 60 breaths per minute)
» severe chest indrawing
» nasal flaring or grunting respiration
» bulging fontanelle
» umbilical redness extending to the skin and draining pus
» low or high temperature
many or severe skin pustules
swollen eyes with pus draining from eye
lethargic or unconscious or less than normal movements
shallow or slow breathing
poor feeding
diarrhoea (obvious)
vomiting everything or bile-stained vomitus
abdominal distension or passing blood per rectum
pallor
jaundice within the first 24 hours of life

General measures
Keep the neonate warm, the axillary temperature should be 36.5–37°C.
This is best done by “Kangaroo Care” where the neonate is kept naked against the mother’s skin between her breasts inside her clothing.
Alternatively, use an incubator or heated cloths. Monitor temperature of baby once the temperature is normal.

Drug treatment
If baby’s tongue and lips are blue:
• Oxygen, using nasal catheter at 2 L/minute

If infection is suspected and jaundice has been excluded:
• Ceftriaxone, IM, 50 mg/kg into the lateral thigh

! CAUTION !
Do not administer calcium containing fluids, e.g. Ringer-lactate, within 48 hours of administering ceftriaxone.
Contra-indicated in neonatal jaundice.
Annotate dose and route of administration in referral letter.

Monitor blood glucose and exclude hypoglycaemia. If less than 2.6 mmol/L and baby able to suckle or take orally:
• Breastfeed
or
• Dextrose 10%, oral
If unable to take orally consider nasogastric tube feeding or IV infusion.

Referral
Urgent
• All newborns with jaundice on the first day or life or with pallor or with poor feeding
• All other newborns with increasing, deep or persistent (more than 10 days) jaundice should be referred as soon as possible
• All cases
If possible, always send mother with the child as well as any clinical notes.
6.5.2 Neonatal resuscitation

Ask 3 questions to evaluate the infant:
1. Is the baby breathing adequately and not just gasping?
2. Is the baby’s heart rate (HR) above 100 beats per minute?
3. Is the baby centrally pink, i.e. no central cyanosis.

» If the answer to all three questions is “yes”, the baby does not need resuscitation.
» If the answer to any of the questions is “no”, the baby needs resuscitation.

Assess the infant using the above 3 questions every 30 seconds during resuscitation.
» If the baby is improved, then the intervention e.g. ventilation can be stopped and the response observed.
» If the baby is not responding or getting worse – check that each step is being applied effectively. If so, continue to apply the intervention, whilst also adding the next step/intervention (see algorithm).

If the newborn response to resuscitation is inadequate once the ventilation and circulation are adequately supported the following steps should be carried out:

If the mother is known or suspected to have had narcotic pain relief:
• Naloxone, IV, 0.1 mg/kg

Check the blood glucose of the child.
If hypoglycaemia is present:
• Dextrose 10%, IV, 2.5–5 mL/kg

If no adequate response has occurred by this stage a person skilled in neonatal resuscitation should be consulted and the child transferred with ongoing resuscitation to a higher level of care.

Newborns requiring minimal resuscitation with prompt and complete response may be watched with their mothers. Newborns who, after resuscitation, are not completely normal should be referred to a higher level for care using transport with necessary support, e.g. oxygen, temperature control.

Consider discontinuation of resuscitation if the unsatisfactory response to resuscitation persists for > 20 minutes and underlying treatable conditions e.g. hypoglycaemia, pneumothorax, have been excluded; or > 10 minutes of unresponsive cardiac arrest (asystole); or > 20 minutes of unsustainable respiration.
An unsatisfactory response to resuscitation includes:

» a sustained slow heart rate, usually less than 60/minute or a progressive decrease in heart rate

» episodes of cardiac arrest, with a progressively weaker response to chest compressions, positive pressure ventilation and medicines

» a decreasing blood pressure, increasing acidosis, severe hypotonia with central cyanosis or intense pallor

» apnoea or only abnormal and, irregular respiratory efforts (brain stem gasping)

### Drugs used during Neonatal Resuscitation

<table>
<thead>
<tr>
<th>Drug and dose</th>
<th>Indications</th>
<th>Effect</th>
</tr>
</thead>
</table>
| **Adrenaline** | » asystole  
» heart rate <60/minute | » ↑Heart rate 
» ↑Myocardial contractility 
» ↑Arterial pressure |
| o IV, 0.01 mg/kg/dose  
(0.1 mL/kg of a 1:10 000 dilution) | | |
| o *ET, 0.03 mg/kg/dose  
(0.3 mL/kg of a 1:10 000 dilution) | | |
| **Naloxone** | » maternal administration of opiates with apnoeic infant | » Corrects apnoea and/or hypoventilation |
| o ET*/IV/SC/IM, 0.1 mg/kg | | |
| **Dextrose** | » hypoglycaemia | » Corrects hypoglycaemia |
| o IV, 2 mL/kg of 10% dextrose water  
(10% solution: draw up 4 ml of 50% dextrose water into a 20 ml syringe then draw up 16 mL water for injection – mix by agitating the syringe) | | |

*ET = Endotracheal tube
Chapter 6 Obstetrics and gynaecology

AIRWAY
Remove MECONIUM or BLOOD if present before stimulating

Warm, position, Clear Airway, Dry and Stimulate

breathing, blue and HR < 100
breathing, blue and HR > 100

Administer oxygen

Assess:
Breathing, colour and heart rate

Supportive

Apnoea or blue or HR < 100

30 sec

BREATHE
Ventilation Rate 40 – 60/minute

Assess:
Breathing, colour and heart rate

HR < 60
HR > 60

CHEST COMPRESSIONS
Rate: 120/minute
Ratio: 3 compressions: 1 ventilation until intubated

Assess:
Breathing, colour and heart rate

HR < 60
HR > 60

DRUGS
Adrenaline 0.01 mg/kg, IV/ET, after 3 – 5 minutes if required
6.6 Post partum care

6.6.1 Feeding options for HIV positive mother

Feeding during the first 6 months:
» Feeding choices need to be individualised based on patients’ circumstances.
» The feeding options for the first 6-months of life are exclusive breastfeeding or exclusive formula feeding. Breast feeding should be continued (ideally until 2 years of age) in infants who are known to be HIV infected (positive PCR test).
» HIV may be transmitted via breast milk of HIV infected mothers.
» For each mother, the Acceptability, Feasibility, Affordability, Safety and Sustainability criteria (AFASS) should be assessed and discussed, and the mother should be assisted to make the feeding choice that would be most appropriate for her individual situation.

Mixed feeding carries the highest risk of HIV transmission and should be discouraged.

6.6.2 Cracked nipples during breastfeeding

Description
The areola and nipple are protected by the secretion of a lubricant from Montgomery’s glands. Cracked nipples may lead to infection and mastitis.

Causes of cracked nipples include:
» poor attachment
» removing the baby from the breast before suction is broken

The four signs of good attachment are:
» chin touching breast (or very close)
» mouth wide open
» lower lip turned outward
» more areola visible above than below the mouth

General measures
» Apply expressed breast milk to the nipples between feeds.
» If too painful, express the milk and nurse the baby on the other breast until improvement.
» Keep areola clean.
Chapter 6  Obstetrics and gynaecology

Referral
» No improvement after 3 days

Gynaecology

6.7 Pregnancy, ectopic
O00.9

Description
Pregnancy outside the uterus, usually presenting with the combination of:
» missed menstruation
» sudden lower abdominal pain
» dizziness
» shock
» anaemia
» urine pregnancy test usually positive
» shoulder tip pain

Note:
Consider ectopic pregnancy in any young woman who complains of lower abdominal pain.

Referral
» All suspected cases of ectopic pregnancy
» Treat shock if indicated

6.8 Bleeding, vaginal
N93.9

Note:
Women should receive regular screening for cervical cancer after the age of 30 years.

6.8.1 Abnormal vaginal bleeding during fertile years
N92.0/N92.1

Description
Increased vaginal blood flow either in volume, duration and/or frequency, including menorrhagia or dysfunctional uterine bleeding.
Chapter 6  Obstetrics and gynaecology

General measures
» Assess current contraceptives used.
» Exclude pregnancy complication or organic disease e.g. fibroids.

Drug treatment
• Combined oral contraceptive pill (levonorgestrel and ethinyl oestradiol) for 3–6 months
• Ibuprofen, oral, 200–400 mg 8 hourly with or after food as needed for 2–3 days
  Ibuprofen may reduce blood loss in menorrhagia associated with:
  o intrauterine contraceptive device (IUCD)
  o chronic salpingitis (See chapter 12: Sexually transmitted infections)

If blood loss has been severe or there are signs of anaemia:
• Ferrous sulphate compound BPC, oral, 170 mg three times daily after food.
  o Continue ferrous sulphate for 3 months until haemoglobin has normalised.

Referral
» No improvement
» Girls less than 12 years with vaginal bleeding before the development of their secondary sexual characteristics
» For investigation of other causes such as:
  – sexual abuse
  – foreign bodies
  – tumours of the genital tract
» Severe anaemia

6.8.2 Bleeding, post-menopausal
N95.0

Description
Vaginal bleeding following the cessation of menstruation for 1 year.

Note:
If bleeding profuse stabilise before referral.

Referral
» All cases, to exclude underlying malignancy and other pathology
6.9 Dysmenorrhea

**Description**

Pain associated with menstrual cycles. In primary dysmenorrhea there is no known cause. Secondary dysmenorrhea has an organic cause.

**General measures**

» Advise and reassure women with primary dysmenorrhea about the nature of the condition.
» Encourage patient to carry on with normal everyday activities.

**Drug treatment**

- Ibuprofen, oral, 400 mg 8 hourly with or after food as needed for 2–3 days

Treat for pelvic infection when present.

**Referral**

» Poor response to treatment
» If an organic cause is suspected, e.g. fibroids

6.10 Hormone replacement therapy

**Indications:**

» Menopausal symptoms, e.g. hot flushes
» Urogenital atrophy
» Osteoporosis prevention and treatment
» Oophorectomy in pre-menopausal woman

For menopausal women, treatment should not be longer than 5 years. A risk benefit assessment should be individualised in all patients.

**Contra-indications:**

» endometrial cancer  » undiagnosed vaginal bleeding
» breast cancer  » recent myocardial infarction
» previous deep vein thrombosis  » liver disease
» porphyria  » uncontrolled hypertension

**Drug treatment** (Doctor initiated)

**Women with intact uterus per cycle:**

- Oestradiol, oral, 0.5–1 mg daily.
  
  or

  Conjugated oestrogens, oral, 0.3 mg–0.625 mg daily.
and
- Medroxyprogesterone, oral 5 mg

Women with no uterus (post-hysterectomy):
- Oestradiol, oral, 0.5–1 mg daily
  or
  Conjugated oestrogens, oral, 0.3 mg–0.625 mg daily

**Referral**
» Annually, for re-evaluation

### 6.11 Ulcers, vaginal
*(See Chapter 12: Sexually transmitted in infections)*

### 6.12 Vaginal discharge/lower abdominal pain in women
*(See Chapter 12: Sexually transmitted in infections)*

A54.9
Chapter 7: Family planning

7.1 Contraception, hormonal
    7.1.1 Contraceptives, injectable
    7.1.2 Contraceptive, oral
7.2 Contraception, intrauterine device (IUCD)
7.3 Contraception, barrier methods
7.4 Contraception and HIV and AIDS
7.5 Contraception, missed pills
7.6 Contraception, emergency
Chapter 7

Family planning

The appropriate choice of family planning method should be decided on by the woman in consultation with the health care professional taking into consideration safety, efficacy, acceptability and access. A complete medical and sexual history must be obtained and an appropriate physical examination performed to identify potential risks to the individual's health. Exclude pregnancy before commencing contraception.

7.1 Contraception, hormonal

! CAUTION!

Hormonal contraception does not prevent sexually transmitted infections, including HIV. Additional use of condoms is recommended if there is a risk of exposure to infection.

7.1.1 Contraceptives, injectable

Injectable contraceptives are recommended:
» for women who prefer injectable contraception, or
» in whom oestrogen containing contraceptives are contraindicated or adherence is likely to be a problem, e.g.:
   – mental retardation
   – cardiac or renal disease
   – women with epilepsy, on anti-TB drugs

Injectable contraceptives are not suitable if pregnancy planned within a year.

- Medroxyprogesterone acetate (long-acting), IM, 150 mg, 12 weekly
  or
  Norethisterone enanthate, IM, 200 mg, 8 weekly

Note:
It is not necessary to shorten the dosage interval for women taking concomitant enzyme-inducing drugs, e.g. rifampicin, antiretrovirals and anticonvulsants.

7.1.2 Contraceptives, oral

Oral contraceptives are recommended for highly motivated, women where good, reliable adherence is more likely.
Chapter 7  

**Monophasic: progestogen only tablets**  
Indicated for breastfeeding patients not willing to use injectable contraceptives.  
- Levonorgestrel, oral, 0.03 mg daily  

Contraindications include:  
- abnormal uterine bleeding of unknown cause  
- myocardial infarction or stroke  
- liver disease  
- cancer of the breast or genital tract  
- known or suspected pregnancy  

**Monophasic: combination of progestogen and oestrogen in each tablet**  
Formula 1:  
- Levonorgestrel/ethinyl oestradiol 0.15/0.03 mg, oral  
Formula 2:  
- Norgestrel/ethinyl oestradiol 0.5/0.05 mg, oral  

**Triphasic preparations: combination of progestogen and oestrogen**  
- Levonorgestrel/ethinyl oestradiol, oral  
  - 6 tablets levonorgestrel 0.05 mg and ethinyl oestradiol 0.03 mg  
  - 5 tablets levonorgestrel 0.075 mg and ethinyl oestradiol 0.04 mg  
  - 10 tablets levonorgestrel 0.125 mg and ethinyl oestradiol 0.03 mg  
  - 7 tablets placebo  

Combination preparations are contraindicated in certain conditions. Consult the package insert or pharmacist in this regard. Examples of contraindications include:  
- heart disease  
- liver disease  
- thromboembolism  
- certain cancers  

**7.2 Contraception, intrauterine device (IUCD)**  
Z30.1  

A medical examination must be done prior to insertion of an IUCD to exclude a contraindication.  
HIV infection is not a contraindication to the use of an IUCD and may be indicated in patients on ARVs.  
- 380 mm² copper – standard type  

Use according to manufacturers instructions.  

---  

!CAUTION!  
IUCDs do not prevent sexually transmitted infections, including HIV. Additional use of condoms is recommended if at risk of exposure to infection.
Chapter 7  
Family planning

7.3 Contraception, barrier methods
Z30.9

Barrier methods are the optimum means to prevent STI and HIV transmission. Barrier methods are recommended in all individuals not in a long term monogamous relationship or where either of the partners are known to have a STI, including HIV.

- Condoms, male and female

7.4 Contraception and HIV and AIDS

The selection of contraception should always be done in consultation with the HIV practitioner as there may be drug interactions leading to reduced efficacy and other risks.

7.5 Contraception, missed pills

Missing active pills and extending hormone free interval leads to decreased contraceptive efficacy.

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>One active pill forgotten</td>
<td>Take pill as soon as remembered and take next one at usual time</td>
</tr>
<tr>
<td>Two active pills forgotten</td>
<td>Take last missed pill as soon as remembered and next one at usual time. Use condoms or abstinence for the following 7 days.</td>
</tr>
<tr>
<td>Two or more pills forgotten in the last 7 active pills of the pack</td>
<td>Omit the inactive tablets and immediately start the first active pill of the next pack.</td>
</tr>
<tr>
<td>Two or more pills forgotten during the first 7 active pills of the pack and sexual intercourse has occurred</td>
<td>Give emergency contraception, restart active pills 12 hrs later and advise additional precautions for the following 7 days</td>
</tr>
</tbody>
</table>

7.6 Contraception, emergency
Z30.9

! CAUTION !
Tablets must be taken as soon as possible, preferably within 72 hours of unprotected intercourse and not more than 5 days later.
Chapter 7  Family planning

- Levonorgestrel 0.75 mg, oral, 2 tablets as a single dose as soon as possible after unprotected intercourse.

Or if unavailable:
- Norgestrel/ethinyl oestradiol 0.5/0.05 mg, oral, 2 tablets as soon as possible after unprotected intercourse, followed by 2 tablets 12 hours later.
Chapter 8: Kidney and urological disorders

Kidney section
8.1 Chronic kidney disease (CKD)
8.2 Acute renal failure (ARF)
8.3 Glomerular disease (GN)
   8.3.1 Glomerular disease – Nephritic syndrome
   8.3.2 Glomerular disease – Nephrotic syndrome
8.4 Urinary tract infection
8.5 Prostatitis

Urology section
8.6 Haematuria
8.7 Benign prostatic hyperplasia
8.8 Prostate cancer
8.9 Enuresis
8.10 Impotence
8.11 Renal calculi
8.1 Chronic kidney disease (CKD)

**Description**
Structural or functional kidney damage present for > 3 months, with or without a decreased glomerular filtration rate (GFR).

Markers of kidney damage include:
- abnormalities in urine e.g. proteinuria or haematuria,
- abnormalities in blood e.g. uraemia,
- abnormalities in imaging tests e.g. small kidneys on ultrasound,
- abnormalities on pathological specimens e.g. glomerular disease on renal biopsy.

The creatinine clearance (CrCl) approximates GFR and may be estimated by the following formula:

**Adults**

- **Males:**
  \[
  \text{eGFR (mL/minute)} = \frac{(140-\text{age}) \times \text{weight (kg)}}{\text{serum Cr (micromol/L)}}
  \]

- **Females:**
  Multiply estimated CrCl by 0.85

**Children**

- **eGFR (mL/minute) =**
  \[
  \frac{K^* \times \text{height (cm)}}{\text{serum Cr (micromol/L)}}
  \]

  Where **K** is:
  - infants 0–18 months = 40
  - girls 2–16 years = 49
  - boys 2–13 years = 49
  - boys 13–16 years = 60

Common causes of chronic kidney disease include:
- hypertension
- diabetes mellitus
- glomerular diseases

Chronic kidney disease can be entirely asymptomatic BUT early detection and management can improve the outcome of this condition.
# Chapter 8  
## Kidney and urological disorders

### Treatment and prevention strategies according to stages

Estimation of the degree of kidney damage and staging is important to guide management and further prevent adverse outcomes of chronic kidney disease.

**Note:**

Adults with early CKD i.e. stages 0–3 can all be managed at primary care level **once** the cause and plan for care has been established. All children should be referred for investigation and initial management.

### Staging of kidney disease is essential for adequate management of CKD

<table>
<thead>
<tr>
<th>CKD Stage.</th>
<th>Description</th>
<th>Action</th>
</tr>
</thead>
</table>
| **Stage 0 or GFR > 90** | At increased risk for CKD, e.g.: diabetes mellitus, hypertension, glomerular disease and HIV | » Screening for advanced CKD and CVD disease  
» CKD risk reduction i.e. treat hypertension, diabetes and HIV |
| **Stage 1 or GFR > 90** | Kidney damage with normal GFR | » Diagnose and treat comorbid conditions  
See for Stage 0 |
| **Stage 2 or GFR 60–89** | Kidney damage with mild ↓ GFR | » Refer to determine cause and develop care plan.  
» While on the care plan, monitor the GFR in these patients and make sure kidney function is not worsening rapidly and watch for stage 3 |
| **Stage 3 or GFR 30–59** | Moderate ↓ GFR | Refer |
| **Stage 4 or GFR 15–29** | Severe ↓ GFR | Refer |
| **Stage 5 or GFR < 15** | Kidney failure requiring renal replacement therapy  
End stage renal disease | Refer |

GFR should be done yearly in all patients at increased risk.
Chapter 8  Kidney and urological disorders

General measures
» Reduce salt intake.
» Low protein diet is indicated in the presence of CKD stage 4 and 5.

Drug treatment
» Treat underlying conditions.
» Decrease significant proteinuria, if present.
  – Significant proteinuria = spot urine protein creatinine ratio of > 0.1 g/mmol or ACR (albumin-creatinine ratio) > 100 g/mol, confirm as positive if raised on at least 2 of 3 occasions, in the absence of infection, cardiac failure and menstruation.
See section 9.7.2: Diabetic nephropathy

Proteinuria
» In established chronic kidney disease, decrease proteinuria, irrespective of presence or absence of systemic hypertension.
» Monitor renal function and potassium especially with impaired renal function.
» If volume depleted, first rehydrate before commencing ACE-inhibitor.
» ACE-inhibitor are contraindicated in:
  – hyperkalaemia
  – known allergy to ACE-inhibitor
» Begin with low dosage of ACE-inhibitor and titrate up ensuring blood pressure remains in normal range and no side effects are present, up to the maximum dose or until the proteinuria disappears – whichever comes first.

Adults
• ACE inhibitor, e.g. enalapril, oral, 10–20 mg 12 hourly.

If ACE inhibitor cannot be used, refer.

Hyperlipidaemia
If hyperlipidaemia is a co-existent risk factor manage according to section 4.1: Prevention of ischaemic heart disease and atherosclerosis

Diabetes mellitus
» In diabetics, optimise control according to section 9.6: Diabetes mellitus type 2, in adults
» Avoid oral hypoglycaemics if GFR is < 60 because of the risk of lactic acidosis with metformin and prolonged hypoglycaemia with long acting sulphonylureas.

Hypertension
Treat if present.
See Section 4.7: Hypertension
Fluid overload
Treat fluid overload if present and refer.

Adults
- Furosemide, slow IV or oral, 12 hourly.
  - Adults: 40–80 mg
  - If poor response, repeat after 1 hour.
  - Do not give IV fluids – use heparin lock or similar IV access.

Children
- Furosemide, IV, 1 mg/kg immediately.
  - Do not put up a drip or run in any IV fluids

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Injection 10 mg/mL</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 3.5–5 kg</td>
<td>4 mg</td>
<td>0.4 mL</td>
<td>≥1–3 months</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>6 mg</td>
<td>0.6 mL</td>
<td>≥3–6 months</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>8 mg</td>
<td>0.8 mL</td>
<td>≥6–12 months</td>
</tr>
<tr>
<td>≥ 9–11 kg</td>
<td>10 mg</td>
<td>1 mL</td>
<td>≥12–18 months</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>12 mg</td>
<td>1.2 mL</td>
<td>≥18 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>15 mg</td>
<td>1.5 mL</td>
<td>≥3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>20 mg</td>
<td>2 mL</td>
<td>≥5–7 years</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>30 mg</td>
<td>3 mL</td>
<td>≥7–11 years</td>
</tr>
<tr>
<td>≥ 35 kg and above</td>
<td>40 mg</td>
<td>4 mL</td>
<td>≥11 years and adults</td>
</tr>
</tbody>
</table>

Note:
Exclude heart failure in patients with persistent pedal oedema.

Referral
- All cases of suspected chronic kidney disease stages 3–5 for assessment and planning
- All children
- All cases of CKD with:
  - haematuria,
  - proteinuria
  - raised blood urea or creatinine initially for assessment and planning
- Uncontrolled hypertension/fluid overload
- CKD associated with hyperlipidaemia
- No resolution of proteinuria with ACE-I therapy

Patients who might qualify for dialysis and transplantation or who have complications should be referred early to ensure improved outcome and survival on dialysis, i.e. as soon as GFR drops below 30 mL/min/1.73 m², or as soon as diagnosis is made/suspected.
8.2 Acute renal failure (ARF)

**Description**
This is (usually) reversible kidney failure, most commonly as a result of:
- dehydration and fluid loss
- drugs/toxins,
- urinary tract obstruction, and
- acute glomerulonephritis in older children

It is often recognised by:
- fluid overload
- decreased or no urine output
- blood result abnormalities of urea, creatinine or electrolytes.
- convulsions in children

**General measures**
- Give oxygen, and nurse in semi-Fowler’s position if patient has respiratory distress.
  Early referral is essential.
- If fluid overloaded:
  - stop all fluids oral and give no IV fluids
  - stop intake of all salt and potassium containing foods and fluids
- If not overloaded, dehydrated nor shocked:
  - no IV fluids
  - restrict oral fluid intake to 10 mL/kg/day daily plus visible fluid losses
  - arrange referral in the meantime
- If dehydrated or shocked:
  - treat immediately as in shock section.

**Drug treatment**

**Children**

- Under 6 years of age: > 120 mmHg systolic BP or 90 mmHg diastolic BP
- 6–15 years: > 130 mmHg systolic BP or 95 mmHg diastolic BP

- Nifedipine, oral, 0.25–0.5 mg/kg squirited into mouth.
  - Withdraw contents of 5 mg capsule with a 1 mL syringe:
    - 10 to 25 kg: 2.5 mg
    - 25 to 50 kg: 5 mg
    - over 50 kg: 10 mg
If there is respiratory distress (rapid respiration, chest indrawing):
- Furosemide, IV, 1 mg/kg immediately.
  - Do not put up a drip or run in any IV fluids

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Injection 10 mg/mL</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 3.5–5</td>
<td>4</td>
<td>0.4 mL</td>
<td>≥1–3 months</td>
</tr>
<tr>
<td>≥ 5–7</td>
<td>6</td>
<td>0.6 mL</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥ 7–9</td>
<td>8</td>
<td>0.8 mL</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥ 9–11</td>
<td>10</td>
<td>1 mL</td>
<td>≥12–18 months</td>
</tr>
<tr>
<td>≥ 11–14</td>
<td>12</td>
<td>1.2 mL</td>
<td>≥18 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5</td>
<td>15</td>
<td>1.5 mL</td>
<td>≥3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–25</td>
<td>20</td>
<td>2 mL</td>
<td>≥5–7 years</td>
</tr>
<tr>
<td>≥ 25–35</td>
<td>30</td>
<td>3 mL</td>
<td>≥7–11 years</td>
</tr>
<tr>
<td>≥ 35 kg and above</td>
<td>40</td>
<td>4 mL</td>
<td>≥ 11 years and adults</td>
</tr>
</tbody>
</table>

Adults
If diastolic blood pressure is greater than 100 mmHg or systolic blood pressure is above 150 mmHg:
- Amlodipine, oral, 5 mg as a single dose.

If there is respiratory distress (rapid respiration, orthopnoea):
- Furosemide, as an IV bolus, 80 mg.
  - Do not put up a drip and do not give a fluid infusion.

Referral
» All cases

Where adequate laboratory and clinical resources exists, management according to the hospital level guidelines may be instituted

8.3 Glomerular Diseases (GN)
N00–N08

Description
Glomerular disease may be a result of a primary condition of the kidney, or may be secondary to a systemic disorder. Can present with any, or a combination of the following:
» proteinuria
» reduced GFR (and its effects)
» haematuria
» hypertension and oedema.
Approach to care is outlined under the syndromes which follow.
Chapter 8  Kidney and urological disorders

Referral

» Unexplained haematuria on two to three consecutive visits
» Proteinuria > 1 g/24 hours or PCR > 0.1 g/mmol or ACR > 100 g/mol
» Nephritic syndrome
» Nephrotic syndrome
» Chronic Kidney Disease

Note:
Where facilities are available investigation should be done e.g. urine and electrolytes calculate the GFR or PCR

8.3.1 Glomerular disease - Nephritic syndrome
N01/N03

Description
Presents with a varied combination of:
» painless macroscopic turbid, bloody or brownish urine
» peripheral and facial oedema
» pulmonary oedema (circulatory overload)
» hypertension or hypertensive encephalopathy with impaired level of consciousness or convulsions
» little or no urine excretion

In children this is most commonly due to acute post streptococcal glomerulonephritis, but not exclusively so.

General measures
» Give oxygen, and nurse in semi-Fowlers position if patient has respiratory distress.
» Early referral essential especially if patient has had a hypertensive episode or fluid overload.
» If fluid overloaded:
  – stop all fluids oral and give no IV fluids
  – stop intake of all salt and potassium containing foods and fluids
» If not overloaded, dehydrated nor shocked:
  – no IV fluids
  – restrict oral fluid intake to 10 mL/kg/day daily plus visible fluid losses
  – arrange referral in the meantime
» If dehydrated or shocked:
  – treat immediately as in shock section.
Chapter 8  
Kidney and urological disorders

Drug treatment

Children
Fluid overload (rapid respiration, chest indrawing)
- Furosemide, IV, 1 mg/kg immediately.
  - Do not put up a drip or run in any IV fluids

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Injection 10 mg/mL</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 3.5–5 kg</td>
<td>4 mg</td>
<td>0.4 mL</td>
<td>≥ 1–3 months</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>6 mg</td>
<td>0.6 mL</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>8 mg</td>
<td>0.8 mL</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥ 9–11 kg</td>
<td>10 mg</td>
<td>1 mL</td>
<td>≥ 12–18 months</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>12 mg</td>
<td>1.2 mL</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>15 mg</td>
<td>1.5 mL</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>20 mg</td>
<td>2 mL</td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>30 mg</td>
<td>3 mL</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>≥ 35 kg and above</td>
<td>40 mg</td>
<td>4 mL</td>
<td>≥ 11 years and adults</td>
</tr>
</tbody>
</table>

If hypertension
Under 6 years of age: > 120 mmHg systolic BP or 90 mmHg diastolic BP
6–15 years: > 130 mmHg systolic BP or 95 mmHg diastolic BP
- Nifedipine, oral, 0.25–0.5 mg/kg squirited into mouth.
  - Withdraw contents of 5 mg capsule with a 1 mL syringe:
    - 10 to 25 kg: 2.5 mg
    - 25 to 50 kg: 5 mg
    - over 50 kg: 10 mg

Adults
Fluid overload
- Furosemide, as an IV bolus, 80 mg.
  - Do not put up a drip and do not give a fluid infusion

If hypertension
If diastolic blood pressure is greater than 100 mmHg or systolic blood pressure is above 150 mmHg:
- Amlodipine, oral, 5 mg as a single dose

Referral
» All cases
Chapter 8  Kidney and urological disorders

The definitive treatment of nephritis depends on the cause – an assumption of acute post streptococcal nephritis or any other disease cannot be made without specific investigation which may include renal biopsy.

8.3.2 Glomerular disease - Nephrotic syndrome

Description
Glomerular disease characterised by:
» severe proteinuria defined as:
  – children: ≥ 3 + proteinuria on dipstick test, or urine protein: creatinine ratio (PCR) ≥ 0.2 g/mmol on spot urine sample
  – adults: 2.5 g/day, or greater as determined by a spot urine protein measurement, i.e. protein creatinine ratio (PCR)
» and resultant ‘classical’ clinical picture (not always present) which includes:
  – oedema and
  – hypoalbuminaemia and
  – hyperlipidaemia.

Accurate diagnosis requires a renal biopsy.

Drug treatment
The management of glomerular disease depends on the type/cause of the disease and is individualised guided by a specialist according to the biopsy result.

Referral
» All cases

8.4 Urinary tract infection (UTI)

Description
Urinary tract infections may involve the upper or lower urinary tract. Infections may be complicated or uncomplicated.
Uncomplicated cystitis is a lower UTI in a non-pregnant woman of reproductive age and who has a normal urinary tract.
All other UTIs should be regarded as complicated.

Differentiation of upper from lower urinary tract infection in young children is not possible on clinical grounds.
Upper UTI is a more serious condition and requires longer and sometimes intravenous treatment. Features of upper UTI (pyelonephritis) that may be
detected in adults and adolescents include:

- flank pain/tenderness
- temperature 38°C or higher
- other features of sepsis, i.e.:
  - tachypnoea,
  - tachycardia
  - confusion, and
  - hypotension
- vomiting

In complicated, recurrent or upper UTIs, urine should be sent for microscopy, culture and sensitivity.

**Features of urinary tract Infections in children**

Signs and symptoms are related to the age of the child and are often non-specific.

Uncomplicated urinary tract infections may cause very few signs and symptoms. Complicated infections may present with a wide range of signs and symptoms.

**Neonates may present with:**

- fever
- poor feeding
- vomiting
- failure to thrive
- hypothermia
- sepsis
- prolonged jaundice
- renal failure

**Infants and children may present with:**

- failure to thrive
- persisting fever
- abdominal pain
- diarrhoea
- frequency
- dysuria
- enuresis or urgency

**In any child with fever of unknown origin, the urine must be examined.**

In children the diagnosis must be confirmed.

If a bag specimen reveals the following, a urine specimen must be collected aseptically for culture and sensitivity:

- positive leukocytes or nitrites on dipsticks in freshly passed urine
- motile bacilli and increased leukocytes or leukocyte casts on urine microscopy

Urine dipstix should be performed on a fresh urine specimen.

- If leucocytes and nitrites are not present, a urinary tract infection is highly unlikely.
- If leucocytes are present on a second specimen, a urinary tract infection must be suspected.
General measures

» Women with recurrent UTIs, should be advised to:
  – void bladder after intercourse and before retiring at night
  – not postpone voiding when urge to micturate occurs
  – change from use of diaphragm to an alternative type of contraception

Drug treatment

Empirical treatment is indicated only if:

» positive leucocytes and nitrites on freshly passed urine, or
» leucocytes or nitrites with symptoms of UTI, or
» systemic signs and symptoms.

Alkalising agents are not advised.

Uncomplicated cystitis

Adults:

- Ciprofloxacin, oral, 500 mg as single dose

Complicated cystitis

Adults:

- Ciprofloxacin, oral, 500 mg 12 hourly for 7 days

For pregnant women and adolescents:

- Amoxicillin/clavulanic acid 250/125 mg, oral, 1 tablet 8 hourly for 7 days

Children who do not meet criteria for urgent referral:

- Amoxicillin/clavulanic acid, oral, 12.5–20 mg/kg of amoxicillin component, 8 hourly for 5 days

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 3.5–5 kg</td>
<td>75/18.75 mg</td>
<td>Syrup 125/31.25 mg per 5 mL</td>
<td>3 mL 1.5 mL –</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>100/25 mg</td>
<td>Syrup 250/62.5 mg per 5 mL</td>
<td>4 mL 2 mL –</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>125/31.25 mg</td>
<td>–</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥ 9–11 kg</td>
<td>150/37.5 mg</td>
<td>Tablet 500/125 mg</td>
<td>6 mL 3 mL –</td>
</tr>
<tr>
<td>≥11–14 kg</td>
<td>187.5/46.9 mg</td>
<td>–</td>
<td>≥8 months–3 years</td>
</tr>
<tr>
<td>≥ 14–25 kg</td>
<td>250/62.5 mg</td>
<td>–</td>
<td>≥ 3–7 years</td>
</tr>
<tr>
<td>≥25 kg and above</td>
<td>250/125 mg</td>
<td>1 tablet</td>
<td>≥ 7 years and adults</td>
</tr>
</tbody>
</table>
Acute pyelonephritis
Outpatient therapy is only indicated for women of reproductive age, who do not have any of the danger signs – see referral criteria. All other patients should be referred.

- Ciprofloxacin, oral, 500 mg 12 hourly for 7–10 days

It is essential to give at least a 7-day course of therapy.

Referral

Urgent

» Acute pyelonephritis with:
  - vomiting
  - sepsis
  - diabetes mellitus

» Acute pyelonephritis in:
  - pregnant women
  - women beyond reproductive age
  - men

» Children over 3 months who appear ill.

» Children less than 3 months of age with any UTI.

Ill patients awaiting transfer

» Ensure adequate hydration with intravenous fluids

- Ceftriaxone, IM, 50–80 mg/kg/dose immediately as a single dose

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following injections mixed with water for injection (WFI):</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 2–2.5 kg</td>
<td>125 mg</td>
<td>250 mg WFI 2 mL 0.5 mL –</td>
<td>–</td>
</tr>
<tr>
<td>≥ 2.5–3.5 kg</td>
<td>200 mg</td>
<td>500 mg WFI 2 mL 1 mL –</td>
<td>≥ 1–3 months</td>
</tr>
<tr>
<td>≥ 3.5–5.5 kg</td>
<td>250 mg</td>
<td>1 000 mg WFI 3.5 mL 2 mL –</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>375 mg</td>
<td>500 mg WFI 3 mL 1 mL –</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>500 mg</td>
<td>625 mg WFI 4 mL 2 mL –</td>
<td>≥ 12–18 months</td>
</tr>
<tr>
<td>≥ 9–11 kg</td>
<td>500 mg</td>
<td>750 mg WFI 6 mL 3 mL –</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>625 mg</td>
<td>1 000 mg WFI 5 mL 3 mL –</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>750 mg</td>
<td>1 000 mg WFI 6 mL 4 mL 3.5 mL</td>
<td>≥ 5 years and adult</td>
</tr>
<tr>
<td>≥ 17.5 kg and above</td>
<td>1 000 mg</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

! CAUTION!
Do not administer calcium containing fluids, e.g. Ringer-lactate, within 48 hours of administering ceftriaxone.
Contra-indicated in neonatal jaundice.
Annotate dose and route of administration in referral letter.
Chapter 8  Kidney and urological disorders

Non-urgent
» All children for urinary tract investigations after completion of treatment
» No response to treatment.
» UTI more than 3 times within a one-year period in women, and more than 1 time for men
» Recurrent UTI in children for assessment and consideration of prophylaxis

8.5 Prostatitis
N41.0

Description
Infection of the prostate caused by urinary or STI pathogens.

Clinical features include:
» perineal, sacral or suprapubic pain
» dysuria and frequency
» varying degrees of obstructive symptoms which may lead to urinary retention
» sometimes fever
» acutely tender prostate on rectal examination

The condition may be chronic, bacterial or non-bacterial, the latter usually being assessed when there is failure to respond to antibiotics.

Drug treatment
Acute bacterial prostatitis
In men < 35 years or if there are features of associated urethritis (STI regimen):
• Cefixime, oral, 400mg as a single dose
Followed by:
• Doxycycline, oral, 100 mg 12 hourly for 7 days

In men > 35 years or if there is associated cystitis:
• Ciprofloxacin, oral, 500 mg 12 hourly for 14 days

Referral
» No response to treatment
» Urinary retention
» High fever
» Chronic/relapsing prostatitis
8.6 Haematuria

**Description**
Bleeding from the urinary tract, which can be from the kidneys, collecting system, bladder, prostate and urethra. Glomerular disease is suggested if proteinuria is present as well as casts on routine microscopy. Schistosomiasis (bilharzia) is a common cause of haematuria. **Exclude schistosomiasis.** When haematuria is accompanied by colicky pain a kidney stone should be excluded.

**Note:**
The presence of blood on urine test strips does not indicate infection and should be investigated as above.

**Drug Treatment**
If evidence of Schistosomiasis – treat as in Section 10.13: Schistosomiasis
If symptoms of UTI and leucocytes and nitrite positive in urine – treat as UTI

If Haematuria does not resolve rapidly after treatment referral for formal investigation will be required, i.e. next 48 hours.

**Referral**
» All cases not associated with schistosomiasis or UTI
» All cases not responding to specific drug treatment

8.7 Benign prostatic hyperplasia

**Description**
Benign prostatic hyperplasia is a noncancerous (benign) growth of the prostate gland. May be associated with both obstructive (weak, intermittent stream and urinary hesitancy) and irritative (frequency, nocturia and urgency) voiding symptoms. Digital rectal examination reveals a uniform enlargement of the prostate. Urinary retention with a distended bladder may be present in the absence of severe symptoms, therefore it is important to palpate for an enlarged bladder during examination.
Chapter 8  
**Kidney and urological disorders**

**General measures**

Annual follow-up with digital rectal examination (DRE). For patients presenting with urinary retention, insert a urethral catheter as a temporary measure while patient is transferred to hospital. Remove drugs that prevent urinary outflow e.g. tricyclics and neuroleptics.

**Referral**

» All patients with suspected BPH

**8.8 Prostate cancer**

D29.1

**Description**

Usually occurs in men over 50 years and is most often asymptomatic. Systemic symptoms, i.e. weight loss, bone pain, etc. occurs in 20% of patients. Obstructive voiding symptoms and urinary retention are uncommon.

The prostate gland is hard and may be nodular on digital rectal examination. As the axial skeleton is the most common site of metastases, patients may present with back pain or pathological fractures. Lymph node metastases can lead to lower limb lymphoedema.

Serum prostate specific antigen (PSA) is generally elevated and may be markedly so in metastatic disease.

**Referral**

» All patients with suspected cancer

**8.9 Enuresis**

R32

**Description**

Enuresis is bedwetting after the age of 5 years. It is a benign condition which mostly resolves spontaneously. It is important, however, to differentiate between nocturnal enuresis and enuresis during daytime with associated bladder dysfunction. Secondary causes of enuresis include:

» diabetes mellitus

» urinary tract infection

» physical or emotional trauma
Clinical evaluation should attempt to exclude the above conditions. Urine examination should be done on all patients.

**General measures**
- Motivate, counsel and reassure child and parents.
- Advise against punishment and scolding.
- Spread fluid intake throughout the day.
- Nappies should never be used as this will lower the child’s self esteem.

**Referral**
- Suspected underlying systemic illness or chronic kidney disease.
- Persistent enuresis in a child 8 years or older.
- Diurnal enuresis

**8.10 Impotence**
N48.4/F52.2

**Description**
The inability to attain and maintain an erect penis with sufficient rigidity for vaginal penetration. Organic causes include neurogenic, vasculogenic, endocrinological as well as many systemic diseases and medications.

**General measures**
- Thorough medical and psychosexual history
- Physical examination should rule out gynaecomastia, testicular atrophy or penile abnormalities.
- Consider the removal of drugs that may be associated with the problem.
- A change in lifestyle or medications may resolve the problem, e.g. advise cessation of smoking and alcohol abuse.

**Drug treatment**
- Treat the underlying condition.

**8.11 Renal calculi**
N20.2

**Description**
This is a kidney stone or calculus which has formed in the renal tract i.e. pelvis, ureters or bladder as a result of urine which is supersaturated with respect to a stone-forming salt.
Clinical features of obstructing urinary stones may include:

» sudden onset of acute colic, localized to the flank, causing the patient to move constantly.

» nausea and vomiting

» referred pain to the scrotum or labium on the same side as the stone moves down the ureter

Urinalysis usually reveals microscopic or macroscopic haematuria.

**General measures**

» Ensure adequate hydration.

**Drug treatment**

Adults:

Analgesia for pain, if needed:

- Morphine, 10–15 mg, IM/slow IV as a single dose and refer.

**Referral**

» All patients
Chapter 9: Endocrine System

Diabetes mellitus
9.1 Diabetes mellitus type 1, in children
9.2 Diabetes mellitus type 2, in adolescents
9.3 Diabetes mellitus type 1, in adults
9.4 Diabetic emergencies
   9.4.1 Hypoglycaemia in diabetics
   9.4.2 Diabetic ketoacidosis (DKA)
9.5 Metabolic syndrome/obesity/dyslipidaemia
9.6 Diabetes mellitus type 2, in adults
9.7 Microvascular complications of diabetes
   9.7.1 Diabetic foot
   9.7.2 Diabetic nephropathy
Diabetes mellitus

Description
Diabetes occurs either because of a lack of insulin (type 1) or additionally because of the presence of factors that oppose the action of insulin (type 2). The result is an increase in blood glucose concentration.

Diagnostic criteria
1. Symptoms of diabetes plus a random blood glucose $\geq 11.1$ mmol/L. Random is defined as any time of day without regard to time since last meal. The classic symptoms of diabetes include polyphagia, polyuria and, polydypsia, and in type 1 diabetes, unexplained weight loss.
2. Fasting plasma glucose $\geq 7.0$ mmol/L, or fasting blood glucose $\geq 6.1$ mmol/L. Fasting is defined as no caloric intake for at least 8 hours.
3. Two hour blood glucose $\geq 11.1$ mmol/L during oral glucose tolerance test using a 75 g glucose load.

General measures
» Achieve and maintain optimum weight.
» Dietary emphasis should be on fruit, vegetables, and low-fat dairy products on the one hand; and reduced amounts of fat, red meat, sweets, and sugar-containing beverages on the other.
   – a diet high in fruit and vegetables
   – low fat dairy products
   – variety of unsalted nuts
   – fish/skinless chicken in preference to red meat
   – restrict amounts of red meat

Person centred approach to diet therapy
The following issues need to be explored before counselling can be given:
» weight (and preferably weight history)
» most recent and previous glycated haemoglobin ($\text{HbA}_{1\text{c}}$) results
» diabetes medication
» diet assessment
» lifestyle and physical activity
» cultural, social and economic issues

Monitoring
» $\text{HbA}_{1\text{c}}$ annually in patients who meet treatment goals and 3–6 monthly in patients whose therapy has changed.
» Blood glucose should ideally be monitored at home in all patients on more than 2 daily doses of insulin.
» Weight, abdominal circumference (target less than 88 cm in women and 102 cm in men) and blood pressure at every visit.
» Potassium, creatinine and lipids annually
Chapter 9  

Endocrine System

» Fundoscopy annually (following dilation of the pupils)
» Proteinuria annually – See chapter 8: Kidney and urological disorders

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Optimal</th>
<th>Acceptable</th>
<th>Additional action suggested</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capillary blood glucose values (finger-prick)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>fasting (mmol/L)</td>
<td>4–6</td>
<td>6–8</td>
<td>&gt; 8</td>
</tr>
<tr>
<td>2-hour post-prandial (mmol/L)</td>
<td>4–8</td>
<td>8–10</td>
<td>&gt; 10</td>
</tr>
<tr>
<td>Glycated haemoglobin (HbA&lt;sub&gt;1c&lt;/sub&gt;) (%)</td>
<td>&lt; 7</td>
<td>7–8</td>
<td>&gt; 8</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>18.5 – 25</td>
<td></td>
<td>&gt; 27</td>
</tr>
</tbody>
</table>

Diabetes mellitus type 1 is always treated with insulin.
In diabetes mellitus type 2, drug treatment is initiated with oral hypoglycaemic agents, insulin may be needed at a later stage.

9.1 Diabetes mellitus type 1, in children

E10.9

Description

Diabetes mellitus type 1, previously known as juvenile onset diabetes mellitus and as insulin-dependent diabetes mellitus (IDDM).

Suspect diabetes in any child presenting with the following symptoms:
» loss of weight despite a good appetite
» polyuria
» polydipsia
» sweet smell on the breath with a positive test for urine ketones with or without loss or impairment of consciousness
» tiredness
» abdominal pain

Diagnosis

A diagnosis can be made when the classic symptoms of polyuria and polydipsia are associated with hyperglycaemia:
» random blood glucose (RBG) 11.1 mmol/L or higher

or

» fasting blood glucose (FBG) 7 mmol/L or higher

A small proportion of children present with less severe symptoms and may require fasting blood glucose measurement and referral to a specialist centre for assessment. Others may present with features of ketoacidosis.
Chapter 9

General measures

» A regular meal pattern is important.
» Regular exercise.
» Lifestyle modification, including self care practices.
» The patient should be told to carry a disease identification bracelet, necklace or card.
» Regular self glucose monitoring should be continued and the patients taught to self adjust insulin doses

Drug treatment

» Oral antidiabetic drugs should not be used to treat patients with type 1 diabetes.
» Almost all childhood diabetics require several insulin injections per day to control their diabetes.
» Prefilled insulin syringes should be made available for all children.
» The regimen is individualised depending on factors such as adherence. If adherence is good, then these patients may be candidates for basal / bolus regimens. Other children may be managed with biphasic insulin given twice daily.
» Adherence to insulin treatment regimens should be emphasised.

Referral

All children with suspected diabetes mellitus type 1 should be referred to hospital immediately for:
» confirmation of diagnosis
» initiation and stabilisation of therapy
» education
» long term monitoring of control
» ideally, management at a hospital with specialised services

9.2 Diabetes mellitus type 2, in adolescents

Description

The majority of adolescent diabetics are of type 1. However, an increasing number of adolescents are being diagnosed with type 2 diabetes. These patients may be diagnosed on screening; later presentation includes the classical symptoms of diabetes.

Criteria for screening for type 2 diabetes in children

» Body mass index is > 85% for age and gender
» Family history of diabetes
» Presence of hyperlipidaemia, hypertension or, polycystic ovarian syndrome.

and
Chapter 9  

Endocrine System

» Physical signs of puberty or age > 10 years

Referral

» All

9.3 Diabetes mellitus type 1, in adults  
E10.9

Description
Diabetes mellitus type 1, previously known as juvenile onset diabetes mellitus and as insulin-dependent diabetes mellitus (IDDM).

Diabetes mellitus type 1 presents with:

» hunger  » thirst
» polyuria  » weight loss
» ketoacidosis  » tiredness

Note:
All patients must be referred on presentation for diagnosis, stabilisation, initiation of treatment and planning.

General measures

» Dietary control, regular exercise and self care practices are important control factors.
» Regular home blood glucose monitoring.

Note:
The patient should be advised to carry a disease identification bracelet, necklace or card.

Drug treatment

As diabetes mellitus type 1 usually presents with diabetic ketoacidosis, treatment is usually initiated with insulin and the patient is stabilised at hospital level.

Types of insulins

• Insulin, short acting, SC, three times daily, 30 minutes prior to meals
  o Regular human insulin.
  o Onset of action: 30 minutes.
  o Peak action: 2–5 hours.
  o Duration of action: 5–8 hours.

• Insulin, intermediate acting, SC, once or twice daily usually at night at bedtime, approximately 8 hours before breakfast
  o Neutral Protamine Hagedorn (NPH) insulin.
Chapter 9  Endocrine System

- Onset of action: 1–3 hours.
- Peak action: 6–12 hours.
- Duration of action: 16–24 hours.

- Insulin, biphasic, SC, once or twice daily
  - Mixtures of regular human insulin and NPH insulin in different proportions, e.g. 30/70 (30% regular insulin and 70% NPH insulin).
  - Onset of action: 30 minutes.
  - Peak action: 2–12 hours.
  - Duration of action: 16–24 hours.

**Drawing up insulin from vials**

Clean the top of the insulin bottle with an antiseptic swab. Draw air into the syringe to the number of marks of insulin required and inject this into the bottle; then draw the required dose of insulin into the syringe. Before withdrawing the needle from the insulin bottle, expel the air bubble if one has formed.

» The skin need not be specially cleaned.
» Repeated application of antiseptics hardens the skin.
» Stretching the skin at the injection site is the best way to obtain a painless injection. In thin people it may be necessary to pinch the skin between thumb and forefinger of the left hand.
» The needle should be inserted briskly at almost 90 degrees to the skin to almost its whole length (needles are usually 0.6cm to 1.2 cm long).
» Inject the insulin.
» To avoid insulin leakage, wait 5 –10 seconds before withdrawing the needle.
» Injection sites need to be rotated to avoid lipohypertrophy.

**Referral**

» All patients

### 9.4 Diabetic emergencies

**Description**

Diabetics may present with a decreased level of consciousness due to hyperglycaemia (diabetic ketoacidosis (DKA) or hyperosmolar non-ketotic coma (HONK)) or hypoglycaemia. A blood glucose determination and urine test for ketones are essential to distinguish these conditions, as each one needs urgent management.

In all patients with abnormal levels of consciousness, try to determine if the blood glucose level is high or low.

If a diagnosis cannot be made, treat as hypoglycaemia and refer urgently. Low blood glucose presents the most immediate danger to life.
Chapter 9

Endocrine System

Diagnostic criteria

<table>
<thead>
<tr>
<th></th>
<th>Hyperglycaemia</th>
<th>Hypoglycaemia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DKA</td>
<td>HONK</td>
</tr>
<tr>
<td>Blood glucose test</td>
<td>11.1 mmol/L or higher</td>
<td>3.5 mmol/L or lower</td>
</tr>
<tr>
<td>Urine test for ketones</td>
<td>Usually positive and &gt; 1+</td>
<td>Negative usually negative</td>
</tr>
</tbody>
</table>

9.4.1 Hypoglycaemia in diabetics

E16.2

Description

Diabetic patients on therapy may experience hypoglycaemia for reasons such as intercurrent illness (e.g. diarrhoea), missed meals, inadvertent intramuscular injections of insulin or miscalculated doses of insulin, alcohol ingestion, and exercise without appropriate dietary preparation.

Hypoglycaemia in diabetic patients can be graded according to the table below:

<table>
<thead>
<tr>
<th>Mild hypoglycaemia</th>
<th>Moderate hypoglycaemia</th>
<th>Severe hypoglycaemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>» Capable of self treatment*</td>
<td>» Cannot respond to hypoglycaemia (i.e. cannot self treat)</td>
<td>» Semi-conscious or Unconscious/comatose</td>
</tr>
<tr>
<td>» Requires help from someone else</td>
<td>» Requires medical help</td>
<td></td>
</tr>
<tr>
<td>» May respond to prompting</td>
<td></td>
<td></td>
</tr>
<tr>
<td>» Oral treatment is successful</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Except children less than 6 years

Symptoms (autonomic)

- Tremors,
- Palpitations,
- Sweating,
- Hunger,
- Fatigue

Neurological symptoms (neuroglycopenia)

- Headache
- Mood changes
- Low attentiveness

Neurological signs (neuroglycopenia)

- Depressed level of consciousness/convulsions

*Note:

Children, particularly under 6 years of age, generally are not capable of self management and are reliant on supervision from an adult.

Patients may fail to recognise that they are hypoglycaemic when neuroglycopenia (impaired thinking, mood changes, irritability, dizziness, tiredness) occurs before autonomic activation.
Diagnosis

» Blood glucose < 3.5 mmol/L with symptoms in a known diabetic patient
» Blood glucose levels should be measured with a glucometer to confirm hypoglycaemia.

Hypoglycaemia must be managed as an emergency.
If a diabetic patient presents with an altered level of consciousness and a glucometer is not available, treat as hypoglycaemia.

Treatment

Mild or moderate hypoglycaemia
Immediate: oral rapidly absorbed simple carbohydrate, e.g.
» Sugar, oral, 5–15 g (± 1–3 teaspoons)
  – Wait 10–15 minutes.
  – If no response, repeat above.
As symptoms improve: the next meal or oral complex carbohydrate should be ingested, e.g. fruit, bread, cereal, milk, etc.

Severe hypoglycaemia

Children
• Dextrose 10%, IV, 2–5 mL/kg over 5 minutes
  o 10% solution – dilute 1 part dextrose 50% with 4 parts water for injection
or
If the IV route is not easily accessible
• Dextrose 10%, 5 mL/kg via a carefully placed nasogastric tube

Give adequate glucose to maintain normal blood glucose levels.

Adults
See section 21.11 Hypoglycaemia and hypoglycaemic coma

9.4.2 Diabetic ketoacidosis (DKA)
E10.1/E11.1

Description
Clinical features of DKA include:
» dehydration
» abdominal pain
» vomiting
» deep sighing respiration
» drowsiness, confusion, coma
» acetone/fruity smelling breath
Drug treatment

Note:
Early administration of large amounts of fluid initially is life saving.

Adults
Average deficit 6 L, and may be as much as 12 L.
Be cautious in renal and cardiac disease.
In the absence of renal or cardiac compromise:

- Sodium chloride 0.9%, IV, 15–20 mL/kg in the first hour
  - Subsequent infusion rate varies from 5–15 mL/kg/hour depending on the clinical condition.
  - Correction of estimated deficits should take place over 24 hours.
  - The volume infused in the first 4 hours should not exceed 50 mL/kg.

Refer urgently with drip in place and running at planned rate.

When referral will take more than 2 hours and a diagnosis of diabetes with hyperglycaemia is confirmed:

- Insulin, short acting, IM, 0.1 unit/kg

<table>
<thead>
<tr>
<th>!CAUTION!</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do not administer IV short-acting insulin if the serum electrolyte status, especially potassium is not known.</td>
</tr>
<tr>
<td>Continue with IV fluids but delay giving insulin in these cases in consultation with referral facility as this delay should not negatively influence the patient, but hypokalaemia with resultant cardiac dysrhythmias definitely will.</td>
</tr>
<tr>
<td>See section 21.10: Hyperglycaemia and ketoacidosis</td>
</tr>
</tbody>
</table>

Children

If in shock:

- Sodium chloride 0.9%, IV, 20 mL/kg within 1 hour as a bolus
  - If shock not corrected, repeat the bolus

If no shock or after shock is corrected

- Sodium chloride 0.9%, IV
  - 10 – 20 kg 75 mL/hour
  - 20 – 30 kg 110 mL/hour
  - 30 – 40 kg 140 mL/hour
  - 40 – 50 kg 165 mL/hour

Refer urgently with drip in place and running at planned rate.

When referral will take more than 2 hours and a diagnosis of diabetes with hyperglycaemia is confirmed and provided glucose is monitored hourly

- Insulin, short acting, IM, 0.1 units/kg as a bolus
  - When giving insulin IM, do not use insulin needle
Description
The metabolic syndrome is a cluster of risk factors:
» impaired glucose metabolism
» central obesity
» dyslipidaemia
» hypertension.

Diagnostic criteria
There is still some controversy as to whether the metabolic syndrome is a true syndrome or a cluster of risk factors. There are also varying diagnostic criteria around the world.

The more components of the syndrome, the higher the risk.
» Abdominal obesity, i.e. waist circumference > 102 cm in men, and > 88 cm in women.
» BMI: determined by weight in kg ÷ (height in m)²

<table>
<thead>
<tr>
<th>BMI (kg/m²)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>18.5 – 24.9</td>
<td>normal</td>
</tr>
<tr>
<td>25.0 – 29.9</td>
<td>overweight</td>
</tr>
<tr>
<td>30.0 – 34.9</td>
<td>mildly obese</td>
</tr>
<tr>
<td>35.0 – 39.9</td>
<td>moderately obese</td>
</tr>
<tr>
<td>&gt; 40</td>
<td>extremely obese</td>
</tr>
</tbody>
</table>

» Fasting plasma triglycerides > 1.70 mmol/L (HDL cholesterol < 1.04 mmol/L in men, and < 1.30 mmol/L in women)
» Blood pressure > 130/85 mmHg
» Fasting blood glucose > 6.10 mmol/L

General measures
A decrease in food intake together with an increase in physical activity is crucial to losing weight.

Drug treatment
Treat the metabolic risk factors, i.e. dyslipidemia, hypertension, and hyperglycemia
Hyperlipidaemia
Dyslipidemia may be successfully treated through lifestyle modifications alone. However, LDL-lowering medications may be indicated to achieve target LDL levels in higher risk patients, and thereby reduce risk for major cardiovascular disease events.

HMGC\(\text{CoA}\) reductase inhibitors (statins) are the first-choice lipid-lowering agents e.g.:
- Simvastatin, oral, 10 mg daily

Hypertension
See section 4.7: Hypertension

Hyperglycaemia
See section 21.10: Hyperglycaemia and ketoacidosis

9.6 Diabetes mellitus type 2, adults
E11

Description
Diabetes mellitus type 2 is a chronic debilitating metabolic disease characterised by an abnormally high blood glucose level with serious acute and chronic complications. It is an important component of the metabolic syndrome (syndrome X).

In adults the condition may only be diagnosed when complications are discovered, e.g.:
- ischaemic heart disease
- peripheral artery disease
- stroke
- deteriorating eyesight
- foot ulcers

Symptoms of an abnormally high blood sugar level are:
- thirst, especially noticed at night
- polyuria
- tiredness
- periodic changes in vision due to fluctuations in the blood glucose level
- susceptibility to infections, especially of the urinary tract, respiratory tract and skin

Note:
It is important to distinguish diabetes mellitus type 2 from diabetes mellitus type 1.
### Treatment targets

<table>
<thead>
<tr>
<th>Biochemical Index</th>
<th>Optimal</th>
<th>Acceptable</th>
<th>Additional action suggested</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capillary blood glucose values (finger-prick)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>fasting (mmol/L)</td>
<td>4 – 6</td>
<td>6 – 8</td>
<td>&gt; 8</td>
</tr>
<tr>
<td>2-hour post-prandial (mmol/L)</td>
<td>4 – 8</td>
<td>8 – 10</td>
<td>&gt; 10</td>
</tr>
<tr>
<td>Glycated haemoglobin (HbA₁C) (%)</td>
<td>&lt; 7</td>
<td>7–8</td>
<td>&gt; 8</td>
</tr>
<tr>
<td>Weight BMI (kg/m²)</td>
<td>&lt; 25</td>
<td>&gt; 27</td>
<td></td>
</tr>
</tbody>
</table>

- Control the blood sugar level and HbA₁C (value) within acceptable limits (determined by the physician) (glycaemic control)
- Prevent acute complications, e.g. hyperglycaemic and hypoglycaemic coma
- Manage chronic conditions associated with diabetes
- Prevent complications, e.g. foot care to prevent gangrene

### General measures

#### Diet and lifestyle

**Lifestyle changes** include:

- Weight loss
- Moderate daily exercise and increased physical activity e.g. walking at least half an hour for 3 days a week, clean house, climb stairs, etc.

See ideal weight table on page xxix

#### Diet rich in fruit and vegetables

- Eat 4 or 5 portions on a daily basis
  - One portion of which is a good source of vitamin C, e.g. tomato, cabbage family, citrus fruit and guavas
  - One portion, a dark green vegetable e.g. broccoli, green beans, spinach and baby marrow, or
  - One dark yellow/orange vegetable, e.g. carrots, pumpkin and butternut prepared without butter.
- Eat only one fruit (fresh) at a time.
  - Fruit must preferably be eaten with a meal or as a snack.
  - When eating dried fruit, limit the portion to the equivalent of a fresh fruit, e.g. 2 dried pear halves = 1 pear
- Low fat dairy products
  - Adults require 2 cups of milk per day i.e. skimmed milk
  - Limit the intake of cheese to a 30 g portion (a matchbox size or a third cup grated cheese) three times per week.
  - Where possible use low fat cheese.
- Nuts
- Fish/chicken in preference to red meat.
  - Chicken without the skin; fish should not be fried but steamed or grilled.
- Small amounts of red meat (lean portions) not more than three times per
Chapter 9

Endocrine System

week.
» Reduce total intake of fat and saturated fat
   - Use healthy types of fat, e.g. avocado pear, nuts, peanut butter, canola oil, canola margarine, olive oil and olives
   - Unhealthy fats include: hard margarine, butter, cheese and any type of oil heated to a high temperature.
   - Soft low fat margarine (in the tub) should preferably be used instead of butter or hard margarine.
   - Never use 2 “fats” on bread e.g. when using a spread containing fat, do not use margarine as well
» Restrict the intake of food high in cholesterol, e.g. egg yolks, tripe, caviar, fish roe, calamari, prawns and meat
   - A maximum of 1 egg a day is allowed.
» Increase intake of fibre
» Avoid refined foods e.g. sweets and sugary foods
   - Use food and drinks containing sugar sparingly and not between meals.
» Make starchy foods the basis of most meals e.g. whole-wheat or brown bread, rye bread, high fibre porridge (oats or whole wheat cereals),
» Other recommended foods:
   - Legumes, e.g. dried peas and beans, lentils and soya products
   - Brown rice
   - Samp
   - Whole-wheat pasta
» Water
   - Women should drink at least 4 glasses (of 250 mL) of water per day
   - Men should drink at least 6 glasses (of 250 mL) of water per day.

Drug treatment

To prevent long-term cardiovascular complications of diabetes:
» Statin therapy should be added to lifestyle changes for all type 2 diabetic patients, regardless of baseline lipid levels:
  • Simvastatin, oral, 10 mg daily
    o Maximum dose at PHC level: 10 mg daily
    o If higher doses are required, refer patient

Persistent proteinuria
See chapter 9: Kidney and urological disorders.
### STEP 1
Lifestyle modification plus metformin

<table>
<thead>
<tr>
<th>Entry to Step 1</th>
<th>Treatment and duration</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>» Typical symptoms - thirst, tiredness, polyuria and » Random blood glucose above 11 mmol/L or » Fasting blood glucose level ≥ 7 mmol/L</td>
<td>» Lifestyle modification for life » Appropriate diet » Weight loss until at ideal weight » Initiate drug therapy with: • Metformin » Assess monthly » If indicated: • Aspirin • Simvastatin</td>
<td>» Random blood glucose below 10 mmol/L or fasting glucose 6–8 mmol/L and/or » HbA$_1c$ 6–7.5%</td>
</tr>
</tbody>
</table>

**Biguanide**
In overweight patients biguanides should be the first choice unless contraindicated.

**Biguanides (metformin)**
Contraindicated in:
» chronic kidney disease, CrCl < 60 mL/min
» severe hepatic impairment
» pregnancy
- Metformin, oral, 500 mg daily.
  - Dose increments if the blood glucose is uncontrolled:
    - Increase to 500 mg 12 hourly after two weeks
    - Increase to 850 mg 12 hourly after another two weeks, if needed
- Maximum dose: 850 mg 8 hourly
**STEP 2**
**Add sulphonylurea**

<table>
<thead>
<tr>
<th>Entry to Step 2</th>
<th>Treatment and duration</th>
<th>Target</th>
</tr>
</thead>
</table>
| » Failed step 1: HbA₁<sub>c</sub> > 8 % or fasting blood glucose above 8 mmol/L despite adherence to treatment plan in step 1 and maximal dose of metformin for 2–3 months | » Lifestyle modification and  
» Combination oral hypoglycaemic agents, i.e.:  
• Metformin  
• Sulphonylurea | » Random blood glucose below 10 mmol/L  
or | 
» fasting glucose 6 – 8 mmol/L and/or | 
» HbA₁<sub>c</sub> 6 – 7.5% |
| or | Random blood glucose above 10 mmol/L despite adherence to treatment plan in step 1 and maximal dose of metformin for 2–3 months |

**Sulphonylureas** (glibenclamide or gliclazide)
Contraindicated in:
» chronic kidney disease, CrCl < 60 mL/min
» severe hepatic impairment
» pregnancy

**Missing meals while taking sulphonylureas may lead to hypoglycaemia.**

- Glibenclamide, oral, 2.5 mg in the morning with a meal.
  o Dose increments if the blood glucose is uncontrolled:
    Increase with 2.5 mg daily at two-weekly intervals.
    Maximum dose: 15 mg daily.
    If 7.5 mg daily or more is needed, divide the total daily dose into two, with the larger dose in the morning.
  o Use with caution in the elderly due to an increased risk of hypoglycaemia.
  o Every dose should be taken with a meal.

  or

- Gliclazide, oral, 40 mg daily in the morning with a meal.
  o Dose increments if the blood glucose is uncontrolled:
    Increase with 40 mg daily at two-weekly intervals.
    Maximum dose: 160 mg twice daily
    If more than 80 mg daily is needed then divide the total daily dose into two
  o Every dose should be taken with a meal.
STEP 3
Insulin therapy – See section 9.3: Diabetes mellitus type 1 in adults

» Insulin is indicated when oral combination therapy fails.
» Continue lifestyle modification.
» Insulin therapy must be initiated by a doctor
» Sulphonylurea should be discontinued once insulin therapy is initiated but continue with metformin.

Education on insulin therapy should include:

» types of insulin
» injection technique and sites
» insulin storage
» glucose monitoring, urine and blood
» meal frequency as this varies according to the type and frequency of insulin, e.g. patients may need a snack at night about 3–4 hours after the evening meal
» recognition and treatment of acute complications, e.g. hypoglycaemia and hyperglycaemia

<table>
<thead>
<tr>
<th>Insulin type</th>
<th>Starting dose</th>
<th>Increment</th>
<th>Maximum daily dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Add on therapy:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Intermediate to long-acting</td>
<td>10 units in the evening before bedtime</td>
<td>If 10 units not effective, increase gradually to 20 units</td>
<td>20 units</td>
</tr>
<tr>
<td>Substitution therapy:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Biphasic</td>
<td>Twice daily</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total daily dose: 15 units divided as follows:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 2/3 of total daily dose, i.e. 10 units, 30 minutes before breakfast</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 1/3 of total daily dose, i.e. 5 units, 30 minutes before supper</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4 units weekly</td>
<td>First increment is added to dose before breakfast</td>
<td>30 units</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Second increment is added to dose before supper.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Refer if more than 30 units are needed</td>
<td></td>
</tr>
</tbody>
</table>
Referral

Urgent – same day
- Metabolic complications:
- Dehydration and hypotension
- Nausea and vomiting
- Ketonuria (more than 1+)
- Keto-acidosis
- Hyperglycaemia over 25 mmol/L
- Complications, e.g. infections which may have the following symptoms:
  - slow onset of progressive apathy leading to confusion, stupor, pre-coma and coma
  - gangrene
  - sudden deterioration of vision
  - serious infections

Note:
Before transferring very ill patients, consider IV infusion with sodium chloride 0.9%.

Referral
- All type 1 diabetics
- Pregnancy
- Failure of step 4 to control diabetes

9.7 Microvascular complications of diabetes

9.7.1 Diabetic foot
E10.5/E11.5

Description
Ulcers develop at the tips of the toes and on the plantar surfaces of the metatarsal heads and are often preceded by callus formation. If the callus is not removed then haemorrhage and tissue necrosis occurs below the plaque of callus which leads to ulceration. Ulcers can be secondarily infected by staphylococci, streptococci, coliforms, and anaerobic bacteria which can lead to cellulites, abscess formation, and osteomyelitis.

Diagnosis
The three main factors that lead to tissue necrosis in the diabetic foot are:
- Neuropathy
- Infection, and
- Ischaemia.
General measures

» Removal of excess keratin by a chiropodist with a scalpel blade to expose the floor of the ulcer and allow efficient drainage of the lesion.
» Cleanse with sodium chloride 0.9% solution daily and apply non-adherent dressing

Drug treatment

• Amoxicillin/clavulanic acid 500/125 mg (625 mg), oral 8 hourly for 10 days

Referral

Urgent

Threatened limb, i.e. if the ulcer is associated with:
» Cellulitis
» Abscess
» Discolouration of surrounding skin, or
» Crepitus

9.7.2 Diabetic nephropathy

E10.2/E11.2

Description

Significant proteinuria = spot urine protein creatinine ratio of > 0.1 g/mmol or ACR (albumin-creatinine ratio) > 100 g/mol. Confirm as positive if raised on at least 2 of 3 occasions, in the absence of infection, cardiac failure and menstruation.

General measures

Screening

» Check annually for proteinuria in an early morning urine sample using a dipstix
» If dipstix positive:
  – check for urinary tract infection
  – obtain a laboratory urine protein: creatinine ratio (PCR)
» If dipstix negative, check urine albumin using laboratory or site-of-care urine albumin:creatinine ratio
» Measure serum creatinine annually, and calculate GFR
» If PCR or ACR is raised, repeat within 4 months.
» Confirm as positive if proteinuria or raised urine albumin on both occasions

Diet and lifestyle

» Limit protein intake < 0.8 g/kg daily, if proteinuric
» Advise smoking cessation
Drug treatment
Raised urine albumin or proteinuria or reduced GFR:
  » Start treatment with an ACE inhibitor and increase gradually to maximal
dose if tolerated, e.g.:
  • Enalapril, oral, 10 mg 12 hourly
    o  Monitor potassium.

Hypertension
Target BP: < 130/80 mm Hg
See section 4.7: Hypertension

Diabetes mellitus
Aim for HbA$_{1c}$ < 7%.
  » Intensify other renal and cardiovascular protection measures (not smoking,
aspirin therapy, lipid lowering therapy).

Referral
To nephrologists:
  » When GFR < 60 mL/minute or earlier if symptomatic.
Chapter 10: Infections and related conditions

10.1 Fever
10.2 Antiseptics and disinfectants
10.3 Chickenpox
10.4 Cholera
10.5 Dysentery, amoebic
10.6 Dysentery, biliary
10.7 Giardiasis
10.8 Malaria
  10.8.1 Falciparum malaria, severe
  10.8.2 Malaria, prophylaxis (Self provided care)
10.9 Measles
10.10 Meningitis
10.11 Mumps
10.12 Rubella (German measles)
10.13 Schistosomiasis
10.13 Typhoid fever
10.14 Tuberculosis
10.1 Fever

**Description**

Fever, i.e. temperature of 38°C or more, is a natural and sometimes useful response to infection, inflammation or infarction.

Fever alone is not a diagnosis.

Fever can cause convulsions in children under 6 years of age.

Heat stroke is a life threatening medical emergency, which is due to failure of heat loss usually following physical exertion in hot, humid environment. The temperature is more than 40.5°C. Treatment is urgent evaporative cooling – See Treatment

**Note:**

Temperature above 40°C needs urgent lowering with evaporative cooling. See Treatment.

Fluid losses are increased with fever.

In neonates and the elderly fever is often absent or preceded by other symptoms like confusion, failure to feed.

Malaria must be seriously considered in anyone with fever living in a malaria endemic area or if a malaria area has been visited in the past 12 weeks.

**General measures**

For patients with heat stroke or fever not responding to paracetamol:

- place patient in a cool place
- remove clothing
- cover patient with a wet sheet or towel – the water should be tepid and not too cold
- keep the sheet or towel wet with regular sponging
- fan the patient

**Drug treatment**

Only some patients with fever need to be treated:

- children under 6 years of age
- significant symptoms

- **Paracetamol**, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum of 4 doses per 24 hours
  - In children under 6 months calculate dose by weight

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 3.5–5 kg</td>
<td>48 mg</td>
<td>Syrup 120 mg/5mL</td>
<td>Tablet 500 mg</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>60 mg</td>
<td>2 mL</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.5 mL</td>
<td>–</td>
</tr>
</tbody>
</table>
Chapter 10  Infections and related conditions

<table>
<thead>
<tr>
<th>Weight Range</th>
<th>Dosage</th>
<th>Volume</th>
<th>Tablets</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 7–9 kg</td>
<td>96 mg</td>
<td>4 mL</td>
<td>–</td>
</tr>
<tr>
<td>9–14 kg</td>
<td>120 mg</td>
<td>5 mL</td>
<td>–</td>
</tr>
<tr>
<td>14–17.5 kg</td>
<td>180 mg</td>
<td>7.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>17.5–35 kg</td>
<td>240 mg</td>
<td>10 mL</td>
<td>¼ tablet</td>
</tr>
<tr>
<td>35–55 kg</td>
<td>500 mg</td>
<td>–</td>
<td>1 tablet</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>Up to 1000 mg</td>
<td>–</td>
<td>Up to 2 tablets</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Weight Range</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 6–12 months</td>
<td>–</td>
</tr>
<tr>
<td>≥ 12 months–3 years</td>
<td>–</td>
</tr>
<tr>
<td>≥ 3–5 years</td>
<td>–</td>
</tr>
<tr>
<td>≥ 5–11 years</td>
<td>–</td>
</tr>
<tr>
<td>≥ 11–15 years</td>
<td>–</td>
</tr>
<tr>
<td>≥ 15 years and adults</td>
<td>–</td>
</tr>
</tbody>
</table>

**CAUTION!**
Do not treat undiagnosed fever with antibiotics.
Do not give aspirin to children with fever.

**Referral**

» All patients with heat stroke.
» All children under 60 days of age with any one of the following:
  - axillary temperature > 37.5°C
  - decreased level of consciousness
  - breathing difficulties, i.e. respiratory rate > 60, chest indrawing or apnoea
  - bulging fontanelle
  - pus forming conditions, i.e. umbilical sepsis, skin sepsis, eye discharge associated with swollen eyelids and ear discharge
» All children in whom a definite and easily managed cause is not found.
» Fever that lasts for more than 3 days without finding a treatable cause.
» Fever that recurs.
» Fever combined with:
  - signs of meningitis
  - coma or confusion
  - toxic-looking patient
  - jaundice
  - convulsion
  - failure to feed

10.2 Antiseptics and disinfectants

**Description**

Disinfectants are used to kill micro-organisms on working surfaces and instruments, but cannot be relied on to destroy all micro-organisms. Antiseptics are used for sterilising skin and mucous membranes. **Do not** mix products.

**Disinfecting surfaces**

**Guidelines for the use of disinfectants**

» Never use a chemical if other more reliable methods are available.
Cleansing is the first and most important step in chemical disinfection. The disinfection fluid must entirely cover the object and penetrate all crevices. Use the recommended strengths for specific purposes. Disinfectants cannot sterilise surgical instruments. No chemical agent acts immediately - note the recommended exposure time. Equipment has to be rinsed after immersion in a chemical. Recontamination is very easy at this stage. Make sure that the rinsing water and all other apparatus are sterile. Equipment must not be stored in chemical disinfectants. The best disinfectant for killing HIV and other pathogens is a chlorinated solution such as bleach or hypochlorite:
- solutions must be prepared freshly
- and discarded after 24 hours to disinfect properly
- do not use on the skin

Intact skin
- Alcohol swabs may be used to swab before injections.
- Antiseptics like povidone iodine or chlorhexidine are used for surgical scrubbing.

Wounds and mucous membranes
- Chlorhexidine 0.05% aqueous solution can be used to clean dirty wounds.
- Sodium chloride 0.9% and sterile water are also used on clean wounds.
- Gentian violet 0.5% solution may be painted onto mucous membranes.

<table>
<thead>
<tr>
<th>Disinfectant</th>
<th>Indications</th>
<th>Directions for application</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chlorhexidine solution</td>
<td>Skin disinfection before surgery.</td>
<td>Remove all dirt, pus and blood before use.</td>
</tr>
<tr>
<td>o 0.05% aqueous solution</td>
<td>Cleaning dirty wounds.</td>
<td>Clean dirty wounds with 0.05% aqueous solution.</td>
</tr>
<tr>
<td>o 0.5% in 70% alcohol</td>
<td></td>
<td>Disinfect instruments with 0.5% in 70% alcohol solution.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Expensive, do not use for normal cleaning.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Use the correct concentration for a specific purpose.</td>
</tr>
</tbody>
</table>
Chapter 10  
Infections and related conditions

<table>
<thead>
<tr>
<th>Disinfectant</th>
<th>Indications</th>
<th>Directions for application</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Povidone iodine</td>
<td>» Skin and wound infections</td>
<td>» Use ointment for skin infection.</td>
</tr>
<tr>
<td>o solution 10%</td>
<td></td>
<td>» Use solution for cleaning skin and wounds.</td>
</tr>
<tr>
<td>o ointment 10%</td>
<td></td>
<td>» Avoid using on large wounds because of danger of iodine absorption</td>
</tr>
<tr>
<td>o cream 5%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Articles and instruments
» Adhere to the appropriate cleansing and disinfection policy.

10.3 Chickenpox
B01.9

Description
A mild viral infection that presents 2–3 weeks after exposure, with:
» mild fever preceding the rash
» lesions beginning on the trunk and face, later spreading to the arms and legs
» small, red, itchy spots that turn into blisters and burst to form scabs. These stages may all be present at the same time.

Chickenpox is infective for 6 days after the lesions have appeared or until all the lesions have crusted.
The infection is self-limiting with a duration of about 1 week.
Complications of encephalitis and pneumonia occur rarely and are more likely in adults and immunocompromised patients.

General measures
Isolate from immunocompromised people, and pregnant women until all lesions have crusted.
Ensure adequate hydration.
Cut fingernails very short and discourage scratching.

Drug treatment

! CAUTION!
Avoid the use of aspirin in children and adolescents under 16 years because of risk of Reye’s syndrome.
Chapter 10  Infections and related conditions

For itch:
- Calamine lotion, applied as needed.

In severe cases
- Chlorpheniramine, oral, 0.1 mg/kg/dose 6–8 hourly

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 9–11 kg</td>
<td>1 mg</td>
<td>Syrup 2 mg/5mL 2.5 mL</td>
<td>12–18 months</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>1.2 mg</td>
<td>–</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>1.5 mg</td>
<td>4 mL –</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>2 mg</td>
<td>5 mL –</td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>3 mg</td>
<td>7.5 mL –</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>≥35 kg and above</td>
<td>4 mg</td>
<td>1 tablet</td>
<td>≥ 11 years and adults</td>
</tr>
</tbody>
</table>

For pain and fever:
- Paracetamol, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum of 4 doses per 24 hours
  - In children under 6 months calculate dose by weight

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥3.5–5 kg</td>
<td>48 mg</td>
<td>Syrup 120 mg/5mL 2 mL</td>
<td>1–3 months</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>60 mg</td>
<td>2.5 mL –</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>96 mg</td>
<td>4 mL –</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥ 9–14 kg</td>
<td>120 mg</td>
<td>5 mL –</td>
<td>≥ 12 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>180 mg</td>
<td>7.5 mL –</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–35 kg</td>
<td>240 mg</td>
<td>10 mL ½ tablet</td>
<td>≥ 5–11 years</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>500 mg</td>
<td>–</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td>≥55 kg and above</td>
<td>Up to 1000 mg</td>
<td>Up to 2 tablets</td>
<td>≥ 15 years and adults</td>
</tr>
</tbody>
</table>

If skin infection is present due to scratching, treat as for bacterial skin infection.
Chapter 10  
Infections and related conditions

Immunocompromised patients and all cases with severe chickenpox: 
(Best results are achieved if treatment is started within 24 hours of the onset of rash)
- Aciclovir, oral, 6 hourly for 7 days (Doctor initiated)

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 3.5–5 kg</td>
<td>100 mg</td>
<td>Susp 200 mg /5 mL, Tablet 200 mg</td>
<td>≥ 1–3 months</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>140 mg</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>160 mg</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>≥ 9–11 kg</td>
<td>200 mg</td>
<td>5 mL, 1 tablet</td>
<td>≥ 12–18 months</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>240 mg</td>
<td>6 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 14–25 kg</td>
<td>300 mg</td>
<td>7.5 mL, 1½ tablets</td>
<td>≥ 3–7 years</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>400 mg</td>
<td>10 mL, 2 tablets</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>600 mg</td>
<td>–</td>
<td>3 tablets</td>
</tr>
<tr>
<td>≥55 kg and above</td>
<td>800 mg</td>
<td>–</td>
<td>4 tablets</td>
</tr>
</tbody>
</table>

Referral
- Complications such as:
  - meningoencephalitis
  - pneumonia
- Severely ill patients
- Pregnant women
- Neonates whose mothers had chicken pox within 7 days of delivery

10.4 Cholera  
(See Chapter 2 - Gastrointestinal conditions)

10.5 Dysentery, amoebic  
(See Chapter 2 - Gastrointestinal conditions)

10.6 Dysentery, bacillary  
(See Chapter 2 - Gastrointestinal conditions)

10.7 Giardiasis  
(See Chapter 2 - Gastrointestinal conditions)
**Chapter 10  Infections and related conditions**

**10.8 Malaria**

B54

**Note:** notifiable condition.

**Description**

The most important element in the diagnosis of malaria is a high index of suspicion in both endemic and non-endemic areas. Test any person resident in or returning from a malaria area **and** who presents with fever (usually within 3 months of exposure). The progression to severe falciparum malaria is rapid and early diagnosis and effective treatment is crucial.

**Pregnant women and young children up to 5 years of age are at particularly high risk of developing severe malaria.**

Clinical features include:

- severe headache
- fever above 38°C
- muscle and joint pains
- shivering attacks
- nausea and vomiting
- flu-like symptoms

Progression to severe malaria may occur and present with the following additional clinical features:

- sleepiness, unconsciousness or coma, convulsions
- respiratory distress and/or cyanosis
- jaundice
- renal failure
- shock
- repeated vomiting
- hypoglycaemia
- severe anaemia (Hb < 6 g/dL)

**Diagnosis**

Microscopic examination of thick and thin blood smears. Thick films are more sensitive than thin films in the detection of malaria parasites. Where rapid diagnostic tests, e.g. plasma reagent dipsticks are available, these can be used to diagnose malaria within 10–15 minutes.

**Note:**

If neither microscopy nor rapid tests are available diagnosis should be made on the basis of clinical symptoms.

A blood smear should be made and sent for microscopic examination.

One negative malaria test does not exclude the diagnosis of malaria.

**General measures**

Provide supportive and symptomatic relief.

Monitor for complications.
Chapter 10  Infections and related conditions

Ensure adequate hydration. All patients with *Plasmodium falciparum* malaria should be carefully observed for the first 24 hours.

**Drug treatment**

All first doses of drugs must be given under supervision and patients must be observed for at least an hour as vomiting is common in patients with malaria. Treatment must be repeated if the patient vomits within the first hour. Vomiting oral treatment is one of the commonest reasons for treatment failure.

In endemic areas of RSA where malaria occurs seasonally, it should be treated at PHC level. In other areas, patients should be referred for treatment.

**Uncomplicated *P. falciparum* malaria in South Africa**

(If unsure of species, treat as for *P. falciparum* malaria)

- Artemether/lumefantrine 20/120 mg, oral, with fat containing food/milk to ensure adequate absorption
  - Give the first dose immediately
  - Follow with second dose 8 hours later
  - Then 12 hourly for another 2 days (total number of doses in 3 days = 6)

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Tablet Artemether/lumefantrine 20/120 mg</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 10–15 kg</td>
<td>1 tablet</td>
<td>≥ 1–3 years</td>
</tr>
<tr>
<td>≥ 15–25 kg</td>
<td>2 tablets</td>
<td>≥ 3–8 years</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>3 tablets</td>
<td>≥ 8–12 years</td>
</tr>
<tr>
<td>≥ 35–65 kg</td>
<td>4 tablets</td>
<td>≥ 12 years and adults</td>
</tr>
</tbody>
</table>

For fever:

- **Paracetamol**, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum of 4 doses per 24 hours
  - In children under 6 months calculate dose by weight

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Syrup 120 mg/5mL</td>
<td>Tablet 500 mg</td>
</tr>
<tr>
<td>≥3.5–5 kg</td>
<td>48 mg</td>
<td>2 mL –</td>
<td>–</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>60 mg</td>
<td>2.5 mL –</td>
<td>–</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>96 mg</td>
<td>4 mL –</td>
<td>–</td>
</tr>
<tr>
<td>≥ 9–14 kg</td>
<td>120 mg</td>
<td>5 mL –</td>
<td>–</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>180 mg</td>
<td>7.5 mL –</td>
<td>–</td>
</tr>
<tr>
<td>≥ 17.5–35 kg</td>
<td>240 mg</td>
<td>10 mL ½ tablet</td>
<td>–</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>500 mg</td>
<td>– 1 tablet</td>
<td>–</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>Up to 1000 mg</td>
<td>– Up to 2 tablets</td>
<td>–</td>
</tr>
</tbody>
</table>
Chapter 10  Infections and related conditions

Referral

» All patients in non endemic areas.
» Patients not responding to oral treatment within 48 hours.
» Patients with *P. vivax* and *P. ovale* malaria.

10.8.1 Falciparum malaria, severe

**Description**

Any one of the following is associated with a higher mortality and requires urgent referral (give initial quinine dose as below):

» cerebral malaria (depressed level of consciousness or convulsions)
» severe anaemia (haemoglobin < 6 g/dL)
» jaundice
» vomiting
» shock
» spontaneous bleeding
» hypoglycaemia
» respiratory distress

**Drug treatment**

- Quinine dihydrochloride, IV or IM, 15–20 mg/kg immediately as a single dose and refer urgently.
  - IM: dilute quinine dihydrochloride in sodium chloride 0.9% (NaCl) to between 60 and 100 mg/mL. Inject half the volume immediately as a single dose in each thigh (anterior lateral) to reduce pain and prevent sterile abscess formation.
  - IV: dilute with 5–10 mL/kg of dextrose 5% and administer over 4 hours

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Injection 300 mg/mL</th>
<th>Use one of the following:</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 9–11 kg</td>
<td>150</td>
<td>0.5 mL</td>
<td>IM volume of NaCl 2 mL, IV volume of dextrose 5% 75 mL</td>
<td>≥ 12–18 months</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>200</td>
<td>0.7 mL</td>
<td>IM volume of NaCl 2.5 mL, IV volume of dextrose 5% 100 mL</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>250</td>
<td>0.8 mL</td>
<td>IM volume of NaCl 3 mL, IV volume of dextrose 5% 125 mL</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>350</td>
<td>1.2 mL</td>
<td>IM volume of NaCl 4.5 mL, IV volume of dextrose 5% 175 mL</td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>500</td>
<td>1.7 mL</td>
<td>IM volume of NaCl 7.5 mL, IV volume of dextrose 5% 250 mL</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>700</td>
<td>2.3 mL</td>
<td>IM volume of NaCl 10 mL, IV volume of dextrose 5% 350 mL</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>900</td>
<td>3 mL</td>
<td>IM volume of NaCl 10 mL, IV volume of dextrose 5% 450 mL</td>
<td>≥ 15 years and adults</td>
</tr>
</tbody>
</table>
Chapter 10  Infections and related conditions

Due to evolving resistance patterns in South Africa, refer to the most recent Malaria Treatment Guidelines from the Department of Health for the most suitable management in the various endemic areas. As these guidelines are updated regularly, the most recently updated guidelines should be followed.

Referral

Urgent
» Features of severe malaria.
» All children less than 1 year.
» Pregnant women, give dose of medication prior to referral.

10.8.2 Malaria, prophylaxis (Self provided care)

In the high-risk malaria areas from September to May in South Africa, malaria prophylaxis should be used, together with preventive measures against mosquito bites. State facilities do not provide prophylactic therapy. It is recommended that persons intending to travel to high-risk areas take the relevant prophylactic therapy.

Preventative measures against mosquito bites include:
» use of treated mosquito nets, screens, coils or pads
» application of insect repellent to exposed skin and clothing
» wearing long sleeves, long trousers and socks if outside between dusk and dawn, as mosquitoes are most active at this time
» visiting endemic areas only during the dry season

! CAUTION!
Pregnant women and children under 5 years should avoid visiting malaria-endemic areas, as they are more prone to the serious complications of malaria

Refer to National Malaria Guidelines.

10.9 Measles

Note: notifiable condition.

Case definition
» Fever
and
» Maculopapular (blotchy) rash
and
» Cough or coryza (runny nose) or conjunctivitis

172
Chapter 10  Infections and related conditions

Inform the local EPI co-ordinator about all cases of suspected measles, (i.e. which fulfil the case definition criteria). Send clotted blood and urine to confirm (or exclude) a diagnosis of measles.

Description
A viral infection that is especially dangerous in malnourished children or in children who have other diseases such as TB or HIV/AIDS. Initial clinical features occur 7–14 days after contact with an infected individual.

These include:
» symptoms and signs of a cold or flu
» fever
» diarrhoea
» conjunctivitis which may be purulent
» cough, bronchitis and otitis media

After 2–3 days a few tiny white spots like salt grains appear in the mouth (Kopliks’ spots)
The skin rash appears 1–2 days later and lasts about 5 days and:
» usually starts behind the ears and on the neck
» then on the face and body
» thereafter, on the arms and legs

Secondary bacterial infection (bronchitis, bronchopneumonia, otitis media) may occur, especially in children with poor nutrition or other concomitant conditions.

General measures
» Isolate the patient to prevent spread.

Drug treatment
All children under five years of age with measles should be given an extra dose of vitamin A unless the last dose received within a month:
• Vitamin A (retinol), oral, as a single dose
  o children 6 – 12 months: 100 000 IU
  o children more than 12 months: 200 000 IU

Give the first dose immediately. If the child is sent home, the caregiver should be given a second dose to take home, which should be given the following day.
For fever above 38.5°C (axillary), pain, or a history of febrile convulsions:

- **Paracetamol**, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum of 4 doses per 24 hours
  
  - In children under 6 months calculate dose by weight

<table>
<thead>
<tr>
<th>Weight</th>
<th>Dose</th>
<th>Use one of the following:</th>
<th>Age</th>
</tr>
</thead>
<tbody>
<tr>
<td>kg</td>
<td>mg</td>
<td>Syrup 120 mg/5mL</td>
<td>Tablet 500 mg</td>
</tr>
<tr>
<td>≥3.5–5 kg</td>
<td>48 mg</td>
<td>2 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥5–7 kg</td>
<td>60 mg</td>
<td>2.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥7–9 kg</td>
<td>96 mg</td>
<td>4 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥9–14 kg</td>
<td>120 mg</td>
<td>5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥14–17.5 kg</td>
<td>180 mg</td>
<td>7.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥17.5–35 kg</td>
<td>240 mg</td>
<td>10 mL</td>
<td>½ tablet</td>
</tr>
<tr>
<td>≥35–55 kg</td>
<td>500 mg</td>
<td>–</td>
<td>1 tablet</td>
</tr>
<tr>
<td>≥55 kg and above</td>
<td>Up to 1000 mg</td>
<td>–</td>
<td>Up to 2 tablets</td>
</tr>
</tbody>
</table>

**Children with diarrhoea:**

Treat dehydration according to Acute diarrhoea in children (Section 2.8.1)

**Children with pneumonia or otitis media:**

- **Amoxicillin**, oral, 25–30 mg/kg/dose 8 hourly for 5 days

<table>
<thead>
<tr>
<th>Weight</th>
<th>Dose</th>
<th>Use one of the following:</th>
<th>Capsule 250 mg</th>
<th>Age</th>
</tr>
</thead>
<tbody>
<tr>
<td>kg</td>
<td>mg</td>
<td>Syrup 125 mg/5mL</td>
<td>250 mg/5mL</td>
<td>months/years</td>
</tr>
<tr>
<td>≥2–2.5 kg</td>
<td>62.5 mg</td>
<td>2.5 mL</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>≥2.5–3.5 kg</td>
<td>100 mg</td>
<td>4 mL</td>
<td>2 mL</td>
<td>Birth to 1 month</td>
</tr>
<tr>
<td>≥3.5–5 kg</td>
<td>125 mg</td>
<td>5 mL</td>
<td>2.5 mL</td>
<td>≥ 1–3 months</td>
</tr>
<tr>
<td>≥5–7 kg</td>
<td>175 mg</td>
<td>7 mL</td>
<td>3.5 mL</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥7–11 kg</td>
<td>250 mg</td>
<td>10 mL</td>
<td>5 mL</td>
<td>≥ 6–18 months</td>
</tr>
<tr>
<td>≥11–14 kg</td>
<td>375 mg</td>
<td>15 mL</td>
<td>7.5 mL</td>
<td>≥ 18 months–5 years</td>
</tr>
<tr>
<td>≥14–55 kg</td>
<td>500 mg</td>
<td>–</td>
<td>10 mL</td>
<td>≥ 5–15 years</td>
</tr>
</tbody>
</table>
**Chapter 10  Infections and related conditions**

**Penicillin–allergic patients:**
- Erythromycin, oral, 10–15 mg/kg/dose 6 hourly

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months / years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 2.5–3.5 kg</td>
<td>35 mg</td>
<td>Syrup 125 mg / 5 mL</td>
<td>Tablet 250 mg</td>
</tr>
<tr>
<td>≥ 3.5–5 kg</td>
<td>50 mg</td>
<td>2 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>75 mg</td>
<td>3 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>100 mg</td>
<td>4 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 9–11 kg</td>
<td>125 mg</td>
<td>5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>150 mg</td>
<td>6 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 14–17.5</td>
<td>200 mg</td>
<td>8 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>250 mg</td>
<td>10 mL</td>
<td>1 tablet</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>375 mg</td>
<td>15 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 35 kg and above</td>
<td>500 mg</td>
<td>–</td>
<td>2 tablets</td>
</tr>
</tbody>
</table>

**Purulent conjunctivitis:**
- Chloramphenicol, 1%, ophthalmic ointment 8 hourly into lower conjunctival sac

**Referral**
- All adults
- Children under 6 months
- Children who are malnourished or immunocompromised, or who have TB
- Where complications are present. These include:
  - stridor/croup
  - pneumonia
  - dehydration
  - neurological complications
  - severe mouth and eye complications

Provide emergency treatment, if needed, before referral.

**10.10 Meningitis**
*(See Chapter 15 - Central nervous system)*
Chapter 10  Infections and related conditions

10.11 Mumps
B26.9

Description
Incubation period: 14–21 days
A viral infection primarily involving the salivary glands.
Signs and symptoms:
» fever
» pain on opening the mouth or eating
» about two days later a tender swelling appears below the ears at the angle of the jaw
» often first on one side and later on the other
» the swelling disappears in about 10 days

General measures
» Bed rest during febrile period.
» Isolate until swelling subsides.
» Advise on oral hygiene.
» Recommend plenty of fluids and soft food during acute stage.
» Patient is infectious from 3 days before parotid swelling to 7 days after it started. Children may return to school 1 week after initial swelling

Drug treatment
- **Paracetamol**, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum of 4 doses per 24 hours
  - In children under 6 months calculate dose by weight

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥3.5–5 kg</td>
<td>48 mg</td>
<td>2 mL Syrup 120 mg/5mL</td>
<td>≥1–3 months</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>60 mg</td>
<td>2.5 mL Tablet 500 mg</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>96 mg</td>
<td>4 mL –</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥ 9–14 kg</td>
<td>120 mg</td>
<td>5 mL –</td>
<td>≥ 12 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>180 mg</td>
<td>7.5 mL –</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–35 kg</td>
<td>240 mg</td>
<td>10 mL ½ tablet</td>
<td>≥ 5–11 years</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>500 mg</td>
<td>– 1 tablet</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td>≥55 kg and above</td>
<td>Up to 1000 mg</td>
<td>– Up to 2 tablets</td>
<td>≥ 15 years and adults</td>
</tr>
</tbody>
</table>

Referral
» Abdominal pain (to exclude pancreatitis)
» Painful testes or orchitis
» Suspected meningo-encephalitis
Chapter 10  Infections and related conditions

10.12 Rubella (German measles)
B06.9

Description
Incubation period: 14–21 days.
A viral infection with skin lesions that is less severe than measles and lasts only
3–4 days.
A maculopapular rash starts on the face spreading to the trunk, arms and legs. It
usually fades as it spreads.

Note:
If cough, coryza or conjunctivitis are also present, it is essential to exclude
measles – See case definition of measles.

Clinical features include:
» mild rash
» swollen and tender lymph nodes behind the ears (suboccipital)
» in adults, a small joint arthritis may occur

Note:
Infection during the first or second trimester of pregnancy may lead to severe
permanent deformities in the baby. Family should be counselled regarding these
risks and termination of pregnancy should be offered in all cases.

General measures
Bed rest if needed.
Isolate from pregnant women for seven days after onset of the rash.

Drug treatment
• Paracetamol, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum
  of 4 doses per 24 hours
  o In children under 6 months calculate dose by weight

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥3.5–5</td>
<td>48 mg</td>
<td>2 mL Syrup 120 mg/5mL</td>
<td>≥ 1–3 months</td>
</tr>
<tr>
<td>≥5–7</td>
<td>60 mg</td>
<td>2.5 mL Syrup 120 mg/5mL</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥7–9</td>
<td>96 mg</td>
<td>4 mL Syrup 120 mg/5mL</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥9–14</td>
<td>120 mg</td>
<td>5 mL Tablet 500 mg</td>
<td>≥ 12 months–3 years</td>
</tr>
<tr>
<td>≥14–17.5</td>
<td>180 mg</td>
<td>7.5 mL Tablet 500 mg</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥17.5–35</td>
<td>240 mg</td>
<td>10 mL Tablet 500 mg</td>
<td>≥ 5–11 years</td>
</tr>
<tr>
<td>≥35–55</td>
<td>500 mg</td>
<td>– 1 tablet 500 mg</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td>≥55 kg and above</td>
<td>Up to 1 000 mg</td>
<td>– Up to 2 tablets</td>
<td>≥ 15 years and adults</td>
</tr>
</tbody>
</table>
Chapter 10  Infections and related conditions

Referral

Urgent
» Pregnant women with rubella
» Pregnant women who have been in contact with a patient with rubella

10.13 Schistosomiasis
B65.9

Description
A parasitic infestation with:
» *Schistosoma haematobium*: primarily involves the bladder and renal tract, or
» *Schistosoma mansoni*: primarily involves the intestinal tract.
Infestation occurs during washing, bathing or paddling in water harbouring snails shedding this parasite.
Clinical features vary with the location of the parasite.
Most cases are asymptomatic.
Acute schistosomiasis, consisting of a non-specific febrile illness with marked eosinophilia, may occur in non-immunes several weeks following initial exposure, especially with *Schistosoma mansoni* infection.

Chronic schistosomiasis may present with local or systemic complications due to fibrosis, including urinary tract obstruction with ensuing renal failure, portal hypertension or other organ involvement.

<table>
<thead>
<tr>
<th>Clinical features</th>
<th><em>Schistosoma haematobium</em></th>
<th><em>Schistosoma mansoni</em></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>» blood in the urine</td>
<td>» diarrhoea with blood</td>
</tr>
<tr>
<td></td>
<td>» recurrent cystitis</td>
<td>and mucus in the</td>
</tr>
<tr>
<td></td>
<td>» other urinary symptoms</td>
<td>stools</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>» eggs in urine or stool on microscopy</td>
<td>» colicky abdominal pain</td>
</tr>
<tr>
<td></td>
<td>» rectal biopsy</td>
<td>» enlarged liver and spleen</td>
</tr>
</tbody>
</table>

General measures
If bilharzia is endemic, educate the community to avoid contact with contaminated water.
**Do not** urinate or pass stools near water used for drinking, washing or bathing.
**Do not** swim in contaminated water.
Collect water from rivers and dams at sunrise when the risk of infestation is lowest.
Chapter 10 Infections and related conditions

Boil all water before use

Drug treatment
In endemic areas patients with haematuria should be treated empirically. Exclude possible glomerulonephritis: raised blood pressure, oedema and shortness of breath. – See section 8.3: Glomerular Diseases (GN)
In non-endemic areas treatment should be given only if eggs of *S. haematobium* or *S. mansoni* are found in the urine/faeces.

- Praziquantel, oral, 40 mg/kg as a single dose

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Tablet 600 mg</th>
<th>Age years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 10–17.5 kg</td>
<td>600 mg</td>
<td>1 tablet</td>
<td>≥ 2–5 years</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>900 mg</td>
<td>1½ tablets</td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>1 200 mg</td>
<td>2 tablets</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>1 800 mg</td>
<td>3 tablets</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>3 000 mg</td>
<td>5 tablets</td>
<td>Adults</td>
</tr>
</tbody>
</table>

Referral
- Children under 2 years
- Ongoing urinary tract symptoms
- Signs of bleeding disorders or glomerulonephritis

10.13 Typhoid fever
(See Chapter 2 - Gastrointestinal conditions)

10.14 Tuberculosis
(See Chapter 17 - Respiratory conditions)
Chapter 11: Human immunodeficiency virus and acquired immunodeficiency syndrome (HIV AND AIDS)

Human immunodeficiency virus infection in adults
11.1 Antiretroviral therapy, adults
11.2 Opportunistic infections, prophylaxis in adults
   11.2.1 TB chemoprophylaxis
11.3 Opportunistic infections, treatment in adults
   11.3.1 Aphthous ulcers in HIV infection
   11.3.2 Candidiasis, oral
   11.3.3 Candida oesophagitis
   11.3.4 Diarrhoea, HIV associated
   11.3.5 Eczema, seborrhoeic
   11.3.6 Fungal nail infections
   11.3.7 Fungal skin infections
   11.3.8 Gingivitis, acute, necrotising, ulcerative
   11.3.9 Herpes simplex ulcers, chronic
   11.3.10 Herpes zoster (Shingles)
   11.3.11 Meningitis, cryptococcal
   11.3.12 Papular pruritic eruption
   11.3.13 Pneumonia, bacterial
   11.3.14 Pneumonia, pneumocystis
   11.3.15 Toxoplasmosis
   11.3.16 Tuberculosis (TB)

Human immunodeficiency virus infection in children
11.4 Antiretroviral therapy, children
11.5 Opportunistic infections, prophylaxis in children
   11.5.1 Immunisation
   11.5.2 TB chemoprophylaxis
11.6 Opportunistic infections, treatment in children
   11.6.1 Candidiasis, oral (thrush), recurrent
   11.6.2 Candida oesophageal
   11.6.3 Diarrhoea
   11.6.4 Pneumonia
   11.6.5 Measles and chickenpox
11.6.6 Skin conditions
11.6.7 Tuberculosis (TB)
11.7 Developmental delay or deterioration
11.8 Anaemia
11.9 Supportive care
11.10 HIV and kidney disease
Description

HIV enters lymphocytes and replicates, leading to progressive destruction of the immune system, until the infected person becomes unable to fight infection and develops the syndrome of Acquired Immune Deficiency Syndrome (AIDS).

During the course of the initial HIV infection antibodies are developed to the virus and the person changes from HIV negative to HIV positive. This is known as seroconversion or primary infection and is characterised by:
- glandular fever type illness
- maculopapular rash
- small orogenital ulcers

South African Adapted WHO staging system for HIV infection and disease in adults and adolescents

Clinical stage I
- Asymptomatic
- Persistent generalized lymphadenopathy

Clinical stage II
- Unexplained moderate weight loss (less than 10% of presumed or measured body weight)
- Recurrent respiratory tract infections (sinusitis, otitis media and pharyngitis)
- Herpes zoster (shingles)
- Angular cheilitis
- Recurrent oral ulceration
- Papular pruritic eruption
- Seborrhoeic dermatitis
- Fungal nail infections

Clinical stage III*
- Unexplained severe weight loss (more than 10% of presumed or measured body weight)
- Unexplained chronic diarrhoea for longer than 1 month
- Unexplained persistent fever (above 37.5°C intermittent or constant for longer than 1 month)
- Persistent oral candidiasis (thrush)
- Oral hairy leukoplakia
- Tuberculosis (pulmonary and extrapulmonary)
- Severe recurrent bacterial infections (such as pneumonia, empyema, pyomyositis, bone or joint infection, meningitis or bacteraemia)
- Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis
- Unexplained anaemia (< 8 g/dL), neutropaenia (< 0.5 × 10⁹/L) and/or chronic thrombocytopenia (< 50 × 10⁹/L)
Clinical stage IV*
» HIV wasting syndrome
» Pneumocystis pneumonia
» Recurrent severe bacterial pneumonia
» Chronic herpes simplex infection (orolabial, genital or anorectal of more than one month duration or visceral at any site)
» Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs)
» Kaposi's sarcoma
» Cytomegalovirus infection (retinitis or infection of other organs)
» Central nervous system toxoplasmosis
» HIV encephalopathy
» Extrapulmonary cryptococcosis including meningitis
» Disseminated non-tuberculous mycobacterial infection
» Progressive multifocal leukoencephalopathy
» Chronic cryptosporidiosis
» Chronic Isosporiasis
» Disseminated mycosis (extrapulmonary histoplasmosis or coccidiomycosis)
» Recurrent sepsicaemia (including non-typhoidal Salmonella)
» Lymphoma (cerebral or B cell non-Hodgkin)
» Invasive cervical carcinoma
» Atypical disseminated leishmaniasis
» Symptomatic HIV-associated nephropathy or symptomatic HIV-associated cardiomyopathy

* Note that TB has been moved to Stage 3 in the South African Adapted WHO Staging

Diagnosis
» Adequate pre- and post-test counselling must be provided
» Ensure patient confidentiality
» HIV in adults must be confirmed with a second test. This can either be two rapid tests, using kits from different manufacturers or with a laboratory test, usually ELISA
» There is a window period of up to 3 months in which antibodies are not detected by blood tests. This is the time period between becoming infected and the appearance of antibodies, which are detectable by blood tests

General measures
» Patients and their families must be supported and encouraged to join support or peer groups.
» Counsel patients on preventive methods of reducing the spread of the disease
  – use condoms during sexual intercourse
  – seek early treatment for sexually transmitted infections
  – safe handling of blood spills
Multivitamin, oral, once daily
  o Do not exceed the dose
  o Do not give with vitamin B complex

**Proposed content of formulation:**
- vitamin A: 700–800 mcg
- vitamin D: 200–300 units
- vitamin E: 10–15 mg
- ascorbic acid: (vitamin C) 70–90 mg
- folic acid: 200–400 mcg
- thiamine (vitamin B₁): 1.4–1.5 mg
- niacin: 10–20 mg
- riboflavin (vitamin B₂): 1.4–1.6 mg
- vitamin B₆: 1.9 mg–2.5 mg
- vitamin B₁₂: 1–3 mcg
- iron: 4–9 mg
- zinc: 5–15 mg
- selenium: 55–65 mcg
- copper: 1.5–2 mg

### 11.1 Antiretroviral therapy, adults

Only facilities accredited as CCMT service points may initiate long term ARV therapy.

For detail of criteria for initiation of ART, consult the latest National Clinical Guidelines for the Management of HIV and AIDS in Adults.

What follows in the text below is only a summary, which may not be applicable to patients with complications.

**! CAUTION !**

Anti-retroviral drugs frequently interact with TB drugs.
Consult the latest National Clinical Guidelines for the management of HIV and AIDS in adults.

All HIV-infected patients must have a CD4 count requested and WHO clinical staging done. The CD4 count should be repeated every 6 months. All eligible patients must be referred to the nearest CCMT service point for antiretroviral therapy. The patients should be counselled about antiretroviral therapy prior to referral.
Chapter 11 Human immunodeficiency virus and acquired immunodeficiency syndrome

Regimen 1

- Stavudine, oral, 30 mg 12 hourly

and

- Lamivudine, oral, 150 mg 12 hourly

plus

- Efavirenz, oral, 600 mg at night

For overweight patients with a BMI >28:

- Zidovudine, oral, 300 mg 12 hourly

For women of child-bearing potential:

- Nevirapine, oral, 200 mg daily for the first 2 weeks increasing to 200 mg 12 hourly thereafter

Regimen 2

- Zidovudine, oral, 300 mg 12 hourly

and

- Didanosine, oral, 400 mg once daily on an empty stomach
  - If < 60 kg: 250 mg once daily

plus

- Lopinavir/ritonavir 400/100 mg, oral, 12 hourly

Patients on long term ARV treatment, who become pregnant, should be referred back to their CCMT site.

Patients with a positive hepatitis B surface antigen:
The combination of tenofovir 300 mg daily and lamivudine 300 mg daily will replace:

- stavudine and lamivudine in regimen 1
- zidovudine and didanosine in regimen 2

Note:
In patients with hepatitis B, do not stop tenofovir and lamivudine as this can cause a severe flare of hepatitis B. Even if patients fail regimen 1 and commence regimen 2, continue with tenofovir and lamivudine, replacing zidovudine and didanosine.

Tenofovir may be substituted for stavudine if lipo-atrophy occurs. Tenofovir and lamivudine are recommended to substitute for stavudine and lamivudine or zidovudine and didanosine if patients develop symptomatic hyperlactataemia.
Primary prophylaxis with cotrimoxazole prevents many infections, e.g.:
- Pneumocystis pneumonia
- toxoplasmosis
- bacterial pneumonia
- bacteraemia
- isosporiasis

**Indications for primary prophylaxis:**
- WHO Clinical stage II, III or IV for HIV infection and disease in adults and adolescents
- CD4 count less than 200 cells/microL

**Prophylaxis may be discontinued if the CD4 count increases on antiretroviral therapy to more than 200 cells/microL for at least 6 months.**
- Cotrimoxazole, oral, 160/800 daily.

**Note:**
Cotrimoxazole hypersensitivity is common and usually presents as a maculopapular rash. If there are systemic features or mucosal involvement associated with the use of cotrimoxazole, the drug must be immediately and permanently stopped and the patient referred to hospital.
If a patient is referred back on antiretroviral agents, and the CD4 count has risen to more than 200 cells/microL, prophylaxis with cotrimoxazole can be stopped.

**11.2.1 TB chemoprophylaxis**

Patients with HIV infection are more susceptible to TB infection than HIV-negative patients.

The indication for preventive therapy is a Mantoux 5 mm or larger or a recent TB contact. Initiate only once active TB is excluded.

- Isoniazid, oral, 300 mg daily for 6 months.
  - Educate patients on the symptoms of hepatotoxicity and the need to be followed up monthly.
  - Instruct patient to present early if these symptoms arise.
- Pyridoxine, oral, 25 mg once daily

**Note:**
Only some primary care facilities are able to do Mantoux testing and exclude TB reliably. Consult with local TB Programme managers.
11.3 Opportunistic infections, treatment in adults

11.3.1 Aphthous ulcers in HIV infection
B20.3

**Description**
Painful ulcers in the oropharynx. Minor ulcers (<1 cm diameter) usually heal within 2 weeks. Major ulcers (>1 cm diameter) are very painful, often very deep and persist. Major ulcers generally resolve rapidly on antiretroviral therapy. Herpes simplex, histoplasmosis and mycobacteria may also present with major mucosal ulcers

**Drug treatment**
Minor aphthous ulcers:
- Choline salicylate/ cetalkonium chloride 8.7/0.01% oral gel, applied 6 hourly until healed

**Referral**
» Major aphthous ulcers for further diagnostic evaluation

11.3.2 Candidiasis, oral
B20.4

See section 1.2: Candidiasis, oral (thrush)

11.3.3 Candida oesophagitis
B20.4

**Description**
Infection of the oesophagus with candida, a fungus causing oral thrush. Occurs in patients with oral thrush who have pain or difficulty on swallowing. (See section 1.2: Candidiasis, oral (thrush))

**General measures**
» Maintain hydration

**Drug treatment**
- Fluconazole, oral, 200 mg daily for 14 days
  Note: Women of child-bearing age should use an effective contraceptive
Chapter 11  Human immunodeficiency virus and acquired immunodeficiency syndrome

Referral
» Inability to swallow
» Frequent relapses
» Poor response to fluconazole
» For ARV treatment

11.3.4 Diarrhoea, HIV associated
A09

Description
Diarrhoea that persists for longer than 2 weeks. Often associated with wasting. Stool for ova, cysts and parasites should be requested in all cases.

Drug treatment
If stool is negative for parasites or shows Cryptosporidium:
• Loperamide, oral, 2 mg as required
  o Maximum 8 mg daily

If stool shows Isospora belli:
• Cotrimoxazole, oral, 1920 mg (4 tablets) 12 hourly for 10 days followed by 960 mg (two tablets) daily

Referral
» Stool contains blood or mucus
» All cases for consideration for ARV treatment

11.3.5 Eczema, seborrheic
L30.9

See section 5.7.3: Dermatitis, seborrhoeic

11.3.6 Fungal nail infections
B37.2

This is common in HIV infected patients and can involve multiple nails. Treatment is not generally recommended because it is mostly of only cosmetic importance and therefore the risk of systemic therapy is not warranted. It generally resolves when patient is on antiretroviral therapy.
11.3.7 Fungal skin infections

B37.2

See section 5.5: Fungal infections of the skin

11.3.8 Gingivitis, acute necrotising ulcerative

K05.0

See section 1.3.3: Necrotising peridontitis

11.3.9 Herpes simplex ulcers, chronic

B20.3

**Description**

Painful ulcers due to herpes simplex virus, involving the skin around the anogenital area or in and around the mouth and nostrils in patients with advanced HIV infection. Ulcers persist for weeks and may be several centimeters in diameter.

**General measures**

» Keep affected areas clean with soap and water or diluted antiseptic solution.

**Drug treatment**

- Aciclovir, oral, 400 mg 8 hourly for 7 days

*For pain relief*

- Paracetamol, oral 1 000 mg when needed up to 4 times a day

**Referral**

» No response to therapy

» Frequent relapses

» For ARV treatment

11.3.10 Herpes zoster (Shingles)

B20.3

**Description**

Painful vesicular rash in a dermatomal distribution, usually presenting as a band on one side of the body, due to recrudescence of the varicella-zoster virus that causes chickenpox. The surrounding skin is inflamed and the vesicles often contain cloudy fluid. Secondary bacterial infection is often suspected, but is very uncommon. The elderly and HIV-infected are most affected.
Severe pain can occur after shingles has healed (post-herpetic neuralgia).

**Drug treatment**

If fresh vesicles are present:
- Aciclovir, oral, 800 mg five times daily (4 hourly missing the middle of the night dose) for 7 days.

If secondary infection is present:
- Erythromycin, oral, 500 mg 6 hourly

**For pain relief**
- Paracetamol, oral, 1 000 mg 6 hourly when needed

**plus**

**If inadequate pain relief**

**Add:**
- Tramadol, oral, 50 mg 6 hourly (Doctor initiated)

**For prolonged pain occurring after shingles has healed (post herpetic neuralgia), or if pain not responding to paracetamol and tramadol:**
- Amitriptyline, oral, 25 mg at night.
  - Increase dose to 50 mg after two weeks if needed
  - Increase further to 75 mg after a further two weeks if needed.

**Referral**

- Involvement of the eye
- Disseminated disease (many vesicles extending beyond the main area)
- Features of meningitis (headache and neck stiffness)
- Severe post-herpetic neuralgia not responding to amitriptyline

---

### 11.3.11 Meningitis, cryptococcal

**Description**

Fungal meningitis occurring in advanced HIV infection.
Present with headache, often lasting for weeks.
Neck stiffness is often absent.
Decreased level of consciousness, confusion and fever are common.

**Drug treatment**

All patients should be treated for cryptococcal meningitis at hospital level.
Patients may be down referred for secondary prophylaxis treatment.
Secondary prophylaxis
After completion of fluconazole 400 mg daily for 8 weeks:
- Fluconazole, oral, 200 mg daily for a minimum of 12 months.
  - Continue with fluconazole if the CD4 count does not increase to >200 cells/microL on antiretroviral therapy.

Referral
» All patients for initial management in hospital
» For ARV treatment

11.3.12 Papular pruritic eruption
L30.9

Description
Itchy inflamed papules at different stages of evolution. Healed lesions are often hyperpigmented. The itch is difficult to manage. It may flare after starting antiretroviral therapy, but generally improves as the CD4 count increases. It is essential to exclude scabies.

General measures
» Minimise exposure to insect bites, e.g. by regularly dipping pets.

Drug treatment
- Chlorpheniramine, oral, 4 mg 8 hourly
- Hydrocortisone acetate 1% cream, applied twice daily for 7 days.
  - Apply sparingly to the face.

11.3.13 Pneumonia, bacterial
J15

See section 17.3: Respiratory infections

11.3.14 Pneumonia, pneumocystis
B20.6

See section 17.3: Respiratory infections
11.3.15 Toxoplasmosis
B58.9

Initial diagnosis can only be made at hospital level.
- Cotrimoxazole, oral, 320/1 600 mg 12 hourly for 4 weeks,
  - Then 160/ 800 mg 12 hourly for 12 weeks.

Secondary prophylaxis
- Cotrimoxazole, oral 160/ 800 mg daily
  - Continue until the CD4 count has risen to >200 cells/microL on antiretroviral therapy.

Referral
  » For ARV treatment

11.3.16 Tuberculosis (TB)
B20.0

See section 17.3: Respiratory infections.

Human immunodeficiency virus infection in children
B33.3

Description
HIV enters lymphocytes and replicates, leading to progressive destruction of the immune system (CD4 cells). As the disease progresses, the CD4 cells decrease in number and quality making the HIV-infected person at risk of infections and other diseases e.g. cancers. The most advanced stage of disease is Acquired Immunodeficiency Syndrome (AIDS).

WHO staging of HIV and AIDS for children with confirmed HIV infection

Clinical Stage 1
  » Asymptomatic
  » Persistent generalised lymphadenopathy

Clinical Stage 2
  » Unexplained persistent hepatosplenomegaly
  » Papular pruritic eruptions
  » Extensive wart virus infection
  » Extensive molluscum contagiosum
  » Fungal nail infections
Recurrent oral ulcerations
Unexplained persistent parotid enlargement
Lineal gingival erythema
Herpes zoster
Recurrent or chronic upper respiratory tract infections (otitis media, otorrhoea, sinusitis, tonsillitis)

Clinical Stage 3
Unexplained moderate malnutrition not adequately responding to standard therapy
Unexplained persistent diarrhoea (14 days or more)
Unexplained persistent fever (above 37.5°C intermittent or constant, for longer than one month)
Persistent oral candidiasis (after the first 6 weeks of life)
Oral hairy leukoplakia
Acute necrotising ulcerative gingivitis or periodontitis
Lymph node tuberculosis
Pulmonary TB
Severe recurrent presumed bacterial pneumonia
Symptomatic lymphoid interstitial pneumonitis
Chronic HIV-associated lung disease including bronchiectasis
Unexplained anaemia (< 8 g/dL), neutropaenia (<0.5x10⁹/L) and/or chronic thrombocytopaenia (< 50x10⁹/L)

Clinical Stage 4
Unexplained severe wasting or severe malnutrition not responding to standard therapy
Pneumocystis pneumonia
Recurrent severe bacterial infections (such as empyema, pyomyositis, bone or joint infection or meningitis but excluding pneumonia)
Chronic herpes simplex infection; (orolabial or cutaneous of more than one month’s duration)
Extrapulmonary tuberculosis
Kaposi sarcoma
Oesophageal candidiasis (or candida of trachea, bronchi or lungs)
Central nervous system toxoplasmosis (after one month of life)
HIV encephalopathy
Cytomegalovirus infection: retinitis or cytomegalovirus infection affecting another organ with onset at age older than 1 month
Extrapulmonary cryptococcosis (including meningitis)
Disseminated endemic mycosis (extrapulmonary histoplasmosis, coccidiomycosis)
Chronic cryptosporidiosis
Chronic isosporiasis
Disseminated non-tuberculous mycobacteria infection
Cerebral or B cell non-hodgkin lymphoma
Progressive multifocal leukoencephalopathy
Symptomatic HIV-associated nephropathy or HIV-associated cardiomyopathy
Diagnosis in children

Infant HIV testing (0–18 months)

» Early HIV testing in infants exposed to HIV during pregnancy and/or breastfeeding is essential to optimise child survival because children can then access care, treatment and support as early as possible. HIV tests can never be 100% accurate. Therefore if HIV test results are discrepant with the clinical picture, repeat the HIV test.

» Testing children younger than 18-months:
  - Virological testing using PCR is the test of choice.
  - After counselling and consent is obtained, test ALL HIV-exposed infants at six weeks of age using PCR.
  - **If an infant is symptomatic for HIV infection, do not wait until 6 weeks** to perform the PCR test. Perform the test and retrieve the result as a matter of urgency. If PCR test result is negative, consider other causes for symptoms.
  - If the PCR test was performed earlier than 4 weeks of age in an HIV-exposed child and the result is negative, repeat the PCR at 6 weeks of age to exclude HIV infection.
  - Up to 18 months, an antibody test could be falsely positive, because of the presence of the circulating antibodies from the mother. An antibody test cannot definitively diagnose HIV in this age group.
  - However, a negative antibody test in children under the age of 18 months can be helpful in excluding HIV infection in symptomatic children.
  - In an HIV-exposed, HIV PCR negative breastfed infant, repeat PCR 6 weeks after cessation of breastfeeding. If the cessation of breastfeeding happens after the child turns 18 months then an antibody test is done.
  - In an HIV-exposed, HIV PCR negative breastfed child becomes symptomatic for HIV infection, perform a repeat PCR.

Testing children older than 18 months:

» At 18 months ALL HIV exposed children (PCR negative and positive) should be tested with an antibody test to confirm their HIV status to rule out false positive results and also to exclude a new infection

» HIV antibody testing can be used to confirm HIV status in children older than 18 months as contained in the VCT policy

» Testing should be done with counselling of parent/legal guardian/primary caregiver and, where appropriate, the child

Management of HIV infected children

All HIV positive children

All HIV positive children should receive standard preventative care, i.e.:

Immunisation – See chapter 15: Immunisation
Deworming – See section 2.1: Helminth infestation
Vitamin A – See section 3.3: Vitamin A deficiency
Chapter 11 Human immunodeficiency virus and acquired immunodeficiency syndrome

Children under 1 year of age:
» Refer as soon as possible to an accredited CCMT service point for assessment.

Children over 1 year of age:
» At PHC facility, do:
  – Routine clinical staging every 3 months
  – 6 monthly CD4 percentage and absolute count
» Once the child fulfils the medical and social criteria for ART, refer to a CCMT service point for initiation of ART.

Stabilised children on ART at PHC
» Ongoing care for children on ART includes:
  – Monitoring treatment adherence
  – Ensuring the child receives the necessary ARVs on a monthly basis
  – Referral for laboratory investigations and re-assessment as required
  – Assessment for drug side effects or other complications
  – Routine care for immunisation and weight monitoring as per the EPI schedule and the Road-to-Health card.
  – Management of intercurrent infections, including TB
  – Counselling and support of the parents/caregivers
  – Arranging for palliative care where appropriate with the support of NGOs.

General measures
» Ensure that a well-balanced diet is maintained.
» Support all members of the family:
  – psychosocial support
  – community support
» Infant feeding:
  – feeding choices are either, exclusive formula/replacement feeding or exclusive breastfeeding based on the AFASS criteria.
  – mixed breastfeeding should be discouraged
For each woman, the Acceptability, Feasibility, Affordability, Safety and Sustainability (AFASS) of avoiding all breastfeeding should be considered. The woman should be assisted to make the feeding choice that would be most appropriate for her individual situation, taking into account her home circumstances, the SAFETY of avoiding all breastfeeding and the background profile of childhood illness and mortality rate in the areas in which she lives.
11.4 Antiretroviral therapy, children

**CAUTION!**
Anti-retroviral drugs frequently interact with TB drugs. Consult the latest National Guideline for the Management for HIV-infected children.

**Eligibility for antiretroviral therapy**
Patients must satisfy all the clinical and social criteria before being accepted for treatment.

**Clinical Criteria**
Consult the latest National Guideline for the Management for HIV-infected children.

**Social criteria**
- At least one identifiable caregiver who is able to supervise the child for administering medication
  - All efforts should be made to ensure that the social circumstances of vulnerable children, e.g. orphans, are addressed so that they too can receive treatment.
- These criteria are extremely important for the success of the program and need to be adhered to – the principle is that adherence to treatment must be at least probable.

**Antiretroviral drug choices for children**
Only facilities accredited as CCMT service points may initiate long term ARV therapy. For detail of ARV therapy, consult the current National Guidelines. What follows in the text below is only a summary, which may not be applicable to patients with complications.

<table>
<thead>
<tr>
<th>Starting age under 3 years</th>
<th>1st Line</th>
<th>2nd Line</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Stavudine (d4T)</td>
<td>Zidovudine (AZT)</td>
</tr>
<tr>
<td></td>
<td>Lamivudine (3TC)</td>
<td>Didanosine (ddI)</td>
</tr>
<tr>
<td></td>
<td>Lopinavir/ritonavir (LPV/r)</td>
<td>Nevirapine (NVP) or Efavirenz (EFV)*</td>
</tr>
</tbody>
</table>

*Efavirenz if the child is over 3 years and > 10 kg; otherwise use nevirapine

<table>
<thead>
<tr>
<th>Starting age over 3 years and &gt; 10 kg</th>
<th>1st Line</th>
<th>2nd Line</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Stavudine (d4T)</td>
<td>Zidovudine (AZT)</td>
</tr>
<tr>
<td></td>
<td>Lamivudine (3TC)</td>
<td>Didanosine (ddI)</td>
</tr>
<tr>
<td></td>
<td>Efavirenz (EFV)</td>
<td>Lopinavir/ritonavir (LPV/r)</td>
</tr>
</tbody>
</table>
First line regimens

**Option 1.1**  
Age birth to 3 years or < 10 kg  
•  Stavudine, oral, 1 mg/kg/dose 12 hourly  
plus  
•  Lamivudine, oral, 4 mg/kg/dose 12 hourly  
plus  
•  Lopinavir/ritonavir 80/20, oral, 230 mg/m$^2$/dose of lopinavir component 12 hourly.  
  o  Administer with food.  
  o  A high-fat meal increases absorption, especially of the solution.  
  o  If co-administered with didanosine, didanosine should be given 1 hour before or 2 hours after lopinavir/ritonavir

**Option 1.2**  
Age > 3 years and > 10 kg  
•  Stavudine, oral, 1 mg/kg/dose 12 hourly  
plus  
•  Lamivudine, oral, 4 mg/kg/dose 12 hourly  
plus  
If < 40 kg  
•  Efavirenz, oral, 350 mg/m$^2$/dose as a single daily dose

Second line regimens

**Option 2.1**  
If previously on stavudine, lamivudine and lopinavir/ritonavir:  
•  Zidovudine, oral, 180–240 mg/m$^2$/dose 12 hourly after checking full blood count  
plus  
•  Didanosine, oral, 12 hourly  
  < 8 months  
  •  100 mg/m$^2$/dose  
  > 8 months  
  •  120 mg/m$^2$/dose  
  o  Can be given as a single daily dose in older children.  
  o  Do not give simultaneously with other ARV medication.  
  o  Administer 2 hours before/after other ARV medication.  
plus  
If age < 3 years or < 10 kg  
•  Nevirapine, oral, 120 mg/m$^2$/dose as a single daily dose for 2 weeks, then 12 hourly if no rash or severe side effects  
or  
If age > 3 years or > 10 kg  
•  Efavirenz, oral, 350 mg/m$^2$/dose as a single daily dose
Option 2.2
If previously on stavudine, lamivudine and efavirenz:

- Zidovudine, oral, 180–240 mg/ m²/dose 12 hourly
- Didanosine, oral, 12 hourly
  - < 8 months 100 mg/m²/dose
  - > 8 months 120 mg/m²/dose
  - Can be given as a single daily dose in older children.
  - Do not give simultaneously with other ARV medication.
  - Administer 2 hours before/after other ARV medication.
- Lopinavir/ritonavir 80/20, oral, 230 mg/m²/dose of lopinavir component 12 hourly
  - Administer with food.
  - A high-fat meal increases absorption, especially of the solution.
  - If co-administered with didanosine, didanosine should be given 1 hour before or 2 hours after lopinavir/ritonavir
  - Where TB treatment and lopinavir/ritonavir are given together seek expert advice on dosage adjustment
### Important side effects of ARVs requiring referral to/consultation with CCMT site:

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continue ART with careful monitoring.</td>
<td>Consider single drug replacement with expert advice.</td>
</tr>
<tr>
<td>Consider stopping treatment URGENTLY.</td>
<td>Consult expert.</td>
</tr>
<tr>
<td><strong>Symptomatic hyperlactataemia/lactic acidosis</strong></td>
<td>lactate 2.5–5 mmol/L</td>
</tr>
<tr>
<td><strong>anaemia</strong></td>
<td>Hb = 7.0–9.9 g/dL</td>
</tr>
<tr>
<td><strong>neutropenia</strong></td>
<td>0.4–1.2 X 10⁹/L</td>
</tr>
<tr>
<td><strong>increase liver enzymes and hepatitis</strong></td>
<td>≤ 9.9 X upper normal limit</td>
</tr>
<tr>
<td><strong>increased serum triglycerides</strong></td>
<td>5.65 – 8.48 mmol/L</td>
</tr>
<tr>
<td><strong>increased LDL cholesterol</strong></td>
<td>3.35–4.9 mmol/L</td>
</tr>
<tr>
<td><strong>skin reactions</strong></td>
<td>diffuse maculo-papular rash, or dry desquamation</td>
</tr>
<tr>
<td><strong>peripheral neuropathy</strong></td>
<td></td>
</tr>
<tr>
<td><strong>myopathy</strong></td>
<td></td>
</tr>
<tr>
<td><strong>abdominal pain</strong></td>
<td></td>
</tr>
<tr>
<td><strong>nausea and vomiting</strong></td>
<td></td>
</tr>
<tr>
<td><strong>pancreatitis</strong></td>
<td></td>
</tr>
<tr>
<td><strong>headache</strong></td>
<td></td>
</tr>
<tr>
<td><strong>fatigue</strong></td>
<td></td>
</tr>
<tr>
<td><strong>sedative effect</strong></td>
<td></td>
</tr>
<tr>
<td><strong>sleep disturbance</strong></td>
<td></td>
</tr>
<tr>
<td><strong>confusion</strong></td>
<td></td>
</tr>
<tr>
<td><strong>abnormal thinking</strong></td>
<td></td>
</tr>
<tr>
<td><strong>probably teratogenic</strong></td>
<td></td>
</tr>
<tr>
<td><strong>clinical evaluation:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Discuss all cases with a clinician with antiretroviral experience, before interrupting therapy</strong></td>
<td></td>
</tr>
</tbody>
</table>
Knowledge about HIV and AIDS is constantly being updated. Practices may require changes based on the latest information.

- Multivitamin syrup (with the recommended daily allowance of zinc), oral, daily
  - Less than 6 months: 2.5 mL
  - 6 months – 5 years: 5 mL
  - over 5 years: 10 mL

### 11.5 Opportunistic infections, prophylaxis in children

**Description**

Primary prophylaxis with cotrimoxazole prevents many infections, e.g.:

- Pneumocystis pneumonia
- toxoplasmosis
- bacterial pneumonia
- bacteraemia
- isosporiasis

Do a PCR test at 6 weeks (or earlier if child is symptomatic).

For long term prophylaxis if PCR is positive or until PCR is known to be negative:

- Cotrimoxazole, oral, once daily

<table>
<thead>
<tr>
<th>Age</th>
<th>Weight</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 6 weeks –2 months</td>
<td>≥ 2.5–5 kg</td>
<td>2.5 mL</td>
</tr>
<tr>
<td>≥ 2 –12 months</td>
<td>≥ 5–10 kg</td>
<td>5 mL</td>
</tr>
<tr>
<td>≥ 12 – 24 months</td>
<td>≥ 10–15 kg</td>
<td>7.5 mL</td>
</tr>
<tr>
<td>≥ 24–60 months</td>
<td>≥ 15–20 kg</td>
<td>10 mL</td>
</tr>
</tbody>
</table>

**When can prophylaxis be stopped?**

When there is evidence of immune reconstitution, i.e. in a child 18 months or older with a CD4 count of > 20% on more than 2 occasions no less than 3 months apart. If CD4 count is not available consider stopping cotrimoxazole only after 6 months of good ART adherence with clinical evidence of immune reconstitution. Cotrimoxazole may be of benefit even with clinical improvement. Mother no longer breastfeeding.
11.5.1 Immunisation
Z26.9

Follow the normal immunisation schedule. Siblings should also be fully immunised.

Do not give BCG to children with symptomatic HIV.
See chapter 13: Immunisation

11.5.2 TB Chemoprophylaxis
B20.0

See section 17.3.9: Tuberculosis

11.6 Opportunistic infections, treatment in children

11.6.1 Candidiasis, oral (thrush), recurrent
B20.4

- Nystatin suspension, oral, 100 000 IU/mL, 0.5 mL after each feed.
  or
  Gentian violet, 0.5%, topical aqueous solution, applied to the inside of the mouth three times daily
  o  Continue for 48 hours after cure.

If there is oral candidiasis and the child cannot swallow, this indicates the presence of oesophageal candidiasis – see below.
11.6.2 Candidiasis, oesophageal

- Fluconazole, oral, 3 mg/kg per day as a single daily dose for 21 days.
  - Maximum dose 200 mg a day.

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 2.5–3.5 kg</td>
<td>10 mg</td>
<td>1 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 3.5–5.5 kg</td>
<td>15 mg</td>
<td>1.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>25 mg</td>
<td>2.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>30 mg</td>
<td>3 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 9–11 kg</td>
<td>40 mg</td>
<td>4 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>50 mg</td>
<td>5 mL</td>
<td>1 capsule</td>
</tr>
<tr>
<td>≥ 14–25 kg</td>
<td>75 mg</td>
<td>7.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>100 mg</td>
<td>10 mL</td>
<td>2 capsules</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>150 mg</td>
<td>15 mL</td>
<td>3 capsules</td>
</tr>
</tbody>
</table>

11.6.3 Diarrhoea

See section 2.8: Diarrhoea

11.6.4 Pneumonia

See section 17.3: Respiratory infections

11.6.5 Measles and chickenpox

» Refer all patients

11.6.6 Skin conditions

These are common and include scabies, seborrhoeic eczema and others. See chapter 5: Skin conditions.

If no response to care as directed in the chapter, refer.
11.6.7 Tuberculosis (TB)  
B20.0

Manage children with TB according to the national TB guidelines. See section 17.3.9: Tuberculosis

TB should be considered earlier in non-resolving pneumonias. Tuberculin tests are often not reliable and a negative test does not exclude TB. If TB is suspected but cannot be proven, refer for diagnosis.

11.7 Developmental delay or deterioration  
B23.8

» Refer for assessment

11.8 Anaemia  
B23.8

See section 3.1: Anaemia

11.9 Supportive Care

Respite care in hospital or hospice or help in the home by community health workers, etc. can provide relief from the burden of nursing a dying family member and providing care at the same time. Counselling, listening, caring and loving can provide relief from grief and bereavement.

Pain relief  
See section 20.2: Chronic non-cancer pain.
Fever relief

» Tepid sponging

and/or

• **Paracetamol**, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum of 4 doses per 24 hours
  ○ In children under 6 months calculate dose by weight

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥3.5–5 kg</td>
<td>48 mg</td>
<td>Syrup 120 mg/5mL 2 mL</td>
<td>≥1–3 months</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>60 mg</td>
<td>Tablet 500 mg – 2.5 mL</td>
<td>≥3–6 months</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>96 mg</td>
<td>–</td>
<td>≥6–12 months</td>
</tr>
<tr>
<td>≥ 9–14 kg</td>
<td>120 mg</td>
<td>5 mL</td>
<td>≥12 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>180 mg</td>
<td>7.5 mL – 10 mL ½ tablet</td>
<td>≥3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–35 kg</td>
<td>240 mg</td>
<td></td>
<td>≥5–11 years</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>500 mg</td>
<td>1 tablet</td>
<td>≥11–15 years</td>
</tr>
<tr>
<td>≥55 kg and above</td>
<td>Up to 1000 mg</td>
<td>Up to 2 tablets</td>
<td>≥15 years and adults</td>
</tr>
</tbody>
</table>

### 11.10 HIV and kidney disease

**Description**

Various forms of kidney disorders are described among patients who are HIV positive.

Early detection of HIV kidney disease may be beneficial in an attempt to protect the kidney from further disease progression.

Screening should include all patients at time of HIV diagnosis.

Patients at high risk or susceptible for HIV renal disease include:

» CD4 count < 200 cells/microL

» History of nephrotoxic medications

» Comorbidity such as diabetes mellitus, hypertension, or hepatitis C virus co-infection

**Screening in HIV for Renal Disease**

» Tests should include:
  – A urinalysis for haematuria and proteinuria or albuminuria
  – A measure of kidney function, i.e. creatinine to estimate GFR

» If there is no evidence of kidney disease at the initial evaluation, screening
should be repeated annually.

6 monthly monitoring of kidney function and urinary markers of kidney damage is warranted for patients receiving tenofovir.

**Referral**

- Patients with persistent abnormal urinalysis.
- Estimated creatinine clearance less than 60 mL/minute.
Chapter 12: Sexually transmitted infections

12.1 Lower abdominal pain (LAP)
12.2 Vaginal discharge syndrome (VDS)
12.3 Male urethritis syndrome (MUS)
12.4 Scrotal swelling (SSW)
12.5 Genital ulcer syndrome (GUS)
12.6 Bubo
12.7 Balanitis/balanoposthitis (BAL)
12.8 Syphilis serology and treatment
12.9 Treatment of more than one STI syndrome
12.10 Genital molluscum contagiosum (MC)
12.11 Genital warts (GW) Condylomata Accuminata
12.12 Pubic lice (PL)

The syndromic approach to STI diagnosis and management is to treat the signs or symptoms (syndrome) of a group of diseases rather than treating a specific disease. This allows for the treatment of one or more conditions that often occur at the same time and has been accepted as the management of choice.

General measures

- Educate, ensure adherence, and counsel.
- Promote abstinence from penetrative sex during the course of treatment.
- Promote and demonstrate condom use, and provide condoms.
- Stress the importance of partner treatment and issue one notification slip for each sexual partner. Follow up partner treatment during review visits.

Promote HIV counselling and testing.
For negative test results repeat test after 3 months.
**If severe penicillin allergic, i.e. angioedema, anaphylactic shock or bronchospasm, replace ceftriaxone with:**
- **Ciprofloxacin**, oral, 500 mg 12 hourly for 3 days.
If no response after 48 hours – refer
Chapter 12 Sexually transmitted infections

12.2 Vaginal discharge syndrome

- Patient complains of abnormal vaginal discharge/dysuria or vulval itching/ burning

- Sexually active within the last 3 months?

  - NO

  - Consider vaginal candidiasis and/or bacterial vaginosis
    - Treatment
      - Metronidazole, oral, 2 g immediately as a single dose
      - Clotrimazole vaginal pessary 500 mg inserted immediately as a single dose or Clotrimazole vaginal cream, inserted with applicator 12 hourly for 7 days

  - YES

  - Abnormal discharge or vulval itching/burning confirmed?

    - YES

    - Treatment
      - Cefixime, oral, 400 mg as a single dose
      - Doxycycline, oral, 100 mg 12 hourly for 7 days
      - Metronidazole oral, 2 g immediately as a single dose

      In pregnancy / during breastfeeding:
      - Cefixime, oral, 400 mg as a single dose
      - Amoxicillin, oral, 500 mg 8 hourly for 7 days
      - Metronidazole, oral, 2 g immediately as a single dose
Sexually transmitted infections

Repeat treatment

Chapter 12

People who are allergic to penicillin may also react to cephalosporins.
**If severe penicillin allergic, i.e. angioedema, anaphylactic shock or
bronchospasm, replace cefixime with:
•
Ciprofloxacin, oral, 500 mg as a single dose (not in pregnancy or during
breast-feeding)
If no response after 48 hours – refer
***Penicillin allergic pregnant/breast-feeding women, replace amoxicillin
and cefixime with:
•
Erythromycin, oral 500 mg 6 hourly for 7 days
209


210

Chapter 12  Sexually transmitted infections

12.3 Male urethritis syndrome (MUS)

N34.1

People who are allergic to penicillin may also react to cephalosporins. **If severe penicillin allergic, i.e. angioedema, anaphylactic shock or bronchospasm, replace cefixime with:**
- Ciprofloxacin, oral, 500 mg as a single dose
If no response after 48 hours – refer.
Sexually active patient complains of scrotal swelling/pain

Take history and examine. Emphasise HIV testing.

» Scrotal swelling or pain confirmed?

YES

» Testes rotated and elevated or history of trauma or other non-tender swelling not thought to be due to sexual activity?

NO

Treatment
- Ceftriaxone, IM, 250 mg single dose**
- Doxycycline, oral, 100 mg 12 hourly for 14 days

Ask patient to return in 7 days if symptoms persist

YES

Complete treatment and discharge patient

NO

Refer urgently if suspected torsion.

Refer for surgical opinion.

People who are allergic to penicillin may also react to cephalosporins.

**If severe penicillin allergic, i.e. angioedema, anaphylactic shock or bronchospasm, replace ceftriaxone with:
- Ciprofloxacin, oral, 500 mg 12 hourly for 3 days.

If no response after 48 hours – refer
Chapter 12  Sexually transmitted infections

12.5 Genital ulcer syndrome (GUS)

A60.9

Patient complains of genital sore or ulcer with/without pain

Take history (including gynaecological) and examine (abdominal and vaginal). Emphasise HIV testing.

Sexually active within the last 3 months?

NO

Consider genital herpes
Emphasise HIV testing.

Treatment
• Aciclovir, oral, 400 mg 8 hourly for 7 days

YES

Treatment
• Benzathine benzylpenicillin*, IM, 2.4 MU immediately as a single dose
plus
• Erythromycin, oral, 500 mg 6 hourly for 7 days
plus
• Aciclovir, oral, 400 mg 8 hourly for 7 days

Pain relief if indicated
Review in 1 week.

Ulcer(s) healed or clearly improving?

NO

Emphasise HIV testing.
If no improvement, refer.

YES

Discharge patient

* Penicillin allergic men and non-pregnant women:
  » replace benzathine benzylpenicillin with:
  • Doxycycline, oral, 100 mg 12 hourly for 14 days
  » And replace erythromycin with:
  • Ciprofloxacin, oral, 500 mg 12 hourly for 3 days

* Penicillin allergic pregnant women/breast feeding women, replace benzathine benzylpenicillin with:
• Erythromycin, oral, 500 mg 6 hourly for 14 days
If no response after 48 hours – refer.
Chapter 12  Sexually transmitted infections

12.6 Bubo

A58

Patient complains of hot tender inguinal swelling with surrounding erythema and/or oedema

Take history and examine. Emphasise HIV testing. Exclude hernia or femoral aneurysm.

» Bubo confirmed?

YES

Treatment

- Doxycycline, oral, 100 mg 12 hourly for 14 days
- Ciprofloxacin, oral, 500 mg 12 hourly for 3 days

In pregnancy/during breast-feeding, replace the above with:
- Erythromycin, oral, 500 mg 6 hourly for 14 days

If bubo is fluctuant

Aspirate pus in sterile manner. Repeat every 72 hours, as necessary.

If ulcer is also present

- Benzathine benzylpenicillin, IM, 2.4 MU immediately as a single dose
- Aciclovir, oral, 400 mg 8 hourly for 7 days
Chapter 12  Sexually transmitted infections

12.7 Balanitis/balanoposthitis (BAL)

Patient complains of soreness / itching of glans, inability to retract foreskin, malodour

Take history and examine. Emphasise HIV testing.

Retract foreskin, clean with water filled syringe and dry
Re-examine

» Foreskin cannot be retracted

Complicated case: Refer.

» Symptoms confirmed?

YES

Treatment
Instruct on retraction of foreskin when washing. Wash daily with water avoid soap while inflamed
• Clotrimazole cream, applied 12 hourly for 7 days
Perform urinalysis for glycosuria. If positive, refer.

Patient returns after 7 days

» Poor adherence to clotrimazole?

NO
Treatment failure: Refer.

YES
Repeat treatment
12.8 Syphilis serology and treatment

Syphilis serology

The Rapid Plasmin Reagin (RPR) and Venereal Diseases Reference Laboratory (VDRL) tests measure disease activity, but are not specific for syphilis. False RPR/VDRL positive reactions may occur, notably in patients with connective tissue disorders (false positive reactions are usually low titre <1:8). For this reason, positive RPR/VDRL results should be confirmed as due to syphilis by further testing of the serum with a specific treponemal test, e.g.:

- Treponema pallidum haemagglutination assay (TPHA),
- Treponema pallidum particle agglutination assay (TPPA)
- Fluorescent Treponemal Antibody (FTA) test, and
- Treponema pallidum ELISA.

Once positive, specific treponemal tests generally remain positive for life.

The RPR/VDRL can be used:

- to determine if the patient’s syphilis disease is active or not,
- to measure a successful response to therapy (at least a fourfold reduction in titre, e.g. 1:256 improving to 1:64), or
- to determine a new re-infection.

Some patients, even with successful treatment for syphilis, may retain life-long positive RPR/VDRL results at low titres (≤1:8), which do not change by more than one dilution difference over time (so-called serofast patients).

Note:

Up to 30% of primary syphilis cases, i.e. those with genital ulcers, may have a negative RPR/VDRL.
The RPR/VDRL is always positive in the secondary syphilis stage and remains high during the first two (infectious) years of syphilis.

**RPR/VDRL should be repeated in three months in patients following sexual assault.**
Chapter 12  Sexually transmitted infections

Perform RPR/VDRL if indicated:
- sexual assault case
- suspected secondary syphilis
- suspected tertiary syphilis
- 3 month follow-up of recently treated early syphilis case
- pregnancy as routine screening

RPR/VDRL Positive

YES

RPR/VDRL Negative

NO

Previous RPR/VDRL results available?

NO

Symptoms/ signs of genital ulcer or secondary syphilis present?

YES

Benzathine benzylpenicillin, IM, 2.4 MU immediately as a single dose

NO

Benzathine benzylpenicillin, IM, 2.4 MU once weekly for 3 weeks

YES

What was the last positive RPR/VDRL?

Current RPR/VDRL is 4 fold or more higher than the previous RPR/VDRL, e.g. was 1:8 now 1:32 or higher

Last RPR/VDRL less than 2 years ago?

YES

Benzathine benzylpenicillin, IM, 2.4 MU immediately as a single dose

NO

Benzathine benzylpenicillin, IM, 2.4 MU once weekly for 3 weeks

Current RPR/VDRL is 4 fold lower, or in a known serofast patient, is the same, lower or no more than 2 fold higher than the previous RPR/VDRL, e.g. was 1:4 now no more than 1:8 (*See text)
Chapter 12  Sexually transmitted infections

Late and early syphilis
» record titre on patient’s record
» issue a partner notification slip
and
» repeat RPR/VDRL in 3 months

Drug Treatment
Early syphilis treatment
Check if treated at initial visit.
• Benzathine benzylpenicillin, IM, 2.4 MU immediately as a single dose

In penicillin-allergic patients:
• Doxycycline, oral, 100 mg twice daily for 14 days

If penicillin-allergic and pregnant: See Section 6.2.4 Syphilis in pregnancy.
• Erythromycin, oral, 500 mg four times a day for 14 days

Note:
Erythromycin does not reliably cure syphilis in either the mother or the baby. It is essential to re-treat both the mother and the baby.

Baby
See Section 6.2.4 Syphilis in pregnancy.

Mother, once she has stopped breast-feeding
• Doxycycline, oral, 100 mg twice daily for 14 days

Late syphilis treatment
Check if treatment was commenced at initial visit.
• Benzathine benzylpenicillin, IM, 2.4 MU once weekly for 3 weeks

In penicillin-allergic patients:
• Doxycycline, oral, 200 mg twice daily for 21 days

If penicillin-allergic and pregnant:
See Section 6.2.4 Syphilis in pregnancy.
• Erythromycin, oral, 500 mg four times a day for 28 days

Note:
Erythromycin does not reliably cure syphilis in either the mother or the baby. It is essential to re-treat both the mother and the baby.

Baby
See Section 6.2.4 Syphilis in pregnancy.

Mother, once she has stopped breast-feeding
• Doxycycline, oral, 200 mg twice daily for 21 days
## 12.9 Treatment of more than one STI syndrome

<table>
<thead>
<tr>
<th>STI syndromes</th>
<th>Treatment (new episode)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MUS + SSW</td>
<td>Treat according to SSW flow chart</td>
</tr>
</tbody>
</table>
| MUS + BAL     | Treat according to MUS flow chart  
plus  
- Clotrimazole cream, 12 hourly for 7 days  

| MUS + GUS     |  
• Cefixime, oral, 400 mg immediately as a single dose  
plus  
• Benzathine benzylpenicillin*, IM, 2.4 MU immediately as a single dose  
plus  
• Doxycycline, oral, 100 mg 12 hourly for 7 days  
plus  
• Aciclovir, oral, 400 mg 8 hourly for 7 days  

| VDS + LAP     | Treat according to LAP flow chart  
plus  
treat for candidiasis, if required  

| VDS + GUS (non-pregnant) |  
• Cefixime, oral, 400 mg immediately as a single dose  
plus  
• Metronidazole, oral, 2 g immediately as a single dose  
plus  
• Benzathine benzylpenicillin*, IM, 2.4 MU immediately as a single dose  
plus  
• Doxycycline, oral, 100 mg 12 hourly for 7 days  
plus  
• Aciclovir, oral, 400 mg 8 hourly for 7 days  
plus  
• treat for candidiasis, if required  

---
## Chapter 12  Sexually transmitted infections

<table>
<thead>
<tr>
<th>STI syndromes</th>
<th>Treatment (new episode)</th>
</tr>
</thead>
</table>
| VDS + GUS (pregnant, breastfeeding) | • Cefixime, oral, 400 mg immediately as a single dose  
  • Metronidazole, oral 2 g immediately as a single dose  
  • Benzathine benzylpenicillin*, IM, 2.4 MU immediately as a single dose  
  • Amoxicillin, oral, 500 mg 8 hourly for 7 days  
  • Aciclovir, oral, 400 mg 8 hourly for 7 days  
  • treat for candidiasis, if required |
| LAP + GUS                       | • Ceftriaxone, IM, 250 mg immediately as a single dose  
  • Metronidazole, oral, 400 mg 12 hourly for 14 days  
  • Doxycycline, oral, 100 mg 12 hourly for 14 days  
  • Aciclovir, oral, 400 mg 8 hourly for 7 days |

**Penicillin allergic men and non-pregnant women, replace benzathine benzyl penicillin with:**  
• Doxycycline, oral, 100 mg 12 hourly for 14 days  

**Penicillin allergic pregnant or breastfeeding women, replace benzathine benzylpenicillin and amoxicillin with:**  
• Erythromycin, oral 500 mg 6 hourly for 14 days


Chapter 12  Sexually transmitted infections

12.10 Genital molluscum contagiosum (MC)  B08.1

Description
This is a viral infection which can be transmitted sexually and non-sexually. It is usually self-limiting but can be progressive in an advanced stage of immunodeficiency.

Clinical signs include papules at the genitals or other parts of the body. Usually, the papules have a central dent (umbilicated papules).

Drug treatment
- Tincture of iodine BP
  - Apply with an applicator to the core of lesions

12.11 Genital warts (GW): condylomata acuminate  A63.0

Description
The clinical signs include:
- warts on the anogenital areas, vagina, cervix, meatus or urethra
- warts can be soft or hard

General Measures
- if warts do not look typical or are fleshy or wet, perform an RPR/VDRL test to exclude secondary syphilis, which may present with similar lesions.
- Emphasise HIV testing.

Drug treatment
Soft warts (< 10 mm)
- Tincture of podophyllin solution 20 %
  - Apply at weekly intervals to the lesions at the clinic by a health care professional until lesions disappear
  - Apply petroleum jelly to the surrounding skin for protection
  - Wash the solution off after 4 hours
  - If lesions do not improve after 5 treatments, refer
  - Podophyllin is a cytotoxic agent
  - Avoid systemic absorption.
  - Contraindicated in pregnancy
  - Exclude pregnancy before using podophyllin
Chapter 12  Sexually transmitted infections

Referral
» All patients with:
  - hyper-keratinised warts
  - warts larger than 10 mm
  - inaccessible warts, e.g. intra-vaginal or cervical warts
  - non-responding soft warts

12.12 Pubic lice (PL)
B85.1

Description
Infestation of lice mostly confined to pubic and peri-anal areas, and occasionally involves eyelashes. The bites cause intense itching, which often results in scratching with bacterial super-infection.

General measures
Thoroughly wash clothing and bed linen that may have been contaminated by the patient in the 2 days prior to start of treatment in hot water and then iron.

Drug treatment
• Benzyl benzoate 25%
  o Apply to affected area.
  o Leave on for 24 hours, then wash thoroughly.
  o Repeat in 7 days

Pediculosis of the eyelashes or eyebrows
• Petroleum jelly
  o Apply to the eyelid margins (cover the eyelashes) daily for 10 days to smother lice and nits.
  o Do not apply to eyes.

Referral
» All children with lice on pubic, perianal area and eyelashes to exclude sexual abuse
Chapter 13: Immunisation

13.1  Immunisation schedule
13.2  Dosage and administration
13.3  Vaccines for routine administration
13.4  The cold chain
13.5  The revised opened multi-dose vial policy
13.1 Immunisation schedule

» Every clinic day is an immunisation day.
» Immunisations are given in a specific sequence at certain ages. This is known as the immunisation schedule.
» Never miss a chance to immunise – never turn a child away if an immunisation is needed, even if it means opening a multidose vial for just one child.
» Check the Road to Health Chart every time the child visits the clinic, and give missed immunisations.
» Mild illnesses are not a contra-indication to immunisation – any child who is well enough to be sent home, is well enough to be immunised.
» Do not immunise a sick child if the mother seriously objects, but encourage her to bring the child for immunisation on recovery.
» Give doses no closer than 4 weeks - make follow-up dates with a minimum of 4 weeks from the previous dose.
» Give an extra dose if in doubt whether a child has had a certain dose or not, as extra doses are not harmful.
» All vaccines listed in the table can be given safely at the same time, but should not be mixed in the same syringe.

Serious adverse events following immunisation are uncommon. All adverse events other than mild systemic symptoms (irritability, fever < 39°C) and minor local reactions (redness/swelling at infection site) should be reported.

There are very few contra-indications, but many missed opportunities!

Adverse events requiring reporting

Local reactions
» Severe local reaction (swelling extending more than five cm from the injection site or redness and swelling for more than three days)
» Lymphadenitis
» Injection site abscess.

Systemic reactions
» All cases of hospitalisation (thought to be related to immunisation)
» Encephalopathy within seven days
» Collapse or shock-like state within 48 hours
» Fever or more than 40.5°C within 48 hours
» Seizures within three days
» All deaths (thought to be related to immunisation).

Conditions that are not contraindications to any of the standard EPI vaccines
» Family history of any adverse reactions following vaccination
» Family history of convulsions
» Previous convulsions
» Previous measles, mumps, rubella or pertussis-like illness
Chapter 13  

Immunisation

» Preterm birth
» History of jaundice after birth
» Stable neurological conditions such as cerebral palsy and trisomy 21
» Contact with an infectious disease
» Minor illness (without systemic illness and with a temperature below 38.5°C)
» Treatment with antibiotics
» Asthma, eczema, hay fever or ‘snuffles’
» Treatment with locally acting (inhaled or low-dose topical) steroids
» Child’s mother is pregnant
» Child being breastfed
» Underweight, but otherwise healthy child
» Over the age recommended in vaccination schedule
» Recent or imminent surgery

13.2 Dosage and administration

Immunisation schedule for children

<table>
<thead>
<tr>
<th>Age</th>
<th>Vaccine dose *</th>
</tr>
</thead>
<tbody>
<tr>
<td>At birth</td>
<td>BCG, OPV0**</td>
</tr>
<tr>
<td>6 weeks</td>
<td>OPV1, DTP1, HepB1, Hib1</td>
</tr>
<tr>
<td>10 weeks</td>
<td>OPV2, DTP2, HepB2, Hib2</td>
</tr>
<tr>
<td>14 weeks</td>
<td>OPV3, DTP3, HepB3, Hib3</td>
</tr>
<tr>
<td>9 months</td>
<td>Measles1</td>
</tr>
<tr>
<td>18 months</td>
<td>Measles2, OPV4, DTP4</td>
</tr>
<tr>
<td>6 years</td>
<td>OPV5, Td</td>
</tr>
<tr>
<td>12 years</td>
<td>Td</td>
</tr>
</tbody>
</table>

*The number that follows the immunisation name (e.g. DTP3) indicates the dose number of that immunisation.

** Refers to dose at birth.

The following vaccines will be introduced over the next few years:

- Pneumococcal vaccine (PCV)
- Rotavirus vaccine (RV)

Consult the latest EPI schedule for further information.

Catch-up doses

Any child who is unimmunised should be given a full schedule of immunisations.

Note:

» BCG is given until one year of age provided HIV infection has been excluded by PCR.
» DTP-Hib combination given until two years of age (above two years give Td).
Chapter 13  Immunisation

If more than one vaccine is overdue, it is appropriate to give all the vaccines at one visit.

**Pregnant women**

First pregnancy

» Give three doses of TT:
  - **first dose** on first contact
  - **second dose** 4 weeks later
  - **third dose** 6 months later (even if it is given in the postnatal period)

Subsequent pregnancy:

» One dose TT during the antenatal period (up to a total of 5 recorded doses)

**Trauma**

» Give booster dose of TT after each trauma episode (unless given in previous 5 years)

**All personnel working in a health care facility (including cleaning staff)**

» Hepatitis B, 3 doses of 1 mL
  - **first dose** administered immediately
  - **second dose** 1 month after the first dose
  - **third dose** 6 months after the first dose.

13.3 Vaccines for routine administration

**Note:**

Children with HIV should receive the full schedule of vaccines. Exception: BCG should not be given to children with symptomatic HIV-infection children

**BCG (Bacillus Calmette-Guérin)**

Protects against **TB meningitis and miliary TB** in children under 2 years.

- BCG, 0.05 mL of reconstituted intradermal BCG vaccine, administered into the skin (intradermally) on the right upper arm, at insertion of the deltoid

  » Storage:
    - Store diluent and vaccine in fridge at 2–8°C
    - Discard opened vial after 6 hours or at end of immunisation session, whichever comes first

  » Adverse events:
    - Initial reaction to intradermal vaccination is a papule formation that lasts a maximum of 4–6 weeks. This develops into a scar (visible in 40%)
    - In 1–10% there is oozing, ulceration and lymphadenopathy after vaccination. This is a usual reaction and not a cause for alarm.
    - Lymphadenopathy less than 1.5 cm is not clinically significant
    - Occasionally the papule becomes a pustule.
Refer all cases with significant lymphadenopathy or a draining sinus

Contraindications:

- Children with signs of symptomatic HIV infection (AIDS) should not get BCG vaccination

**DTP** (Diptheria, tetanus and pertussis vaccine)
Protects against diphtheria, tetanus and pertussis.

- **DTP, IM, 0.5 mL**
  - under 1 year: outer side of left thigh
  - over 1 year: upper arm
  
  **Storage:**
  - Fridge middle shelves at 2–8°C
  - Easily damaged by freezing
  - Keep opened vials for next session if kept at correct temperature and not contaminated
  - Discard after 30 days
  - Record date of reconstitution

  **Adverse events:**
  - 60% have fever and pain at the injection site
  - Some infants have excessive somnolence and disruption of daily routines
  - 5% have prolonged inconsiderable crying lasting more than 4 hours
  - Side-effects: mild fever, pain, local swelling occasionally

  **Contraindications:** Do not use if:
  - over 2 years
  - previous severe reaction to DTP
  - epilepsy that is not controlled

**Td** (Tetanus and diphtheria vaccine)
Protects against diphtheria and tetanus.

- **Td, IM, 0.5 mL in upper arm**

  **Storage:**
  - Fridge middle shelves at 2–8°C
  - Easily damaged by freezing
  - Keep opened vials for next session if kept at correct temperature and not contaminated
  - Discard after 30 days
  - Record date of reconstitution

  **Adverse events:**
  - Mild fever
  - Pain
  - Local swelling occasionally

  **Contraindications:**
  - Previous anaphylaxis
Chapter 13

Immunisation

HepB (Hepatitis B vaccine)
Protects against hepatitis B.
- HepB, IM, 0.5 mL (paediatric vaccine)
  - under 1 year: outer side of right thigh
  - over 1 year: upper arm
  - use opposite side to DTP/Td
    » Storage:
      - Fridge middle shelves at 2–8°C
      - Easily damaged by freezing
      - Keep opened vials for next session if kept at correct temperature and not contaminated
      - Discard after 30 days
      - Record date of reconstitution
    » Side effects:
      - Mild fever
      - Pain
      - Local swelling occasionally
    » Contraindications:
      - Previous anaphylaxis

Hib (Haemophilus influenzae type b vaccine)
Protects against Hib disease (meningitis, pneumonia, otitis media)
- Hib, given as DTP-Hib, IM into outer side of the left thigh
  » Storage:
    - Fridge middle shelves at 2–8°C
    - Easily damaged by freezing
    - Keep opened vials for next session if kept at correct temperature and not contaminated
    - Discard after 7 days
    - Record date of reconstitution
  » Contraindications:
    - Previous anaphylaxis

OPV (Oral polio vaccine)
Protects against polio.
- OPV, oral, 2 drops given by mouth
  - If spat out or vomited, repeat immediately
  - Not affected by feeding (breast or other)
    » Storage:
      - Fridge: top shelf (in clinics); or freezer (in Pharmacy)
      - Not damaged by freezing
      - easily damaged by temperature above 8°C
      - vials can be reused if the VVM's inner square remains lighter than the outer circle
Chapter 13	Immunisation

» Adverse events:
  – May be associated with a flu-like illness and gastroenteritis
  – Mild fever
» Contraindications:
  – Previous anaphylaxis

Measles
• Measles vaccine, IM, 0.5 mL into outer mid right thigh over one year of age use upper arm
  » Storage:
    – Fridge at 2–8°C, diluent on middle shelf and vaccine on top shelf.
    – Discard opened vial after 6 hours or at end of immunisation session (whichever comes first)
  » Adverse events:
    – Transient morbilliform rash and mild pyrexia 6–11 days after vaccination
  » Contraindications:
    – Previous anaphylaxis

TT (Tetanus toxoid)
Protects against tetanus (neonatal and after wounds)
• TT, IM, 0.5 mL into arm
  » Storage:
    – Fridge middle shelves at 2–8°C
    – Easily damaged by freezing
    – Keep opened vials for next session if kept at correct temperature and not contaminated
    – Discard after 30 days
    – Record date of reconstitution
  » Contraindications:
    – Previous anaphylaxis

Influenza vaccine
Recommended for:
» Elderly patients over 65 years
» Medical and nursing personnel
» HIV-infected people (Do not use the live vaccine)
» All patients with chronic cardiac or pulmonary conditions
• Influenza vaccine, IM, 0.5 mL

13.4 The cold chain

Maintaining the cold chain means keeping vaccines at the right temperature throughout distribution, storage and use. The cold chain can be maintained by:
» never exposing vaccines to heat or freezing conditions, especially during
Chapter 13 Immunisation

transportation from one point to another
- always using a cold box to keep the vaccines cold during transport and immunisation

Correct packing of the cold box
- Fully conditioned ice packs (the ice should rattle inside the pack) are placed on the bottom, at the sides and on top
- If there are not enough ice packs, place available ice packs at the sides and on top of the vaccines
- DTP, Td, TT, HepB and Hib vaccines must not be allowed to freeze
- Keep measles and polio vaccines very cold - place on bottom of the cold box, closest to the ice packs
- BCG can be placed anywhere in the box
- Keep the lid firmly closed and the box out of the sun
- Keep a thermometer in the cold box with the vaccines and the temperature 2–8°C
- Live vaccines (BCG, OPV, measles) contain weakened organisms and are very sensitive to heat, sunlight and skin antiseptics

How to pack your fridge correctly
- Top shelf: measles and polio vaccines in the coldest part
- Middle shelf: BCG, DTP, Td, HepB, Hib and TT vaccines (do not freeze) with sufficient diluent for the BCG and measles for 2 days
- Do not let DTP, Td, HepB, Hib and TT vaccines touch the evaporator plate at the back of the fridge - they are destroyed by freezing
- Do not keep vaccines in the fridge door
- Store the same kind of vaccines together in one tray
- Leave about 5 cm space between each tray to allow the cold air to move around
- Bottles filled with salt water stored in the bottom of the fridge will keep the fridge contents cold when the door is opened
- Do not keep food in the same fridge as the vaccines to avoid unnecessary opening of the door
- If there has been a power failure consult the supervisor
- Monitor and record temperature twice daily

! CAUTION!
Do not use vaccines that have expired, missed the cold chain or that VVM has reached discard point.
Keep the fridge temperature between 2–8°C.

Note:
All vaccines with a “T” in the name are sensitive to freezing – DTP, TT, Td HepaTiTis B, liquid Hib-Type B and even diluenT.
13.5 The Revised Opened Multi-Dose Vial Policy

Opened vials of DTP, TT, Td, HepB and OPV vaccines:
» May be used in subsequent immunisation sessions for a maximum of one month, provided that each of the following conditions have been met:
  – the expiry date has not passed
  – each vial must be dated when opened
  – the vaccines are stored under appropriate cold chain conditions (2–8°C with temperature monitoring and recording)
  – the vaccine vial septum has not been submerged in water
  – aseptic technique has been used to withdraw all doses

If one of these vaccines has a VVM e.g. OPV, the vaccine vial monitor (VVM) will indicate the potency of the vaccine and the vaccine may be used for any length of time as long as the VVM has not reached discard point, and the other conditions above apply.

Reconstituted vials of DTP-Hib may be used for 7 days if:
» each vial is dated when reconstituted
» the vaccines are stored under appropriate cold chain conditions (2–8°C with temperature monitoring and recording, measured by the condition of the VVM, if any)
» the expiry date has not passed
» the vaccine vial septum has not been submerged in water
» aseptic technique has been used to withdraw all doses
» the VVM, if attached, has not reached the discard point

Opened vials of measles, BCG
Check the VVM and expiration date prior to reconstitution
Reconstituted vials of measles and BCG vaccines must be discarded at the end of each immunisation session or at the end of six hours, whichever comes first.

All opened vials must be discarded immediately if:
• sterile procedures have not been fully observed
• there is even a suspicion that the opened vial has been contaminated
• there is visible evidence of contamination such as a change in appearance or floating particles, etc.
Chapter 14: Musculoskeletal conditions

14.1 Arthralgia
14.2 Arthritis, rheumatoid
14.3 Arthritis, septic
14.4 Gout
   14.4.1 Gout, acute
   14.4.2 Gout, chronic
14.5 Osteoarthrosis (osteoarthritis)
Section 14.1 Arthralgia

**Description**

Joint pain without swelling, warmth, redness or systemic manifestations such as fever. It is usually self-limiting.

Arthralgia may be a manifestation of degenerative joint conditions (osteoarthritis) or of many local and systemic diseases, in which arthralgia may be an early manifestation.

Suspect rheumatic fever in children, especially if arthralgia affects several joints in succession.

Arthralgia may follow injury to the joint, e.g. work, play and position during sleep.

**General measures**

Advise patient to:

- apply heat locally to the affected joint, taking precautions not to burn oneself
- exercise after relief from pain
- reduce weight if overweight to decrease stress on the joint

Reassure patient after other causes have been excluded.

**Drug treatment**

Treat for 1 week (maximum 2 weeks) provided no new signs develop.

- Methyl salicylate ointment, topical, applied to affected areas may be considered in selected patients.

- **Paracetamol**, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum of 4 doses per 24 hours
  - In children under 6 months calculate dose by weight

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥3.5–5</td>
<td>48 mg</td>
<td>Syrup 120 mg/5mL</td>
<td>≥ 1–3 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tablet 500 mg</td>
<td></td>
</tr>
<tr>
<td>≥5–7</td>
<td>60 mg</td>
<td>2.5 mL</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>≥7–9</td>
<td>96 mg</td>
<td>4 mL</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>≥9–14</td>
<td>120 mg</td>
<td>5 mL</td>
<td>≥ 12 months–3 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>≥14–17.5</td>
<td>180 mg</td>
<td>7.5 mL</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>≥17.5–35</td>
<td>240 mg</td>
<td>10 mL</td>
<td>≥ 5–11 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td>½ tablet</td>
<td></td>
</tr>
<tr>
<td>≥35–55</td>
<td>500 mg</td>
<td>1 tablet</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥55 kg and above</td>
<td>Upto 1000 mg</td>
<td>Up to 2 tablets</td>
<td>≥ 15 years and adults</td>
</tr>
</tbody>
</table>

**Referral**

- Pain for 1 week in children
- Pain for over 2 weeks in adults
Chapter 14  Musculoskeletal conditions

» Recurrent pain
» Severe pain
» Backache with radiation to one or other lower limb or neurological signs
» Signs of arthritis (swelling, redness, tender on pressure, warmth)
» Fever

14.2 Arthritis, rheumatoid
M06.9

Description
A chronic, inflammatory, systemic condition of fluctuating course. It may affect many organs, predominantly joints with:
» swelling or fluid, affecting at least 3 joint areas simultaneously
» pain
» limited movement with morning stiffness for longer than 30 minutes, which improves with activity. This distinguishes osteoarthrosis from rheumatoid arthritis.
» destruction
The arthritis affects mainly the small joints of the fingers and hands with the exception of the distal interphalangeal joints, although any joint can be involved. The distribution is symmetrical.

Referral
» All patients

14.3 Arthritis, septic
M00.9

Description
An acute infective condition involving one or more joints. The joint is hot, swollen, severely painful and with restricted movements.

Signs of systemic infection, including fever, are usually present. The infection is usually blood borne, but may follow trauma to the joint. The course may be acute or protracted. A wide spectrum of organisms is involved, including staphylococci and *N. gonorrhoea*.

Note:
Haemophiliacs may present with an acute arthritis similar to septic arthritis. This is due to a joint bleed and not due to infection.
Chapter 14  Musculoskeletal conditions

Referral

Urgent
» All patients for stabilisation and surgical drainage

If referral in children is delayed for longer than 2 hours, administer:
• Ceftriaxone, IM, 50–80 mg/kg/dose immediately as a single dose

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following injections mixed with water for injection (WFI):</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>250 mg WFI 2 mL</td>
<td>500 mg WFI 2 mL</td>
</tr>
<tr>
<td>≥ 2–2.5 kg</td>
<td>125 mg</td>
<td>1 mL 0.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 2.5–3.5 kg</td>
<td>200 mg</td>
<td>1.6 mL 0.8 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 3.5–5.5 kg</td>
<td>250 mg</td>
<td>2 mL 1 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>375 mg</td>
<td>3 mL 1.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>500 mg</td>
<td>4 mL 2 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 9–11 kg</td>
<td>625 mg</td>
<td>5 mL 2.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>750 mg</td>
<td>6 mL 3 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>1 000 mg</td>
<td>– 4 mL 3.5 mL</td>
<td></td>
</tr>
<tr>
<td>≥ 17.5 kg and above</td>
<td>1 000 mg</td>
<td>– 4 mL 3.5 mL</td>
<td></td>
</tr>
</tbody>
</table>

! CAUTION!
Do not administer calcium containing fluids, e.g. Ringer-lactate, within 48 hours of administering ceftriaxone.
Contra-indicated in neonatal jaundice.
Annotate dose and route of administration in referral letter.

Treat shock if present, while preparing for transfer.

14.4 Gout

14.4.1 Gout, acute
M10.9

Description
A metabolic disease in which uric acid crystal deposition occurs in joints and other tissues and is characterised by following features:
» recurrent attacks of a characteristic acute arthritis
» often one joint
» extreme pain and tenderness
Chapter 14 Musculoskeletal conditions

- swelling
- redness and very hot
- inflammation may extend beyond the joint
- in the majority of patients the first metatarso-phalangeal joint is initially involved
- the instep, ankle, heel, and knee are also commonly involved
- bursae (such as the olecranon) may be involved

The condition is most common in men above 40 years of age and postmenopausal women.

Investigations

- Increased serum uric acid concentration. However, this may be normal during acute attacks.
- Serum creatinine

General measures

Immobilise the affected joint during the acute painful attack.
Increase (high) fluid intake.
Avoid alcohol.
Avoid aspirin.
Advise on weight reduction, if overweight.

Drug treatment

Initiate treatment as early as possible in an acute attack.
- NSAID, e.g. ibuprofen, oral, 800 mg 8 hourly with or after a meal for 24–48 hours.
  Thereafter, if needed:
  Ibuprofen, oral, 400 mg 8 hourly with or after a meal until pain and inflammation has subsided

If NSAIDS are contraindicated, e.g. peptic ulceration, warfarin therapy and renal dysfunction:
- Prednisone, oral, 40 mg daily for 3–5 days. (Doctor initiated)

Referral

- No response to treatment
- Confirmation of diagnosis, if in doubt
- Patients with chronic kidney disease
- Patients with suspected secondary gout (e.g. haematological malignancies)

Note:
Patients with suspected metabolic syndrome often have impaired renal function and the use of NSAIDs has safety implications.
Chapter 14  Musculoskeletal conditions

Gout may be secondary to other medical conditions, e.g. haematological malignancies.
Gout may co-exist with hypertension, diabetes mellitus (as a risk factor for degenerative vascular disease) and chronic renal disease. The medicine treatment of these conditions could precipitate gout.

14.4.2 Gout, chronic
M10.9

Description
Gout with one or more of the following:
» uric acid deposits in and around the joints and cartilages of the extremities (tophi)
» initial involvement of the first metatarsal phalangeal joint in the majority of patients
» involvement of the instep, ankle, heel and knee
» further involvement of bursae (such as the olecranon)
» significant periarticular inflammation
» serum uric acid over 0.5 mmol/L
» bone destruction
» prolongation of attacks, often with reduction in pain severity
» incomplete resolution between attacks

General measures
Avoid known precipitants and drugs that increase uric acid, if possible, e.g.: low dose aspirin, ethambutol, pyrazinamide, diuretics, especially hydrochlorothiazide 25 mg or greater.
Encourage weight loss.
Avoid alcohol.
Avoid aspirin.

Drug treatment
Uric acid lowering therapy
Urate lowering therapy is required in all of the following:
» > 2 acute attacks per year
» chronic tophaceous gout
» urate renal stones
» urate nephropathy

When the acute attack has settled completely, i.e. usually after 3 weeks:
• Allopurinol, oral, 100 mg daily. (Doctor initiated)
  o Increase monthly by 100 mg according to urate blood levels.
  o Titrate dose to reduce serum urate to < 0.3 mmol/L.
  o Average dose: 300 mg/day.
Chapter 14  Musculoskeletal conditions

- Maximum dose: 400 mg daily.
  The elderly and patients with renal impairment require lower doses.

**Referral**
- Suspected secondary gout
- No response to treatment
- Non-resolving tophaceous gout

### 14.5 Osteoarthrosis (osteoarthritis)
M19.9

**Description**
A degenerative disorder typically affecting weight-bearing joints.

Signs and symptoms include:
- pain
- limited movement
- morning stiffness, lasting less than 30 minutes
- joint swelling

**General measures**
Patient and family education on:
- weight reduction
- exercise

Rest during acute painful episodes.
Recommend the use of a walking stick or crutch to alleviate stress on the weight bearing joint.
Physiotherapy and/or occupational therapy.

**Drug treatment**

**For pain relief:**
- Paracetamol, oral, 1 000 mg, 6 hourly.
  - Maximum 4 000 mg per day.
- Methyl salicylate ointment, topical, applied to affected areas may be considered in selected patients.

If patient responds to paracetamol reduce the dose to:
- Paracetamol, oral, 500 mg, 6–8 hourly as needed.

If no response and inflammation is present:
**add**
- NSAID, e.g. ibuprofen, oral, 200–400 mg, 8 hourly with or after meals, as needed. (Doctor initiated)
Chapter 14  Musculoskeletal conditions

! CAUTION!
Long-term use of NSAIDs has adverse effects on renal and cardiac function, the GIT and on joint cartilage.

Referral
All cases with:
» intractable pain
» infection
» uncertain diagnosis
» for consideration of joint replacement
Chapter 15: Central nervous system conditions

15.1 Stroke
15.2 Seizures (convulsions/fits)
15.3 Febrile convulsions
15.4 Epilepsy
15.5 Meningitis
   15.5.1 Meningitis, acute bacterial
   15.5.2 Meningitis, meningococcal, prophylaxis
15.6 Status epilepticus
15.7 Headache, mild, non-specific
Chapter 15  Central nervous system conditions

15.1 Stroke

Description
Stroke consists of rapidly developing clinical signs of focal (at times global) disturbance of cerebral function, lasting more than 24 hours or leading to death. Most strokes are ischaemic (embolism or thrombosis) whilst others may be caused by cerebral haemorrhage.

A transient ischaemic attack (TIA) is defined as stroke symptoms and signs that resolve within 24 hours.

The diagnosis of stroke depends on the presentation of sudden onset of neurological loss, including:
» Weakness, numbness or paralysis of the face or an arm or a leg on one or both sides of the body
» Sudden onset of blurred or decreased vision in one or both eyes or double vision
» Difficulty speaking or understanding
» Dizziness, loss of balance or any unexplained fall or unsteady gait
» Headache (severe, abrupt)

Treatment
Acute management
» Assess airway, breathing, circulation and disability.
» Measure blood glucose and treat hypoglycaemia if present. – See section 21.11 Hypoglycaemia and hypoglycaemic coma.
» Patients should be nil by mouth until swallowing is formally assessed.

Secondary prevention
All patients, if not contra-indicated (e.g. haemorrhagic stroke, peptic ulcer, etc):
• Aspirin, oral, 150 mg daily


Hypertension
For blood pressure management, section 4.7: Hypertension

Diabetes mellitus
See chapter 9: Endocrine system
Chapter 15  Central nervous system conditions

Referral

» All patients including patients with TIA
  – A witness should be encouraged to accompany the patient
  – All medications should be brought with the patient
  – History of event, including time of onset, signs and symptoms and
    previous medical, drug, and social history, should be taken from patient
    and/or witness

15.2 Seizures (convulsions/fits)
R56.8

Description

A seizure is a change in movement, attention or level of awareness that is
sustained or repetitive, and occurs as a result of abnormal neuronal discharge
within the brain. Seizures may be secondary (where there is an underlying cause)
or idiopathic (where no underlying cause is evident). When seizures are recurrent
or typical of a specific syndrome, then the term epilepsy is used.

Seizures should be differentiated from:
» syncope
» hyperventilation
» transient ischaemic attack (TIA)
» pseudoseizure

Important conditions that should be excluded include:
» meningitis
» encephalitis or encephalopathy (including hypertensive encephalopathy)
» metabolic conditions, e.g. hypoglycaemia
» brain lesions

Treatment

If convulsing:

Children

- Diazepam, rectal, 0.5 mg/kg/dose for convulsions as a single dose.
  - Diazepam for injection 10 mg in 2 mL is used undiluted.
  - Draw up the required volume in a 2 mL syringe.
  - Remove needle then insert the whole barrel of the lubricated syringe
    into the rectum and inject the contents.
  - Remove syringe and hold buttocks together to minimise leakage

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Dose (mg)</th>
<th>Ampoule 10 mg/2 mL</th>
<th>Approx age</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 3–6</td>
<td>2</td>
<td>0.4 mL</td>
<td>Less than 6 months</td>
</tr>
<tr>
<td>≥ 6–10</td>
<td>2.5</td>
<td>0.5 mL</td>
<td>≥ 6 months–1 year</td>
</tr>
</tbody>
</table>
Chapter 15  Central nervous system conditions

<table>
<thead>
<tr>
<th>Weight Range</th>
<th>Dosage</th>
<th>Volume</th>
<th>Age Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 10–18 kg</td>
<td>5 mg</td>
<td>1 mL</td>
<td>≥ 1–5 years</td>
</tr>
<tr>
<td>≥ 18–25 kg</td>
<td>7.5 mg</td>
<td>1.5 mL</td>
<td>≥ 5–8 years</td>
</tr>
<tr>
<td>≥ 25–40 kg</td>
<td>10 mg</td>
<td>2 mL</td>
<td>≥ 8–12 years</td>
</tr>
</tbody>
</table>

- Maximum dose: 10 mg in 1 hour.
- May be repeated after 10 minutes if convulsions continue.
- Expect a response within 1–5 minutes.

If no response after the second dose of diazepam, manage as Status Epilepticus – See section 21.19: Status epilepticus

**Adults**

- **Diazepam**, slow IV infusion, 10 mg at a rate not exceeding 2 mg/minute
  - Repeat within 10–15 minutes, if needed.
  - If no response after the second dose of diazepam manage as Status Epilepticus – See section 21.19: Status epilepticus.

Always check blood glucose levels to exclude hypoglycaemia.

**After seizure**

- All patients presenting with a first seizure need to be investigated to exclude underlying causes.
- Meningitis must always be excluded.
- A patient who presents with a first seizure should not automatically be labeled as an epileptic, or started on treatment.
- When indicated, long term therapy should be initiated by a doctor.

**Referral**

**Urgent:**

- All patients with status epilepticus or suspected meningitis – See section 15.5: Meningitis
- All patients following a first seizure should be examined by a doctor to exclude underlying causes

**Note:**

Known persons with epilepsy who recover fully following a seizure do not usually require referral – see criteria for referral under epilepsy

**15.3 Febrile convulsions**

R56.0

**Description**

A febrile convolution is a seizure occurring in a child between the ages of 6 months and 5 years in association with a significant fever in the absence of an intracranial infection. These are the most common type of seizures in children of this age.
Chapter 15 Central nervous system conditions

However, the diagnosis requires the exclusion of other causes of seizures.

Febrile convulsions can be simple or complex. Simple febrile convulsions:
» are generalised
» occur once per illness
» always lasts for less than 15 minutes (typically lasting 1–2 minutes)
» are not associated with any neurological deficit

Children with febrile convulsions have a good prognosis, and very rarely develop epilepsy

If convulsing:
Children
- Diazepam, rectal, 0.5 mg/kg/dose for convulsions as a single dose.
  - Diazepam for injection 10 mg in 2 mL is used undiluted.
  - Draw up the required volume in a 2 mL syringe.
  - Remove needle then insert the whole barrel of the lubricated syringe into the rectum and inject the contents.
  - Remove syringe and hold buttocks together to minimise leakage

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Dose (mg)</th>
<th>Ampoule (10 mg/2 mL)</th>
<th>Approx age</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 3–6 kg</td>
<td>2 mg</td>
<td>0.4 mL</td>
<td>Less than 6 months</td>
</tr>
<tr>
<td>≥ 6–10 kg</td>
<td>2.5 mg</td>
<td>0.5 mL</td>
<td>≥ 6 months–1 year</td>
</tr>
<tr>
<td>≥ 10–18 kg</td>
<td>5 mg</td>
<td>1 mL</td>
<td>≥ 1–5 years</td>
</tr>
<tr>
<td>≥ 18–25 kg</td>
<td>7.5 mg</td>
<td>1.5 mL</td>
<td>≥ 5–8 years</td>
</tr>
<tr>
<td>≥ 25–40 kg</td>
<td>10 mg</td>
<td>2 mL</td>
<td>≥ 8–12 years</td>
</tr>
</tbody>
</table>

- Maximum dose: 10 mg in 1 hour.
- May be repeated after 10 minutes if convulsions continue.
- Expect a response within 1–5 minutes.

If no response after the second dose of diazepam, manage as Status epilepticus – See section 21.19: Status epilepticus

» Look for a cause of the fever.
» **Always exclude meningitis**
  - For the first episode in children under 12 months of age, this will require lumbar puncture.

**General measures**
» If the child is feverish:
  - remove excess clothing
  - cool the body by tepid sponging with lukewarm water
» Parents/caregivers should be counselled on how to prevent a rapid rise in temperature during illnesses:
Chapter 15 Central nervous system conditions

- remove excess clothing
- tepid sponging
- give child paracetamol

**Drug treatment**

» Treat the underlying cause.

- **Paracetamol**, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum of 4 doses per 24 hours

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Syrup 120 mg/5mL</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 7 – 14 kg</td>
<td>120 mg</td>
<td>5 mL</td>
<td>≥ 6 months–3 years</td>
</tr>
<tr>
<td>≥ 14 –17.5 kg</td>
<td>180 mg</td>
<td>7.5 mL</td>
<td>≥ 3–5 years</td>
</tr>
</tbody>
</table>

**Referral**

» All febrile convulsions except where:
  - the diagnosis of recurrent simple febrile seizures has been well established and
  - the child regains full consciousness and function immediately after the seizure and
  - meningitis has been excluded

» Complex convulsions

**15.4 Epilepsy**

G40.9

**Description**

Epilepsy is defined as recurrent seizures. Epilepsy is associated with many psychological, social and legal problems, and cultural perceptions.

**Diagnosis**

» is usually made clinically

» requires an accurate witness description of the seizure

**Some different types of seizure**

<table>
<thead>
<tr>
<th>Partial</th>
<th>simple partial</th>
<th>Seizure on one side of the body with no loss of consciousness</th>
</tr>
</thead>
<tbody>
<tr>
<td>complex partial</td>
<td>Partial seizure associated with loss of consciousness</td>
<td></td>
</tr>
<tr>
<td>Generalised</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| » **generalised tonic clonic**
|   Loss of consciousness preceded by:
|   » a brief stiff phase followed by
|   » jerking of all of the limbs |
| » **tonic**
|   One or more limbs become stiff without any jerking |
| » **myoclonic**
|   Brief, usually generalised jerks, with retained awareness |
| » **absence**
|   » occurs in childhood
|   » sudden cessation of activity followed by a blank stare
|   » usually no muscle twitching
|   » some children will smack their lips |

**General measures**

» Extensive health education.
» Record keeping in a seizure diary recording dates and if possible the times of the seizures.
» Present seizure diary at each consultation for assessment of therapy.
» Carry a disease identification bracelet, necklace or card.
» Counselling and advice on:
  - the adverse effect of alcohol on seizures
  - the effect of missing a dose of medication
  - discontinuing the drug treatment without advice of the doctor

**Patient should be counseled about driving, working at heights and operating machinery - the patient should sign in the notes that they have received this advice.**

**Drug treatment**

**Note:**

» General rule: a single drug is best.
» Combination therapy should only be initiated by a specialist.
» Recommended doses are general guides and will be effective in most patients. Some patients may need much higher or lower doses. Doses should only be increased at 2 weekly intervals. Therapeutic monitoring will assist with dosage adjustments, or in suspected non-adherence. However, it is only mandatory in the case of higher than usual doses of phenytoin.

Carbamazepine, phenytoin and phenobarbitone are associated with many drug interactions.

» Always check for possible interactions before prescribing any other drug in combination with these agents.
» Oral contraceptives may be less effective, and depot or IUCD is preferred. See chapter 7: Family planning.
Generalised tonic clonic seizures

**Adults**
- Phenytoin, oral, 4.5–5 mg/kg daily on lean body mass, at night
  or
  Carbamazepine, oral, 100 mg 12 hourly for one week then, 200 mg 12 hourly.
    - Titrate further upwards every 2 weeks according to response up to a maximum dose of 600 mg 12 hourly.
  » The choice between these two agents must be made on the acceptability of side-effects and how the number of doses influences lifestyle.
  » Carbamazepine is preferred in women because phenytoin may cause hirsutism and coarsening of the facial features.
  » Be aware of dose-related side effects. Phenytoin is a useful and effective agent. However, all doses above 300 mg/day are potentially toxic, and increased dosages should be monitored carefully, both clinically and by drug levels.

**Children**
The decision to initiate long-term therapy is generally made if the child has experienced two or more convulsions (except febrile convulsions).
  » Phenobarbitone and carbamazepine are both effective in generalised tonic clonic seizures.
  » The behaviour profile and academic performance of children on phenobarbitone should be monitored. Treatment should be changed if any problems are identified.
  - Phenobarbitone, oral, 3.5–5 mg/kg at night (under 6 months of age). (Doctor initiated.)
    or
    Carbamazepine, oral, 5 mg/kg 12 hourly for 2 weeks, then 7.5 to 10 mg/kg 12 hourly. (Doctor initiated.)
    - Maximum dose: 10 mg/kg 12 hourly.

**HIV infected individuals on ARVS**

**Children**
For HIV infected children on ARV therapy, valproate is preferred because of fewer drug interactions. When switching to valproate, commence treatment with maintenance dose of the drug as below and discontinue the other anticonvulsant after 7 days.
  - Valproate, oral, 7.5–10 mg/kg 12 hourly.
    - Titrate according to response over 4 weeks up to 15 mg/kg 12 hourly.
    - If poorly tolerated divide total daily dose into 3 equal doses.
Chapter 15  Central nervous system conditions

Adults
For HIV infected adults on ARV therapy, lamotrigine is preferred because of fewer drug interactions. When switching to lamotrigine, commence treatment as below and discontinue the other anticonvulsant after 28 days.

- Lamotrigine, oral
  - 25 mg daily for 2 weeks
  - Then 50 mg daily for 2 weeks
  - Thereafter increased by 50 mg every 2 weeks according to response
  - Usual maintenance dose: 100–200 mg/day as a single dose

Note:
The dose of lamotrigine will need to be doubled when patients are switched from regimen 1 (either efavirenz- or nevirapine-based ARV therapy) to lopinavir/ritonavir because the metabolism of lamotrigine is induced by lopinavir/ritonavir.

Poorly controlled epilepsy
Ask about the following as these can influence decisions on drug therapy:

» has the patient been compliant in taking the medication regularly for at least 2 weeks or more before the seizure? Ask about drug dosage and frequency.
» has the patient recently used some other medication?
» is there a chance that alcohol or some other drug is involved?
If one or more of the above can be identified as a problem there is no need to adjust therapy at this time.

Referral

» All new patients, for diagnosis and initiation of therapy by a doctor
» Patients with seizures other than generalised tonic clonic seizures, including absence seizures
» Increased number of seizures or changes in the seizure type
» Patients who have been seizure free on therapy for 2 years or more (to review therapy)
» Pregnancy or planned pregnancy
» Development of neurological signs and symptoms
» Adverse drug reactions
» Suspected toxicity

Information on the seizures that should accompany each referral case

» Number and frequency of seizures per month (or year)
» Date and time of most recent seizures
» Detailed description of the seizures, including
  - aura or warning sign
  - what happens during the seizure? (give a step-by-step account)
  - is the person conscious during the seizure?
  - how long do the seizures last on average?
  - what does the patient experience after the seizure?
  - how long does this experience last?
» Is there a family history of seizures?
15.5 Meningitis

15.5.1 Meningitis, acute bacterial
G00.9

**Description**
Infection of the membranes of the brain.
Clinical signs and symptoms include:
» headache
» neck stiffness
» vomiting
» fever
» impaired level of consciousness
» photophobia
» bulging fontanelle in infants

Neck stiffness is generally not elicited in young children, and especially neonates, and may be absent in adults, especially debilitated patients and the elderly. Young children with fever, vomiting and convulsions or an impaired level of consciousness must be assumed to have meningitis. Signs may be even more subtle in newborns.

**Initial management**
» If possible perform a lumbar puncture. Send cerebro-spinal fluid (CSF) in separate sterile containers (for culture, microscopy and chemistry and for glucose) with patients.

**Emergency measures**
» Stabilise before referral.
» Treat for shock if present.
» If patient’s level of consciousness is depressed:
  – maintain airway
  – give oxygen
» Ensure hydration
Chapter 15 Central nervous system conditions

If convulsing:

Children

- Diazepam, rectal, 0.5 mg/kg/dose for convulsions as a single dose.
  - Diazepam for injection 10 mg in 2 mL is used undiluted.
  - Draw up the required volume in a 2 mL syringe.
  - Remove needle then insert the whole barrel of the lubricated syringe into the rectum and inject the contents.
  - Remove syringe and hold buttocks together to minimise leakage

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Ampoule 10 mg/2 mL</th>
<th>Approx age</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 3–6 kg</td>
<td>2 mg</td>
<td>0.4 mL</td>
<td>Less than 6 months</td>
</tr>
<tr>
<td>≥ 6–10 kg</td>
<td>2.5 mg</td>
<td>0.5 mL</td>
<td>≥ 6 months–1 year</td>
</tr>
<tr>
<td>≥ 10–18 kg</td>
<td>5 mg</td>
<td>1 mL</td>
<td>≥ 1–5 years</td>
</tr>
<tr>
<td>≥ 18–25 kg</td>
<td>7.5 mg</td>
<td>1.5 mL</td>
<td>≥ 5–8 years</td>
</tr>
<tr>
<td>≥ 25–40 kg</td>
<td>10 mg</td>
<td>2 mL</td>
<td>≥ 8–12 years</td>
</tr>
</tbody>
</table>

- Maximum dose: 10 mg in 1 hour.
- May be repeated after 10 minutes if convulsions continue.
- Expect a response within 1–5 minutes.

If no response after the second dose of diazepam, manage as Status Epilepticus – See section 21.19: Status epilepticus.

Adults

- Diazepam, slow IV infusion, 10 mg at a rate not exceeding 2 mg/minute
  - Repeat within 10–15 minutes, if needed
  - If no response after the second dose of diazepam manage as Status Epilepticus – See section 21.19: Status epilepticus.

Drug treatment

If bacterial meningitis is strongly suspected, or if any danger signs are present (depressed level of consciousness, purpura), initiate drug treatment before transfer. The threshold for giving antibiotics before referral to young children, especially neonates, should be extremely low.
### Chapter 15 Central nervous system conditions

- Ceftriaxone, IM, 50–80 mg/kg/dose immediately as a single dose before referral.
  - Do not administer if calcium containing IV fluids administered within 48 hours.
  - Do not inject more than 1 g (1 000 mg) at one injection site.

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Dose (mg)</th>
<th>Injection mixed with water for injection (WFI): (Chose one of the below)</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 2–2.5 kg</td>
<td>200 mg</td>
<td>250 mg WFI 1.6 mL, 500 mg WFI 0.8 mL, 1 000 mg WFI 3.5 mL</td>
<td>-</td>
</tr>
<tr>
<td>≥ 2.5–3.5 kg</td>
<td>250 mg</td>
<td>250 mg WFI 2 mL, 500 mg WFI 1 mL, 1 000 mg WFI 2 mL</td>
<td>Birth – 1 month</td>
</tr>
<tr>
<td>≥ 3.5–5.5 kg</td>
<td>375 mg</td>
<td>375 mg WFI 3 mL, 500 mg WFI 1.5 mL, 1 000 mg WFI 3 mL</td>
<td>≥ 1–3 months</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>500 mg</td>
<td>500 mg WFI 4 mL, 700 mg WFI 2 mL, 1 000 mg WFI 2 mL</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>700 mg</td>
<td>700 mg WFI 5 mL, 800 mg WFI 3.2 mL, 1 000 mg WFI 3 mL</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥ 9–11 kg</td>
<td>800 mg</td>
<td>800 mg WFI 6.4 mL, 1 000 mg WFI 4 mL, 1 000 mg WFI 3 mL</td>
<td>≥ 12–18 months</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>1 000 mg</td>
<td>1 000 mg WFI 4 mL, 2 000 mg WFI 3 mL, 1 000 mg WFI 3.5 mL</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>1 250 mg</td>
<td>1 250 mg WFI 5 mL, 1 500 mg WFI 4.4 mL, 1 500 mg WFI 5 mL</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>1 500 mg (1½ g)</td>
<td>1 500 mg WFI 6 mL, 2 000 mg WFI 5.25 mL, 2 000 mg WFI 6 mL</td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td>≥ 25–55 kg</td>
<td>1 750 mg</td>
<td>1 750 mg WFI 7 mL, 2 000 mg WFI 6.1 mL, 2 000 mg WFI 6.1 mL</td>
<td>≥ 7–15 years</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>2 000 mg (2 g)</td>
<td>2 000 mg WFI 7 mL, 2 000 mg WFI 7 mL, 2 000 mg WFI 7 mL</td>
<td>≥ 15 years and above</td>
</tr>
</tbody>
</table>

**! CAUTION!**

Do not administer calcium containing fluids, e.g. Ringer-lactate, within 48 hours of administering ceftriaxone.

Contra-indicated in neonatal jaundice.

Annotate the dose and route of administration on the referral letter.

### Referral

- All patients with meningitis, or suspected meningitis

### 15.5.2 Meningitis meningococcal, prophylaxis

A39.9

In cases of confirmed meningococcal infection, the following close contacts should receive prophylaxis. Close contacts include:

- household members,
- child-care center contacts, and
- anyone directly exposed to the patient’s oral secretions, e.g., through kissing, mouth-to-mouth resuscitation, endotracheal intubation, or
Chapter 15 Central nervous system conditions

endotracheal tube management.

Chemoprophylaxis is only effective for the present exposure.

Drug treatment

Prophylaxis
Children < 6 years
• Ceftriaxone, IM, 125 mg, single dose

! CAUTION !
Do not administer calcium containing fluids, e.g. Ringer-lactate, within 48 hours of administering ceftriaxone.
Contra-indicated in neonatal jaundice.

Children 6 – 12 years
• Ciprofloxacin, oral, 250 mg, single dose

Children > 12 years and adults
• Ciprofloxacin, oral, 500 mg, single dose

15.6 Status epilepticus
(See Chapter 21 - Trauma and emergencies)
G41.9

15.7 Headache, mild, non-specific
R51

Description
Headache can be benign or serious.
Headache can have serious underlying causes including:

» encephalitis » hypertensive emergencies
» meningitis » venous sinus thrombosis
» mastoiditis » stroke
» benign intracranial hypertension » brain tumour
Headache due to a serious disease will often be associated with neurological symptoms and signs including:

- vomiting
- fever
- mood change
- cranial nerve fall-out
- convulsions
- confusion
- impaired consciousness
- pupillary changes and difference in size
- focal paralysis
- visual disturbances
- neck stiffness
- fever
- pupillary changes and difference in size
- mood change
- cranial nerve fall-out
- convulsions
- confusion
- vomiting
- impaired consciousness
- pupillary changes and difference in size
- mood change
- cranial nerve fall-out
- convulsions
- confusion
- vomiting
- impaired consciousness
- pupillary changes and difference in size
- mood change
- cranial nerve fall-out
- convulsions
- confusion

Tension headache due to muscle spasm:

- may be worse in the afternoon, but often present all day.
- is normally felt in the neck and the back of the head, but may be felt over the entire head
- is often associated with dizziness and/or blurring of vision
- is often described as a tight band around the head or a pressure on the top of the head
- does not progress through stages like a migraine (no nausea, no visual symptoms)

**General measures**

- Teach relaxation techniques where appropriate.
- Reassurance, where applicable.

**Drug treatment**

- **Paracetamol**, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum of 4 doses per 24 hours
  - In children under 6 months calculate dose by weight

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Dose (mg)</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 11–14 kg</td>
<td>120 mg</td>
<td>Syrup 120 mg/5mL</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>180 mg</td>
<td>Tablet 500 mg</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–35 kg</td>
<td>240 mg</td>
<td>7.5 mL</td>
<td>≥ 5–11 years</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>500 mg</td>
<td>10 mL, ½ tablet</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td>≥55 kg and above</td>
<td>Up to 1000 mg</td>
<td>1 tablet, Up to 2 tablets</td>
<td>≥ 15 years and adults</td>
</tr>
</tbody>
</table>

**Referral**

- Suspected meningitis should be referred immediately after initial treatment – See section 15.5: Meningitis
- Headache in children lasting for 3 days
- Recent headache of increasing severity
Chapter 15  Central nervous system conditions

» Headache with neurological manifestations
» Newly developed headache persisting for more than 1 week in an adult.
» Chronic recurrent headaches in an otherwise healthy patient, refer if no improvement after 1 month of treatment
» Tension headache due to muscle spasm, refer if no improvement after 1 month of treatment
Chapter 16: Mental health conditions

16.1 Aggressive disruptive behaviour
16.2 Anxiety and stress related disorders
16.3 Delirium – acutely confused, aggressive patient
16.4 Mood disorders
16.5 Acute Psychosis
Chapter 16 Mental health conditions

Maintenance treatment of medicines mentioned in this chapter may be continued by nurses with proven competency to do so, under medical supervision and subject to regular review in accordance with best practice and prevailing legislation.

16.1 Aggressive disruptive behaviour
F23.9

Manage as Acute psychosis. See Section 16.5: Psychosis, acute

16.2 Anxiety and stress related disorders
F41.9

Referral
- Poor response to counselling

16.3 Delirium – acutely confused, aggressive patient
F05.9

See section 21.5: Delirium with acute confusion and aggression.

16.4 Mood disorders
F32.9

Description
Mood disorders include:
- major depressive disorder: episodes of major depression
- dysthymia: not all the criteria for a major depression episode are met
  - lasts at least 2 years
- bipolar mood disorder: both episodes of major depression and of mania
- mood disorder due to a general medical disorder: the mood disturbance is secondary to an underlying medical condition
- substance-induced mood disorder: mood disorder is secondary to substance use or withdrawal

Disorders with disturbances of mood include:
- adjustment disorder with depressed mood: depressive symptoms as a response to a major crisis or event
  - usually lasts no longer than 6 months unless the stressor persists
Major depressive disorder
Major depressive disorder is a mood disorder characterised by at least 2 weeks of depressed mood as well as diminished interest and pleasure in activities and is associated with:
» somatic symptoms, e.g. change in appetite and sleep, agitation or retardation and loss of energy
» psychic symptoms, e.g. feeling of worthlessness, guilt, diminished concentration or indecisiveness, thoughts of death and suicide

Major depressive episodes can be further described in terms of:
» severity: mild, moderate or severe
» duration: chronic
» other features: e.g. psychotic, postpartum

Note:
Consultation with a community psychiatrist or medical practitioner is recommended to verify diagnosis and to rule out other conditions, e.g. hypothyroidism.

General measures
Effective psychotherapies include:
» cognitive-behavioural psychotherapy
» interpersonal psychotherapy
Broader stressors may need to be addressed:
» stress management / coping skills
» marital and family issues
» accommodation and vocational issues

Medicine treatment
Major depressive disorder, particular if there are severe or melancholic features:
Adults
- Amitriptyline, oral, at bedtime.
  o Initial dose 25–50 mg per day.
  o Increase by 25 mg per day at 3–5 day intervals.
  o Maximum dose: 150 mg per day.
Elderly
- Amitriptyline, oral, at bedtime.
  o Initial dose 25 mg per day.
  o Increase by 25 mg per day at 7–10 day intervals.
  o Maximum dose: 75 mg per day.
Chapter 16 Mental health conditions

<table>
<thead>
<tr>
<th>! CAUTION!</th>
</tr>
</thead>
<tbody>
<tr>
<td>» Tricyclic antidepressants can be fatal in overdose.</td>
</tr>
<tr>
<td>» Caution is advised when prescribing these agents to outpatients with possible suicidal ideation and requires risk assessment.</td>
</tr>
<tr>
<td>» The elderly are more sensitive to side-effects and need lower doses of tricyclic antidepressants (amitriptyline).</td>
</tr>
<tr>
<td>» Avoid tricyclic antidepressants (amitriptyline) in patients with heart disease, urinary retention, glaucoma, epilepsy.</td>
</tr>
</tbody>
</table>

Major depressive disorder, dysthymia or if amitriptyline is contra-indicated:

**Adults**
- Fluoxetine, oral.
  - Initial dose: 20 mg per day (in morning).
  - Increase to 40 mg per day if there is partial, or no response after 4–8 weeks and if well tolerated.
  - Refer if no response after 8 weeks.

**Elderly and in patients with panic attacks:**
- Fluoxetine, oral.
  - Initial dose: 10 mg per day.

**Note:**
In cases of first episode of major depressive disorder, continue medicine treatment for at least 9 months after symptoms have ceased.
In cases where there have been multiple episodes, or where other complications exist, longer treatment is indicated which should be reviewed every 2 years.
Do not increase the dose too quickly. Although some patients show early improvement, in others response is delayed for up to 4–8 weeks.

<table>
<thead>
<tr>
<th>! CAUTION!</th>
</tr>
</thead>
<tbody>
<tr>
<td>» Do not prescribe antidepressants to a patient with bipolar disorder without consultation, as a manic episode may be precipitated</td>
</tr>
<tr>
<td>» be careful of interactions between antidepressants and other agents including herbs</td>
</tr>
</tbody>
</table>

**Referral**
- Suicidal ideation
- Major depression with psychotic features
- Bipolar disorder
- Failure to respond to available antidepressants
- Patients with concomitant medical illness, e.g. heart disease, epilepsy
- Poor social support systems
- Pregnancy and lactation
- Children and adolescents
Description
Schizophrenia is the most common psychotic disorder and is characterised by a loss of contact with reality. It is further characterised by:
» positive symptoms, delusions and hallucinations and thought process disorder
» negative symptoms, blunting of affect, social withdrawal
» mood symptoms such as depression may be present

Clinical features include:
» delusions: fixed, unshakeable false beliefs (not shared by society)
» hallucinations: perceptions without adequate stimuli, e.g. hearing voices
» disorganised thoughts and speech: e.g. derailment or incoherence
» grossly disorganised or catatonic behaviour
» negative symptoms: affective flattening, social withdrawal
» social and/or occupational dysfunction

Only make the diagnosis if:
» there is social or occupational dysfunction
» signs and symptoms are present for at least 6 months (if less: consider schizophreniform disorder)
» general medical and substance-related causes are excluded

General measures
Supportive intervention includes:
» family counselling and psycho-education
» cognitive-behavioural psychotherapy for schizophrenia in stabilised patients
» supportive group therapy for patients with schizophrenia
Rehabilitation may be enhanced by:
» assertive community programs
» work assessment, occupational therapy and bridging programmes prior to return to the community
» appropriate placement and supported employment

Note:
Consultation with a community psychiatrist is essential to confirm diagnosis and treatment.
Chapter 16  Mental health conditions

**Medicine treatment**

**Schizophrenia where a less sedating agent is required:**

**Adults**
- Haloperidol, oral.
  - Initial dose: 2.5 mg daily.
  - Gradually increase until symptoms are controlled or until a maximum of 12.5 mg per day is reached.
  - Once stabilised, administer as a single dose at bedtime.

**Elderly**
- Haloperidol, oral.
  - Initial dose: 0.5 mg twice daily.
  - Increase dose more gradually until symptoms are controlled or until a maximum of 12.5 mg daily, if tolerated, is reached.
  - Once stabilised, administer as a single dose at bedtime.

**Schizophrenia where a more sedating agent is required:**

- Chlorpromazine, oral.
  - Initial dose: 25 mg three times daily.
  - Gradually increase until symptoms are controlled.
  - Once stabilised, administer as a single dose at bedtime.
  - Maintenance dose: 75–300 mg at night, but may be as high as 1 000 mg.

**Management of acute psychosis (including mania):**

- Lorazepam, IM, 2 mg immediately
  - Haloperidol, IM, 2–5 mg. May be repeated after 60 minutes if needed.
    - May be repeated 4–8 hourly.
    - Maximum dose 10 mg in 24 hours.
    - Refer if higher doses are required.

*or*

**If known schizophrenia and non-aggressive:**
- Zuclopenthixol acetate, IM, 50 mg immediately. Do not repeat within 2 days.

**Violent patients:**
- Zuclopenthixol acetate, IM, 150 mg immediately.

---

**CAUTION**

- Always monitor for acute dystonic reactions after administration of short acting depot antipsychotic agents (see below for treatment)
Only for health care workers with advanced psychiatric training
The management of acute psychosis includes the use of antipsychotic agents and benzodiazepines in order to:
» decrease agitation
» decrease positive symptoms

| ! CAUTION !

Always consult with a doctor, preferably a psychiatrist where possible, when prescribing antipsychotic medication to:
» children and adolescents
» the elderly
» pregnant and lactating women

After the acute phase:
• Haloperidol, oral dose range of 1.5–10 mg/day, administered 2–3 times daily in divided doses.

Long-term therapy:
• Haloperidol, oral, 1.5–10 mg daily given as a single dose or in two divided doses.
  or
  Fluphenazine decanoate, IM, 25–50 mg every 4 weeks.
    o Initial dose: 12.5 mg.
  or
  Flupenthixol, decanoate, IM, 40 mg every 4 weeks.
    o Initial dose: 20 mg.
  or
  Zuclopenthixol decanoate, IM, 200 mg every 4 weeks.
    o Initial dose: 100 mg.

Note:
Long acting antipsychotics are particularly useful in patients unable to adhere to their oral medication regimes
Long-term therapy should always be in consultation with a doctor or a psychiatrist. Patients should be re-assessed every 6 months.

Extra pyramidal side-effects
If extrapyramidal side-effects occur with the lowest effective dose of antipsychotic medication:
» an anticholinergic agent, e.g. orphenadrine or biperiden can be co-prescribed for dystonia or rigidity
» the low potency agent, chlorpromazine, is less likely to cause dystonia
Chapter 16  Mental health conditions

- Orphenadrine, oral, 50–150 mg, daily according to individual response
  - 50 mg twice daily is usually enough
  - do not prescribe more than 150 mg per day at primary care level
  - use with caution in the elderly as it may cause confusion and urinary retention

For acute dystonic reaction:
- Biperiden, IM, 2 mg – may be repeated every 30 minutes.
  - Maximum of four doses within 24 hours.

Referral
  - First psychotic episode
  - Poor social support
  - High suicidal risk or risk of harm to others
  - Children and adolescents
  - The elderly
  - Pregnant and lactating women
  - No response to treatment
  - Intolerance to medicine treatment
  - Concurrent medical or other psychiatric illness
  - Epilepsy with psychosis
Chapter 17 - Respiratory conditions

17.1 Conditions with predominant wheeze
   17.1.1 Bronchospasm, acute associated with asthma and chronic obstructive bronchitis
   17.1.2 Asthma, chronic
   17.1.3 Chronic obstructive pulmonary disease (COPD)
   17.1.4 Bronchiolitis, acute in children

17.2 Upper airways obstruction
   17.2.1 Croup (laryngotracheobronchitis) in children

17.3 Respiratory infections
   17.3.1 Common cold and influenza
   17.3.2 Bronchitis, acute in adults or adolescents
   17.3.3 Pneumonia
   17.3.4 Pneumonia in children
   17.3.5 Pneumonia, uncomplicated in adults
   17.3.6 Pneumonia in adults with underlying medical conditions or over 65 years
   17.3.7 Pneumonia, severe in adults
   17.3.8 Pneumocystis pneumonia in adults
   17.3.9 Tuberculosis
Chapter 17  
Respiratory conditions

17.1 Conditions with predominant wheeze

17.1.1 Bronchospasm, acute associated with asthma and chronic obstructive bronchitis

J45.9

Description

This is an emergency situation recognised by various combinations of:

» wheeze
» breathlessness
» tightness of the chest
» respiratory distress
» chest indrawing in children
» cough

In adults bronchospasm is usually associated with asthma (where the bronchospasm is usually completely reversible) or chronic obstructive pulmonary disease (COPD) (where the bronchospasm is partially reversible).

The clinical picture of pulmonary oedema due to left ventricular heart failure may be similar to that of asthma. In patients over 50 years presenting with asthma for the first time, the diagnosis of pulmonary oedema due to left ventricular heart failure should be considered.

Bronchospasm in children is usually associated with asthma or with infections such as bronchiolitis or bronchopneumonia. Foreign bodies or obstruction of airways due to tuberculous nodes or congenital malformation should also be considered, especially if the wheeze is unilateral.

All PHC facilities should have peak expiratory flow (PEFR) meters, as asthma cannot be correctly managed without measuring PEFR.

Recognition and assessment of severity of attacks in children

<table>
<thead>
<tr>
<th></th>
<th>Moderate</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory rate</td>
<td>more than 40 per minute</td>
<td>more than 40 per minute</td>
</tr>
<tr>
<td>Chest indrawing/recession</td>
<td>present</td>
<td>present</td>
</tr>
<tr>
<td>PEF (if &gt; 5 years old)</td>
<td>50–70% of predicted</td>
<td>below 50% of predicted</td>
</tr>
<tr>
<td>Speech</td>
<td>normal or difficult</td>
<td>unable to speak</td>
</tr>
<tr>
<td>Feeding</td>
<td>difficulty with feeding</td>
<td>unable to feed</td>
</tr>
<tr>
<td>Wheeze</td>
<td>present</td>
<td>absent</td>
</tr>
<tr>
<td>Consciousness</td>
<td>normal</td>
<td>impaired</td>
</tr>
</tbody>
</table>
Chapter 17  
Respiratory conditions

Recognition and assessment of severity of attacks in adults

<table>
<thead>
<tr>
<th></th>
<th>Moderate</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Talks in</td>
<td>phrases</td>
<td>words</td>
</tr>
<tr>
<td>Alertness</td>
<td>usually agitated</td>
<td>agitated, drowsy or confused</td>
</tr>
<tr>
<td>Respiratory rate</td>
<td>20–30 per/minute</td>
<td>often more than 30 per minute</td>
</tr>
<tr>
<td>Wheeze</td>
<td>loud</td>
<td>loud or absent</td>
</tr>
<tr>
<td>Pulse rate</td>
<td>100–120 per minute</td>
<td>above 120 per minute</td>
</tr>
<tr>
<td>PEF after initial</td>
<td>approx. 50–75%</td>
<td>below 50%; may be too</td>
</tr>
<tr>
<td>nebulisation</td>
<td></td>
<td>short of breath to blow in</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PEF meter</td>
</tr>
</tbody>
</table>

Note:
PEF is expressed as a percentage of the predicted normal value for the individual, or of the patient’s personal best value obtained previously when on optimal treatment.

Drug treatment

- Oxygen, 40% or higher, using highest concentration face mask
  Note:  
  In chronic obstructive pulmonary disease:  
  Oxygen, should be given with care (preferably by 24% or 28% facemask if available) and patients should be observed, as a small number may develop increasing hypercarbia deterioration of their condition.

- Salbutamol 0.5%, solution, nebulised over 3 minutes preferably driven by oxygen
  Children: 0.5–1 mL in 3 mL of sodium chloride 0.9%
  Adults: 1–2 mL in 3 mL of sodium chloride 0.9%
  - If no relief, repeat every 20–30 minutes in the first hour
  - Thereafter repeat every 2–4 hours if needed

If reversal of bronchospasm is incomplete after the first nebulisation:  
Children with asthma

- Prednisone, oral, 1–2 mg/kg immediately then once daily for 7 days

<table>
<thead>
<tr>
<th>Weight</th>
<th>Dose</th>
<th>Tablet</th>
<th>Age</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 11–14 kg</td>
<td>20 mg</td>
<td>4 tablets</td>
<td>≥ 2–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>30 mg</td>
<td>6 tablets</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5 kg and above</td>
<td>40 mg</td>
<td>8 tablets</td>
<td>≥ 5 years and adult</td>
</tr>
</tbody>
</table>
Chapter 17  
Respiratory conditions

If oral prednisone cannot be taken:
- Hydrocortisone, IV, 4–6 mg/kg immediately.
  - Maximum dose: 100 mg.

<table>
<thead>
<tr>
<th>Weight</th>
<th>Dose</th>
<th>Injection</th>
<th>Age</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 11–14 kg</td>
<td>50 mg</td>
<td>1 mL</td>
<td>≥ 2–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>75 mg</td>
<td>1.5 mL</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5 kg and above</td>
<td>100 mg</td>
<td>2 mL</td>
<td>≥ 5 years and adult</td>
</tr>
</tbody>
</table>

Adults with asthma or COPD
- Prednisone, oral, 40 mg immediately then 20–40 mg once daily for 7 days
- Hydrocortisone, IV, 100 mg immediately

and
- Ipratropium bromide, solution, added to salbutamol solution
  - Children 0.5–1 mL (0.125–0.25 mg)
  - Adults 2 mL (0.5 mg)

If no nebuliser available
- Salbutamol, inhalation, 4–8 puffs, using a spacer, every 4 hours.
  - Inhale one puff at a time and allow for 4 breaths through the spacer between puffs.

If there is no immediate response:
add
- Ipratropium bromide, inhalation, 4 puffs, using a spacer, every 4 hours.

If no relief:
Repeat salbutamol every 20–30 minutes in the first hour.
Thereafter repeat every 2–4 hours if needed

Note:
Administering salbutamol via a spacer is as effective as and cheaper than using a nebuliser.
In severe cases, nebulisation must be given with oxygen.

! CAUTION !
Avoid sedation of any kind.
Assessment of response in children

<table>
<thead>
<tr>
<th></th>
<th>Response</th>
<th>No response</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEF (if possible)</td>
<td>improvement by more than 20%</td>
<td>improvement by less than 20%</td>
</tr>
<tr>
<td>Respiratory rate</td>
<td>less than 40 per minute</td>
<td>more than 40 per minute</td>
</tr>
<tr>
<td>Chest indrawing or recession</td>
<td>absent</td>
<td>present</td>
</tr>
<tr>
<td>Speech</td>
<td>normal</td>
<td>impaired</td>
</tr>
<tr>
<td>Feeding</td>
<td>normal</td>
<td>impaired</td>
</tr>
</tbody>
</table>

Assessment of response in adults

<table>
<thead>
<tr>
<th></th>
<th>Response</th>
<th>No response</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEF (if possible)</td>
<td>improvement by more than 20%</td>
<td>improvement by less than 20%</td>
</tr>
<tr>
<td>Respiratory rate</td>
<td>less than 20 per minute</td>
<td>more than 20 per minute</td>
</tr>
<tr>
<td>Speech</td>
<td>normal</td>
<td>impaired</td>
</tr>
</tbody>
</table>

Patients responding to treatment:
» Routine prescription of antibiotics is not indicated for acute asthma.
» Review current treatment and possible factors causing acute attack including poor adherence and poor inhaler technique.
» Advise patient or caregiver on further care at home, danger signs and of follow up required.
» Caution patient on the high chance of further wheezing in the week following an acute attack.
» Patients with a first attack should be fully assessed for maintenance treatment.
» Ask about smoking: if yes, urge patient to stop.

Referral

Urgent
» Any general danger sign and life-threatening features:
  – tachycardia (pulse > 120 before nebulisation)
  – drowsiness
  – confusion
  – silent chest
  – cyanosis
  – collapse
  – inability to complete a sentence in one breath
» No response to initial treatment.
Chapter 17  
Respiratory conditions

- PEFR of less than 75% of the predicted normal or of personal best value 15–30 minutes after nebulisation.
- A lower threshold to admission is appropriate in patients when:
  - seen in the afternoon or evening, rather than earlier in the day
  - recent onset of nocturnal symptoms or aggravation of symptoms
  - previous severe attacks, especially if the onset was rapid

Referral

- Patients needing repeated courses of oral corticosteroids (more than twice over six months) should be assessed for maintenance therapy (see chronic asthma below).

17.1.2 Asthma, chronic  
J45.9

Description

A chronic inflammatory disorder with reversible airways obstruction. In susceptible patients, exposure to various environmental triggers, allergens or viral infections result in inflammatory changes, bronchospasm, increased bronchial secretions, mucus plug formation and if not controlled, eventual bronchial muscle hypertrophy of the airways’ smooth muscle. All these factors contribute to airways obstruction. Asthma varies in intensity and is characterised by recurrent attacks of:

- wheezing
- dyspnoea or shortness of breath
- cough, especially nocturnal and
- periods of no airways obstruction between attacks

Acute attacks may be caused by:

- exposure to allergens
- respiratory viral infections
- non-specific irritating substances
- exercise

Asthma must be distinguished from chronic obstructive pulmonary disease, which is often mistaken for asthma – See section 17.1.3. The history is a reliable diagnostic guideline and may be of value in assessing treatment response.
### Chapter 17 Respiratory conditions

<table>
<thead>
<tr>
<th>Asthma</th>
<th>COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>» Young age onset, usually before 20</td>
<td>» Older age onset, usually after 40</td>
</tr>
<tr>
<td>» History of hay fever, eczema and/or allergies.</td>
<td>» Symptoms slowly worsen over a long period of time.</td>
</tr>
<tr>
<td>» Family history of asthma.</td>
<td>» Long history of daily or frequent cough before the onset of</td>
</tr>
<tr>
<td>» Symptoms are intermittent with periods of normal breathing in</td>
<td>shortness of breath.</td>
</tr>
<tr>
<td>between.</td>
<td>» Symptoms are persistent rather than only at night or during the</td>
</tr>
<tr>
<td>» Symptoms are usually worse at night or in the early hours of the</td>
<td>early morning.</td>
</tr>
<tr>
<td>morning, during an upper respiratory tract infection, when the</td>
<td>» History of heavy smoking (more than 20 cigarettes/day for 15 years</td>
</tr>
<tr>
<td>weather changes or when upset.</td>
<td>or more), heavy cannabis use or previous TB.</td>
</tr>
<tr>
<td>» Marked improvement with beta agonist.</td>
<td>» Little improvement with beta agonist.</td>
</tr>
</tbody>
</table>

Asthma cannot be cured, but it can be controlled with regular treatment.

**Note:**
The diagnosis of asthma can be difficult in children under 6 years of age. If the diagnosis of asthma is uncertain, refer the patient.

### General measures

» No smoking by an asthmatic or in the living area of an asthmatic.
» Avoid contact with household pets.
» Avoid exposure to known allergens and stimulants or irritants.
» Education on early recognition and management of acute attacks.
» Patient and caregiver education including:
   – emphasising the diagnosis and explaining the nature and natural course of the condition
   – teaching and monitoring the technique for use of inhalers
   – reassuring parents and patients of the safety and efficacy of continuous regular controller therapy

### Assessing response to therapy

Response to treatment is based primarily on symptoms:
» Frequency of asthma symptoms
» Use of reliever medication
» Nighttime/early morning awakening
» Limitation of daily activities

**Peak Expiratory Flow Rate (PEFR)**

Refer to pages xxx – xxxii for PEF charts
Chapter 17  Respiratory conditions

The Peak Expiratory Flow Rate (PEFR) may provide additional information for assessing response to therapy. See below.

» PEFR is best assessed in the morning and evening
  – The patient is requested to blow forcibly into the device after a deep inspiratory effort
  – Three blows are performed at each testing point.
  – The highest value is taken as the true value.

» The PEFR can be helpful in confirming a diagnosis of asthma in primary care.
  – An improvement of 60 L/minute or 20% or more of the pre-bronchodilator PEFR, 10–20 minutes after inhalation of a beta agonist, e.g. 2 puffs of salbutamol 100 mcg, confirms a diagnosis of asthma.
  – A normal PEFR excludes the possibility of moderate and severe COPD.

» PEFR may be useful in assessing response to therapy.
  – Any value more than 80% of the personal best prior to the use of a bronchodilator is regarded as adequate control. Ensure that pre-bronchodilator values are measured at follow-up visits.

Note:
Initiating and optimising inhalation corticosteroid therapy for moderate and severe asthma should always be done with the use of a peak flow meter to assess severity and treatment response of asthma.

Inhalation therapy
Inhaled therapy is preferable to oral therapy.

Spacer devices
» Spacers are vital for an adequate therapeutic effect of inhaled therapy.
» Spacer devices should be used for all inhaled medications in all age groups to improve efficacy of drug delivery and limit adverse effects.
» Use the spacer appropriate for the age of the patient.

<table>
<thead>
<tr>
<th></th>
<th>Spacer volume</th>
<th>Face mask</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infants</td>
<td>150–250 mL</td>
<td>mandatory</td>
</tr>
<tr>
<td>Children</td>
<td>500 mL</td>
<td>highly recommended</td>
</tr>
<tr>
<td>Adolescents and adults</td>
<td>750 mL</td>
<td></td>
</tr>
</tbody>
</table>

» Inhalation spacer devices enable parents to administer inhaled therapy even to small children
» Children under 3 years should have a spacer with a face mask while older children and adults can use the spacer with a mouth piece directly
» Demonstrate steps 2–6 of the relevant inhaler technique more than once to ensure the correct procedure

Patient and caregiver education on inhaler and spacer techniques.
» Under the age of 3 years a mask attachment should be used with the spacer.
**Chapter 17**  

**Respiratory conditions**

**Inhalation therapy without a spacer in adults:**
1. remove the cap from the mouthpiece
2. shake the inhaler well
3. while standing or sitting upright, breathe out as much air as possible
4. place the mouth piece of the inhaler between the lips and gently close the lips around it
5. while beginning to inhale, press down the canister of the metered dose inhaler once to release one puff while breathing in as deeply as possible
6. hold the breath for 5–10 seconds, if possible
7. breathe out slowly and rest for a few breaths (30–60 seconds)
8. repeat steps 2–6 for the second puff

**Inhalation therapy with a spacer in adults and older children:**
1. remove the caps from the inhaler and the spacer
2. shake the inhaler well
3. insert the mouthpiece of the metered dose inhaler into the back of the spacer
4. insert the mouthpiece of the spacer into the mouth and close the lips around the mouthpiece. Avoid covering any small exhalation holes.
5. press down the canister of the metered dose inhaler once to release one puff into the spacer
6. immediately take 3–4 slow deep breaths.
7. repeat steps 4–6 for each puff prescribed, waiting at least 30 seconds between puffs
8. rinse mouth after inhalation of corticosteroids

**Inhalation therapy with the spacer alone in younger children:**
1. allow to breathe slowly in and out of the spacer continuously for 30 seconds
2. while still breathing, release one puff from the inhaler into the spacer
3. continue breathing for 3–4 breaths
4. if breathing is through the nose, pinch the nose gently while breathing from the spacer

**Inhalation therapy with a spacer and mask for infants and small children:**
1. remove the caps from the inhaler and the spacer
2. shake the inhaler well
3. infants may be placed on the caregiver's lap or laid on a bed while administering the medication
4. apply the mask to the face, ensuring that the mouth and nose are well covered
5. with the mask held firmly onto the face, press down the canister of the metered dose inhaler once to release one puff into the spacer
6. keep the mask in place for at least six breaths, then remove
7. repeat steps 4–6 for each puff prescribed, waiting at least 30 seconds between puffs
Chapter 17

**Drug treatment**

Drug treatment is based on the severity of the asthma and consists of therapy to prevent the inflammation leading to bronchospasm (controller) and to relieve bronchospasm (reliever).

**Reliever drugs in asthma:**
- **Beta₂ agonists**, e.g. salbutamol (short acting)
  - are indicated for the immediate relief of the symptoms of acute attacks
  - can be used as needed
  - increasing need for reliever drug indicates poor asthma control

**Beta₂ agonists:**
- **Beta₂ agonists** e.g. salbutamol, inhalation, 100–200 mcg (2 puffs), as required 4–6 hourly until relief is obtained (not continuously).

**Controller drugs in asthma:**
- **Inhaled corticosteroids**, e.g. budesonide and beclomethasone.
  - Must be used twice daily, even when the patient feels well.

Once symptoms and PEFR have improved, the dose should be reduced to the minimum maintenance dose needed for control.

**Children:**
- Budesonide or beclomethasone, inhalation, 100 mcg, 12 hourly regularly.

**Adults:**
- Budesonide or beclomethasone, inhalation, 200 mcg, 12 hourly regularly provided the efficacy is controlled with a peak flow meter.

If no improvement, refer to doctor.

**Higher doses - doctor initiated as per peak flow results**

**Children:**
- Budesonide or beclomethasone, inhalation, 200 mcg 12 hourly regularly.

**Adults:**
- Budesonide or beclomethasone, inhalation, 400 mcg, 12 hourly regularly.

**STEP 1: MILD INTERMITTENT ASTHMA**

Indications for **only** intermittent reliever therapy:
- not more than one or two episodes of daytime cough and/or wheeze per week
- less than one night-time cough and/or wheeze per month
- no recent (within the last year) admission to hospital for asthma
- PEFR more than 80% predicted between attacks
- exercise-induced asthma – inhaler should be used before exercise
Chapter 17 Respiratory conditions

Children and adults:
- Beta₂ agonist, e.g. salbutamol, inhalation, 1–2 puffs 3–4 times daily as needed until symptoms are relieved.

**STEP 2: MILD PERSISTENT ASTHMA**

» 3–4 episodes of wheeze and/or cough per week
» 2–4 episodes of night time wheeze or cough per month
» PEFR more than 80% predicted between attacks

Children:
- Budesonide or beclomethasone, inhalation, 100 mcg, 12 hourly regularly.
  and
- Beta₂ agonist, e.g. salbutamol, inhalation, 1–2 puffs 3–4 times daily as needed until symptoms are relieved.

Adults:
- Budesonide or beclomethasone, inhalation, 200 mcg, 12 hourly regularly.
  and
- Beta₂ agonist, e.g. salbutamol, inhalation, 1–2 puffs 3–4 times daily as needed until symptoms are relieved.

**STEP 3: MODERATE PERSISTENT ASTHMA**

- more than 4 episodes of day time wheeze, tightness or cough per week
- more than 4 night time awakenings per month
- PEFR more than 60% but less than 80% predicted

Children:
- Budesonide or beclomethasone, inhalation, initiate with 100 mcg 12 hourly regularly.
  o If no response, refer to doctor to uptitrate to 200 mcg, 12 hourly regularly.
  and
- Beta₂ agonist, e.g. salbutamol, inhalation, 1–2 puffs 3–4 times daily as needed until symptoms are relieved.

Adults:
- Budesonide or beclomethasone, inhalation, initiate with 200 mcg, 12 hourly regularly.
  o If no response, refer to doctor to uptitrate to 400 mcg, 12 hourly regularly.
  and
- Beta₂ agonist, e.g. salbutamol, inhalation, 1–2 puffs 3–4 times daily as needed until symptoms are relieved.
Chapter 17  Respiratory conditions

STEP 4: MODERATE PERSISTENT ASTHMA NOT CONTROLLED ON THESE DOSAGES

**Adults:**
Add slow release theophylline, doctor initiated.

- Oral theophylline has a limited place in the treatment of asthma after insufficient response to inhaled beta₂ stimulants and corticosteroids in sufficient doses and should be prescribed only on the basis of proven benefit via pulmonary function testing in individual patients.
- Ongoing use of theophylline should be re-evaluated periodically – if there is no benefit after 4 weeks it should be discontinued.
- Theophylline slow release, oral, initially 200 mg 12 hourly and may be increased to 300 mg 12 hourly. (Doctor initiated)
  - Higher dosages of theophylline in adherent patients should only be considered using blood level monitoring.
  - The elderly are more susceptible to theophylline toxicity.

**CHRONIC MANAGEMENT ASPECTS OF ASTHMA**

**Stepping treatment down or up**
- Review treatment every 3 months

**Stepping down treatment:**
- Attempt a reduction in therapy if the patient has not had any acute exacerbation of asthma in the preceding 6 months
- Gradually reduce the dose or stop regular inhaled corticosteroid therapy
- If the symptoms are seasonal, corticosteroids may often be stopped until the next season
- If symptoms reappear, increase the therapy to the level on which the patient was previously controlled

**Stepping up treatment:**
- Therapy should be stepped up if a patient is not appropriately controlled
- Inadequate control is recognised by:
  - increasing symptoms
  - increasing use of reliever
  - deteriorating peak flow rates as detected from record in an asthma diary

**Referral**
- All children less than 6 years should be evaluated by a doctor for assessment and confirmation of diagnosis
- Any patient who has received more than 2 courses of oral prednisone within a 6 month period
- Brittle asthma (very sudden, very severe attacks)
- Inadequate response to acute or chronic treatment
Chapter 17  Respiratory conditions

» Diagnosis is uncertain
» With or after a life-threatening episode
» Pregnant women with aggravated asthma
» Children not responding to treatment in step 3: moderate persistent asthma
» Adults not responding to treatment in step 4: moderate persistent asthma
not controlled on these dosages

17.1.3 Chronic Obstructive Pulmonary Disease (COPD)

J44.9

Also referred to as chronic obstructive airways disease (COAD), and includes chronic bronchitis and emphysema.

**Description**

Chronic bronchitis and emphysema are conditions manifested by:

» chronic cough with or without sputum production on most days of 3 or more months for 2 or more consecutive years
» dyspnoea or shortness of breath
» wheezing

This condition is primarily caused by smoking.

The onset is very gradual with progressively worse symptoms. Due to the large reserve capacity of the lungs, patients often present when there is considerable permanent damage to the lungs. The airways obstruction is not fully reversible. The main causes of chronic bronchitis and emphysema are chronic irritation of the airways caused by smoking, air pollution, previous TB, previous cannabis (dagga) smoking although there are many other causes. It is not primarily an infection, but a degenerative condition.

Patients usually present with some of the following:

» wheezing
» shortness of breath
» cough with or without sputum
» manifestations of right-sided heart failure
» acute bronchitis after a cold or flu with the above symptoms

**Note:**
The airways obstruction of chronic bronchitis and emphysema is not completely reversible as in asthma.

Oral corticosteroids may be required for acute exacerbations, but these have severe long-term complications and should only be used long term if benefit can be proven by lung function testing.
Chapter 17  
Respiratory conditions

General measures

» Smoking cessation, including cannabis (dagga), is the mainstay of therapy.
» Chest physiotherapy to improve breathing and coughing mechanics and during infective episodes
» Encourage adequate fluid intake especially in the elderly and those with prolonged dyspnoea

Drug treatment

Acute lower airways obstruction
Treat as for acute asthma

Chronic obstruction management:

» In a stable patient, check PEFR.
» Then give a test dose of salbutamol – 2 puffs.
» Repeat PEFR 15 minutes later.
» If there is a 15% or greater improvement in peak flow, treat as for asthma.
  See section 17.1.2
» The routine use of inhaled corticosteroids is not recommended, unless there is a 15% or greater improvement in PEFR after a test dose of salbutamol.

Patients failing to respond to the test dose of salbutamol:
• Beta₂ agonist, e.g. salbutamol, inhalation, 1–2 puffs 3–4 times daily as needed for relief of wheeze

and if not controlled:
• Ipratropium bromide, MDI, 2 puffs 6–8 hourly – doctor initiated

If response to inhaler therapy is poor:
• Theophylline slow release, oral, initially 200 mg 12 hourly (Doctor initiated)
  o May be increased to 300 mg 12 hourly.
  o Higher dosages of theophylline in adherent patients should only be considered using blood level monitoring.
  o The elderly are more susceptible to theophylline toxicity.
  o Theophylline interacts with many other drugs including antibiotics such as erythromycin and quinolones.

Acute infective bronchitis:
• Doxycycline, oral, 100 mg 12 hourly for 10 days
  or
  Amoxicillin, oral, 500 mg 8 hourly for 10 days

Prophylaxis against respiratory tract infections:
• Influenza vaccination, annually
• Pneumococcal vaccination, 5 yearly
Chapter 17 Respiratory conditions

Referral
» Poor response to above therapy, for further investigations and adjustment of treatment

17.1.4 Bronchiolitis, acute in children
J21.9

Description
Acute bronchiolitis is a common cause of wheezing and cough in the first two years of life. It is caused by viral infections and presents with lower airways obstruction due to inflammation and plugging of the small airways. Recurrent episodes can occur, usually during winter.

Child presents with:
» rapid breathing
» chest indrawing
» decreased breath sounds
» an audible wheeze

General measures
» Minimise contact with other children.
» Avoid use of antibiotics and corticosteroids.
» Do not sedate child.

Drug treatment
• Oxygen, humidified, using nasal canula at 1–2 L per minute
• Salbutamol 0.5%, solution, 0.5–1 mL diluted to 2–4 mL with sodium chloride 0.9%, nebulised over 3 minutes (single dose)
  o Evaluate the response to salbutamol.
  o Send patient home on salbutamol metered dose inhaler with spacer if there is a good response.

Referral
» Chest indrawing and distress not responding to salbutamol
» Difficulty in feeding
» Sleep disturbance
» Previous admission for same problem
» Oxygen saturation less than 90% in room air
17.2 Upper airways obstruction

17.2.1 Croup (Laryngotracheobronchitis) in children

Description
Croup is a common cause of potentially life-threatening airway obstruction in childhood. It is characterised by inflammation of the larynx, trachea and bronchi. Most common causative pathogens are viruses, including measles.

A clinical diagnosis of viral croup can be made if a previously healthy child develops progressive inspiratory airway obstruction with stridor and a barking cough, 1–2 days after the onset of an upper respiratory tract infection. A mild fever may be present.

Suspect foreign body aspiration if there is a sudden onset of stridor in an otherwise healthy child.

Suspect epiglottitis if the following are present in addition to stridor:
» very ill child
» high fever
» drooling saliva
» unable to swallow
» sitting upright with head held erect

Assessment of the severity of airway obstruction and management in croup

<table>
<thead>
<tr>
<th>Grade 1</th>
<th>inspiratory stridor only</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 2</td>
<td>inspiratory and expiratory stridor</td>
</tr>
</tbody>
</table>

- Prednisone, oral, 1–2 mg/kg, single dose
  - Do not give if measles or herpes infection present
  - Refer

- Adrenaline, 1:1 000 diluted in sodium chloride 0.9%, nebulised, immediately
  - Dilute 1 mL of 1:1 000 adrenaline with 1 mL sodium chloride 0.9%
  - Repeat every 15–30 minutes until expiratory stridor disappears
- Prednisone, oral, 1–2 mg/kg, immediately as a single dose
  - Refer
Chapter 17  Respiratory conditions

| Grade 3 | Inspiratory and expiratory stridor with active expiration using abdominal muscles | Treat as above |
|         |                                                                                  | If no improvement within one hour, refer **urgently** (intubate before referral if possible) |
| Grade 4 | Cyanosis, apathy, marked retractions, impending apnoea                           | intubate (if not possible give treatment as above) |
|         |                                                                                  | Refer **urgently** |

**General measures**

- Keep child comfortable.
- Continue oral fluids.
- Encourage parent or caregiver to remain with the child.

**Drug treatment**

- **Paracetamol**, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum of 4 doses per 24 hours
  - In children under 6 months calculate dose by weight

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Syrup 120 mg/5mL</td>
<td>Tablet 500 mg</td>
</tr>
<tr>
<td>≥3.5–5 kg</td>
<td>48 mg</td>
<td>2 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>60 mg</td>
<td>2.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>96 mg</td>
<td>4 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 9–14 kg</td>
<td>120 mg</td>
<td>5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>180 mg</td>
<td>7.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 17.5–35 kg</td>
<td>240 mg</td>
<td>10 mL</td>
<td>½ tablet</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>500 mg</td>
<td>–</td>
<td>1 tablet</td>
</tr>
<tr>
<td>≥55 kg and above</td>
<td>Up to 1000 mg</td>
<td>–</td>
<td>Up to 2 tablets</td>
</tr>
</tbody>
</table>

**If the child requires referral - while awaiting transfer:**

- Adrenaline, 1:1000, nebulised, immediately using a nebuliser.
  - If there is no improvement, repeat every 15 minutes, until the child is transferred
  - Dilute 1 mL of 1:1000 adrenaline with 1 mL sodium chloride 0.9%.
  - Nebulise the entire volume with oxygen at a flow rate of 6–8 L/minute

- **Prednisolone**, oral, 1–2 mg/kg immediately then once daily for 7 days

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Tablet 5 mg</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 11–14 kg</td>
<td>20 mg</td>
<td>4 tablets</td>
<td>≥ 2–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>30 mg</td>
<td>6 tablets</td>
<td>≥ 3–5 years</td>
</tr>
</tbody>
</table>
Chapter 17  Respiratory conditions

If epiglottitis suspected

- Ceftriaxone, IM, 50–80 mg/kg/dose immediately as a single dose

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following injections mixed with water for injection (WFI):</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>250 mg WFI 2 mL</td>
</tr>
<tr>
<td>≥ 2–2.5 kg</td>
<td>125 mg</td>
<td>1 mL</td>
</tr>
<tr>
<td>≥ 2.5–3.5 kg</td>
<td>200 mg</td>
<td>1.6 mL</td>
</tr>
<tr>
<td>Birth–1 month</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 3.5–5.5 kg</td>
<td>250 mg</td>
<td>2 mL</td>
</tr>
<tr>
<td>≥ 1–3 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>375 mg</td>
<td>3 mL</td>
</tr>
<tr>
<td>≥ 3–6 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>500 mg</td>
<td>4 mL</td>
</tr>
<tr>
<td>≥ 6–12 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 9–11 kg</td>
<td>625 mg</td>
<td>5 mL</td>
</tr>
<tr>
<td>≥ 12–18 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>750 mg</td>
<td>6 mL</td>
</tr>
<tr>
<td>≥ 18 months–3 years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>1 000 mg</td>
<td>–</td>
</tr>
<tr>
<td>≥ 3–5 years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥17.5 kg and above</td>
<td>1 000 mg</td>
<td>–</td>
</tr>
<tr>
<td>5 years and adult</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

!CAUTION!

Do not administer calcium containing fluids, e.g. Ringer-lactate, within 48 hours of administering ceftriaxone.

Contra-indicated in neonatal jaundice.

Annotate dose and route of administration in referral letter.

Management during transfer:

» Give the child oxygen
» Continue nebulisations with adrenaline
» If grade 3 contact ambulance or nearest doctor
» If grade 4 intubate and transfer

Referral

Urgent

» All children grade 2 or more stridor
» Children with
  – chest indrawing.
  – rapid breathing
  – altered consciousness
  – inability to drink or feed
» For confirmation of diagnosis
» Suspected foreign body
» Suspected epiglottitis
17.3 Respiratory infections

17.3.1 Common cold and influenza

Description
Colds and influenza are self-limiting viral conditions that may last up to 14 days. Colds begin to clear within 3 days and influenza within 7 days.

Colds present with nasal stuffiness and throat irritation. In addition, influenza presents with headache, muscular pain and fever.

Malnourished children, the elderly and debilitated patients are at greater risk of developing complications.

<table>
<thead>
<tr>
<th>CAUTION!</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malaria, measles, and HIV sero conversion may present with flu-like symptoms.</td>
</tr>
</tbody>
</table>

Complications
Secondary bacterial infections, including:
- pneumonia secondary to influenza
- otitis media
- sinusitis

General measures
- “Steam” inhalations.
- Bed rest if feverish.
- Ensure adequate hydration.
- Advise patient to return to clinic if earache, tenderness or pain over sinuses develops and cough or fever persists for longer than a week.

Drug treatment
Antibiotics are of no value for the treatment of the common cold and influenza.
Chapter 17    Respiratory conditions

Pain and fever:
• Paracetamol, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum of 4 doses per 24 hours
  o In children under 6 months calculate dose by weight

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥3.5–5 kg</td>
<td>48 mg</td>
<td>2 mL Syrup 120 mg/5mL</td>
<td>≥ 1–3 months</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>60 mg</td>
<td>2.5 mL Tablet 500 mg</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>96 mg</td>
<td>4 mL</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥ 9–14 kg</td>
<td>120 mg</td>
<td>5 mL Syrup 120 mg/5mL</td>
<td>≥ 12 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>180 mg</td>
<td>7.5 mL Tablet 500 mg</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–35 kg</td>
<td>240 mg</td>
<td>10 mL ½ tablet</td>
<td>≥ 5–11 years</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>500 mg</td>
<td>– 1 tablet</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td>≥55 kg and above</td>
<td>Up to 1 000 mg</td>
<td>–</td>
<td>≥ 15 years and adults</td>
</tr>
</tbody>
</table>

Infants:
• Sodium chloride 0.9%, instilled into each nostril

Referral
» Severe complications

17.3.2 Bronchitis, acute in adults or adolescents
J20.9

Description
Acute airways infections mostly of viral origin, accompanied by cough, sputum production and sometimes a burning retrosternal chest pain in patients with otherwise healthy lungs.
Clinical features:
» initially – non productive cough
» later – productive cough with yellow or greenish sputum

Viral bronchitis is usually part of an upper respiratory viral infection. It may be accompanied by other manifestations of viral infections. It is important to exclude underlying bronchiectasis or an acute exacerbation of chronic bronchitis in adults.

No antibiotics are indicated in uncomplicated acute bronchitis. However, antibiotics may be considered for HIV positive patients because of the higher incidence of bacterial lower respiratory tract infections in this subgroup:
• Amoxicillin, oral, 500 mg 8 hourly for 5 days
In penicillin-allergic HIV positive patients:
- Erythromycin, oral, 500 mg 6 hourly for 5 days

For symptomatic relief
- Cough syrup, oral

17.3.3 Pneumonia
J18.9

Description
Infection of the lung parenchyma, usually caused by bacteria, especially Pneumococcus.

Management is guided by:
» age
» health status
» severity of the pneumonia

Manifestations include:
» malaise
» fever, often with sudden onset and with rigors
» cough, which becomes productive of rusty brown or yellow-green sputum
» pleuritic type chest pain
» shortness of breath
» in severe cases, shock and respiratory failure

On examination there is:
» fever
» tachypnoea
» crackles or crepitations
» bronchial breath sounds

There may be a pleural rubbing sound or signs of a pleural effusion.

Predisposing conditions include:
» the very young and old
» other concomitant diseases
» malnutrition
» HIV infection

Pneumococcal pneumonia often occurs in previously healthy adults. Adults with mild to moderately severe pneumonia may be managed at PHC level, depending on the response to initial treatment (see below).
Chapter 17  
Respiratory conditions

17.3.4 Pneumonia in children

Description

Pneumonia should be distinguished from viral upper respiratory infections. The most valuable sign in pneumonia is the presence of rapid breathing.

Assess the child for the severity of the pneumonia

Classify children according to the severity of the illness:

» no pneumonia – fever and cough
» pneumonia – fever, cough and rapid breathing
» severe pneumonia – fever, cough, rapid breathing, chest indrawing (of the lower chest wall) and flaring nostrils.

Note:
Children less than 2 months of age with rapid breathing should be classified as having severe pneumonia.

Rapid breathing is defined as:

» infants birth to 2 months  60 or more breaths per minute
» infants 2 months to 1 year  50 or more breaths per minute
» children 1–5 years  40 or more breaths per minute

Danger signs indicating urgent and immediate referral include:

» low oxygen saturation of less than 90% in room air
» inability to drink
» impaired consciousness
» cyanosis
» age less than 2 months
» grunting

General measures

» Ensure adequate hydration
» Continue feeding
Chapter 17  Respiratory conditions

Drug treatment

For pneumonia:

- Amoxicillin, oral, 25–30 mg/kg/dose 8 hourly for 5 days

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Syrup 125 mg/5 mL</td>
<td>Capsule 250 mg</td>
</tr>
<tr>
<td>≥ 3.5–5 kg</td>
<td>125 mg</td>
<td>5 mL 2.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>175 mg</td>
<td>7 mL 3.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 7–11 kg</td>
<td>250 mg</td>
<td>10 mL 5 mL</td>
<td>1 capsule</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>375 mg</td>
<td>15 mL 7.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 14–25 kg</td>
<td>500 mg</td>
<td>– 10 mL</td>
<td>2 capsules</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>750 mg</td>
<td>– –</td>
<td>3 capsules</td>
</tr>
<tr>
<td>≥ 35 kg and above</td>
<td>1000 mg</td>
<td>– –</td>
<td>4 capsules</td>
</tr>
</tbody>
</table>

Penicillin–allergic patients:

- Erythromycin, oral, 10–15 mg/kg/dose 6 hourly for 5 days

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Syrup 125 mg/5 mL</td>
<td>Tablets 250 mg</td>
</tr>
<tr>
<td>≥ 3.5–5 kg</td>
<td>50 mg</td>
<td>2 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>75 mg</td>
<td>3 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>100 mg</td>
<td>4 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 9–11 kg</td>
<td>125 mg</td>
<td>5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>150 mg</td>
<td>6 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>200 mg</td>
<td>8 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>250 mg</td>
<td>10 mL</td>
<td>1 tablet</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>375 mg</td>
<td>15 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 35 kg and above</td>
<td>500 mg</td>
<td>–</td>
<td>2 tablets</td>
</tr>
</tbody>
</table>
Chapter 17  Respiratory conditions

- **Paracetamol**, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum of 4 doses per 24 hours
  - In children under 6 months calculate dose by weight

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥3.5–5 kg</td>
<td>48 mg</td>
<td>Syrup 120 mg/5mL</td>
<td>≥ 1–3 months</td>
</tr>
<tr>
<td>≥5–7 kg</td>
<td>60 mg</td>
<td>2 mL</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥7–9 kg</td>
<td>96 mg</td>
<td>4 mL</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥9–14 kg</td>
<td>120 mg</td>
<td>5 mL</td>
<td>≥ 12 months–3 years</td>
</tr>
<tr>
<td>≥14–17.5 kg</td>
<td>180 mg</td>
<td>7.5 mL</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥17.5–35 kg</td>
<td>240 mg</td>
<td>10 mL</td>
<td>≥ 5–11 years</td>
</tr>
<tr>
<td>≥35–55 kg</td>
<td>500 mg</td>
<td>1 tablet</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td>≥55 kg and above</td>
<td>Up to 1 000 mg</td>
<td>–</td>
<td>1 tablet</td>
</tr>
</tbody>
</table>

**Severe pneumonia:**

- Oxygen, using nasal canula at 1–2 L per minute before and during transfer

- **Ceftriaxone**, IM, 50–80 mg/kg/dose immediately as a single dose

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following injections mixed with water for injection (WFI):</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥2–2.5 kg</td>
<td>125 mg</td>
<td>250 mg WFI 2 mL 0.5 mL</td>
<td>Birth–1 month</td>
</tr>
<tr>
<td>≥2.5–3.5 kg</td>
<td>200 mg</td>
<td>500 mg WFI 2 mL 1 mL</td>
<td>≥ 1–3 months</td>
</tr>
<tr>
<td>≥3.5–5.5 kg</td>
<td>250 mg</td>
<td>1 000 mg WFI 3.5 mL</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥5–7 kg</td>
<td>375 mg</td>
<td>2 mL</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥7–9 kg</td>
<td>500 mg</td>
<td>1 mL</td>
<td>≥ 12–18 months</td>
</tr>
<tr>
<td>≥9–11 kg</td>
<td>625 mg</td>
<td>5 mL</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>≥11–14 kg</td>
<td>750 mg</td>
<td>5 mL</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥14–17.5 kg</td>
<td>1 000 mg</td>
<td>– 4 mL 3.5 mL</td>
<td>≥ 5 years and adult</td>
</tr>
<tr>
<td>≥17.5 kg and above</td>
<td>1 000 mg</td>
<td>– 4 mL 3.5 mL</td>
<td></td>
</tr>
</tbody>
</table>

**CAUTION!**

Do not administer calcium containing fluids, e.g. Ringer-lactate, within 48 hours of administering ceftriaxone.

Contra-indicated in neonatal jaundice.

Annotate dose and route of administration on referral letter.
Chapter 17  Respiratory conditions

and
• Cotrimoxazole, oral, initial dose (before referral)

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Use one of the following:</th>
<th>Age Month/years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Suspension mL</td>
<td>Tablet 80/400 mg</td>
</tr>
<tr>
<td>≥ 2.5–3.5 kg</td>
<td>2.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 3.5–7 kg</td>
<td>5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 7–11 kg</td>
<td>7.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 11–17.5 kg</td>
<td>10 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>15 mL</td>
<td>1½ tablets</td>
</tr>
<tr>
<td>≥ 25–35 kg and above</td>
<td>20 mL</td>
<td>2 tablets</td>
</tr>
</tbody>
</table>

Referral

Urgent
» All children with severe pneumonia, i.e. chest indrawing (of the lower chest wall), flaring nostrils or cyanosis
» All children under 2 months

Non-urgent
» Inadequate response to treatment
» Children coughing for more than 3 weeks to exclude other causes such as TB, foreign body aspiration, pertussis

17.3.5 Pneumonia, uncomplicated in adults

J18.9

A chest X-ray should ideally be taken in all patients to confirm the diagnosis. Two sputum smears to exclude TB should be done.

General measures
» Encourage high oral fluid intake

Drug treatment
If not severely ill (see referral criteria below):
• Benzylpenicillin, IM, 2 MU immediately
and
• Amoxicillin, oral, 1 000 mg 8 hourly for 5 days

If no response to treatment after 48 hours add:
• Erythromycin, oral, 500 mg 6 hourly for 5 days
Chapter 17  
Respiratory conditions

In penicillin-allergic patients:

- Erythromycin, oral, 500 mg 6 hourly for 5 days

For fever:

- Paracetamol, oral, 1 000 mg oral 4–6 hourly when required to a maximum of four doses daily

**Referral**

Any of the following:

- Confusion or decreased level of consciousness
- Cyanosis
- Respiratory rate of 30 breaths or more per minute
- Systolic BP less than 90 mmHg
- Diastolic BP less than 60 mmHg
- Deterioration at any point
- No response to treatment after 48 hours
- Patients with pneumonia
  - from a poor socio-economic background
  - who are unlikely to comply with treatment
  - living a considerable distance from health centres
  - have no access to immediate transport

**17.3.6 Pneumonia in adults with underlying medical conditions or over 65 years**

J18.9

Common underlying conditions include:

- Diabetes mellitus
- HIV infection
- Cardiac failure
- COPD
- Alcoholism
- Chronic liver disease
- Chronic kidney disease

Most of these patients will require referral to a doctor.

**Mild pneumonia:**

- Amoxicillin/clavulanic acid 250/125 (375), oral 8 hourly for 5–10 days
- Amoxicillin, oral, 500 mg 8 hourly for 5–10 days.
17.3.7 Pneumonia, severe in adults

J18.9

Pneumonia is defined as severe by 2 or more of the following:
» confusion or decreased level of consciousness
» respiratory rate of 30 breaths or more per minute
» systolic BP less than 90 mmHg
» diastolic BP less than 60 mmHg
» age over 65 years

While awaiting transfer:
• Oxygen

• Ceftriaxone, IV/IM, 1 000 mg, single dose before referral

! CAUTION!
Do not administer calcium containing fluids, e.g. Ringer-lactate, within 48 hours of administering ceftriaxone.

Referral
Urgent
» All patients

17.3.8 Pneumocystis pneumonia in adults

B59

Description
Interstitial pneumonia occurring with advanced HIV infection due to *Pneumocystis jiroveci* (formerly *carinii*). Patients usually present with shortness of breath or dry cough with onset within 12 weeks. Chest X-ray may be normal in the early stages but typically shows bilateral interstitial or ground glass pattern.

This diagnosis cannot be made without a chest X-ray.

General measures
» Ensure adequate hydration
Chapter 17  
Respiratory conditions

**Drug treatment**

- Cotrimoxazole, oral, 6 hourly for 14–21 days

<table>
<thead>
<tr>
<th>Approx weight kg</th>
<th>Use one of the following</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tablet 80/400</td>
</tr>
<tr>
<td>less than 40 kg</td>
<td>2 tablets</td>
</tr>
<tr>
<td>≥ 40–56 kg</td>
<td>3 tablets</td>
</tr>
<tr>
<td>≥ 56 kg and above</td>
<td>4 tablets</td>
</tr>
</tbody>
</table>

For secondary prophylaxis:

- Cotrimoxazole, oral, daily

<table>
<thead>
<tr>
<th>Use one of the following</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tablet 80/400</td>
</tr>
<tr>
<td>2 tablets</td>
</tr>
<tr>
<td>Tablet 160/800</td>
</tr>
<tr>
<td>1 tablet</td>
</tr>
</tbody>
</table>

**Referral**

» Breathing rate more than 24 per minute
» Shortness of breath with mild effort
» Cyanosed patients
» All patients for ARVs

### 17.3.9 Tuberculosis

A16.9

**Note:** notifiable condition

TB guidelines are updated regularly. The most recent National Tuberculosis Control Programme Guidelines should be consulted.

**Description**

Tuberculosis is a disease due to infection by *Mycobacterium tuberculosis*. It is a serious and growing health problem in South Africa and is expanded and complicated by HIV/AIDS and multiple drug-resistant mycobacteria.

**Note:**

A standard TB register monitoring system and treatment guidelines have been introduced.

All patients on TB treatment must be entered into a TB register to enable the completion of quarterly reports for case finding and holding. This is essential for TB control at local, provincial and national level.
Chapter 17  

Respiratory conditions

General measures

» The relationship between the person providing the care and the patient is an important factor for compliance in patient-centred care

» Care providers should explain the importance of completing treatment and the following should be discussed:
  – feelings and emotions
  – expectations
  – potential barriers or problems which may prevent success
  – habits and past experience
  – monitor
  – encouragement and motivation
  – provide feedback on progress

» Lifestyle adjustment

» Avoid the use of tobacco

» Avoid alcohol

» If more than two doses of treatment are missed, extra effort should be made to identify and manage any problems the patient might have

Note:
A private practitioner may elect to monitor the progress of the patient personally. In this case, the patient should remain on the clinic TB patient register.

Drug treatment

The total daily amount of each drug should be administered in one dose and not divided.

Ethambutol and isoniazid as single formulations will be retained to facilitate appropriate doses of available fixed-dose combinations in the continuation phase of treatment

Fixed-dose combinations are strongly encouraged in adults to enhance patient adherence and reduce the risk of inappropriate monotherapy.

Adult TB patients

» during pregnancy

» in alcoholics

» with diabetes mellitus

» with epilepsy

» with HIV infection

• Pyridoxine, oral, 25 mg daily

Important drug interactions

Rifampicin reduces the efficacy of oral contraceptives, resulting in possible unplanned pregnancies (See chapter 7: Family planning)
Chapter 17    Respiratory conditions

Discuss contraception and explain the problem and the consequences
If necessary, alter the oral contraceptive to a high dose preparation for the
duration of TB treatment or use an injectable contraception or IUCD
Combined oral contraceptives should contain at least 50 mcg of
ethinylestradiol

! CAUTION !
Antiretroviral drugs frequently interact with TB drugs.
Consult the DoH antiretroviral treatment guidelines.

Contra-indications to TB drugs
  » Streptomycin should not be given to:
    − pregnant women
    − persons over 65 years old
    − persons with impaired renal function
  » Ethambutol should not be given to:
    − children under 8 years
    − persons with impaired renal function
  » All patients with jaundice and suspected drug induced hepatitis
    − manage at hospital level
    − stop treatment and refer

Adverse effects of TB drugs:
  » Nausea
    − May be a manifestation of liver dysfunction. If available, serum
      transaminase levels should be done in these patients.
    − taking drugs with meals can minimise nausea
  » Skin hypersensitivity or allergy
    − can be severe and may need anti-histamines, e.g. chlorpheniramine
    − discontinue treatment and refer if extensive.
  » Neuropathy (adults only)
    − can be prevented by taking pyridoxine on the same day as TB treatment

TB CHEMOPROPHYLAXIS
Initiate only after active disease is excluded.
See TB and HIV and AIDS section below

Indication for TB chemoprophylaxis:
  » Children less than 5 years in close household contact with a smear-positive
case of pulmonary TB (Contacts of MDR or XDR TB should be referred for
expert advice)
  and
  » Children less than 5 years of age who have a positive tuberculin test but
show no other evidence of disease, including on chest X-ray.
**Chapter 17**  
**Respiratory conditions**

- Isoniazid, oral, 10–15 mg/kg daily for 6 months.
  - Maximum dose: 300 mg daily.

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Daily isoniazid (INH) 100 mg tablet</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 2–3.4 kg</td>
<td>¼ tablet</td>
</tr>
<tr>
<td>≥ 3.5–6.9 kg</td>
<td>½ tablet</td>
</tr>
<tr>
<td>≥ 7–9.9 kg</td>
<td>1 tablet</td>
</tr>
<tr>
<td>≥ 10–14.9 kg</td>
<td>1½ tablets</td>
</tr>
<tr>
<td>≥ 15–19.9 kg</td>
<td>2 tablets</td>
</tr>
<tr>
<td>≥ 20–24.9 kg</td>
<td>2½ tablets</td>
</tr>
<tr>
<td>≥ 25 kg</td>
<td>3 tablets</td>
</tr>
</tbody>
</table>

**Plus for adults and children with HIV or malnutrition:**
- Pyridoxine, oral, daily for duration of prophylaxis.
  - Adults: 25 mg
  - Children: 12.5 mg

**TB AND HIV AND AIDS**

Sputum smears in HIV and AIDS patients with TB are often negative as cavitation does not occur until the TB is far advanced. Sputum culture is more useful in these patients to confirm the diagnosis of tuberculosis.

HIV/AIDS patients with suspected TB should have two or more negative sputum smears before sputum is sent for culture.

Standard treatment regimens are also effective in patients with HIV/AIDS. Advise HIV/AIDS patients to present to a clinic if they develop common TB symptoms:
- persistent cough
- night sweats
- loss of weight

Side-effects of TB drugs are more pronounced in HIV/AIDS patients.

**TB prophylaxis in HIV infection:**

Indicated for patients with HIV who have either been in contact with a person with open TB or is tuberculin test positive and has no evidence of TB disease on chest X-ray or clinically.

Refer contacts of MDR or XDR for expert advice.
Chapter 17  Respiratory conditions

- Isoniazid, oral, 10–15 mg/kg daily for 6 months.
  - Maximum dose: 300 mg daily.

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Daily isoniazid (INH)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 2–3.4 kg</td>
<td>¼ tablet</td>
</tr>
<tr>
<td>≥ 3.5–6.9 kg</td>
<td>½ tablet</td>
</tr>
<tr>
<td>≥ 7–9.9 kg</td>
<td>1 tablet</td>
</tr>
<tr>
<td>≥ 10–14.9 kg</td>
<td>1½ tablets</td>
</tr>
<tr>
<td>≥ 15–19.9 kg</td>
<td>2 tablets</td>
</tr>
<tr>
<td>≥ 20–24.9 kg</td>
<td>2½ tablets</td>
</tr>
<tr>
<td>≥ 25 kg</td>
<td>3 tablets</td>
</tr>
</tbody>
</table>

plus for adults and children with HIV or malnutrition:
- Pyridoxine, oral, daily for duration of prophylaxis.
  - Adults: 25 mg
  - Children: 12.5 mg

MULTIPLE DRUG-RESISTANT (MDR) TB
All cases should be referred to a specialised centre.

MDR TB is usually the result of irregular adherence to TB treatment and is identified when there is resistance to rifampicin and isoniazid on sputum culture sensitivity testing. The current regimen is 18–24 months. The cure rate is only between 30–50%

Resistance can be prevented by ensuring cure the first time round.

The effectiveness of preventive therapy in persons exposed to MDR TB bacteria is not known. All close contacts should be screened for signs and symptoms of MDR TB and by sputum sampling to detect early disease.

TB CONTROL PROGRAM DRUG REGIMENS
Treatment should be given once daily seven days per week in both the intensive and continuation phases.

All adult patients and children with malnutrition or HIV infection should receive pyridoxine 25 mg daily for the duration of therapy.

R – Rifampicin
H – Isoniazid
Z – Pyrazinamide
E – Ethambutol

<table>
<thead>
<tr>
<th>Fixed dose drug combination available</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults</td>
</tr>
<tr>
<td>RH –150,75 mg</td>
</tr>
<tr>
<td>RH – 150,150 mg</td>
</tr>
<tr>
<td>RH –300,150 mg</td>
</tr>
<tr>
<td>RHZE–150,75,400,275 mg</td>
</tr>
</tbody>
</table>
### Regimen 1 – New cases with age above 8 years and adults
New smear-positive and new smear-negative patients and extrapulmonary TB

<table>
<thead>
<tr>
<th>Pre-treatment body weight</th>
<th>Two months initial phase</th>
<th>Four months continuation phase</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Treatment given 7 days a week</td>
<td>Treatment given 7 days a week</td>
</tr>
</tbody>
</table>
|                           | RHZE  
(150,75,400,275) | RH  
(150,75) | RH  
(300,150) |
| 20–24 kg                  | 1½ tablet               | 1½ tablet | – |
| 25–29 kg                  | 1½ tablet               | 2 tablets | – |
| 30–37 kg                  | 2 tablets               | 2 tablets | – |
| 38–54 kg                  | 3 tablets               | 3 tablets | – |
| 55–70 kg                  | 4 tablets               | –         | 2 tablets |
| > 71 kg                   | 5 tablets               | –         | 2 tablets |

### Regimen 2 – Retreatment cases
Previously treated TB patients after cure, completion, interruption and failure
Previously treated TB patients returning for treatment after cure or completion, default and failure.

#### Initial phase:

<table>
<thead>
<tr>
<th>Pre-treatment body weight</th>
<th>Two months initial phase</th>
<th>3rd month initial phase</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Treatment given 7 days a week</td>
<td>Treatment given 7 days a week</td>
</tr>
</tbody>
</table>
|                           | RHZE  
(150,75, 400,275) | Streptomycin  
(g) | RHZE  
(150,75,400,275) |
| 30–37 kg                  | 2 tablets               | 0.5                     | 2 tablets |
| 38–54 kg                  | 3 tablets               | 0.75                    | 3 tablets |
| 55–70 kg                  | 4 tablets               | 1.0                     | 4 tablets |
| ≥71 kg                    | 5 tablets               | 1.0                     | 5 tablets |

### Continuation phase: (after 3rd month initial phase)

<table>
<thead>
<tr>
<th>Pre-treatment body weight</th>
<th>Five months continuation phase</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Treatment given 7 days a week</td>
</tr>
<tr>
<td></td>
<td>RH</td>
</tr>
<tr>
<td>30–37 kg</td>
<td>(150,75)</td>
</tr>
<tr>
<td>38–54 kg</td>
<td>2 tablets</td>
</tr>
<tr>
<td>55–70 kg</td>
<td>3 tablets</td>
</tr>
<tr>
<td>≥71 kg</td>
<td>–</td>
</tr>
</tbody>
</table>

» Streptomycin should NOT be given during pregnancy and to those over 65 years.
» Keep strictly to the correct dose and the duration of treatment.
» Cure of the new PTB patients depends on taking Regimen 1 for 6 months.
Chapter 17  
Respiratory conditions

» Cure of re-treatment PTB patients depends on taking Regimen 2 for 8 months.
» The patient should be continued on the pre-treatment body weight throughout the treatment period, there is no need to adjust the dosages based on weight gain.

Regimen 3 – Children
For treatment of uncomplicated intrathoracic tuberculosis and extra pulmonary tuberculosis such as lymph gland and pleural effusion in children.

<table>
<thead>
<tr>
<th>Body weight kg</th>
<th>Intensive Phase (2 months) Treatment given 7 days a week</th>
<th>Continuation phase (4 months) Treatment given 7 days a week</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RHZ*</td>
<td>RH</td>
</tr>
<tr>
<td></td>
<td>60,30,150</td>
<td>60,30</td>
</tr>
<tr>
<td>2–2.9 kg</td>
<td>½ tablet</td>
<td>½ tablet</td>
</tr>
<tr>
<td>3–5.9 kg</td>
<td>1 tablet</td>
<td>1 tablet</td>
</tr>
<tr>
<td>6–8.9 kg</td>
<td>1½ tablets</td>
<td>1½ tablet</td>
</tr>
<tr>
<td>9–11.9 kg</td>
<td>2 tablets</td>
<td>2 tablets</td>
</tr>
<tr>
<td>12–14.9 kg</td>
<td>2½ tablets</td>
<td>2½ tablets</td>
</tr>
<tr>
<td>15–19.9 kg</td>
<td>3 tablets</td>
<td>3 tablets</td>
</tr>
<tr>
<td>20–24.9 kg</td>
<td>4 tablets</td>
<td>4 tablets</td>
</tr>
<tr>
<td>25–29.9 kg</td>
<td>5 tablets</td>
<td>5 tablets</td>
</tr>
<tr>
<td>30–35.9 kg</td>
<td>6 tablets</td>
<td>6 tablets</td>
</tr>
<tr>
<td>36–40 kg</td>
<td>7 tablets</td>
<td>7 tablets</td>
</tr>
</tbody>
</table>

Keep strictly to the correct dose and the duration of treatment. The patient should be weighed regularly and the dose adjusted according to the current weight.

Referral
» All patients who cannot be managed on an ambulatory basis
» Impaired renal function
» Children under 12 years should have a chest X-ray for diagnostic purposes if mantoux positive and/or symptoms of TB (and sputum negative)
» MDR or XDR TB patients
» Retreatment cases of children
» Children who are contacts of patients with open MDR or XDR TB
Chapter 18: Eye conditions

18.1 Conjunctivitis
   18.1.1 Conjunctivitis, allergic
   18.1.2 Conjunctivitis, bacterial (excluding conjunctivitis of the newborn)
   18.1.3 Conjunctivitis of the newborn
   18.1.4 Conjunctivitis, viral (pink eye)

18.2 Eye injuries
   18.2.1 Eye injury, chemical burn
   18.2.2 Eye injury, (blunt or penetrating) foreign body

18.3 Glaucoma, acute

18.4 Painful red eye

18.5 Structural abnormalities of the eye

18.6 Visual problems
18.1 Conjunctivitis
H10

An inflammatory condition of the conjunctiva. It may be caused by:
- allergies
- bacterial or viral (pink eye) infections

18.1.1 Conjunctivitis, allergic
H10.1

Description
An inflammatory condition caused by allergy to pollen, grass, animal fur, medication, cosmetics etc. There is usually a history of allergies, including hay fever. Common features include:
- itching, watery eyes and photophobia
- conjunctiva may appear normal or slightly red
- conjunctival swelling in severe cases
- normal cornea, iris and pupil
- normal visual acuity

General measures
- Cold compresses to relieve symptoms, i.e. a clean moistened cloth over the eyes for 10 minutes

Drug treatment
Adults and children over the age of 6 months:
- Oxymetazoline 0.025%, eye drops, instil 1–2 drops 6 hourly for 7 days
- Antazoline/tetrahydrozoline HCl 0.05/0.04% eye drops, instil 1–2 drops 6 hourly for 7 days

Severe cases or rhinoconjunctivitis:
For long term use in adults and school going children:
- Cetirizine, oral, once daily at night

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months / years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 14 – 25 kg</td>
<td>5 mg</td>
<td>Syrup 5 mL</td>
<td>≥ 3–7 years</td>
</tr>
<tr>
<td>≥ 25 – 55 kg</td>
<td>10 mg</td>
<td>Tablet 10 mL</td>
<td>≥ 7–15 years</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>10 mg</td>
<td>–</td>
<td>≥ 15 years and adults</td>
</tr>
</tbody>
</table>
Chapter 18  
Eye conditions

or  
Chlorpheniramine, oral, 0.1 mg/kg/dose 6–8 hourly

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th></th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 9–11 kg</td>
<td>1 mg</td>
<td>Syrup 2 mg/5mL</td>
<td>Tablet 4 mg</td>
<td>≥ 12–18 months</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>1.2 mg</td>
<td>–</td>
<td></td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>1.5 mg</td>
<td>4 mL</td>
<td></td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>2 mg</td>
<td>5 mL</td>
<td></td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>3 mg</td>
<td>7.5 mL</td>
<td>–</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>≥35 kg and above</td>
<td>4 mg</td>
<td>–</td>
<td>1 tablet</td>
<td>≥ 11 years and adults</td>
</tr>
</tbody>
</table>

Referral

» No response to treatment
» Persons wearing contact lenses

18.1.2 Conjunctivitis, bacterial (excluding conjunctivitis of the newborn)

H10.9

Description
An inflammatory purulent condition of the conjunctiva caused by bacteria and characterised by:

» itchy eyes and swollen lids
» stickiness of eyelids on awakening in the morning
» discharge from one or both eyes
» redness especially of conjunctival angles (fornices)

General measures

» Patient education on personal hygiene to avoid spread.
» Educate patient on correct application of ophthalmic ointment.
» Advise patient:
  – to wash hands thoroughly before applying ophthalmic ointment
  – not to not share ophthalmic ointments or drops
  – not to rub eyes
  – never to use urine or milk to wash the eyes

Drug treatment

- Chloramphenicol 1%, ophthalmic ointment, applied 6 hourly for 7 days
Chapter 18  Eye conditions

Pain relief, if required:
- **Paracetamol**, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum of 4 doses per 24 hours
  - In children under 6 months calculate dose by weight

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥3.5–5 kg</td>
<td>48 mg</td>
<td>Syrup 120 mg/5mL</td>
<td>≥1–3 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tablet 500 mg</td>
<td></td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>60 mg</td>
<td>2 mL</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>96 mg</td>
<td>2.5 mL</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥ 9–14 kg</td>
<td>120 mg</td>
<td>4 mL</td>
<td>≥ 12 months–12 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>180 mg</td>
<td>5 mL</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–35 kg</td>
<td>240 mg</td>
<td>7.5 mL</td>
<td>≥ 5–11 years</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>500 mg</td>
<td>10 mL (½ tablet)</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td>≥55 kg and above</td>
<td>Up to 1 000 mg</td>
<td>15 m doy</td>
<td>≥ 15 years and adults</td>
</tr>
</tbody>
</table>

**Referral**
- No response after 5 days
- Loss of vision
- Irregularity of pupil
- Haziness of the cornea
- Persistent painful eye

18.1.3 Conjunctivitis of the newborn

P39.1

**Description**
Inflammation of the conjunctiva in the neonatal period presenting with purulent discharge, inflamed conjunctiva and eyelid oedema (in severe cases).
Common infectious agents include *N. gonorrhoea*, *S. aureus*, and *Chlamydia*.

! CAUTION!
If not treated immediately this condition can become worse, damage the cornea and lead to blindness.

**General measures**
- Screen all pregnant women for sexually transmitted infections (STI) and treat
- Cleanse or wipe eyes of all newborn babies with a clean cloth, cotton wool or swab
- Advise against harmful applications, such as urine, to the eyes of newborn babies
**Drug treatment**

**PREVENTION**

Routine administration for every newborn baby:
- Chloramphenicol 1%, ophthalmic ointment, applied as soon as possible after birth

**TREATMENT**

Purulent discharge:
- Ceftriaxone, IM, 50 mg/kg immediately as a single dose
  - Contraindicated in neonatal jaundice

<table>
<thead>
<tr>
<th>! CAUTION !</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do not administer calcium containing fluids, e.g. Ringer-lactate, within 48 hours of administering ceftriaxone.</td>
</tr>
<tr>
<td>Contra-indicated in neonatal jaundice.</td>
</tr>
<tr>
<td>Annotate dose and route of administration in referral letter.</td>
</tr>
</tbody>
</table>

- Sodium chloride 0.9%, eye washes, initially then hourly until referral.

**Sticky eye without purulent discharge:**
- Chloramphenicol 1%, ophthalmic ointment, applied 6 hourly for 7 days

**Referral**

**Urgent**
- All neonates with purulent discharge

---

**18.1.4 Conjunctivitis, viral (pink eye)**

**B30.9**

**Description**

A highly contagious, viral infection, which is spread by contact with:
- hands
- towels
- face cloths

It may start in one eye and spread to the other, or more commonly both eyes are infected. Common symptoms include:
- itchy eyes
- sore eyes, feeling of grittiness (roughness) or burning which can be painful
- photophobia
- watery discharge. A yellow discharge indicates a secondary bacterial infection.
- reddened and swollen conjunctiva, which may become haemorrhagic
- swelling of the eyelids
- enlarged pre-auricular node
Chapter 18  Eye conditions

» The cornea, iris and pupil are completely normal with normal visual acuity.

**General measures**

» Advise on correct cleansing or rinsing of eyes
» Cold compresses for symptomatic relief

**Drug treatment**

**Adults and children over 6 months:**
- Oxymetazoline 0.025%, eye drops, instil 1–2 drops 6 hourly for 7 days

**Pain relief:**
- **Paracetamol**, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum of 4 doses per 24 hours
  - In children under 6 months calculate dose by weight

```
<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥3.5–5 kg</td>
<td>48 mg</td>
<td>Syrup 120 mg/5mL 2 mL</td>
<td>≥ 1–3 months</td>
</tr>
<tr>
<td>≥5–7 kg</td>
<td>60 mg</td>
<td>Tablet 500 mg –</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥7–9 kg</td>
<td>96 mg</td>
<td>–</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥9–14 kg</td>
<td>120 mg</td>
<td>–</td>
<td>≥ 12 months–3 years</td>
</tr>
<tr>
<td>≥14–17.5 kg</td>
<td>180 mg</td>
<td>7.5 mL –</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥17.5–35 kg</td>
<td>240 mg</td>
<td>10 mL ½ tablet</td>
<td>≥ 5–11 years</td>
</tr>
<tr>
<td>≥35–55 kg</td>
<td>500 mg</td>
<td>1 tablet</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td>≥55 kg and above</td>
<td>Up to 1000 mg</td>
<td>Up to 2 tablets</td>
<td>≥ 15 years and adults</td>
</tr>
</tbody>
</table>
```

**Referral**

» A unilateral red eye for more than one day
» Suspected herpes conjunctivitis indicated by vesicles on skin next to eye
» No response after 5 days
» Loss of vision
» Irregularity of pupil
» Haziness of the cornea
» Persistent painful eye
18.2 Eye injuries

18.2.1 Eye injury, chemical burn

This is a medical emergency.

**Description**

Damage to one or both eyes caused by contact with irritating chemical substances e.g. alkali or acid, presenting with:

» pain
» inability to open eye
» blurred vision
» excessive teary and watery eye

**General measures**

» Irrigate or wash the eye immediately and continuously with clean water or saline for at least 20 minutes
» In severe alkaline burn cases, irrigation should be prolonged further.

**Drug treatment**

**Local anaesthetic if needed:**

- Tetracaine 0.5% eye drops, instil 2 drops in the affected eye
  - repeat irrigation or washing out of eye
  - evert upper eyelid and remove debris with cotton bud
- Chloramphenicol 1%, ophthalmic ointment, applied 6 hourly

**Pain relief:**

- **Paracetamol**, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum of 4 doses per 24 hours
  - In children under 6 months calculate dose by weight

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥3.5–5 kg</td>
<td>48 mg</td>
<td>2 mL</td>
<td>≥ 1–3 months</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>60 mg</td>
<td>2.5 mL</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>96 mg</td>
<td>4 mL</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥ 9–14 kg</td>
<td>120 mg</td>
<td>5 mL</td>
<td>≥ 12 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>180 mg</td>
<td>7.5 mL</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–35 kg</td>
<td>240 mg</td>
<td>10 mL ½ tablet</td>
<td>≥ 5–11 years</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>500 mg</td>
<td>1 tablet</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>Up to 1 000 mg</td>
<td>Up to 2 tablets</td>
<td>≥ 15 years and adults</td>
</tr>
</tbody>
</table>
Chapter 18  Eye conditions

Referral

» All cases within 12 hours

18.2.2 Eye injury, (blunt or penetrating) foreign body
S05.9/S05.5

Description

A foreign body may be embedded in the conjunctiva or cornea or deeper, causing:

» possible corneal abrasion
» disturbance of vision which is serious
» complaints of something in the eye
» pain

General measures

» Establish the cause
» Wash eye with clean water or sodium chloride 0.9%,
» Remove foreign body if visible on sclera or conjunctiva with cotton tipped stick or bud.
» If foreign body is not visible, check visual acuity first, before testing with fluorescein
» Stain with fluorescein to reveal corneal foreign body or complications such as abrasion.
» Check after removal of foreign body
» Cover injured eye with eye pad.

Drug treatment

- Sodium chloride 0.9%, eye washes or irrigations as soon as possible.
  - If sodium chloride 0.9% is not available use cooled boiled water or sterile water.

Deep corneal or scleral injuries

Cover with an eye shield and refer immediately

If immediate referral is not possible, while awaiting transfer:

- Atropine, 1%, drops, instilled immediately
- Chloramphenicol 1%, ophthalmic ointment applied immediately
Chapter 18  
Eye conditions

Pain relief:
- **Paracetamol**, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum of 4 doses per 24 hours
  - In children under 6 months calculate dose by weight

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥3.5–5 kg</td>
<td>48 mg</td>
<td>Syrup 120 mg/5mL</td>
<td>≥ 1–3 months</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>60 mg</td>
<td>2 mL</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>96 mg</td>
<td>4 mL</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥ 9–14 kg</td>
<td>120 mg</td>
<td>5 mL</td>
<td>≥ 12 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>180 mg</td>
<td>7.5 mL</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–35 kg</td>
<td>240 mg</td>
<td>10 mL</td>
<td>½ tablet</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>500 mg</td>
<td>–</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td>≥55 kg and above</td>
<td>Up to 1 000 mg</td>
<td>–</td>
<td>Up to 2 tablets</td>
</tr>
</tbody>
</table>

! CAUTION !
Review the problem daily
Do not use an eye pad with ecchymosis, lid oedema or bleeding

Referral
Immediately:
- If the foreign body cannot be removed or an intraocular foreign body is suspected
- Laceration, perforation or diffuse damage to the cornea or sclera
- Damage to other structures of the eye, including the eyelid
- Visual abnormalities or limitation of movement of the eye

18.3 Glaucoma, acute
H40.9

Description
Glaucoma is damage to the optic nerve caused by a level of intra-ocular pressure (often raised), which results in loss of vision usually in one eye only.

Clinical features:
- the pupil is moderately dilated and may be oval in shape
- corneal haziness
- pericorneal conjunctival inflammation
- sudden onset of extremely severe, bursting pain and eye redness
- a unilateral, temporal headache, after being exposed to a period of darkness, e.g. cinema
Chapter 18  Eye conditions

» coloured haloes around lights (bright rings)
» the eye feels hard, compared to the other eye, when measured with finger palpation (this is not an accurate test)
» severe pain in eye (acute)
» nausea and vomiting in severe cases

Emergency drug treatment before referral (Doctor initiated)
• Acetazolamide, oral, 500 mg, immediately, followed by 250 mg 6 hourly.
• Pilocarpine, 1%, eye drops, instilled into the affected eye every 15 minutes for 4 doses

Referral
Urgent
» All patients to an ophthalmologist within 12 hours

18.4 Painful red eye
H57.1

Description
Pain and redness of the eye indicate inflammation of the anterior structures of the eye.

» Exclude bacterial or viral conjunctivitis (often bilateral and associated with irritation, rather than pain)
» Consider acute glaucoma and manage appropriately – See section 18.3: Glaucoma, acute

Referral
Urgent:
» All patients (excluding those with conjunctivitis)

18.5 Structural abnormalities of the eye

These include:
» eyelashes rubbing on the cornea (trichiasis)
» eyelids bent into the eye (entropion)
» eyelids bent out too much (ectropion)
» ptosis (drooping eyelid)

Referral
» All patients
Visual problems may be due to refractive errors, or to damage to the eye or optic nerve. They may be an indication of underlying disease such as diabetes or hypertension.

Assessment

Look for abnormalities of the eye

Determine visual acuity accurately in both eyes by Snellen chart. If vision is diminished (less than 6/12) perform the following tests:

Pin hole test

» Make a hole of about 1 mm wide in a piece of dark/black paper.
» Ask the patient to look through this hole at the Snellen chart.
» If vision improves, this means that the patient has a refractive error.

Red reflex test

The patient looks past the examiner’s head focussing on a distant target.

» with the ophthalmoscope at 0 (zero) the examiner keeps it close to his eye and then focuses the beam of light so that it falls on the pupillary area of the cornea
» the examiner stands about 60 cm away from the patient
» in normal individuals, the examiner should be able to see a red or pink colour (reflex) through the pupil which comes from the retina

Significance of an absent red reflex

If there is a history of trauma or diabetes the absence of a red reflex is probably due to:

» retinal detachment
» a vitreous or internal haemorrhage
» mature cataract

If there are cataracts one usually sees:

» black shadows against the red reflex in immature cataracts
» absence of red reflex in mature cataracts

In a patient above the age of 50 years with no history of trauma, diabetes or previous eye disease, an absent red reflex is almost sure to be due to cataract formation, especially with decreased visual acuity.

Note:

Associated diabetes or hypertension should be adequately managed before referral, as surgery can only be considered with appropriately managed disease.
Chapter 18  
Eye conditions

Referral

Urgent: within 12–24 hours
» Sudden visual loss in one or both eyes
» Pain or redness in one eye only or unilateral watery eye especially with visual and pupil abnormalities,
» Recent proptosis of one or both eyes or enlargement of the eye (buphthalmos / keratoglobus) in children
» Hazy cornea in children
» Squint of recent onset

Within days
» Chronic glaucoma
» Double vision except following recent injury
» Leucokoria (white reflex from the pupil)
» Squint at any age if not previously investigated by ophthalmologist
» Visual loss in patients with systemic disease such as diabetes

Non-urgent referral
» Cataracts
» Refractive errors
» Long-standing blindness – first visit to health facility
Chapter 19: Ear, nose and throat conditions

19.1 Allergic rhinitis
19.2 Epistaxis
19.3 Otitis
   19.3.1 Otitis externa
   19.3.2 Otitis media, acute
   19.3.3 Otitis media, chronic, suppurative
19.4 Sinusitis, acute, bacterial
19.5 Tonsillitis and pharyngitis
19.1 Allergic rhinitis

Description
Recurrent inflammation of the nasal mucosa due to hypersensitivity to inhaled allergens, e.g. pollen, house dust, grasses and animal proteins. Allergic rhinitis is characterised by recurrent episodes of:

» blocked stuffy nose
» watery nasal discharge
» frequent sneezing, often accompanied by nasal itching and irritation
» conjunctival itching and watering
» oedematous pale grey nasal mucosa
» mouth breathing
» snoring at night

Exclude other causes, such as infections, vasomotor rhinitis, overuse of decongestant drops, side effects of antihypertensives and antidepressants.

General measures
» Avoid allergens and irritants.

Drug treatment
- Corticosteroid, e.g. beclomethasone, aqueous nasal solution, 2 sprays in each nostril twice daily
  o Aim the nozzle vertically and not to the back of the throat.
  o Do not sniff vigorously.

For short term symptomatic use:
- Chlorpheniramine, oral, 0.1 mg/kg/dose 6–8 hourly

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 9–11 kg</td>
<td>1 mg</td>
<td>2.5 mL, –</td>
<td>≥ 12–18 months</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>1.2 mg</td>
<td>3 mL, –</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>1.5 mg</td>
<td>4 mL, –</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>2 mg</td>
<td>5 mL, –</td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>3 mg</td>
<td>7.5 mL, –</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>≥ 35 kg and above</td>
<td>4 mg</td>
<td>–, 1 tablet</td>
<td>≥ 11 years and adults</td>
</tr>
</tbody>
</table>

Long-term antihistamines should only be used after an adequate trial of intranasal corticosteroids and should be added to steroid therapy.
For long-term use in adults and school going children:
• Cetirizine, oral, once daily at night

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months / years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 14 – 25</td>
<td>5 mg</td>
<td>5 mL</td>
<td>≥ 3–7 years</td>
</tr>
<tr>
<td>≥ 25 – 55</td>
<td>10 mg</td>
<td>10 mL / 1 tablet</td>
<td>≥ 7–15 years</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>10 mg</td>
<td>– / 1 tablet</td>
<td>≥ 15 years and adults</td>
</tr>
</tbody>
</table>

Referral
» Chronic persistent symptoms
» Severe symptoms

19.2 Epistaxis
(See Chapter 21 - Trauma and emergencies)

19.3 Otitis

19.3.1 Otitis, externa
H60.9

Description
Inflammation of the external ear may be one of the following two types:

<table>
<thead>
<tr>
<th>Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>diffuse</td>
<td>Usually due to an infection, usually a mixed infection, involving one or more of the following organisms:</td>
</tr>
</tbody>
</table>
|             | • Staphylococcus  
|             | • *P. aeruginosa*  
|             | • *E. coli*  
|             | Infections are usually due to:                                                                       |
|             | • mixed infections  
|             | • allergic dermatitis (often caused by shampoo or soaps)  
|             | • swimming pool chemicals  
|             | • trauma caused by scratching, e.g. matchsticks, earbuds.                                             |
| furuncular  | Usually caused by *Staphylococcus*                                                                   |

General measures
» Exclude any underlying chronic otitis media before commencing treatment.
Chapter 19  Ear, nose and throat conditions

» Most cases recover after thorough cleansing and drying of the ear.
» Keep the ear clean and dry.
» Do not leave pieces of cotton wool, etc. in the ear.
» Do not instil anything into the ear unless prescribed.

Drug treatment

Diffuse
Does not usually require an antibiotic.
Make a wick where possible, using ribbon gauze or other suitable absorbent cloth, e.g. paper towel to clean and dry the ear.
- Acetic acid 2% in alcohol, topical, instilled into the ear every 6 hours for 5 days
  - Instill 3–4 drops after cleaning and drying the ear

Furuncular
- Flucloxacillin, oral, 12–25 mg/kg/dose 6 hourly for 5 days

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months / years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 2.5–5 kg</td>
<td>62.5 mg</td>
<td>Syrup 125 mg/5 mL</td>
<td>Capsule 250 mg</td>
</tr>
<tr>
<td>≥ 5 – 11 kg</td>
<td>125 mg</td>
<td>5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 11 – 25 kg</td>
<td>250 mg</td>
<td>10 mL</td>
<td>1 capsule</td>
</tr>
<tr>
<td>≥ 25 kg and above</td>
<td>500 mg</td>
<td>–</td>
<td>2 capsules</td>
</tr>
</tbody>
</table>

Penicillin–allergic patients
- Erythromycin, oral, 10–15 mg/kg/dose 6 hourly

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months / years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 2.5 – 3.5 kg</td>
<td>35 mg</td>
<td>Syrup 125 mg/5 mL</td>
<td>Tablets 250 mg</td>
</tr>
<tr>
<td>≥ 3.5 – 5 kg</td>
<td>50 mg</td>
<td>2 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 5 – 7 kg</td>
<td>75 mg</td>
<td>3 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 7 – 9 kg</td>
<td>100 mg</td>
<td>4 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 9 – 11 kg</td>
<td>125 mg</td>
<td>5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>150 mg</td>
<td>6 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>200 mg</td>
<td>8 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>250 mg</td>
<td>10 mL</td>
<td>1 tablet</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>375 mg</td>
<td>15 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 35 kg and above</td>
<td>500 mg</td>
<td>–</td>
<td>2 tablets</td>
</tr>
</tbody>
</table>
Chapter 19  Ear, nose and throat conditions

Referral

» No response to treatment

19.3.2 Otitis, media, acute  
H66.9

Description
Inflammation of the middle ear characterised by:
» pain
» loss of the normal light reflex of the eardrum
» red bulging eardrum
» drum perforation
» fever in about half of the cases
» loss of hearing
Mild redness of the eardrum and rubbing the ear are not reliable signs.

General measures
» Do not instil anything into the ear.
» Avoid getting the inside of the ear wet.
» Do not plug the ear with cotton wool, etc.

Drug treatment
• Amoxicillin, oral, 25–30 mg/kg/dose 8 hourly for 5 days

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Syrup</td>
<td>Capsule</td>
</tr>
<tr>
<td></td>
<td></td>
<td>125 mg/5mL</td>
<td>250 mg/5mL</td>
</tr>
<tr>
<td>≥ 3.5–5 kg</td>
<td>125 mg</td>
<td>5 mL</td>
<td>2.5 mL</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>175 mg</td>
<td>7 mL</td>
<td>3.5 mL</td>
</tr>
<tr>
<td>≥ 7–11 kg</td>
<td>250 mg</td>
<td>10 mL</td>
<td>5 mL</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>375 mg</td>
<td>15 mL</td>
<td>7.5 mL</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>500 mg</td>
<td>–</td>
<td>10 mL</td>
</tr>
</tbody>
</table>
## Chapter 19  Ear, nose and throat conditions

**Penicillin–allergic patients:**
- Erythromycin, oral, 6 hourly for 5 days

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Dose (mg)</th>
<th>Use one of the following:</th>
<th>Age (months/years)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Syrup 125 mg / 5 mL</td>
<td>Tablets 250 mg</td>
</tr>
<tr>
<td>≥ 2.5 – 3.5</td>
<td>35 mg</td>
<td>1.4 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 3.5 – 5</td>
<td>50 mg</td>
<td>2 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 5 – 7</td>
<td>75 mg</td>
<td>3 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 7 – 9</td>
<td>100 mg</td>
<td>4 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 9 – 11</td>
<td>125 mg</td>
<td>5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 11–14</td>
<td>150 mg</td>
<td>6 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 14–17.5</td>
<td>200 mg</td>
<td>8 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 17.5–25</td>
<td>250 mg</td>
<td>10 mL</td>
<td>1 tablet</td>
</tr>
<tr>
<td>≥ 25–35</td>
<td>375 mg</td>
<td>15 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 35 kg and</td>
<td>500 mg</td>
<td>–</td>
<td>2 tablets</td>
</tr>
<tr>
<td>above</td>
<td></td>
<td></td>
<td>≥ 11 years and adults</td>
</tr>
</tbody>
</table>

For pain relief:
- **Paracetamol**, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum of 4 doses per 24 hours
  - In children under 6 months calculate dose by weight

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Dose (mg)</th>
<th>Use one of the following:</th>
<th>Age (months/years)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Syrup 120 mg / 5 mL</td>
<td>Tablet 500 mg</td>
</tr>
<tr>
<td>≥3.5–5</td>
<td>48 mg</td>
<td>2 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 5–7</td>
<td>60 mg</td>
<td>2.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 7–9</td>
<td>96 mg</td>
<td>4 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 9–14</td>
<td>120 mg</td>
<td>5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 14–17.5</td>
<td>180 mg</td>
<td>7.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 17.5–35</td>
<td>240 mg</td>
<td>10 mL</td>
<td>½ tablet</td>
</tr>
<tr>
<td>≥ 35–55</td>
<td>500 mg</td>
<td>–</td>
<td>1 tablet</td>
</tr>
<tr>
<td>≥55 kg and</td>
<td>Up to 1</td>
<td>Up to 2 tablets</td>
<td>≥ 15 years and adults</td>
</tr>
<tr>
<td>above</td>
<td>000 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Referral
- Severe pain, fever or vomiting, not responding to treatment after 72 hours (if otoscopy confirmed) or after 24 hours (if otoscopy unconfirmed).
- Recurrent otitis media
- Painful swelling behind the ear or tenderness on percussion of the mastoid
- Suspected meningitis
Chapter 19  Ear, nose and throat conditions

19.3.3 Otitis media, chronic, suppurative

H66.3

Description
A purulent discharge from the ear for more than 2 weeks.
If the eardrum has been ruptured for 2 weeks or longer, a secondary infection
with multiple organisms usually occurs. Multiple organism infection makes oral
antibiotic treatment ineffective and patients may need to be referred.
TB is an important cause of a chronically discharging ear in South Africa.
If pain is present, suspect another condition or complications.

Note:
A chronically draining ear can only heal if it is dry.
Drying the ear is time consuming but it is the most effective treatment.

General measures
» Dry mopping is the most important part of the treatment. It should be
demonstrated to the child’s caregiver or patient if old enough.
  – roll a piece of clean absorbent cloth into a wick
  – carefully insert the wick into the ear with twisting action
  – remove the wick and replace with a clean dry wick
  – repeat this until the wick is dry when removed
» Do not leave anything in the ear.
» Do not instill anything else in the ear.
» Avoid getting the inside of the ear wet while swimming and bathing.
» Exclude TB as a cause.

Referral
» All sick children, vomiting, drowsy, etc.
» Painful swelling behind the ear
» No improvement after 4 weeks
» Any attic perforation
» Any perforation not progressively improving after 3 months or closed by 6
  months, even if dry
» Moderate or severe hearing loss

19.4 Sinusitis, acute, bacterial

J01.9

Description
Bacterial infection of one or more sinuses that occurs most often after a viral
nasal infection or allergic rhinitis.
Bacterial sinusitis is characterised by:
» deterioration of a common cold after 5–7 days
Chapter 19 Ear, nose and throat conditions

» purulent nasal discharge, especially if unilateral
» pain and tenderness over one or more sinuses
» nasal obstruction
» occasional fever

Note:
Sinusitis is uncommon in children under 5 years, as sinuses are not fully developed.

General measures
» Steam inhalation may be effective in liquefying and removing secretions blocking the nose.

Drug treatment
- Amoxicillin, oral, 500 mg 8 hourly for 5 days

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Dose (mg)</th>
<th>Use one of the following:</th>
<th>Age (Months/years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 14 kg and above</td>
<td>500 mg</td>
<td>Syrup 250 mg/5 mL, Capsule 250 mg</td>
<td>≥ 3 years and adult</td>
</tr>
</tbody>
</table>

Penicillin–allergic patients:
- Erythromycin, oral, 10–15 mg/kg 6 hourly for 5 days

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Dose (mg)</th>
<th>Use one of the following:</th>
<th>Age (Months/years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 14–17.5 kg</td>
<td>200 mg</td>
<td>Syrup 125 mg/5 mL, Tablets 250 mg</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>250 mg</td>
<td>8 mL, 1 tablet</td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>375 mg</td>
<td>10 mL, 1 tablet</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>≥ 35 kg and above</td>
<td>500 mg</td>
<td>–, 2 tablets</td>
<td>≥ 11 years and adult</td>
</tr>
</tbody>
</table>

Note:
Erythromycin is suboptimal therapy for this because of pneumoccocal resistance.
Chapter 19  Ear, nose and throat conditions

For pain relief:
- **Paracetamol**, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum of 4 doses per 24 hours
  - In children under 6 months calculate dose by weight

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 14–17.5 kg</td>
<td>120 mg</td>
<td>5 mL</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–35 kg</td>
<td>240 mg</td>
<td>10 mL</td>
<td>½ tablet</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>500 mg</td>
<td>–</td>
<td>1 tablet</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>1000 mg</td>
<td>–</td>
<td>Up to 2 tablets</td>
</tr>
</tbody>
</table>

- Oxymetazoline, nose drops, 2 drops in each nostril 6–8 hourly for not more than 5 days continuously
  - Children: 0.025%
  - Adults: 0.05%

and/or
- Sodium chloride 0.9%, nose drops, use frequently and in fairly large volumes.

**Referral**
» Fever lasting longer than 48 hours
» Poor response after 5 days
» Dental focus of infection is present, e.g. apical tooth abscess causing maxillary sinusitis
» Complications, e.g. periorbital cellulitis with periorbital swelling
» Oedema over a sinus
» Recurrent sinusitis
» Meningeal irritation

**19.5 Tonsillitis and pharyngitis**
J03.9

**Description**
A painful red throat and/or enlarged inflamed tonsils. Yellow exudates may be present. Tender anterior cervical lymphadenopathy may be present. Viruses are the cause in the majority of cases. However, streptococcal pharyngitis/tonsillitis may cause local suppurative complications as well as rheumatic fever, which can cause serious heart disease. Antibiotics to eradicate streptococci should be given to patients with pharyngitis/tonsillitis who are at risk for rheumatic fever (age 3 to 15 years) **unless** one of the following features of viral infection is present (do **not** give antibiotics if these are present):
Chapter 19  Ear, nose and throat conditions

» runny nose
» cough
» a rash (excluding scarlet fever)

General measures

» Homemade salt mouthwash, gargle for 1 minute twice daily:
  – ½ medicine measure of table salt in a glass of lukewarm water
  – do not give to children unable to gargle
» Advise adequate hydration.
» Avoid irritants e.g. vaporubs inserted into nostrils.

Drug treatment

Preferred treatment option:
- Benzathine benzylpenicillin, IM, immediately as a single dose

<table>
<thead>
<tr>
<th>Weight</th>
<th>Dose</th>
<th>Use one of the following injections</th>
<th>Age</th>
</tr>
</thead>
<tbody>
<tr>
<td>kg</td>
<td>units</td>
<td>1 200 000 mixed with 4 mL WFI</td>
<td>Months/ years</td>
</tr>
<tr>
<td>Less than 15 kg</td>
<td>300 000</td>
<td>1 mL</td>
<td>18 months–3 years</td>
</tr>
<tr>
<td>15 – 30 kg</td>
<td>600 000</td>
<td>2 mL</td>
<td>3–11 years</td>
</tr>
<tr>
<td>More than 30 kg</td>
<td>1 200 000</td>
<td>4 mL</td>
<td>11–15 years</td>
</tr>
</tbody>
</table>

or

If IM injection refused:
- Phenoxymethylpenicillin, oral, 12 hourly for 10 days

<table>
<thead>
<tr>
<th>Weight</th>
<th>Dose</th>
<th>Use one of the following:</th>
<th>Age</th>
</tr>
</thead>
<tbody>
<tr>
<td>kg</td>
<td>mg</td>
<td>Syrup</td>
<td>Tablet</td>
</tr>
<tr>
<td>≥ 11–35 kg</td>
<td>250 mg</td>
<td>5 mL</td>
<td>1 tablet</td>
</tr>
<tr>
<td>≥ 35 – 55 kg</td>
<td>500 mg</td>
<td>–</td>
<td>2 tablets</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>500 mg</td>
<td>–</td>
<td>2 tablets</td>
</tr>
</tbody>
</table>
### Penicillin–allergic patients

- **Erythromycin, oral, 10–15 mg/kg/dose 6 hourly**

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months / years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 11–14 kg</td>
<td>150 mg</td>
<td>6 mL</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>200 mg</td>
<td>8 mL</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>250 mg</td>
<td>10 mL</td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>375 mg</td>
<td>15 mL</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>≥ 35 kg and above</td>
<td>500 mg</td>
<td>–</td>
<td>≥ 11 years and adult</td>
</tr>
</tbody>
</table>

For pain relief:

- **Paracetamol**, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum of 4 doses per 24 hours
  - In children under 6 months calculate dose by weight

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥3.5–5 kg</td>
<td>48 mg</td>
<td>2 mL</td>
<td>≥ 1–3 months</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>60 mg</td>
<td>2.5 mL</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>96 mg</td>
<td>4 mL</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥ 9–14 kg</td>
<td>120 mg</td>
<td>5 mL</td>
<td>≥ 12 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>180 mg</td>
<td>7.5 mL</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–35 kg</td>
<td>240 mg</td>
<td>10 mL</td>
<td>≥ 5–11 years</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>500 mg</td>
<td>–</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td>≥55 kg and above</td>
<td>Up to 1000 mg</td>
<td>–</td>
<td>≥ 15 years and adults</td>
</tr>
</tbody>
</table>

For children under 6 years of age:

- Simple linctus or tussi infans, oral, 8 hourly for 3 days
  - 0 – 6 months: 2.5 mL
  - 6 months – 5 years: 5 mL

### Referral

- Any suppurative complications, e.g. retropharyngeal or peritonsillar abscess.
- Suspected acute rheumatic fever.
- Suspected acute glomerulonephritis.
- Tonsillitis accompanied by difficulty in opening the mouth (trismus).
- History of previous rheumatic fever or rheumatic heart disease.
- Heart murmurs not previously diagnosed.
Chapter 20: Pain

20.1 Pain control
20.2 Chronic non-cancer pain
20.3 Chronic cancer pain
Chapter 20  Pain

20.1 Pain control
R52.9

**Description**

Pain is an unpleasant sensation or emotional experience associated with actual or potential tissue injury. It is always subjective. It is affected by the patient’s mood, morale and the meaning the pain has for the patient.

Self-report is the key to pain assessment.

In non- or pre verbal children, facial expression is the most valid indicator of pain.

Consider using visual analogue scale or faces pain scale to assess severity.

Pain should be assessed by:

- duration
- severity, e.g. does the patient wake up because of the pain
- site
- character, e.g. stabbing, throbbing, crushing, cramp like
- persistent or intermittent
- relieving or aggravating factors
- accompanying symptoms
- distribution of pain
- referred pain

**Assessment of pain in children**

<table>
<thead>
<tr>
<th>Pain Score (The Alder Hey Pain Triage Score)</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Response</strong></td>
<td><strong>Score 0</strong></td>
<td><strong>Score 1</strong></td>
</tr>
<tr>
<td>1. Cry</td>
<td>no complaint/ cry(normal conversation)</td>
<td>consolable not talking negative</td>
</tr>
<tr>
<td>Voice</td>
<td>normal</td>
<td>short grimace &lt; 50% of time</td>
</tr>
<tr>
<td>2. Facial expression</td>
<td>normal</td>
<td>touching / rubbing / sparing</td>
</tr>
<tr>
<td>3. Posture</td>
<td>normal</td>
<td>reduced or restless</td>
</tr>
<tr>
<td>4. Movement</td>
<td>normal</td>
<td>pale</td>
</tr>
<tr>
<td>5. Colour</td>
<td>normal</td>
<td></td>
</tr>
</tbody>
</table>

This system does not give an absolute assessment of severity of pain, but rather increases observer sensitivity to the presence of pain, the response to analgesia and the child’s experience of pain.

The Pain Score should be used as a tool, to guide interpretation of pain and adequacy of response to analgesia.

**General measures**

- Patient counselling.
- Lifestyle adjustment.
ACUTE PAIN CONTROL

Drug treatment

Acute, mild pain
» Non-opioid treatment

Non-inflammatory or post trauma

Children:
- **Paracetamol**, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum of 4 doses per 24 hours
  - In children under 6 months calculate dose by weight

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Dose (mg)</th>
<th>Use one of the following:</th>
<th>Age (months/years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥3.5–5</td>
<td>48 mg</td>
<td>Syrup 120 mg/5mL</td>
<td>≥ 1–3 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tablet 500 mg</td>
<td></td>
</tr>
<tr>
<td>≥ 5–7</td>
<td>60 mg</td>
<td>2 mL–</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 7–9</td>
<td>96 mg</td>
<td>4 mL–</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 9–14</td>
<td>120 mg</td>
<td>5 mL–</td>
<td>≥ 12 months–3 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 14–17.5</td>
<td>180 mg</td>
<td>7.5 mL–</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 17.5–35</td>
<td>240 mg</td>
<td>10 mL–½ tablet</td>
<td>≥ 5–11 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1 tablet</td>
<td></td>
</tr>
<tr>
<td>≥ 35–55</td>
<td>500 mg</td>
<td>–</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 55 and up</td>
<td>Up to 1000</td>
<td>–</td>
<td>≥ 15 years–adults</td>
</tr>
</tbody>
</table>

Pain associated with trauma or inflammation

Adults:
- Ibuprofen, oral, 400 mg 6–8 hourly with food, to a maximum of 2400 mg daily
  - Nurse may only prescribe up to 1200 mg per day

or

Adults:
If no relief after two or three doses, combine paracetamol and ibuprofen at the above dosages.

Acute, moderate pain

Children:
» If no relief to paracetamol, refer.
If pain is moderate or severe consider careful use of morphine while arranging and during transfer (See Precautions and special comments on the use of morphine below)

Adults
If still no relief to simple analgesics as above, add
- Tramadol, oral, 50 mg, 4–6 hourly as a starting dose. (Doctor initiated)
  - May be increased to a maximum of 400 mg daily.
Acute severe pain
If no response to Step 3 in moderate pain, initiate one of the following opioids:

Children:
» Refer
If pain is severe consider careful use of morphine while arranging and during transfer (See Precautions and special comments on the use of morphine below)

Adults:
• Tramadol, oral, 50 mg, 4–6 hourly as a starting dose. (Doctor initiated)
  o May be increased to a maximum of 400 mg daily.
plus
• Paracetamol, oral 1 000 mg 4–6 hourly, when required to a maximum of eight tablets (4 g) daily

OR
• Morphine, IM, 10–15 mg, 4–6 hourly when required. (Doctor initiated)

OR
• Morphine, IV, 10–15 mg 4–6 hours as required. (Doctor initiated)
  o Dilute in 10 mL sodium chloride 0.9%
  o Administer slowly over 4–5 minutes
  o Titrate dose slowly

Patients requiring morphine for acute pain of unknown cause or pain not responding with 1 dose must be referred for definitive treatment.

Precautions and special comments on the use of morphine
» Morphine may cause respiratory depression. This can be reversed with naloxone. Refer to section 21.6: Exposure to poisonous substances.
» Do not administer morphine in:
  – advanced liver disease
  – severe head injury
  – acute asthma
  – advanced chronic obstructive bronchitis, emphysema or other respiratory disease with imminent respiratory failure
  – untreated hypothyroidism

A systematic review has shown that morphine can be used for acute abdominal pain without leading to surgical misdiagnosis.

» Use morphine with extreme care if there is:
  – recent or concurrent alcohol intake or other CNS depressants
Chapter 20 Pain

− hypovolaemia or shock
− in the elderly

In these circumstances use:

Children:

• Morphine, IV, 0.1 mg/kg/dose 4–6 hourly as necessary
  o Give small portions of the dose every 10 minutes until pain relief is adequate or the maximum dose is reached.

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Injection 10 mg/mL</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 7–9 kg</td>
<td>0.5 mg</td>
<td>0.05 mL</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥ 9–11 kg</td>
<td>0.75 mg</td>
<td>0.075 mL</td>
<td>≥ 12–18 months</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>1 mg</td>
<td>0.1 mL</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>1.25 mg</td>
<td>0.125 mL</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>1.5 mg</td>
<td>0.15 mL</td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>2 mg</td>
<td>0.2 mL</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>≥ 35 – 55 kg</td>
<td>3 mg</td>
<td>0.3 mL</td>
<td>≥ 11–15 years</td>
</tr>
</tbody>
</table>

Adults:

• Morphine, IV, small incremental doses, starting at 2–5 mg with increments of 2 mg every 10 minutes.
  o Maximum dose: 10–15 mg depending on body weight

If morphine has been administered the time and dose should be clearly documented on the referral letter as this may alter some of the clinical features of acute abdomen or head injury.

Referral

» All children with moderate and acute severe pain
» No response to oral pain control and unable to initiate opioid therapy
» Uncertain diagnosis
» Management of serious underlying conditions

20.2 Chronic non-cancer pain

R52.2

Description

Pain that is present for more than 4–6 weeks.
It can arise from:

» tissue damage (nociceptive pain), e.g. arthritis, fibromyalgias, lower back pain, pleurisy, cancer pain (discussed below) etc.; or

» injury to nerves (neuropathic pain) e.g. post herpetic neuralgia (pain following shingles), trigeminal neuralgia, diabetic neuropathy, HIV related
peripheral neuropathy, drug induced peripheral neuropathy or phantom limb; or abnormal nerve activity following disease

Assess pain severity, functional status, medication use including self-medication, co-morbid illnesses, etc. Actively look for concomitant depression and anxiety or somatoform pain disorders.

**General measures**

» Lifestyle adjustments.
» Occupational therapy and physiotherapy as appropriate.
» Address psycho-social problems e.g. stress, anxiety, sleep disturbances

**Drug treatment**

The principles are the same as with cancer pain relief. Analgesics should be given by mouth, regularly, in a stepwise manner to ensure adequate relief. Neuropathic pain is best treated with analgesics in addition to tricyclic antidepressants. It is useful combine different classes of drugs for the additive effects depending on pain severity.

**Mild pain**

Adults:
- Paracetamol, oral, 1 000 mg 6 hourly

**Pain associated with trauma or inflammation**

Adults:
- Ibuprofen, oral 400 mg 6–8 hourly with food.
  - Maximum dose: 2 400 mg daily.
  - Discontinue if no improvement after 2–3 days.
  - Nurse may only prescribe up to 1 200 mg per day.

*or*

Combine paracetamol and ibuprofen at the above dosages.

**Moderate pain**

Adults:
If still no relief to simple analgesics as above, add
- Tramadol, oral, 50 mg, 4–6 hourly as a starting dose. (Doctor initiated)
  - May be increased to a maximum of 400 mg daily.

**Adjuvant therapy**

Adults:
In addition to analgesia as above:
- Amitriptyline, oral, 25 mg at night. (Doctor initiated)
  - Titrate up to a maximum of 75 mg at night.

---

**Under-recognition of pain and under-dosing of analgesics is common in chronic pain. Analgesics should be given regularly rather than only when required in patients with ongoing pain.**
Chapter 20 Pain

Referral
» Pain requiring strong opioids
» Pain requiring definitive treatment for the underlying disease
» All children

20.3 Chronic cancer pain
R52.2

Description
Cancer pain is usually chronic and unremitting. Pain assessment requires training in:
» psycho-social assessment
» assessment of need of type and dose of analgesics
» pain severity assessment
Pain severity and not the presence of pain determines the need for treatment.
Drug treatment for pain should never be withheld.
Pain is what the patient says it is.

Under-recognition of pain and under-dosing with analgesics is common in chronic cancer pain.
Analgesics should be given regularly rather than only when required in patients with ongoing pain.

General measures
» Counselling/hospice care.
» Occupational therapy may be required.
» Management of psycho-social factors.

Note:
Appropriate care is provided from the time of diagnosis.
Home palliative care is provided by the family or caregiver with the support of health care professionals: It also involves:
» spiritual care
» social care
» cultural care
» radiation/chemotherapeutic care as appropriate and adjunctive care for emotional pain, nerve root pain, bone pain
» providing moral support for caregivers

Drug treatment
When pain is not controlled according to step 1 and 2, morphine is the treatment of choice for chronic cancer-related pain. Cancer pain in children is managed by the same principles but using lower doses of morphine than adults.
## Recommended steps in management of cancer pain

<table>
<thead>
<tr>
<th>Mild pain</th>
<th>Moderate pain</th>
<th>Severe pain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Step 1: non-opioid, e.g. paracetamol and/or ibuprofen where anti-inflammatory effect is required</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Step 2: weak opioid e.g. tramadol ± non opioid ± adjuvant therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Step 3: strong opioid e.g. morphine ± non opioid ± adjuvant therapy</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Step 1

- **Non-opioid**
  - **Paracetamol**, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum of 4 doses per 24 hours
  - In children under 6 months calculate dose by weight

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥3.5–5 kg</td>
<td>48 mg</td>
<td>Syrup 120 mg/5mL</td>
<td>Tablet 500 mg</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>60 mg</td>
<td>2 mL –</td>
<td>–</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>96 mg</td>
<td>4 mL –</td>
<td>–</td>
</tr>
<tr>
<td>≥ 9–14 kg</td>
<td>120 mg</td>
<td>5 mL –</td>
<td>–</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>180 mg</td>
<td>7.5 mL –</td>
<td>–</td>
</tr>
<tr>
<td>≥ 17.5–35 kg</td>
<td>240 mg</td>
<td>10 mL ½ tablet</td>
<td>–</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>500 mg</td>
<td>– 1 tablet</td>
<td>–</td>
</tr>
<tr>
<td>≥55 kg and above</td>
<td>Up to 1000 mg</td>
<td>– Up to 2 tablets</td>
<td>–</td>
</tr>
</tbody>
</table>
Chapter 20 Pain

- NSAIDs, e.g.: ibuprofen, oral, 6 hourly with food
  - Paediatric dose: 5 mg/kg/dose
  - Maximum dose in adults: 2 400 mg/day. (Nurse may only prescribe up to 1 200 mg per day)
  - Discontinue if not effective after 2–3 days

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Syrup 100 mg/5mL</th>
<th>Tablet 200 mg</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 9–11 kg</td>
<td>50 mg</td>
<td>2.5 mL</td>
<td>–</td>
<td>≥ 12–18 months</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>60 mg</td>
<td>3 mL</td>
<td>–</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>80 mg</td>
<td>4 mL</td>
<td>–</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5 – 25 kg</td>
<td>100 mg</td>
<td>5 mL</td>
<td>–</td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td>≥ 25 – 35 kg</td>
<td>150 mg</td>
<td>7.5 mL</td>
<td>–</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>≥ 35 – 55 kg</td>
<td>200 mg</td>
<td>10 mL</td>
<td>1 tablet</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>400 mg</td>
<td>–</td>
<td>2 tablets</td>
<td>Adults</td>
</tr>
</tbody>
</table>

Step 2
Add weak opioid to Step 1

Children:
- Codeine, oral, 0.5 mg/kg/dose 6 hourly

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Syrup 25 mg/5mL</th>
<th>Tablet 30 mg</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 14–17.5 kg</td>
<td>10 mg</td>
<td>2 mL</td>
<td>–</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5 – 25 kg</td>
<td>15 mg</td>
<td>3 mL</td>
<td>–</td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td>≥ 25 – 35 kg</td>
<td>20 mg</td>
<td>4 mL</td>
<td>–</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>≥ 35 – 55 kg</td>
<td>30 mg</td>
<td>–</td>
<td>1 tablet</td>
<td>≥ 11–15 years</td>
</tr>
</tbody>
</table>

Adults:
- Tramadol, oral, 50 mg, 4–6 hourly as a starting dose. (Doctor initiated)
  - May be increased to a maximum of 400 mg daily.
Step 3
Paracetamol and/or ibuprofen can be used with morphine in step 3

Children:
- Morphine, oral, 0.2–0.4 mg/kg/dose 4–6 hourly according to severity of the pain

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Dose (mg)</th>
<th>Syrup 1 mg/mL</th>
<th>Tablet 10 mg</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 7–9 kg</td>
<td>2 mg</td>
<td>2 mL</td>
<td>–</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥ 9–11 kg</td>
<td>3 mg</td>
<td>3 mL</td>
<td>–</td>
<td>≥ 12–18 months</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>4 mg</td>
<td>4 mL</td>
<td>–</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>5 mg</td>
<td>5 mL</td>
<td>–</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>6 mg</td>
<td>6 mL</td>
<td>–</td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>7.5 mg</td>
<td>7.5 mL</td>
<td>–</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>10 mg</td>
<td>10 mL</td>
<td>1 tablet</td>
<td>≥ 11–15 years</td>
</tr>
</tbody>
</table>

Adults:
- Morphine, oral, 4 hourly. (Doctor initiated)
  - Start with 5–10 mg.

Elderly adults or severe liver impairment:
- Morphine solution, oral, 4 hourly. (Doctor initiated)
  - Start with 2.5–5 mg.

Titrate the dose and dose frequency against the effect on pain.

Note:
There is no maximum dose for morphine – dose is titrated upward against the effect on pain.
For the management of morphine overdose, see section 21.6: Exposure to poisonous substances.

Adjuvant therapy
Adults:
In addition to analgesia as above:
- Amitriptyline, oral, 25 mg at night. (Doctor initiated)
  - Titrate up to a maximum of 75 mg at night.

For significant nausea and vomiting
Adults:
- Metoclopramide oral, 10 mg, 8 hourly as needed.

For constipation
» A common problem due to long-term use of opioids.
**Chapter 20  Pain**

- Lactulose, oral, 0.5 mL/kg/dose once daily
  - If poor response, increase frequency to 12 hourly

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Syrup 3.3 g/5 mL</th>
<th>Age years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 5–9 kg</td>
<td>2.5 mL</td>
<td>≥ 3 months–1 year</td>
</tr>
<tr>
<td>≥ 9–17.5 kg</td>
<td>5 mL</td>
<td>≥ 1–5 years</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>7.5 mL</td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>10 mL</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>≥ 35 kg and above</td>
<td>10–20 mL</td>
<td>≥ 11 years and adult</td>
</tr>
</tbody>
</table>

For pruritus or nausea
- Chlorpheniramine, oral, 0.1 mg/kg/dose 6–8 hourly

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 9–11 kg</td>
<td>1 mg</td>
<td>Syrup 2 mg/5 mL</td>
<td>≥ 12–18 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tablet 4 mg</td>
<td></td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>1.2 mg</td>
<td>2.5 mL</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>1.5 mg</td>
<td>3 mL</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>2 mg</td>
<td>4 mL</td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>3 mg</td>
<td>5 mL</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>≥ 35 kg and above</td>
<td>4 mg</td>
<td>7.5 mL</td>
<td>≥ 11 years and adults</td>
</tr>
<tr>
<td></td>
<td></td>
<td>–</td>
<td></td>
</tr>
</tbody>
</table>

For anxiety

**Children:**
- Diazepam, oral, 0.04 mg/kg/dose 8–12 hourly
  - May be increased to 0.2 mg/kg/dose
  - Beware of respiratory depression if given with morphin

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following tablets:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 9–11 kg</td>
<td>0.5 mg</td>
<td>2 mg 5 mg</td>
<td>≥ 12–18 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td>¼ tablet –</td>
<td></td>
</tr>
<tr>
<td>≥ 11–17.5 kg</td>
<td>1 mg</td>
<td>½ tablet –</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>1.5 mg</td>
<td>¾ tablet –</td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>2 mg</td>
<td>1 tablet –</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>≥35 kg and above</td>
<td>2.5 mg</td>
<td>½ tablet –</td>
<td>≥ 11 years and adults</td>
</tr>
<tr>
<td></td>
<td></td>
<td>–</td>
<td></td>
</tr>
</tbody>
</table>

**Adults:**
- Diazepam, oral, 2–5 mg every 12 hours for a maximum of two weeks
**Breakthrough pain**

Breakthrough pain is pain that occurs before the next regular dose of analgesia. This is due to an inadequate regular dose.

It is recommended that the full dose equivalent to a 4 hourly dose of morphine be administered for breakthrough pain, but it is important that the next dose of morphine be given at the prescribed time, and not be delayed because of the intervening dose.

The dosage should be titrated upward against the effect on pain in the following way:

1. Add up the amount of “breakthrough morphine” needed in 24 hours.
2. Divide this amount by 6 (the number of 4 hourly doses in 24 hours).
3. The next day increase each dose by that amount.

**Example:**

Patient gets 10 mg morphine every four hours.
The patient has 3 episodes of breakthrough pain:

\[
3 \times 10 \text{ mg} = 30 \text{ mg}
\]

\[
30 \text{ mg} \div 6 = 5 \text{ mg}
\]

The regular 4 hourly dose of 10 mg will be increased by 5 mg

\[
i.e. \quad 10 \text{ mg} + 5 \text{ mg} = 15 \text{ mg}
\]

The increased morphine dose will be 15 mg 4 hourly

**Referral**

- Uncontrolled pain
- Pain uncontrolled by step 1 if no doctor available
- Severe emotional or other distress which may aggravate the perception of pain
- Nausea and vomiting associated with pain in children
Chapter 21: Trauma and emergencies

21.1 Angina pectoris, unstable
21.2 Bites and stings
   21.2.1 Animal and human bites
   21.2.2 Insect stings and spider bites
   21.2.3 Snakebites
21.3 Burns
21.4 Cardiac arrest – cardiopulmonary resuscitation
   21.4.1 Cardiac arrest, adults
   21.4.2 Cardiopulmonary arrest, children
   21.4.3 Management of suspected choking/
       foreign body aspiration in children.
21.5 Delirium with acute confusion and aggression
       in adults
21.6 Exposure to poisonous substances
21.7 Eye, chemical burn
21.8 Eye injury, foreign body
21.9 HIV prophylaxis, post exposure (PEP)
   21.9.1 Penetrative sexual abuse or sexual
       assault
   21.9.2 Occupational post-exposure HIV
       prophylaxis for healthcare workers
       (HCW)
21.10 Hyperglycaemia and ketoacidosis
21.11 Hypoglycaemia and hypoglycaemic coma
21.12 Injuries
21.13 Myocardial infarction, acute (AMI)
21.14 Nose bleeds (epistaxis)
21.15 Pulmonary oedema, acute
21.16 Shock
21.17 Shock, anaphylactic
21.18 Sprains and strains
21.19 Status epilepticus
Chapter 21  

The following conditions are emergencies and must be treated as such. Drugs used for treatment must be properly secured and their use recorded (time, dosage, routine) on the patient’s notes and on the letter of referral.

21.1 Angina pectoris, unstable  
See chapter 4 – Cardiovascular conditions

21.2 Bites and stings

21.2.1 Animal and human bites

T14.1

Note: Rabies and tetanus are notifiable conditions.

Description
Animal bites may be caused by:
- domestic animals (horses, cows, dogs, cats)
- wild animals (meerkats, jackals, mongooses)

Animal or human bites may result in:
- wound infection, often due to mixed aerobic and anaerobic infection
- puncture wounds
- tissue necrosis
- transmission of diseases, e.g. tetanus, rabies, HIV, hepatitis, syphilis

Suspected rabid bite
Any mammal bite can transmit rabies. Rabies incubation period is at least 9–90 days, but could be much longer.

In suspected rabies exposure of a person by a domestic animal, observe the suspected rabid animal for abnormal behaviour for 10 days. If the animal remains normal for 10 days, rabies is unlikely.

Note:
In the event of having to put the animal down, care should be taken to preserve the brain as the brain is required by the state veterinarian for confirmation of diagnosis. Note that the animal must not be killed by shooting it in the head as this will damage the brain.

Classification of rabies exposure
Category 1
- touching or feeding the animal
- licking of intact skin
Chapter 21 Trauma and emergencies

Category 2
» nibbling of uncovered skin
» superficial scratch and no bleeding
» licking of broken skin

Category 3
» bites and scratches which penetrate the skin and draw blood
» licking of mucous membranes

Prevention
» Regular vaccination of domestic cats and dogs.
» Pre-exposure vaccine may be given to those at risk, e.g. occupation, endemic areas, laboratories.

Drug treatment
Emergency management
All bite wounds and scratches need thorough and immediate treatment. Lacerations can be sutured later.

Irrigate and cleanse wound:
• Chlorhexidine 0.05%, solution
  or
  Povidone iodine 10%, solution

! CAUTION!
Do not suture puncture wounds.
Suture lacerations after thorough cleaning and debridement.
Do not apply compressive dressings.

Rabies Vaccine and Immunoglobulin
Rabies vaccine and immunoglobulin are available from the nearest district hospital and should be administered as follows:

Note:
For category 1 rabies exposure, do not administer rabies vaccine if history is reliable. If history is not reliable, treat as for category 2.
Stop vaccination if animal is rabies negative on laboratory test, or remains healthy after 10 days of observation.
## Chapter 21  Trauma and emergencies

<table>
<thead>
<tr>
<th>Previously immunised patients</th>
<th>Non-immune patients</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Less than 48 hours after exposure</td>
<td>More than 48 hours after exposure</td>
</tr>
<tr>
<td>Human anti-rabies immunoglobulin (RIG)</td>
<td>Human anti-rabies immunoglobulin (RIG)</td>
<td>Human anti-rabies immunoglobulin (RIG)</td>
</tr>
<tr>
<td>Do not administer</td>
<td>Administer for category 3 exposure only 20 IU / kg ½ dose IM ½ dose injected in and around the wound</td>
<td>Administer for category 3 exposure only 20 IU / kg ½ dose IM ½ dose injected in and around the wound</td>
</tr>
<tr>
<td>Rabies vaccine</td>
<td>Rabies vaccine</td>
<td>Rabies vaccine</td>
</tr>
<tr>
<td>(categories 1, 2, &amp; 3) Adults: IM (deltoid muscle) Children: IM (anterolateral thigh) Two doses only: day 0 – single dose day 3 – single dose</td>
<td>(categories 1, 2, &amp; 3) day 0 – single dose day 3 – single dose day 7 – single dose day 14 – single dose day 28 – single dose</td>
<td>(categories 1, 2, &amp; 3) day 0 – <strong>double dose</strong> day 3 – single dose day 7 – single dose day 14 – single dose day 28 – single dose</td>
</tr>
</tbody>
</table>

**Tetanus prophylaxis if not previously immunised within the last 5 years**
- Tetanus toxoid vaccine (TT), IM, 0.5 mL

**Note:**
In a fully immunised person, tetanus toxoid vaccine or tetanus immunoglobulin might produce an unpleasant reaction, e.g. redness, itching, swelling or fever, but in the case of a severe injury the administration is justified.

**Pre-emptive antibiotic only if the hand is bitten or for extensive wounds or for human bites**
Data do not support the use of antibiotics in minor animal bites. Amoxicillin/clavulanic acid is recommended in severe animal and human bites.
### Chapter 21: Trauma and emergencies

- Amoxicillin clavulanic acid, oral, 12.5–20 mg/kg of amoxicillin component, 8 hourly for 5 days

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months / years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 3.5–5 kg</td>
<td>75/18.75 mg</td>
<td>Syrup: 125/31.25 mg per 5 mL, Tablet: 250/62.5 mg per 5 mL</td>
<td>≥ 1–3 months</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>100/25 mg</td>
<td>4 mL, 2 mL</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>125/31.25 mg</td>
<td>5 mL, 2.5 mL</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥ 9–11 kg</td>
<td>150/37.5 mg</td>
<td>6 mL, 3 mL</td>
<td>≥ 12–18 months</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>187.5/46.9 mg</td>
<td>7.5 mL, 4 mL</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>≥ 14–25 kg</td>
<td>250/62.5 mg</td>
<td>10 mL, 5 mL</td>
<td>≥ 3–7 years</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>375/93.75 mg</td>
<td>15 mL, 7.5 mL</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>500/125 mg</td>
<td>–</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>500/125 mg</td>
<td>–</td>
<td>≥ 15 years and adults</td>
</tr>
</tbody>
</table>

**Penicillin–allergic patients**

- Erythromycin, oral, 10–15 mg/kg/dose 6 hourly for 5 days

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months / years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 3.5–5 kg</td>
<td>50 mg</td>
<td>Syrup: 125 mg/5 mL, Tablets: 250 mg</td>
<td>≥ 1–3 months</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>75 mg</td>
<td>3 mL, –</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>100 mg</td>
<td>4 mL, –</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥ 9–11 kg</td>
<td>125 mg</td>
<td>5 mL, –</td>
<td>≥ 12–18 months</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>150 mg</td>
<td>6 mL, –</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>200 mg</td>
<td>8 mL</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>250 mg</td>
<td>10 mL, 1 tablet</td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>375 mg</td>
<td>15 mL, –</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>≥ 35 kg and above</td>
<td>500 mg</td>
<td>–</td>
<td>≥ 11 years and adults</td>
</tr>
</tbody>
</table>
plus
• Metronidazole, oral, 7.5 mg/kg/dose 8 hourly for 5 days

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Susp 200 mg/5mL</td>
<td>Tablets 200mg</td>
</tr>
<tr>
<td>≥5–7 kg</td>
<td>40 mg</td>
<td>1 mL – –</td>
<td>≥3–6 months</td>
</tr>
<tr>
<td>≥7–9 kg</td>
<td>60 mg</td>
<td>1.5 mL – –</td>
<td>≥6–12 months</td>
</tr>
<tr>
<td>≥9–11 kg</td>
<td>80 mg</td>
<td>2 mL – –</td>
<td>≥12–18 months</td>
</tr>
<tr>
<td>≥11–14 kg</td>
<td>100 mg</td>
<td>2.5 mL – –</td>
<td>≥18 months–3 years</td>
</tr>
<tr>
<td>≥14–17.5 kg</td>
<td>120 mg</td>
<td>3 mL – –</td>
<td>≥3–5 years</td>
</tr>
<tr>
<td>≥17.5–25 kg</td>
<td>160 mg</td>
<td>4 mL – –</td>
<td>≥5–7 years</td>
</tr>
<tr>
<td>≥25–35 kg</td>
<td>200 mg</td>
<td>5 mL 1 tablet ½ tablet</td>
<td>≥7–11 years</td>
</tr>
<tr>
<td>≥35–55 kg</td>
<td>300 mg</td>
<td>7.5 mL ½ tablets –</td>
<td>≥11–15 years</td>
</tr>
<tr>
<td>≥ 55 kg and adult</td>
<td>400 mg</td>
<td>– 2 tablets 1 tablet</td>
<td>≥ 15 years and adult</td>
</tr>
</tbody>
</table>

Referral
» Deep and large wounds requiring elective suturing
» Shock and bleeding
» Unimmunised or not fully immunised patients for tetanus immunoglobulin
» Possible rabies exposure (for immunoglobulin and vaccination)

21.2.2 Insect stings and spider bites
T63.2/3/4

Description
Injury from spider bites and stings by bees, wasps, scorpions and other insects. Symptoms are usually local such as pain, redness swelling and itching.
» Bees and wasps
  – venom is usually mild but may provoke severe allergic reactions such as laryngeal oedema or anaphylactic shock (see section 21.17).
» Spiders and scorpions
  – most are non-venomous or mildly venomous.

Drug treatment
Emergency treatment:
Treat anaphylactic shock. See section 21.17: Shock, anaphylactic
Chapter 21  

Trauma and emergencies

For severe local symptoms:  
- Chlorpheniramine, oral, 0.1 mg/kg/dose 6–8 hourly

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 9–11 kg</td>
<td>1 mg</td>
<td>2.5 mL</td>
<td>≥ 12–18 months</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>1.2 mg</td>
<td>3 mL</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>1.5 mg</td>
<td>4 mL</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>2 mg</td>
<td>5 mL</td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>3 mg</td>
<td>7.5 mL</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>≥35 kg and above</td>
<td>4 mg</td>
<td>– 1 tablet</td>
<td>≥ 11 years and adults</td>
</tr>
</tbody>
</table>

- Calamine lotion, applied when needed

- **Paracetamol**, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum of 4 doses per 24 hours  
  ▪ In children under 6 months calculate dose by weight

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥3.5–5 kg</td>
<td>48 mg</td>
<td>2 mL</td>
<td>≥ 1–3 months</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>60 mg</td>
<td>2.5 mL</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>96 mg</td>
<td>4 mL</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥ 9–14 kg</td>
<td>120 mg</td>
<td>5 mL</td>
<td>≥ 12 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>180 mg</td>
<td>7.5 mL</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–35 kg</td>
<td>240 mg</td>
<td>10 mL ½ tablet</td>
<td>≥ 5–11 years</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>500 mg</td>
<td>– 1 tablet</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td>≥55 kg and above</td>
<td>Up to 1 000 mg</td>
<td>– Up to 2 tablets</td>
<td>≥ 15 years and adults</td>
</tr>
</tbody>
</table>

**Very painful scorpion stings**  
- Lignocaine 2%, 2 mL injected around the bite as a local anaesthetic

**Refferral**
- Presence of systemic manifestations:  
  - weakness  
  - drooping eyelids  
  - difficulty in swallowing and speaking  
  - double vision

**Note:**
Send the spider or scorpion with the patient if available.
21.2.3 Snakebites

Description

Of all the species of snakes found in South Africa, about 12% are considered to be potentially dangerous to humans. However, all snake bites should be considered dangerous until proven otherwise.

South African poisonous snakes can be broadly divided into 3 groups according to action of their venom although there is significant overlap of toxic effects in some snake venoms.

Cytotoxic venoms

» Venom causes local tissue damage and destruction around the area of bite.
» The bite is painful and symptoms usually start within 10 to 30 minutes after the bite.
» Examples include:
  – Puff adder,
  – Gaboon adder
  – Berg adder
  – Night adder
  – Some dwarf adders and the spitting cobras i.e. Mozambique spitting cobra, black spitting cobra, rinkhals

Neurotoxic venoms

» Neurotoxic venom causes weakness and paralysis of skeletal muscles and respiratory failure.
» Bite is not as painful as cytotoxic venom bites.
» Symptoms usually start in 15–30 minutes.
» Examples include:
  – Cape cobra
  – Black mamba
  – Green mamba
  – Berg adder (Berg adder venom is neurotoxic as well as cytotoxic)
  – Black spitting cobra
  – Rinkhals, etc.

Haemotoxic venoms

» Venom affects the clotting of blood causing bleeding tendency which may delayed.
  – Boomslang
  – Vine snake

Symptoms and signs of snakebite envenomation include:

Local

» Bite marks with or without pain.
Swelling around the bite, which may be severe with discolouration of skin and or blister formation.

**Systemic**
- Nausea, vomiting
- Sweating and hypersalivation.
- Skeletal muscle weakness. Which may cause
  - drooping eyelids
  - double vision
  - difficulty in swallowing
  - difficulty in breathing
- Shock
- Rarely bleeding (epistaxis, haematuria, haematemesis or haemoptysis)

<table>
<thead>
<tr>
<th>! CAUTION !</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do not apply a tourniquet.</td>
</tr>
<tr>
<td>Do not apply a restrictive bandage to the head, neck or trunk.</td>
</tr>
<tr>
<td>Do not squeeze or incise the wound.</td>
</tr>
<tr>
<td>Do not attempt to suck the venom out.</td>
</tr>
</tbody>
</table>

**General measures**

**Emergency treatment**
Remove clothing from site of the bite and clean the wound thoroughly with chlorhexidine 0.05% solution.

For non-cytotoxic bites only:
- To prevent spread to vital organs, apply a wide crepe bandage firmly from just above the bite site up to 10–15 cm proximal to the bite site immediately. Apply no tighter than for a sprained ankle.
- Immobilise the affected part with a splint or sling.
- Try to obtain an accurate history e.g. time of bite, type of snake.
- If no sign and symptoms, observe the patient for 6–8 hours with repeated examinations.
- Absence of symptoms and signs for 6–8 hours usually indicates a harmless bite.
- However, observation for 24 hours is recommended.

**Drug treatment**

**Venom in the eyes:**
Irrigate the eye thoroughly for 15–20 minutes with water or any bland liquid
- Tetracaine 0.5%, drops, instilled into the eye(s) and cover with eye pads.
Refer patient.

**For pain**
Non-opioid analgesics according to severity – See section 20.2: Chronic non-cancer pain.
**Chapter 21**  
**Trauma and emergencies**

**Shock**  
Treat if present.  
See section 21.16: Shock

**Tetanus prophylaxis**  
- Tetanus toxoid (TT), IM, 0.5 mL

| ! CAUTION !  
| Polyvalent antivenom is only effective for the following snake bites:  
| » Cape cobra  
| » Mambas  
| » puff adder  
| » gaboon adder  
| » rinkhals  
| » spitting cobras  

Boomslang requires specific antivenom.

Antivenoms are available from the SAVP.  
SAVP emergency number: 083 6520105

Snakebite antivenoms may be available from specific hospitals in each province.

**Administration of snake bite antivenom**

| ! CAUTION !  
| Antivenom can cause anaphylaxis.  
| Never administer without a good indication.  
| Always have resuscitative equipment and medication ready.

**Note:**  
The majority of patients do not need and should not be given antivenom.  
All patients with suspected black mamba bites should receive antivenom, even before onset of symptoms.  
Patients with bites due to other species should only receive antivenom at the onset of any symptoms.  
The dose of antivenom is the same for adults and children.

**Criteria for antivenom administration**  
All patients with systemic signs and symptoms or severe spreading local tissue damage or should receive antivenom.  
» signs of systemic poisoning  
  – drooping eyelids  
  – double vision  
  – weakness  
  – difficulty in swallowing  
  – difficulty in breathing
» spreading local damage
  – swelling of a hand or foot within 1 hour of a bite (80% of bites are on hands or feet)
  – swelling extends to elbows or knees within 3–6 hours of a bite
  – swelling of the groin or chest at any time or if actively advancing
  – significant swelling of head or neck
  – muscle weakness and/or difficulty in breathing

- Polyvalent antivenom, slow IV infusion, 100 mL in 200 mL sodium chloride 0.9%. (Doctor initiated)
  - In children dilute 100 mL in 5 mL/kg of sodium chloride 0.9%.
  - In children less than 20 kg, seek advice and if not available, administer over 2 hours observing for signs of fluid overload.
  - Administer slowly for the first 15 minutes as most allergic reactions will occur within this period.
  - Increase the flow rate gradually until the infusion is completed within one hour.
  - Repeat if there is no clinical improvement after the infusion.
  - Black mamba bites may require up to 200 mL or more of antivenom.
  - Monitor for anaphylaxis for at least an hour after the infusion.
  - Prepare to treat possible anaphylaxis. See section 21.7: Shock, anaphylactic.

Note:
Ensure that the antivenom solution is clear.

Anaphylaxis
Administer adrenaline followed by hydrocortisone succinate.
See section 21.7: Shock, anaphylactic

Referral
» All patients with bites or likely bites even if puncture marks are not seen.
  If possible take the dead snake to the referral centre for identification.

21.3 Burns
T30.0

Description
Burns lead to skin and soft tissue injury and may be caused by:
» heat, e.g. open flame, hot liquids, hot steam
» chemical compounds
» physical agents, e.g. electrical/lightning) or
» radiation.

The extent and depth may vary from superficial (epidermis) to full-thickness burns of the skin and underlying tissues
Initially, burns are usually sterile.
## Assessment of burns

<table>
<thead>
<tr>
<th>Depth of burn wound</th>
<th>Surface / Colour</th>
<th>Pain sensation/healing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Superficial or epidermal</td>
<td>Dry, minor blisters, erythema</td>
<td>» Painful</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» Heals within 7 days</td>
</tr>
<tr>
<td>Partial thickness superficial or superficial dermal</td>
<td>Blisters, moist</td>
<td>» Painful</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» Heals within 10–14 days</td>
</tr>
<tr>
<td>Partial thickness deep or deep dermal</td>
<td>Moist white or yellow slough, red mottled</td>
<td>» Less Painful</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» Heals within a month or more</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» Generally needs surgical debridement and skin graft</td>
</tr>
<tr>
<td>Full thickness (complete loss of skin)</td>
<td>Dry, charred whitish, brown or black</td>
<td>» Painless, firm to touch</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» Healing by contraction of the margins (generally needs surgical debridement and skin graft)</td>
</tr>
</tbody>
</table>

The figures below are used to calculate body surface area %

These diagrams indicate percentages for the whole leg/arm/head (and neck in adults) not the front or back.

In children the palm of the hand is 1%.

**Children 8 years and adults**

---

Published with kind permission from SAMJ.
South African Burn Society burn stabilisation protocol. JS Karpelowsky, L Wallis, A Maderee and H Rode. SAMJ Vol 9, No 8 Page 574–7
Children < 8 years of age

Paediatric adjustments
< 1 year
» Head and neck are 18% of BSA
» Each leg is 14% of BSA

> 1 year
For each year of life:
» Head decreases by 1% of BSA until 8 years of age
» Leg gains $\frac{1}{2}$ % of BSA until 8 years of age

Emergency treatment
» Remove smouldering or hot clothing.
» Remove constrictive clothing/rings.
» To limit the extent of the burn, soak the affected area generously with, or immerse in cold water for 30 minutes after the burn.
» In all burns > 10% or where carbon monoxide poisoning is possible (enclosed fire, decreased level of consciousness, disorientation) administer high flow oxygen
» Examine carefully to determine the extent and depth of the burn wounds.
» Respiratory obstruction due to thermal injury or soot inhalation, production of black coloured sputum, shortness of breath, hoarse voice and stridor are serious signals.

Drug treatment
Fluid replacement
Burns under 10% TBSA (Total Body Surface Area):
• Oral fluids
Chapter 21  Trauma and emergencies

Burns of over 10% of total body surface area (TBSA)
• IV fluid for resuscitation

Calculation of fluid replacement
Replacement fluids for burns
First 24 hours:
• Sodium chloride 0.9%, IV
  o Calculate total fluid requirement in 24 hours:
    Total % burn ____ x weight (kg) ____ x 4 mL
  o Give half this volume in the first 8 hours.
  o Administer remaining fluid volume in next 16 hours

Note:
If urine output not adequate, increase fluids for the next hour by 50%. Continue at
a higher rate until urine output is adequate, then resume normal calculated rate.

Maintenance fluids in children
In children, add oral or intravenous maintenance fluid to above calculated
volume.

<table>
<thead>
<tr>
<th>Maintenance fluids</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤1 year</td>
</tr>
<tr>
<td>120 mL/kg/24 hours</td>
</tr>
</tbody>
</table>

All children older than 1 year – the sum of the following:

<table>
<thead>
<tr>
<th>First 10 kg body weight</th>
<th>100 mL/kg/24 hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Second 10 kg body weight</td>
<td>50 mL/kg/24 hours</td>
</tr>
<tr>
<td>Additional weight</td>
<td>20 mL/kg/24 hours</td>
</tr>
<tr>
<td>Greater than 20 kg body weight</td>
<td>20 mL/kg/24 hours</td>
</tr>
</tbody>
</table>

Example: 24 kg child with 10% burns

1st 24 hours
• replacement for expected losses:
  4 mL/kg x 24kg x 10% = 960 mL
• maintenance:
  first 10 kg = 10 kg X 100 mL/kg/24 hours = 1000 mL+
  second 10 kg = 10 kg X 50 mL/kg/24 hours = 500 mL+
  remaining 4 kg = 4 kg X 20 mL/kg/24 hours = 80 mL

Total maintenance = 1580 mL
Total fluids in 1st 24 hours = 960 mL + 1580 mL = 2540 mL
Thus
1st 8 hours = total 24 hour volume / 2 = 2540 / 2 = 1270 mL
Next 16 hours = total 24 hour volume / 2 = 2540 / 2 = 1270 mL
Chapter 21  Trauma and emergencies

For pain
- **Paracetamol**, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum of 4 doses per 24 hours
  - In children under 6 months calculate dose by weight

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥3.5–5 kg</td>
<td>48 mg</td>
<td>2 mL –</td>
<td>≥ 1–3 months</td>
</tr>
<tr>
<td>≥5–7 kg</td>
<td>60 mg</td>
<td>2.5 mL –</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥7–9 kg</td>
<td>96 mg</td>
<td>4 mL –</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥9–14 kg</td>
<td>120 mg</td>
<td>5 mL –</td>
<td>≥ 12 months–3 years</td>
</tr>
<tr>
<td>≥14–17.5 kg</td>
<td>180 mg</td>
<td>7.5 mL –</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥17.5–35 kg</td>
<td>240 mg</td>
<td>10 mL ½ tablet</td>
<td>≥ 5–11 years</td>
</tr>
<tr>
<td>≥35–55 kg</td>
<td>500 mg</td>
<td>– 1 tablet</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td>≥55 kg and above</td>
<td>Up to 1000 mg</td>
<td>– Up to 2 tablets</td>
<td>≥ 15 years and adults</td>
</tr>
</tbody>
</table>

Severe pain
See section 20.2: Chronic non-cancer pain.

Wound cleansing
» Clean the burn wound gently
- Sodium chloride 0.9% or clean water

Burn dressing
For patients requiring referral:
» If within 12 hours, transfer wrapped in clean dry sheet and blankets
» If delayed by more than 12 hours paraffin gauze dressing and dry gauze on top
» For full thickness and extensive burns cover with an occlusive dressing

For patients not requiring transfer (burns that can be treated at home):
» Paraffin gauze dressing and then dry gauze on top

If infected burn:
- Povidone iodine 5%, cream, applied daily
  - or
- Chlorhexidine 0.05%, solution, daily

Tetanus prophylaxis
If not vaccinated within the last 5 years:
- Tetanus toxoid (TT), IM, 0.5 mL
Referral

» All children less than 1 year
» All burns greater than 5% from 1–2 years of age
» Third-degree burns of any size in any age group
» Partial thickness burns greater than 10% total body surface area (TBSA)
» Burns of special areas – face, hands, feet, genitalia, perineum and major joints
» Electrical burns, including lightning injury
» Chemical burns
» Inhalation injury – fire or scald injury
» Circumferential burns of the limbs or chest
» Burn injury in a patient with pre-existing medical disorders which could complicate management, prolong recovery or affect mortality
» Any patient with burns and concomitant trauma
» Suspected child abuse
» Burns exceeding the capabilities of the referring centre
» Septic burn wounds

21.4 Cardiac arrest – cardiopulmonary resuscitation

21.4.1 Cardiac arrest adults

Description
Cardiac arrest is the sudden and unexpected cessation of effective cardiac output, on the basis of asystole or a malignant tachyarrhythmia. Irreversible brain damage can occur within 2–4 minutes.

Clinical features include:
» sudden loss of consciousness
» absent carotid and all other pulses
» loss of spontaneous respiration
» dilatation of the pupils

Emergency treatment
» Diagnose rapidly.
» Make a note of the time of starting.
» Place the patient on a firm flat surface and commence resuscitation immediately.
» Call for skilled help.
» Initiate ABC (airways breathing circulation) sequence of CPR (cardiopulmonary resuscitation).
» A single powerful precordial thump is recommended for witnessed cardiac
Chapter 21  

Trauma and emergencies

arrest where a defibrillator is not immediately available.

» Document medication and progress.

Cardiopulmonary resuscitation

Airway

» Remove vomitus or foreign body and dentures from the mouth, if present.

» To open the airway, lift the chin forward with the fingers of the one hand and tilt the head backwards with other hand on the forehead. Do not do this where a neck injury is suspected.

» Insert artificial airway, if available

Where neck injury is suspected:

» To open the airway, place your fingers behind the jaw on each side.

» Lift the jaw upwards while opening the mouth with your thumbs

Breathing

» Keeping the airway open, check the breathing.

» If breathing well, place the patient on the side to protect the airway and support the patient by bending the uppermost arm and leg.

» If there is no breathing, apply artificial respiration at a rate of 8–10 breaths per minute

– mouth-to-mouth

or

– mouth-to-nose

or

– with Ambubag and face mask

Continue until spontaneous breathing occurs

» Oxygenate with 100% oxygen

» Intubate as soon as possible. Oxygenate well before intubation.

Circulation

» Check for carotid pulse.

» If there is no pulse, start chest compressions at 100 compressions per minute.

Continue until return of the pulse and/or respiration

» Initiate IV fluids

• Sodium chloride 0.9%, IV

In pulseless tachyarrhythmias defibrillate if adequately trained.

Call a doctor, if available, without stopping CPR.

Immediate emergency drug treatment

Adrenaline is the mainstay of treatment and should be given immediately, IV or endobronchial, when there is no response to initial resuscitation or defibrillation.
Chapter 21  Trauma and emergencies

- Adrenaline, 1:1 000, 1 mL, IV immediately as a single dose
  or
  If no IV line available
- Adrenaline, endobronchial, 1:1 000, 2 mL through endotracheal tube.
  o Dilute with 5–10 mL of sterile water or sodium chloride 0.9%.
  o Repeat every 3–5 minutes during resuscitation.

For bradycardia
- Atropine, IV, 0.5 mg.
  o Repeat after 2–5 minutes if no response.
  o Maximum dose: 3 mg.

Assess continuously until the patient shows signs of recovery.

Consider stopping resuscitation attempts and pronouncing death if:
  » further resuscitation is clearly clinically inappropriate, e.g. incurable underlying disease
  » no success after all the above procedures have been carried out for 30 minutes or longer

Consider carrying on for longer especially when:
  » hypothermia and drowning
  » poisoning or drug overdose or carbon monoxide poisoning

21.4.2 Cardiopulmonary arrest, children
For advance resuscitation training should be undertaken.

Description
Cardio-pulmonary arrest is the cessation of respiration or cardiac function and in children is usually a pre-terminal event as a result of a pre-existing critical illness. Resuscitation is less often successful in children and it is better to prevent cardio-pulmonary arrest by recognizing serious illness and managing it appropriately.

The effective treatment of cardio-respiratory arrest in children is the prevention of the arrest by early recognition and management of severe disease.
Cardio-respiratory arrest in children usually follows poor respiration, poor circulation or poor respiratory effort (neurological cause). If any of the following are present this is evidence of serious disease/impending failure and needs urgent effective management.

<table>
<thead>
<tr>
<th>Signs of impending failure/severe disease</th>
<th>Neurological</th>
<th>Respiratory</th>
<th>Circulatory</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decreased level of consciousness</td>
<td>Increased respiratory rate &gt; 60</td>
<td>Increased heart rate: &gt; 160 in infants, &gt; 120 in children</td>
<td></td>
</tr>
<tr>
<td>Abnormal posture</td>
<td>Chest indrawing</td>
<td>Decreased pulse volume</td>
<td></td>
</tr>
<tr>
<td>Pupils - abnormal size or equality.</td>
<td>Grunting</td>
<td>Capillary refill time more than 3 seconds</td>
<td></td>
</tr>
<tr>
<td>Presence of convulsions</td>
<td>Flaring alae nasae</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Acute child resuscitation in primary care

SAFE approach:
Shout for help
Approach with care
Free from danger
Evaluate ABC

Airway and Cervical Spine
No trauma: airway chin lift and head position

<table>
<thead>
<tr>
<th>Head tilt position</th>
<th>Infant &lt; 1 year</th>
<th>Child 1 year and above</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Neutral</td>
<td>Sniffing</td>
</tr>
</tbody>
</table>

Suspected trauma: keep head in line, use jaw thrust

Look listen feel for effective airway air movement

Breathing
If no effective breaths, give 5 slow initial breaths to give chest movement

Feel for pulse if no pulse palpable and no signs of life, proceed

Circulation
Cardiac compressions given 100/minute in a ratio of cardiac compressions: lung inflation:
30:2 1 person resuscitation
15:2 2 person resuscitation
Cardiac compression site: one finger breath above xiphisternum

<table>
<thead>
<tr>
<th>Technique</th>
<th>Infant &lt; 1 year</th>
<th>Child 1 year and above</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Two fingers</td>
<td>One or two hands</td>
</tr>
</tbody>
</table>

Recheck pulse for signs of life if none, proceed

Drugs
Continue CPR and give:
- Adrenaline 1:10 000, IV, 0.1 mL/kg
  (Dilute 1 mL of 1: 1 000 solution with 9 mL sterile water or sodium chloride 0.9%)
Emergency treatment

» Diagnose rapidly
» Make a note of the time of starting
» Place the patient on a firm flat surface and commence resuscitation immediately
» Call for skilled help
» Initiate ABC (Airways Breathing Circulation) sequence of CPR (Cardiopulmonary Resuscitation)
» Document medication and progress.
» Collect all ampoules used and total them at the end.

Airway

» Manually remove obvious obstruction from the mouth.

! CAUTION!
Do not use blind finger sweeps of the mouth or posterior pharynx as this can impact any obstruction further down the airway.

» In neonates and infants position head in neutral position, in children position in the sniffing position.
» Lift the chin forward with the fingers under the bony tip of the jaw.
» Look, listen and feel for air movement (breathing) to see if the airway is patent.
» If air movement is not good, insert oral artificial airway if necessary and available (airway size – from tip to top of airway should be the distance between the central upper incisors and the tragus [lobe] of the ear).
» If breathing spontaneously and well, lay the patient on the side to protect the airway and support the patient by bending the uppermost arm and leg.
» If a foreign body; if suspected follow a choking protocol – See section 21.4.3: Management of suspected choking/foreign body aspiration.

Breathing

» If there is no breathing, apply artificial respiration:
  – mouth-to-mouth
  or
  – mouth-to-nose
  or
  – preferably with Ambubag and face mask
» Breathe (infl ate the chest) give 5 slow rescue breaths at 15 times/minute (faster in babies).
» Do not stop unless spontaneous breathing starts, even if cardiac compressions are started – see below.

! CAUTION!
Cardiac massage is ineffective unless there is an open airway and the lungs are being filled with air
Circulation

» Check for a pulse
  – carotid in the older child, or femoral or brachial pulse

If there is no pulse:

» Start cardiac compressions or massage at a rate of 100 beats per minute for 15 compressions then give the following ratio with lung inflations (ventilation):
  – Universal compression-ventilation ratio for all ages (except neonates) is 30 compressions to 2 breaths if there is one rescuer.
  – If two rescuers are present, use a compression – ventilation ratio of 15:2 when giving CPR to children and infants

» Continue until the pulse or respiration returns

Keep patient covered and warm while resuscitating.
Ventilate if there is a pulse but no breathing.
» Call a doctor, if available, without stopping CPR

Immediate emergency Drug treatment

» If still no pulse or signs of life after cardiac compressions and ventilations:
  • Adrenaline, IV, 0.1 mL/kg of diluted solution.
    o Adrenaline 1:1 000, 1 mL diluted with sodium chloride 0.9% to 10 mL.

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Volume of diluted solution (1: 10 000 solution)</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 2.5–7 kg</td>
<td>0.05 mg</td>
<td>0.5 mL</td>
<td>Birth–6 months</td>
</tr>
<tr>
<td>≥ 7–11 kg</td>
<td>0.1 mg</td>
<td>1 mL</td>
<td>≥ 6–18 months</td>
</tr>
<tr>
<td>≥ 11–17.5 kg</td>
<td>0.15 mg</td>
<td>1.5 mL</td>
<td>≥ 18 months–5 years</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>0.2 mg</td>
<td>2 mL</td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>0.3 mg</td>
<td>3 mL</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>0.5 mg</td>
<td>5 mL</td>
<td>≥ 11–15 years</td>
</tr>
</tbody>
</table>

Hypoglycaemia in sick children, especially infants

Look for evidence during resuscitation and treat proven hypoglycaemia:

• Dextrose 10%, solution, IV, 5 mL/kg.
  o Do not give unless hypoglycaemic or hypoglycaemia strongly suspected
  o Do not give excessive volumes.

Drug administration route:

» IV via a drip that flows well.
» Avoid administration of excessive IV fluid during resuscitation.
» Use 60 drop per minute IV administration sets for all drips unless the arrest is due to hypovolaemia.
Assess continuously until the patient shows signs of recovery.

Consider stopping resuscitation attempts and pronouncing death if:
» further resuscitation is clearly clinically inappropriate, e.g. incurable underlying disease
» no signs of life are present after 30 minutes of active resuscitation

However, carry on for longer in cases of:
» hypothermia and drowning
» suspected poisoning or drug overdose or carbon monoxide poisoning

**Referral**
» All patients should be transferred on supportive treatment with accompanying skilled worker until taken over by doctor at receiving institution.

### 21.4.3 Management of suspected choking/foreign body aspiration in children

**Choking child**

Do not use back blows or chest/abdominal thrusts unless sure that foreign body obstruction is life threatening, i.e. apparently complete obstruction.

» To clear foreign body in conscious child with apparently complete obstruction
  – 5 back blows
  ↓
  – 5 chest/abdominal thrusts
  ↓
  – Reassess and repeat if necessary

» In unconscious child
  – Give 5 slow rescue breaths
  ↓
  – Then commence CPR in normal ratio
### Chapter 21 Trauma and emergencies

| **If the child is still able to breathe** | Transfer urgently to hospital for treatment – with someone able to treat acute complete choking accompanying the child. |
| **If the child is able to talk and breathe** | Encourage him to cough repeatedly while arranging transfer urgently with supervision. |
| **If the child is not breathing or is in a life threatening situation with increasing dyspnoea in spite of correct positioning of the head and jaw** | Urgent attempts should be made to dislodge the foreign body. **These should not be done in a child who is able to breathe as in this situation they may make matters worse.** |
| **If the child is unconscious with no effective air movement** | Initiate full CPR after at least 2 slow rescue breaths and continue with full CPR. |
| **If the child is conscious but with no effective cough or air movements** | Give 5 back blows followed by 5 chest/abdominal thrusts followed by re-assessment of breathing and then repeated as a cycle until recovery or failure of resuscitation. |

### Back Blows and chest/abdominal thrusts

**Infants:**
Place the baby along one of the rescuer’s arms in a head down position.
Rest the arm along the thigh and deliver 5 back blows to the child.
If this is ineffective turn the baby over and lay it on the rescuer’s thigh in the head down position.
Apply 5 chest thrusts – use the same landmarks as for cardiac compression but more slowly. If too large to carry out on the thigh this can be done across the lap.

**Children:**
In children back blows are also used but usually across the lap.
In place of the chest thrust, abdominal thrusts are used (Heimlich manoeuvre) and may be used standing, sitting, kneeling or lying.
For abdominal thrust in the standing, sitting or kneeling position the rescuer moves behind the child and passes his arms around the child’s body.
One hand is formed into a fist and placed against the child’s abdomen above the umbilicus and below the xiphisternum. The other hand is placed over the fist and both hands are thrust sharply upwards into the abdomen towards the chest.
In the lying (supine) position the rescuer kneels astride the victim and does the same manoeuvre except that the heel of one hand is used rather than a fist.

This is repeated 5 times and then the breathing reassessed. If not relieved the cycle of back blows →abdominal thrusts→reassessment is repeated until the relief of obstruction or failure of resuscitation.
Delirium is a medical emergency. Delirium is a sudden onset state of confusion in which there is impaired awareness and memory and disorientation. Delirium should not be mistaken for psychiatric disorders like schizophrenia or a manic phase of a bipolar disorder. These patients are mostly orientated for time, place and situation, can in a way make contact and co-operate within the evaluation and are of clear consciousness.

There are many possible causes including extracranial causes. Organic or physical illness should also be considered as possible causes. The elderly are particularly prone to delirium caused by medication, infections, electrolyte and other metabolic disturbances.

Main clinical features are:
- acute onset (usually hours to days)
- impaired awareness
- confusion
- disorientation

Other symptoms may also be present:
- restlessness
- agitation
- hallucinations
- autonomic symptoms such as sweating, tachycardia and flushing
- patients may be hypo-active, with reduced responsiveness to the environment
- a fluctuating course and disturbances of the sleep-wake cycle are characteristic
- aggressiveness
- violent behaviour alone occurs in exceptional cases only

Risk factors for delirium include
- extremes of age
- pre-existing neurological disease e.g. epilepsy
- HIV infection
- drugs such as anticholinergics and hypnotics
- pre-existing dementia
- substance intoxication and withdrawal
- cerebrovascular disease
Checklist for diagnosis:
D – drugs
I – infections
M – metabolic
T – trauma
O – oxygen deficit
P – pre-existing neurological disease, e.g. epilepsy and dementia

Emergency treatment
» Calm the patient
» Manage in a safe environment

If the delirium is caused by seizures or substance withdrawal or if communication is difficult
• Diazepam, IV, 10 mg for immediate sedative or hypnotic action.
  o If no response give a second dose.
  o Do not administer at a rate over 5 mg/minute
  or
  Lorazepam, IM/IV, 2 mg.
  o If no response give a second dose.

Switch to oral once containment is achieved.
» Secure airway
» Exclude hypoglycaemia
» Monitor for respiratory depression

If the most likely cause of delirium is a medical disorder and if very restless:
• Haloperidol, IM, 5 mg, immediately.
  o If no response give a second dose.

Referral
Urgent
» All cases
Exposure to poisonous substances

Note: Poisoning from agricultural stock remedies is notifiable.

MAJOR POISON INFORMATION CENTRES

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gauteng:</strong></td>
<td>(011) 678 2332 Pharmnet Amayeza Info Centre</td>
</tr>
<tr>
<td>(office hours)</td>
<td></td>
</tr>
<tr>
<td><strong>Free State:</strong></td>
<td>(051) 401 3111</td>
</tr>
<tr>
<td>(24-hours, every day)</td>
<td>(051) 401 3177, 082 410 4229</td>
</tr>
<tr>
<td><strong>Western Cape:</strong></td>
<td></td>
</tr>
<tr>
<td>(24-hours, every day)</td>
<td>Tygerberg: (021) 931 6129</td>
</tr>
<tr>
<td></td>
<td>Red Cross: (021) 689 5227</td>
</tr>
</tbody>
</table>

If the above centres cannot be contacted, enquire at the nearest trauma and emergency unit.

Description

Acute poisoning is a common medical emergency. Poisoning may occur by ingestion, inhalation or absorption through skin or mucus membranes. Frequently encountered poisons include:

- analgesics
- anti epileptic agents
- antidepressants and sedatives
- pesticides
- volatile hydrocarbons, e.g. paraffin
- household cleaning agents
- vitamins and minerals, especially iron in children
- antihypertensive and antidiabetic agents
- theophylline

Signs and symptoms vary according to the nature of poisoning.

General Measures

- Remove the patient from the source of poison, especially pesticides, e.g. clothing, etc.
- If skin contact has occurred, especially pesticides, wash the skin with soap and water, ensuring your safety with protective measures e.g., gloves, gowns, masks, etc.
- Establish and maintain the airway.
Chapter 21  Trauma and emergencies

» Ensure adequate ventilation and oxygenation.
» Take an accurate history.
  - Obtain collateral information as well, especially in patients with impaired consciousness.
  - A special effort should be made to obtain tablets, packets, containers, etc. of the suspected agent used in order to identify poisons involved.
» Document and respond to abnormalities of:
  - pulse rate
  - blood pressure
  - respiratory rate
  - level of consciousness
  - pupillary size and reaction

Ingested poisons
• Activated charcoal, through nasogastric tube.
  o Adults: 100 g mixed as a slurry with water.
  o Children: 1 g/kg mixed as a slurry with water.
  o Add 300 – 600 mL of water to charcoal and not vice versa.
  o Do not administer orally if the level of consciousness is reduced.
    Administer via nasogastric tube to avoid the danger of aspiration.

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose g</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 3.5–7 kg</td>
<td>5 g</td>
<td>≥ 1–6 months</td>
</tr>
<tr>
<td>≥ 7–11 kg</td>
<td>10 g</td>
<td>≥ 6–18 months</td>
</tr>
<tr>
<td>≥ 11–17.5 kg</td>
<td>15 g</td>
<td>≥ 18 months–5 years</td>
</tr>
<tr>
<td>≥ 17.5–35 kg</td>
<td>25 g</td>
<td>≥ 5–11 years</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>50 g</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>100 g</td>
<td>15 years and adult</td>
</tr>
</tbody>
</table>

» Activated charcoal should not be given in the case of:
  - volatile hydrocarbon poisoning, e.g. paraffin, petrol
  - corrosive poisons, i.e. acids or alkalis
  - camphor and other convulsants
  - metals, e.g. iron, lithium etc and
  - all alcohols.

» Protect the airway
  - Place in lateral position if decreased level of consciousness.
  - If level of consciousness is depressed to the state where aspiration is likely, intubate the patient.

» Identify the poison and keep a sample of the poison or container.
» Contact the nearest hospital or poison centre for advice
Emergency management

» If the patient is unconscious, perform resuscitation – See section 20.4: Cardiac arrest – cardiopulmonary resuscitation
» Take a history and identify the nature and route of poisoning.
» Thoroughly wash off any poison from the skin with soap and water and remove contaminated clothes in organophosphate poisoning

Note:
Health care workers and relatives should avoid having skin contact with the poison.

Specific antidotes

Hypoxia, especially in carbon monoxide poisoning:
- Oxygen

Organophosphate and carbamate poisoning

Signs and symptoms of organophosphate poisoning include:
- diarrhoea
- vomiting
- hypersecretions (hypersalivation, sweating, lacrimation, rhinorrhoea)
- brochospasm and bronchorhoea, causing tightness in the chest, wheezing, cough and pulmonary oedema
- bradycardia
- muscle twitching
- weakness
- miosis/mydriasis
- confusion
- convulsions
- coma

- Atropine, IV
  - Adults: initial dose 1 mg, repeat doses are 2–4 mg
  - Children: 0.05 mg/kg/dose
  - Repeat the dose every 10–15 minutes until there is control of bronchial secretions.
  - Refer all patients urgently.
  - Response to a first dose suggests organophosphate poisoning.

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following injections:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 3.5–5.5 kg</td>
<td>0.2 mg</td>
<td>0.4 mL</td>
<td>0.2 mL</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>0.3 mg</td>
<td>0.6 mL</td>
<td>0.3 mL</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>0.4 mg</td>
<td>0.8 mL</td>
<td>0.4 mL</td>
</tr>
<tr>
<td>≥ 9–11 kg</td>
<td>0.5 mg</td>
<td>1 mL</td>
<td>0.5 mL</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>0.6 mg</td>
<td>1.2 mL</td>
<td>0.6 mL</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>0.8 mg</td>
<td>1.6 mL</td>
<td>0.8 mL</td>
</tr>
<tr>
<td>≥ 17.5 kg and above</td>
<td>1 mg</td>
<td>2 mL</td>
<td>1 mL</td>
</tr>
</tbody>
</table>
Opioid drug overdose in adults

- Naloxone, IV, 0.4–2 mg immediately.
  - Repeat 0.4 mg every 5 minutes until reversal or pupils dilate.
  - Total effective dose is 10 mg.
  - May be administered endotracheally.
  - Duration of action is short, i.e. 45 minutes.
  - Repeat doses over 24 hours may be required

All patients need to be kept under direct observation until the effect of the opiates has completely worn off.

Further doses of naloxone may be needed while awaiting and during transport as naloxone has a short duration of action.

Refer all patients.

In some patients addicted to opioids, naloxone may precipitate an acute withdrawal syndrome after several hours – this must not prevent the use of naloxone.

Paracetamol poisoning

All patients should be referred urgently for paracetamol blood level and consideration of N-acetylcysteine.

Referral

» All intentional overdoses
» All symptomatic patients
» All children in whom toxicity can be expected, e.g. ingestion with:
  - paracetamol > 6 mL/kg (or 140 mg/kg)
  - anti-epileptics
  - warfarin
  - tricyclic antidepressants
  - sulphonylureas
  - paraffin (unless patient has a normal respiratory rate after 6 hours)
  - iron tablets

If in doubt, consult the referral or poison centre.

Note:

Send the following to hospital with the patient:

» written information
» a sample of the poison or the empty poison container
21.9 HIV prophylaxis, post exposure (PEP)

Z29.2

21.9.1 Penetrative sexual abuse or sexual assault

T74.2

Description

Sexual assault, sexual abuse or rape is considered when a person intentionally and unlawfully commits an act of sexual penetration with another person by force or threat.

Sexual penetration is defined broadly and refers to any act which causes penetration to any extent whatsoever by:

» the genital organs of one person into the mouth, anus or genital organs of another person

» any object, any part of the body of one person into the anus or genital organs of another person in a manner that simulates sexual intercourse.

A person who has sexual intercourse with another person without disclosing that he/she is HIV positive will be guilty of rape, as the consent given will not be valid due to the fact that it was obtained by false pretences.

General measures

If indecision exist with any of the following offer a 1st dose of antiretroviral PEP as soon as possible – the following matters can then be resolved in due course:

» Obtain informed consent from the patient and written consent from parent in case of minors before HIV testing and PEP.

– Children over the age of:
  (i) 12 years of age or older; or
  (ii) under the age of 12 years and of sufficient maturity to understand the benefits, risks and social implications of such a test; may sign their own consent.

» Determine the patient’s HIV-status before initiating PEP.

– Prophylaxis given to a previously infected HIV person will have no clinical benefit and may lead to the development of viral resistance.
It is the patient’s choice to have immediate HIV testing. If the patient declines, only a 3-day starter pack of PEP should be given and the patient encouraged to reconsider testing within those 3 days. **No further PEP will be given in the case of continued refusal of HIV testing.**

A patient presenting after 72 hours will not be given PEP but should be counselled about the possible risk of transmission.

- HIV testing should still be offered at the time of presentation and 3 months later.

Perform a pregnancy test before initiating PEP.
- Pregnant rape patients should be referred.

HIV Elisa positive tested sexually abused children under the age of 18 months must have an HIV DNA PCR (polymerase chain reaction) performed.
- If HIV uninfected or if the child has no access to PCR, they should receive prophylaxis.

Explain the side effects of the ARV drugs, e.g. tiredness, nausea and flu-like symptoms.

Emphasise the importance of compliance with ARV treatment.

Counsel all sexually assaulted patients and caregivers in the case of children.

Provide psychosocial support pertaining to:
- medical risks, e.g. transmission of sexually transmitted infections including HIV, syphilis, hepatitis-B and C
- risk of pregnancy
- psycho-emotional-social effects of the sexual assault according to their level of understanding and maturity
- identify need for support and refer if needed

Discuss issues relating to stress management at subsequent visits. Post traumatic stress may eventually cause exhaustion and illness. Inform the patient of the signs and symptoms of post traumatic stress, including:
- general irritability
- trembling
- pain in neck and/or lower back
- change in appetite
- change in sleep pattern

Medico-legal assessment of injuries

Complete appropriate registers

**Note:**

Refer very young or severely traumatised children to a specialised unit or facility. Children with external signs of genital trauma may need an examination under anaesthesia and should be referred. Trauma to the genital area increases transmission. The character of the exposure should be classified as:

- low risk – non receptive or non traumatic intercourse
- high risk – vaginal and/or rectal penetration and traumatic intercourse
Blood tests
- The patient should sign a consent form for both testing and PEP
- Voluntary rapid HIV testing should be made available and should be done on all opting for PEP
- Further blood tests should include full blood count VDRL-RPR and Hepatitis B serology.
- Full blood count should be repeated at 2 and 4 weeks if patient receives PEP
- Blood should be taken at 4 weeks, 3 months and 6 months for HIV testing
- RPR at baseline and after 6 weeks

Drug treatment

Note:
- Offer PEP if the patient presents within 72 hours of being raped and is HIV non-infected.
- Obtain consent for HIV testing from all patients before initiating PEP.
- Initiate PEP as soon as possible provided the patient is not HIV-infected prior to the incident
  - For low risk exposure, initiate dual therapy.
  - For high risk exposure and children with very physically traumatic assaults, refer for management of these physical injuries and to consider the use of triple therapy. During referral dual therapy should be initiated immediately.
- In children under the age of 15 months antiretroviral therapy should be used while arranging transfer and awaiting confirmation of HIV results
- Initiating therapy within 24 hours is most likely to be effective at preventing transmission of HIV
- Do a pregnancy test in all women and female adolescents. In the case of children who are clearly pre-pubertal this may be omitted.

STI prophylaxis

Non-pregnant women, men:
- Doxycycline, oral, 100 mg 12 hourly for 7 days
- Cefixime, oral, 400 mg immediately as a single dose
- Metronidazole, oral, 2 g immediately as a single dose

Pregnant women:
- Amoxicillin, oral, 500 mg 8 hourly for 7 days
- Cefixime, oral, 400 mg immediately as a single dose
- Metronidazole, oral, 2 g immediately as a single dose
**Children:**

- **Amoxicillin, oral, 8 hourly**

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Syrup</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 2 – 2.5</td>
<td>50</td>
<td>2 mL</td>
<td>34–36 weeks</td>
</tr>
<tr>
<td>≥ 2.5 – 3.5</td>
<td>62.5</td>
<td>2.5 mL</td>
<td>Birth–1 month</td>
</tr>
<tr>
<td>≥ 3.5 – 5.5</td>
<td>75</td>
<td>3 mL</td>
<td>≥ 1–3 months</td>
</tr>
<tr>
<td>≥ 5 – 7</td>
<td>125</td>
<td>5 mL</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥ 7 – 9</td>
<td>150</td>
<td>6 mL</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥ 9 – 11</td>
<td>187.5</td>
<td>7.5 mL</td>
<td>≥ 12–18 months</td>
</tr>
<tr>
<td>≥ 11–17.5</td>
<td>250</td>
<td>10 mL</td>
<td>≥ 18 months–5 years</td>
</tr>
<tr>
<td>≥ 17.5 – 20</td>
<td>375</td>
<td>15 mL</td>
<td>≥ 5–7 years</td>
</tr>
</tbody>
</table>

| 8–12 years: |
|---|---|---|
| • Doxycycline, oral, 100 mg once daily for 7 days |

**Over 12 years:**

- **Doxycycline 100 mg 12 hourly for 7 days**

**plus**

- **Ceftriaxone, IM**
  - Under 25 kg 125 mg
  - Over 25 kg 250 mg

**! CAUTION!**

Do not administer calcium containing fluids, e.g. Ringer-lactate, within 48 hours of administering ceftriaxone.
Contra-indicated in neonatal jaundice.
Annotate the dose and route of administration on the referral letter.

**plus**

- **Metronidazole, oral, as a single dose**
  - 1–3 years 500 mg
  - 3–7 years 600–800 mg
  - 7–10 years 1 g

**Post-coital contraception to prevent unintentional pregnancy in women of reproductive age**

- Levonorgestrel 0.75 mg, oral, 2 tablets as a single dose as soon as possible after unprotected intercourse
Or if unavailable:
- Norgestrel/ethinyl oestradiol 0.05/0.5 mg mg, oral, 2 tablets as soon as possible after unprotected intercourse, followed by 2 tablets 12 hours later.
Chapter 21  

Trauma and emergencies  

<table>
<thead>
<tr>
<th>! CAUTION!</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tablets must be taken as soon as possible, preferably within 72 hours of unprotected intercourse and not more than 5 days later.</td>
</tr>
</tbody>
</table>

An anti-emetic if needed

**Hepatitis-B vaccination**
See section 13.2: Dosage and administration (Chapter 13: Immunisation)

**PEP treatment**

**Children:**
As the body surface area is very difficult to calculate, the following guidelines are provided:

- **Zidovudine, oral, 12 hourly for 28 days.**
  - **Paediatric dose:** 180 mg/m²
  - **Maximum:** 300 mg/dose.
    - Solution: 10 mg/mL; capsules: 100 mg; tablets: 300 mg (not scored)

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Zidovudine</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 5–5.9 kg</td>
<td>6 mL</td>
</tr>
<tr>
<td>≥ 6–6.9 kg</td>
<td>7 mL</td>
</tr>
<tr>
<td>≥ 7–7.9 kg</td>
<td>8 mL</td>
</tr>
<tr>
<td>≥ 8–8.9 kg</td>
<td>9 mL or 1 capsule</td>
</tr>
<tr>
<td>≥ 9–11.9 kg</td>
<td>10 mL or 1 capsule</td>
</tr>
<tr>
<td>≥ 12–13.9 kg</td>
<td>11 mL or 1 capsule</td>
</tr>
<tr>
<td>≥ 14–19.9 kg</td>
<td>2 capsules in the morning and 1 capsule in the evening</td>
</tr>
<tr>
<td>≥ 20–29.9 kg</td>
<td>2 capsules</td>
</tr>
<tr>
<td>≥ 30–40 kg</td>
<td>1 tablet</td>
</tr>
</tbody>
</table>

**Plus**
- **Lamivudine, oral, 4 mg/kg/dose 12 hourly for 28 days.**
  - **Maximum:** 150 mg/dose.
    - Solution: 10 mg/mL; tablet: 150 mg

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Lamivudine</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 5–6.9</td>
<td>3 mL</td>
</tr>
<tr>
<td>≥ 7–9.9</td>
<td>4 mL</td>
</tr>
<tr>
<td>≥ 10–11.9</td>
<td>5 mL</td>
</tr>
<tr>
<td>≥ 12–13.9</td>
<td>6 mL</td>
</tr>
<tr>
<td>≥ 14–19.9</td>
<td>7½ mL or ½ tablet (if divisible tablet)</td>
</tr>
<tr>
<td>≥ 20–24.9</td>
<td>1 tablet in the morning and 7½ mL or ½ tablet (if divisible tablet) in the evening</td>
</tr>
<tr>
<td>≥ 25–40</td>
<td>1 tablet</td>
</tr>
</tbody>
</table>
Chapter 21  Trauma and emergencies

Dosages may be varied by up to 1 mg/kg/dose more or less to allow a convenient volume of medication.
In children needing more than the maximum dose, use the adult dosage regimen.

Adults
• Zidovudine, oral, 300 mg 12 hourly for 28 days
plus
• Lamivudine, oral, 150 mg 12 hourly for 28 days
  o Initially supply medication for 2 weeks.
  o Evaluate patient after 2 weeks at which the remainder of the PEP treatment should be supplied.

Follow up visits should be at 6 weeks, 3 months and 6 months after the rape. HIV testing should be performed at each of these visits.

Referral
» All patients with severe physical or psychological injuries
» Infants with significant evidence of sexual assault need referral after beginning dual therapy as soon as possible.

Note:
Refer if there are inadequate resources with regard to:
» counseling
» laboratory for testing
» medico-legal examination
» drug treatment

21.9.2 Occupational post-exposure HIV prophylaxis for health-care workers (HCW)

Z29.2

Description
Exposure to infectious material from HIV seropositive patients including:
» blood
» CSF
» semen
» vaginal secretions
» synovial, pleural, pericardial, peritoneal, amniotic fluid
» The risk of acquiring HIV following occupational exposure is estimated at 0.3%.
» There is a higher risk when:
» the injury is deep
» involves a hollow needle
» or when the source patient is more infectious, e.g.:
  – terminal AIDS
Chapter 21 Trauma and emergencies

- seroconversion illness
- or known to have a high viral load

Where the source patient is on ARVs or has been on ARVs normal prophylaxis should be started and expert opinion should be sought. An extra blood sample (uncotted - EDTA) of the source patient should be stored in case of need for further viral testing.

Other blood borne infections that can be transmitted include hepatitis B, hepatitis C and syphilis and all source patients should be tested. Comprehensive and confidential pre-test counselling should be offered.

**Drug treatment**

- Initiate PEP immediately after the injury and within 72 hours.
  - Do not wait for the confirmatory test results on the source patient and health care worker.
- With very high risk exposures, initiation of treatment may be considered beyond 72 hours.
  - The risks of prophylaxis in this setting may outweigh the benefits.
- Do not consider initiating HIV prophylactic treatment beyond 7 days after exposure.
- Duration of prophylactic treatment is 4 weeks.
- PEP should not be offered for exposures to body fluids which carry no risk of infection, e.g. vomitus, urine, faeces or saliva.
- PEP is not indicated for health care workers who are HIV-infected.
- PEP is not indicated when the source is HIV sero-negative unless there are features suggesting seroconversion illness.
  - Continue prophylaxis until the results of additional tests are available.
  - These cases should be discussed with virologists
- Test for HIV infection at the time of the exposure and again at 6 weeks, 3 months and 6 months
- Advise about the need to take precautions, e.g. condom use, to prevent infection of their own sexual partners, should seroconversion occur
- Stop PEP if HIV test of the health care worker is positive at the time of the injury
- Perform full blood count after 2 and 4 weeks on PEP

Combinations of anti-retroviral drugs are used in the prevention of HIV infection:

- Lamivudine, oral, 150 mg 12 hourly
- Zidovudine, oral, 300 mg 12 hourly

With high-risk exposures the addition of a third agent, a protease inhibitor, is recommended.
* High risk HIV source patients include terminal AIDS, seroconversion illness or known to have a high viral load.
### Exposure of Healthcare worker

<table>
<thead>
<tr>
<th></th>
<th>HIV status of source patient</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>No PEP</td>
</tr>
<tr>
<td>Intact skin</td>
<td></td>
</tr>
<tr>
<td>Mucosal splash or</td>
<td>Zidovudine + lamivudine</td>
</tr>
<tr>
<td>non-intact skin</td>
<td></td>
</tr>
<tr>
<td>Percutaneous –</td>
<td>Zidovudine + lamivudine</td>
</tr>
<tr>
<td>sharps</td>
<td></td>
</tr>
<tr>
<td>Percutaneous</td>
<td>Zidovudine + lamivudine</td>
</tr>
<tr>
<td>needle in vessel or</td>
<td></td>
</tr>
<tr>
<td>deep injury</td>
<td></td>
</tr>
</tbody>
</table>

### Referral

» Patients in need of a protease inhibitor

**Note:**
Refer if there are inadequate resources with regard to:
» counselling
» laboratory for testing
» medico-legal examination
» drug treatment

### 21.10 Hyperglycaemia and ketoacidosis

See Section 9.4: Diabetic emergencies

### 21.11 Hypoglycaemia and hypoglycaemic coma

**Description**
Hypoglycaemia is a blood sugar less than 3.5 mmol/L (< 2.6 mmol/L in neonate) and can rapidly cause irreversible brain damage and/or death.
Clinical features include:
» tremor
» sweating
» confusion
» delirium
Chapter 21  

Trauma and emergencies

» tachycardia  » coma
» dizziness  » convulsions
» hunger  » transient aphasia or speech disorders
» headache  » irritability
» impaired concentration

There may be few or no symptoms in the following situations:
» chronically low blood sugar
» patients with impaired autonomic nervous system response, e.g.
  – the elderly
  – very ill
  – malnourished
  – those with long-standing diabetes mellitus
  – treatment with beta-blockers

People at risk of hypoglycaemia:
» neonates with low birth weight or ill or not feeding well
» malnourished or sick children
» shocked, unconscious or convulsing patients
» alcohol binge
» liver disease
» diabetics on treatment

Hypoglycaemia may be a marker of deteriorating renal function.

Emergency treatment

» Obtain blood for glucose determination immediately.
» Establish blood glucose level with glucometers or testing strip.

Conscious patient, able to feed
Breastfeeding child
  – administer breast milk
Older children and adults
  – sweets, sugar, glucose by mouth
    or
    oral sugar solution
    Dissolve 3 teaspoons of sugar (15 g) in a 200 mL cup of water.

Conscious patient, not able to feed without danger of aspiration
Administer via nasogastric tube
  – Dextrose 5%
    or
    milk
    or
    sugar solution
Unconscious patient:

Children
- Dextrose 10%, IV, 5 mL/kg
  - 10% solution – e.g. 4 mL 50% dextrose drawn up to 20 mL with water for injection

IV administration of dextrose in children with hypoglycaemia
- Establish an IV line – do not give excessive volumes of fluid
- Take a blood sample for emergency investigations and blood glucose
- Check blood glucose
  - if low, i.e. less than 2.5 mmol/L or if testing strips are not available, administer 5 mL/kg of 10% dextrose solution IV rapidly
  - In the majority of cases an immediate clinical response can be expected.
- Recheck the blood glucose after infusion
  - if still low, repeat 5 mL/kg of 10% dextrose solution
- After recovery, maintain with 5% dextrose solution until blood glucose is stabilised.
- Feed the child as soon as conscious

Adults
- Dextrose 50%, IV, 50 mL immediately and reassess.
  - Followed with dextrose 10% solution.
  - In the majority of cases an immediate clinical response can be expected.
  - Maintain with 5% dextrose solution after recovery until blood glucose is stabilised.

Alcoholics
- Thiamine, IV/IM, 100 mg immediately.

! CAUTION!
Thiamine should be preferably be administered prior to intravenous glucose to prevent permanent neurological damage.
Do not delay the dextrose administration in a hypoglycaemic patient.

Referral
Urgent
- All hypoglycaemic patients on oral hypoglycaemic agents
- Hypoglycaemic patients who do not recover completely after treatment
- All children who have had documented hypoglycaemia unless the cause is clearly identified and safe management instituted to prevent recurrence
**Chapter 21 Trauma and emergencies**

**21.12 Injuries**

**Description**

Soft tissue injury may present as follows:
- pain only
- traumatic swelling
- bruises with intact skin
- cuts
- abrasions
- puncture wounds
- other open wounds of varying size and severity

Injury to internal organs must be recognised and referred, including subtle signs of organ damage, e.g.:
- blood in the urine – kidney or bladder damage
- shock – internal bleeding
- blood or serous drainage from the ear or nose – skull base fracture

Referral must not be delayed by waiting for a diagnosis.

Human and animal bites can cause extensive injuries and infection. See section 21.2.1: Animal and human bites

An injury causing a sprain or strain may be initially overlooked.

Exclude fractures.

Closed injuries and fractures of long bones may be serious and damage blood vessels. Contamination with dirt and soil complicates the outcome of treatment.

**Emergency management**

- Immobilise injured limb.
- Monitor vital signs.
- Monitor pulses below an injury on a limb with swelling.

**Wound care**

- Clean the wound
- Suture or splint when needed
- Avoid primary suture if the wound is infected:
  - dirty or contaminated
  - crushed
  - in need of debridement
  - projectile inflicted
  - caused by bites
Drug treatment

- **Paracetamol**, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum of 4 doses per 24 hours
  - In children under 6 months calculate dose by weight

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥3.5–5 kg</td>
<td>48 mg</td>
<td>Syrup 120 mg/5mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>60 mg</td>
<td>2 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>96 mg</td>
<td>4 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 9–14 kg</td>
<td>120 mg</td>
<td>5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>180 mg</td>
<td>7.5 mL</td>
<td>–</td>
</tr>
<tr>
<td>≥ 17.5–35 kg</td>
<td>240 mg</td>
<td>10 mL</td>
<td>½ tablet</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>500 mg</td>
<td>–</td>
<td>1 tablet</td>
</tr>
<tr>
<td>≥55 kg and above</td>
<td>Up to 1 000 mg</td>
<td>–</td>
<td>Up to 2 tablets</td>
</tr>
</tbody>
</table>

**Tetanus prophylaxis**
If not previously immunised within the last 5 years
- Tetanus toxoid (TT), IM, 0.5 mL

**Note**
In a fully immunised person, tetanus toxoid vaccine might produce an unpleasant reaction, e.g. redness, itching, swelling or fever, but in the case of a severe injury the administration is justified.

**Referral**
**Urgent**
» Extensive closed or open wounds
» Injury to vital structures or internal organs
» Sepsis
» Shock
» Anaemia
» Blood in the urine
» Infants and young children except when the injury is minor
» Enlarging and/or pulsating swelling

**21.13 Myocardial infarction, acute (AMI)**

See section 4.6 Myocardial infarction, acute (AMI)
21.14 Nose bleed (epistaxis)

R04.0

**Description**
Nose bleed may be caused by local or systemic diseases, or local trauma, especially nose picking and occurs from an area anterior and inferior to the nasal septum. Consider other conditions associated with nosebleeds, especially if recurrent, e.g. hypertension and bleeding tendency.

**Management**

**Acute episode**
Most bleeding can be controlled by pinching the nasal wings (alae) together for 5–10 minutes. If this fails, insert nasal tampons or BIPP stripping into bleeding nostril(s). Identify the cause.

**Referral**

» Recurrent nose bleeds
» Failure to stop the bleeding

21.15 Pulmonary oedema, acute

J81

**Description**
A life-threatening condition with abnormal accumulation of fluid in the lungs. Acute heart failure is a common cause.

Persons with pulmonary oedema may present similarly to acute bronchospasm. It is important to distinguish this condition from an acute attack of asthma.

! **CAUTION**!
Morphine is contraindicated in acute asthma.

**Emergency treatment**
Place the patient in a sitting or semi-Fowler’s position.

**Children:**
- Oxygen, using face mask or nasal cannula at 2–3 L per minute
Chapter 21  
Trauma and emergencies

- Furosemide, IV, 1 mg/kg immediately.
  - Do not put up a drip or run in any IV fluids

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Injection 10 mg/mL</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 3.5–5 kg</td>
<td>4 mg</td>
<td>0.4 mL</td>
<td>≥1–3 months</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>6 mg</td>
<td>0.6 mL</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>8 mg</td>
<td>0.8 mL</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥ 9–11 kg</td>
<td>10 mg</td>
<td>1 mL</td>
<td>≥12–18 months</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>12 mg</td>
<td>1.2 mL</td>
<td>≥18 months–3 years</td>
</tr>
<tr>
<td>≥ 14–7.5 kg</td>
<td>15 mg</td>
<td>1.5 mL</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>20 mg</td>
<td>2 mL</td>
<td>≥ 5–7 years</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>30 mg</td>
<td>3 mL</td>
<td>≥ 7–11 years</td>
</tr>
<tr>
<td>≥ 35 kg and above</td>
<td>40 mg</td>
<td>4 mL</td>
<td>≥ 11 years and adults</td>
</tr>
</tbody>
</table>

Adults:
- Oxygen, using face mask to deliver 40% oxygen at a rate of 6–8 L per minute
- Furosemide, IV, 40 mg
  If response is adequate follow with:
  - Furosemide, IV, 40 mg in 2–4 hours
  If no response within 20–30 minutes:
  - Furosemide, IV, 40 mg
  - Morphine, IV.
    - Dilute 10 mg to 10 mL and administer slowly at 1 mg/minute.
    - Discontinue when patient experiences relief.
    - Maximum dose: 10 mg
  and/or
  - Isosorbide dinitrate sublingual 5 mg 4 hourly.
  - Do not administer if hypotensive.

Pulmonary oedema due to a hypertensive crisis
ADD
To treat hypertension
- ACE inhibitors

Referral
Urgent
  » All cases
  Continue oxygen during transfer.
Chapter 21  Trauma and emergencies

21.16 Shock

R57.9

**Description**
Shock is a life threatening condition characterised by hypotension.

**Signs and symptoms of shock**
- Low blood pressure (systolic BP below 80 mmHg) is the key sign of shock.
- Weak and rapid pulse
- Rapid shallow breathing.
- Restlessness and altered mental state
- Weakness
- Low urine output

<table>
<thead>
<tr>
<th>Types of shock</th>
<th>Additional symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>» Hypovolemic shock</td>
<td>Most common type of shock</td>
</tr>
<tr>
<td></td>
<td>Primary cause is loss of fluid from circulation due to haemorrhage, burns, diarrhoea, etc.</td>
</tr>
<tr>
<td></td>
<td>Weak thready pulse, cold and clammy skin.</td>
</tr>
<tr>
<td>» Cardiogenic shock</td>
<td>Caused by the failure of heart to pump effectively e.g. in myocardial infarction, cardiac failure, etc.</td>
</tr>
<tr>
<td></td>
<td>Distended neck veins, weak or absent pulses.</td>
</tr>
<tr>
<td>» Septic shock</td>
<td>Caused by an overwhelming infection, leading to vasodilation.</td>
</tr>
<tr>
<td></td>
<td>Elevated body temperature</td>
</tr>
<tr>
<td>» Neurogenic shock</td>
<td>Caused by trauma to the spinal cord, resulting in sudden decrease in peripheral vascular resistance and hypotension.</td>
</tr>
<tr>
<td></td>
<td>Warm and dry skin</td>
</tr>
<tr>
<td>» Anaphylactic shock</td>
<td>Caused by severe allergic reaction to an allergen, or drug.</td>
</tr>
<tr>
<td></td>
<td>Bronchospasm, angioedema and/or urticaria</td>
</tr>
</tbody>
</table>
Signs and symptoms of shock in children
Shock must be recognised while still in the compensated state to avoid irreversible deterioration. Therefore, the following are primarily assessed in children:
1. Prolonged capillary filling (more than 3 seconds)
2. Decreased pulse volume (weak thready pulse)
3. Increased heart rate (>160/minute in infants, > 120 in children)
4. Decreased level of consciousness (poor eye contact)
5. Rapid breathing
Decreased blood pressure and decreased urine output are late signs and while they can be monitored the above signs are more sensitive in detecting shock before irreversible.

Emergency treatment
Treatment depends on the type of shock. Intravenous fluid therapy is important in the treatment of all types of shock except for cardiogenic shock. Prompt diagnosis of underlying cause is essential to ensure optimal treatment.

» Maintain open airway
» Administer oxygen with face mask and if needed after intubation with assisted ventilation
» Check for and manage hypoglycaemia

Fluid replacement (Not for cardiogenic shock)

**Adults:**
- Sodium chloride 0.9%, IV, 1 L as a rapid bolus.
  - Repeat bolus until blood pressure is improved.

**Children:**
- Sodium chloride 0.9%, IV, 20 mL/kg as a rapid bolus.
  - Repeat bolus if no adequate response.

**Note:**
Do not administer IV fluids in case of cardiogenic shock but maintain IV access. If patient develops respiratory distress, discontinue fluids.

**Septicaemia in children**
All children with shock which is not obviously due to trauma or simple watery diarrhoea should receive antibiotic cover for probable septicaemia.
• Ceftriaxone, IM, 50–80 mg/kg/dose immediately as a single dose

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following injections mixed with water for injection (WFI):</th>
<th>Age Months/ years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 2–2.5 kg</td>
<td>125 mg</td>
<td>250 mg WFI 2 mL</td>
<td>0.5 mL</td>
</tr>
<tr>
<td>≥ 2.5–3.5 kg</td>
<td>200 mg</td>
<td>500 mg WFI 2 mL</td>
<td>1 mL</td>
</tr>
<tr>
<td>≥ 3.5–5.5 kg</td>
<td>250 mg</td>
<td>2 mL</td>
<td>1 mL</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>375 mg</td>
<td>3 mL</td>
<td>1.5 mL</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>500 mg</td>
<td>4 mL</td>
<td>2 mL</td>
</tr>
<tr>
<td>≥ 9–11 kg</td>
<td>625 mg</td>
<td>5 mL</td>
<td>2.5 mL</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>750 mg</td>
<td>6 mL</td>
<td>3 mL</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>1 000 mg</td>
<td>–</td>
<td>4 mL</td>
</tr>
<tr>
<td>≥ 17.5 kg and above</td>
<td>1 000 mg</td>
<td>4 mL</td>
<td>3.5 mL</td>
</tr>
</tbody>
</table>

! CAUTION!
Do not administer calcium containing fluids, e.g. Ringer-lactate, within 48 hours of administering ceftriaxone.
Contra-indicated in neonatal jaundice.
Annotate dose and route of administration on referral letter.

**Referral**

» All patients urgently after resuscitation.

**21.17 Shock, anaphylactic**

**T78.2**

**Description**

A very severe allergic reaction that usually occurs within seconds or minutes after exposure to an allergen, but may be delayed for up to 1 hour. The reaction may be life threatening.

Clinical features include:

» hypotension and/or shock

» bronchospasm

» laryngeal oedema or angioneurotic oedema

**Emergency treatment**

» Resuscitate (ABC) immediately, (see section 21.4)
Chapter 21  
Trauma and emergencies

Drug treatment

Adrenaline is the mainstay of treatment and should be given immediately

- **Adrenaline, IM,**

<table>
<thead>
<tr>
<th>Age years</th>
<th>Dose mg</th>
<th>Injection 1 mg/mL (1:1 000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 2 years</td>
<td>0.1 mg</td>
<td>0.1 mL</td>
</tr>
<tr>
<td>≥ 2 – 5 years</td>
<td>0.2 mg</td>
<td>0.2 mL</td>
</tr>
<tr>
<td>≥ 6 – 12 years</td>
<td>0.3 mg</td>
<td>0.3 mL</td>
</tr>
<tr>
<td>≥ 12 – 15 years</td>
<td>0.5 mg</td>
<td>0.5 mL</td>
</tr>
<tr>
<td>≥ 15 years and adults</td>
<td>1 mg</td>
<td>1 mL</td>
</tr>
</tbody>
</table>

  - Repeat in 5 minutes if no improvement.

- **Hydrocortisone IM/slow IV, immediately**
  - Maximum dose: 100 mg.

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Injection 100 mg/2 mL</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 11–14 kg</td>
<td>50 mg</td>
<td>1 mL</td>
<td>≥ 2–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>75 mg</td>
<td>1.5 mL</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5 kg and above</td>
<td>100 mg</td>
<td>2 mL</td>
<td>≥ 5 years and adult</td>
</tr>
</tbody>
</table>

- **Promethazine, IM/slow IV**
  - Children over 2 years: 0.25 mg/kg
  - Adults: 25–50 mg

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following injections:</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>25 mg/mL</td>
<td>50 mg/2 mL</td>
</tr>
<tr>
<td>≥ 11–17.5 kg</td>
<td>5 mg</td>
<td>0.2 mL</td>
<td>0.2 mL</td>
</tr>
<tr>
<td>≥ 17.5–25 kg</td>
<td>7.5 mg</td>
<td>0.3 mL</td>
<td>0.3 mL</td>
</tr>
<tr>
<td>≥ 25–35 kg</td>
<td>10 mg</td>
<td>0.4 mL</td>
<td>0.4 mL</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>15 mg</td>
<td>0.6 mL</td>
<td>0.6 mL</td>
</tr>
<tr>
<td>≥ 55 kg and above</td>
<td>25 mg</td>
<td>1 mL</td>
<td>1 mL</td>
</tr>
</tbody>
</table>

**Referral**

» All patients

**Note:**

Adrenaline administration may have to be repeated due its short duration of action. Close observation during transport is essential.
**Chapter 21  Trauma and emergencies**

**21.18 Sprains and strains**

**T14.3**

**Description**
Soft tissue injuries.
Clinical features include:
» pain, especially on movement
» tenderness on touch
» limited movement
» history of trauma
May be caused by:
» sport injuries
» slips and twists
» overuse of muscles
» abnormal posture

**Note:**
In children always bear non-accidental injuries (assault) in mind.

**Emergency treatment**
» Immobilise with firm bandage and/or temporary splinting

Children over 12 years and adults:
- Ibuprofen, oral, 200–400 mg 8 hourly with or after a meal
  plus
- **Paracetamol**, oral, 15 mg/kg/dose 4–6 hourly when required to a maximum of 4 doses per 24 hours
  - In children under 6 months calculate dose by weight

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Use one of the following:</th>
<th>Age months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥3.5–5 kg</td>
<td>48 mg</td>
<td>Syrup 120 mg/5mL</td>
<td>≥ 1–3 months</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>60 mg</td>
<td>2 mL</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>96 mg</td>
<td>4 mL</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥ 9–14 kg</td>
<td>120 mg</td>
<td>5 mL</td>
<td>≥ 12 months–3 years</td>
</tr>
<tr>
<td>≥ 14–17.5 kg</td>
<td>180 mg</td>
<td>7.5 mL</td>
<td>≥ 3–5 years</td>
</tr>
<tr>
<td>≥ 17.5–35 kg</td>
<td>240 mg</td>
<td>10 mL ½ tablet</td>
<td>≥ 5–11 years</td>
</tr>
<tr>
<td>≥ 35–55 kg</td>
<td>500 mg</td>
<td>1 tablet</td>
<td>≥ 11–15 years</td>
</tr>
<tr>
<td>≥55 kg and above</td>
<td>Up to 1 000 mg</td>
<td>2 tablets</td>
<td>≥ 15 years and adults</td>
</tr>
</tbody>
</table>

**Referral**
» Severe progressive pain
» Progressive swelling
21.19 Status epilepticus
G41.9

For initial treatment of seizures, see Section 15.2: Seizures

Description
This is a medical emergency.

A series of seizures follow one another lasting more than 30 minutes with no intervening periods of recovery of consciousness. The seizure may be generalised or partial, convulsive or non-convulsive.

Status epilepticus has the potential for causing high mortality.

General measures

- Place the patient in a lateral - prone (recovery) position.
- **Do not** place anything (spoon or spatula etc) in the patient’s mouth.
- Do not try to open the patient’s mouth.
- Maintain airway.
- Assist respiration and give high flow oxygen.
- Prepare for suction and intubation.
- Check blood glucose (exclude hypoglycaemia!)
- Monitor vital signs every 15 minutes.
- Establish an IV line (dextrose 5% in sodium chloride 0.9%).

Drug treatment

Children < 12 years

- Diazepam, rectal, 0.5 mg/kg/dose for convulsions as a single dose.
  - Diazepam for injection 10 mg in 2 mL is used undiluted.
  - Draw up the required volume in a 2 mL syringe.
  - Remove needle then insert the whole barrel of the lubricated syringe into the rectum and inject the contents.
  - Remove syringe and hold buttocks together to minimise leakage
### Chapter 21  Trauma and emergencies

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Ampoule 10 mg/2 mL</th>
<th>Approx age</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 3–6 kg</td>
<td>2 mg</td>
<td>0.4 mL</td>
<td>Less than 6 months</td>
</tr>
<tr>
<td>≥ 6–10 kg</td>
<td>2.5 mg</td>
<td>0.5 mL</td>
<td>≥ 6 months–1 year</td>
</tr>
<tr>
<td>≥ 10–18 kg</td>
<td>5 mg</td>
<td>1 mL</td>
<td>≥ 1–5 years</td>
</tr>
<tr>
<td>≥ 18–25 kg</td>
<td>7.5 mg</td>
<td>1.5 mL</td>
<td>≥ 5–8 years</td>
</tr>
<tr>
<td>≥ 25–40 kg</td>
<td>10 mg</td>
<td>2 mL</td>
<td>≥ 8–12 years</td>
</tr>
</tbody>
</table>

- Maximum dose: 10 mg in 1 hour.
- May be repeated after 10 minutes if convulsions continue.
- Expect a response within 1–5 minutes.

If no response after the second dose of diazepam or if the convulsion has lasted more than 20 minutes, add:
- Phenobarbitone, oral, crushed and given by nasogastric tube, 20 mg/kg as a single dose.
  - Maximum dose: 210 mg

<table>
<thead>
<tr>
<th>Weight kg</th>
<th>Dose mg</th>
<th>Tablet 30 mg</th>
<th>Age Months/years</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 2.5–3.5 kg</td>
<td>45 mg</td>
<td>1½ tablets</td>
<td>Birth–1 month</td>
</tr>
<tr>
<td>≥ 3.5–5.5 kg</td>
<td>60 mg</td>
<td>2 tablets</td>
<td>≥ 1–3 months</td>
</tr>
<tr>
<td>≥ 5–7 kg</td>
<td>90 mg</td>
<td>3 tablets</td>
<td>≥ 3–6 months</td>
</tr>
<tr>
<td>≥ 7–9 kg</td>
<td>120 mg</td>
<td>4 tablets</td>
<td>≥ 6–12 months</td>
</tr>
<tr>
<td>≥ 9–11 kg</td>
<td>150 mg</td>
<td>5 tablets</td>
<td>≥ 12–18 months</td>
</tr>
<tr>
<td>≥ 11–14 kg</td>
<td>180 mg</td>
<td>6 tablets</td>
<td>≥ 18 months–3 years</td>
</tr>
<tr>
<td>≥ 11 kg and above</td>
<td>210 mg</td>
<td>7 tablets</td>
<td>≥ 3 years</td>
</tr>
</tbody>
</table>

**Adults**
- Diazepam, slow IV, 10–20 mg at a rate not exceeding 2 mg/minute
  - Repeat within 10–15 minutes if needed
  - Maximum dose: 30 mg within 1 hour
  - Expect a response within 1–5 minutes

  or
  - Lorazepam, IM/IV, 4 mg as a single dose
    - Repeat after 10–15 minutes, if needed
    - Maximum dose: 8 mg within 12 hours

---

**CAUTION!**

Avoid diazepam IM since absorption is slow and erratic.

Do not mix with other drugs.

plus
- Phenytoin, oral or by nasogastric tube at a loading dose of 20 mg/kg as a
Chapter 21 Trauma and emergencies

single dose.

Referral

Urgent
» Any child where the seizures cannot be controlled within 30 minutes

Non-urgent
» All patients once stabilised
  Clinical notes including detail on medication given should accompany patients.
GUIDELINES FOR THE MOTIVATION OF A NEW MEDICINE ON THE NATIONAL ESSENTIAL MEDICINES LIST

Section 1: Medication details
» Generic name
   A fundamental principle of the Essential Drug Programme is that of generic prescribing. Most clinical trials are conducted using the generic name.
» Proposed indication
   There will usually be many registered indications for the medication. However, this section should be limited to the main indication which is supported by the evidence provided in section 2.
» Prevalence of the condition in South Africa
   This information is not always readily available. However, it is an important consideration in the review of a proposed essential medicine.
» Prescriber level
   Here the proposed prescriber level should be included. If more than one level is proposed each relevant box should be ticked.

Section 2: Evidence and motivation
» Estimated benefit
   – Effect measure: this is the clinical outcome that was reported in the clinical trial such as BP, FEV, CD₄, VL etc.
   – Risk benefit: this should reported in the clinical trial and, in most cases, includes the 95% confidence level (95% CI). Absolute risk reduction, also termed risk difference, is the difference between the absolute risk of an event in the intervention group and the absolute risk in the control group.
   – Number Need to Treat (NNT): gives the number of patients who need to be treated for a certain period of time to prevent one event. It is the reciprocal of the absolute risk or can be calculated using the formula below.
### Calculations

<table>
<thead>
<tr>
<th></th>
<th>Bad outcome</th>
<th>Good outcome</th>
<th>Total patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention group</td>
<td>$a$</td>
<td>$c$</td>
<td>$a + c$</td>
</tr>
<tr>
<td>Control group</td>
<td>$b$</td>
<td>$d$</td>
<td>$b + d$</td>
</tr>
</tbody>
</table>

#### Measure

<table>
<thead>
<tr>
<th>Equation</th>
<th></th>
</tr>
</thead>
</table>
| Absolute risk: & \[
\frac{b}{b+d} - \frac{a}{a+c}\]
| Number needed to treat & \[
\frac{1}{\frac{b}{b+d} - \frac{a}{a+c}}\]
| Relative risk & \[
\frac{a}{a+c} ÷ \frac{b}{b+d}\]
| Odds ratio & \[
\frac{\frac{a}{a+c} ÷ \frac{c}{c+a}}{\frac{b}{b+d} ÷ \frac{d}{d+b}} = \frac{a}{c} ÷ \frac{b}{d}\]

Reference - Aust Prescr 2008;31:12–16

Motivating information (Level of evidence based on the SORT system)

- The National Essential Drug List Committee has endorsed the adoption of the SORT system for categorising levels of evidence. This system contains only three levels:

| Level I | Good quality evidence | Systematic review of RCTs with consistent findings  
High quality individual RCT |
|---------|-----------------------|------------------------------------------------------|
| Level II| Limited quality patient orientated evidence  | Systematic review of lower quality studies or studies with inconsistent findings  
Low quality clinical trial  
Cohort studies  
Case-control studies |
| Level III| Other                 | Consensus guidelines, extrapolations from bench research, usual practice, opinion, disease-oriented evidence (intermediate or physiologic outcomes only), or case series |

A: Newer product: for most newer products, level 1 evidence such as high quality systematic reviews or peer-reviewed high quality randomised controlled trials should be identified and referenced in the space provided.

B: Older products: many of these products were developed prior to the wide use of randomised controlled trials. However, there maybe level 1 evidence where the product was used as the control arm for a newer product. If no level 1 evidence can be identified, then level II data from poorer quality controlled trials or high quality observational studies should be referenced in the space provided.

» Cost considerations
  - Where a published reference supporting the review of cost is available comments should be made regarding its applicability to the South African public sector environment.
  - Possible unpublished information that can be included:
    o Cost per daily dose or course of therapy – for long term or chronic therapy such as hypertension the usual daily dose should be calculated (Dose x number of times a day) and converted into the number of dosing units e.g. tablets. This is then used to calculate the cost per day. For medications used in a course of therapy such as antibiotics this is then multiplied by the number of days in the course of therapy.
    o Cost minimisation is used where there is evidence to support equivalence and aims to identify the least costly treatment by identifying all the relevant costs associated with the treatment.
    o Cost-effectiveness analysis is used to compare treatment alternatives that differ in the degree of success in terms of the therapeutic or clinical outcome. By calculating a summary measurement of efficiency (a cost-effectiveness ratio), alternatives with different costs, efficacy rates, and safety rates can be fairly compared along a level playing field.

Where any of these have been performed tick the relevant block and send as an attachment with all the calculations. If possible, the spread sheet should be supplied electronically.

Section 3: Motivator’s Details
The receipt of all submission will be acknowledged. In addition, all decisions with supporting arguments will be communicated where appropriate. This section therefore forms a vital link between the motivator and the decision making process.
# Motivation form for the inclusion of a new medication on the National Essential Medicines List

## Section 1: Medication details

<table>
<thead>
<tr>
<th>Generic name (or International Nonproprietary Name):</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Proposed indication:</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Prevalence of condition (based on epidemiological data, if any):</th>
<th></th>
</tr>
</thead>
</table>

### Prescriber level

<table>
<thead>
<tr>
<th>Primary Health Care</th>
<th>Medical Officer</th>
<th>Specialist</th>
<th>Designated Specialist</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>

## Section 2: Evidence and motivation

### 2.1 Estimated benefit

<table>
<thead>
<tr>
<th>Effect measure</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Risk difference (95% CI)</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>NNT</th>
<th></th>
</tr>
</thead>
</table>

### 2.2 Motivating information (Level of evidence based on the SORT system)

**A. Newer product:** High quality systematic reviews or peer-reviewed high quality randomised controlled trials (Level I)

<table>
<thead>
<tr>
<th>Author</th>
<th>Title</th>
<th>Journal ref</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**B. Older product with weaker evidence base:** Poorer quality controlled trials or high quality observational studies (Level II)

<table>
<thead>
<tr>
<th>Author</th>
<th>Title</th>
<th>Journal ref</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 2.3 Cost-considerations

<table>
<thead>
<tr>
<th>Have you worked up the cost?</th>
<th>YES</th>
<th>NO</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Daily cost</th>
<th>Cost minimisation</th>
<th>Cost-effectiveness analysis</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Other relevant cost information if available:</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Author</th>
<th>Title</th>
<th>Journal ref</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 2.4 Additional motivating comments.

## Section 3: Motivator’s Details

<table>
<thead>
<tr>
<th>PTC Title</th>
<th>Date submitted:</th>
<th></th>
</tr>
</thead>
</table>
GUIDELINES FOR ADVERSE DRUG REACTION REPORTING

National Pharmacovigilance Programme
The Medicines Control Council (MCC) has a responsibility to ensure the safety, efficacy and quality of all medicines used by the South African public. The National Pharmacovigilance Programme is coordinated by the MCC and has a dedicated Unit, The National Adverse Drug Event Monitoring Centre (NADEMC), in Cape Town, which monitors the safety of all registered medicines in South Africa.

What is Pharmacovigilance?
Pharmacovigilance is defined as the science and activities concerned with the detection, assessment, understanding and prevention of adverse reactions to medicines (i.e. adverse drug reactions or ADRs). The ultimate goal of this activity is to improve the safe and rational use of medicines, thereby improving patient care and public health.

What is an Adverse Drug Reaction (ADR)?
The Medicines Control Council (MCC) defines an Adverse Drug Reaction (ADR) reaction as a response to a medicine which is noxious and unintended, including lack of efficacy, and which occurs at any dosage and can also result from overdose, misuse or abuse of a medicine.

Who should report Adverse Drug Reactions?
All health care workers, including doctors, dentists, pharmacists, nurses and other health professionals are encouraged to report all suspected adverse reactions to medicines (including vaccines, X-ray contrast media, traditional and herbal remedies), especially when the reaction is not in the package insert, potentially serious or clinically significant.

What happens to a report?
All ADR reports are entered into a national ADR database. Each report is evaluated to assess the causal relationship between the event and the medicine. A well-completed adverse drug reaction/product quality form submitted could result in any of the following:

- Additional investigations into the use of the medicine in South Africa
- Educational initiatives to improve the safe use of the medicine
- Appropriate package insert changes to include the potential for the reaction
- Changes in the scheduling or manufacture of the medicine to make it safer

The purpose of ADR reporting is to reduce the risks associated with the use of medicines and to ultimately improve patient care.
Will reporting have any negative consequences on the health worker or the patient?
An adverse drug reaction report does not constitute an admission of liability or that the health professional contributed to the event in any way. The outcome of a report, together with any important or relevant information relating to the reaction, will be sent back to the reporter as appropriate. The details of a report are stored in a confidential database. The names of the reporter or any other health professionals named on a report and that of the patient will be removed before any details about a specific adverse drug reaction are used or communicated to others. The information is only meant to improve the understanding of the medicines used in the country.

Is the event possibly an ADR?
The following factors should be considered when an adverse drug reaction is suspected:

1. What exactly is the nature of the reaction? *(Describe the reaction as clearly as possible and where possible provide an accurate diagnosis.)*

2. Did the reaction occur within a reasonable time relationship to starting treatment with the suspected medicine? *(Some reactions occur immediately after administration of a medicine while others take time to develop.)*

3. Is the reaction known to occur with the particular medicine as stated in the package insert or other reference? *(If the reaction is not documented in the package insert, it does not mean that the reaction cannot occur with that particular medicine.)*

4. Did the patient recover when the suspected medicine was stopped? *(Some reactions can cause permanent damage, but most reactions are reversible if the medication is stopped.)*

5. Did the patient take the medicine again after the reaction abated (i.e. rechallenge). If so, did the same reaction occur again? *(In most situations it is not possible or ethical to rechallenge the patient with the same medicine. If such information is available or if such a rechallenge is necessary, recurrence of the event is a strong indicator that the medicine may be responsible.)*

6. Can this reaction be explained by other causes (e.g. underlying disease/s; other medicine/s; toxins or foods)? *(It is essential that the patient is thoroughly investigated to decide what the actual cause of any new medical problem is. A medicine-related cause should be considered, when other causes do not explain the patient’s condition.)*
What types of reactions should be reported?
The following adverse drug reactions should be reported:

- All ADRs to newly marketed drugs or new drugs added to the EDL
- All serious reactions and interactions
- ADRs that are not clearly stated in the package insert.
- All adverse reactions or poisonings to traditional or herbal remedies

Report even if you are not certain that the medicine caused the event.

What Product Quality Problems should be reported?
The following product quality problems should be reported:

- Suspected contamination
- Questionable stability
- Defective components
- Poor packaging or labeling
- Therapeutic failures

How can ADRs be prevented from occurring?
Some ADRs are unavoidable and cannot be prevented. However, most ADRs can be prevented by following the basic principles of rational use of medicines.

How are adverse drug reactions reported?
An Adverse Drug Reaction/Product Quality Report Form is enclosed in this book and should be completed in as much detail as possible before returning it by fax or post to any of the addresses provided below. Additional forms can be obtained by contacting the MCC at these addresses. Report forms may also be accessed via the following website: http://www.mccza.com

1. The Registrar of Medicines
Medicines Control Council, Department of Health, Private Bag X828
Pretoria, 0001
Tel: (021) 312 0295; Fax: (021) 3123106

2. The National Adverse Drug Event Monitoring Centre (NADEMC)
C/o Division of Pharmacology, University of Cape Town,
Observatory, 7925
(021) 447 1618; Fax: (021) 448 6181
ADVERSE DRUG REACTION AND PRODUCT QUALITY PROBLEM REPORT FORM
(Identities of reporter and patient will remain strictly confidential)

NATIONAL ADVERSE DRUG EVENT MONITORING CENTRE
Medicines Control Council, Tel: (021) 447-1618
The Registrar of Medicines, Fax: (021) 448-6181
Department of Health In collaboration with the WHO International Drug Monitoring Programme

PATIENT INFORMATION
Name (or initials): ____________________ Age: _______ Weight (kg): _______
Sex: [ ] M [ ] F Date Of Birth : __/__/__ Height (cm): _______

ADVERSE REACTION/PRODUCT QUALITY PROBLEM
Adverse reaction and/or Product Quality problem
Date of onset of reaction: __/__/__ Time of onset of reaction: ____h____min
Description of reaction or problem (Include relevant tests/lab data, including dates):

1. MEDICINES/VACCINES/DEVICES (include all concomitant medicines)

<table>
<thead>
<tr>
<th>Trade Name &amp; Batch No. (Asterisk Suspected Product)</th>
<th>Daily Dosage</th>
<th>Route</th>
<th>Date Started</th>
<th>Date Stopped</th>
<th>Reasons for use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ADVERSE REACTION OUTCOME (Check all that apply)

- death
- life-threatening
- disability
- hospitalisation
- congenital anomaly
- Other

Event reappeared on rechallenge: 
[ ] Y [ ] N Rechallenge not done
Treatment (of reaction)

Recovered:
(required intervention to___________) [Y N]

________________________________
prevent permanent_______________
________________________________
impairment/damage______________
________________________________

Sequelae: [Y N]
Describe Sequelae:________________________

COMMENTS: (e.g. Relevant history, Allergies, Previous exposure, Baseline test results/lab data)

2. PRODUCT QUALITY PROBLEM:

<table>
<thead>
<tr>
<th>Trade Name</th>
<th>Batch No</th>
<th>Reg No.</th>
<th>Dosage form &amp; strength</th>
<th>Expiry Date</th>
<th>Size/Type of container</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Product available for evaluation?: [Y N]

REPORTING DOCTOR/PHARMACIST Etc:
NAME:______________________________
QUALIFICATIONS:_____________________
ADDRESS:____________________________
_________________________________
_________________________________
_________________________________
Signature_________________________ Date_________________________

TEL:_______________________________

This report does not constitute an admission that medical personnel or the product caused or contributed to the event.
ADVICE ABOUT VOLUNTARY REPORTING

Report adverse experiences with:
- medications (drugs, vaccines and biologicals)
- medical devices (including in-vitro diagnostics)
- traditional and herbal remedies
- For Adverse Events Following Immunisation (AEFI), please follow the reporting procedure recommended by the Expanded Programme in Immunisation (EPI)

Please report:
- adverse drug reactions to recently marketed products
- serious reactions and interactions with all products
- adverse drug reactions which are not clearly reflected in the package insert.

Report even if:
- you’re not certain the product caused the event
- you don’t have all the details

Report Product Quality Problems such as:
- suspected contamination
- questionable stability
- defective components
- poor packaging or labelling
- therapeutic failures

Important numbers:
Investigational Products and Product Quality Problems:
- (012) 326-4344 to fax a report
- (012) 312-0000 to report by phone

Registered Medicines and Traditional and Herbal remedies:
- (021) 448-6181 to fax a report
- (021) 447-1618 to report by phone

Adverse Events Following Immunisation:
- (012) 312 0110 to phone for information
- (012) 321 9882 to fax a report
Confidentiality: Identities of the reporter and patient will remain strictly confidential.

Your support of the Medicine Control Council’s adverse drug reaction monitoring programme is much appreciated. Information supplied by you will contribute to the improvement of drug safety and therapy in South Africa.
### INDEX OF DRUGS/MEDICINES

<table>
<thead>
<tr>
<th>Drug/Medicine</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE inhibitor</td>
<td>56, 57, 64, 65, 66, 67, 128, 161, 374</td>
</tr>
<tr>
<td>acetazolamide</td>
<td>305</td>
</tr>
<tr>
<td>acetic acid/alcohol</td>
<td>311</td>
</tr>
<tr>
<td>aciclovir</td>
<td>9, 87, 94, 168, 189, 190, 212, 213, 218, 219</td>
</tr>
<tr>
<td>activated charcoal</td>
<td>358</td>
</tr>
<tr>
<td>adrenaline</td>
<td>113, 114, 277, 278, 348, 350, 352, 378</td>
</tr>
<tr>
<td>albendazole</td>
<td>30, 91</td>
</tr>
<tr>
<td>allopurinol</td>
<td>236</td>
</tr>
<tr>
<td>alpha 1 and non-selective beta blocker</td>
<td>57</td>
</tr>
<tr>
<td>aluminium hydroxide/magnesium trisilicate</td>
<td>12</td>
</tr>
<tr>
<td>amitriptyline</td>
<td>190, 256, 324, 328</td>
</tr>
<tr>
<td>amlodipine</td>
<td>54, 64, 65, 67, 131, 133</td>
</tr>
<tr>
<td>amoxicillin</td>
<td>2, 41, 71, 77, 174, 208, 219, 275, 281, 284, 286, 287, 312, 315, 335, 363, 364</td>
</tr>
<tr>
<td>amoxicillin/clavulanic acid</td>
<td>136, 160, 287</td>
</tr>
<tr>
<td>amphotericin-B</td>
<td>4</td>
</tr>
<tr>
<td>antazoline/tetrahydrozoline HCl</td>
<td>297</td>
</tr>
<tr>
<td>anti-D immunoglobulin</td>
<td>99, 109</td>
</tr>
<tr>
<td>antifungal lozenge (troche)</td>
<td>4</td>
</tr>
<tr>
<td>aqueous cream (UEA)</td>
<td>73, 86, 93</td>
</tr>
<tr>
<td>artemether/lumefantrine</td>
<td>170</td>
</tr>
<tr>
<td>aspirin</td>
<td>53, 54, 60, 156, 240</td>
</tr>
<tr>
<td>atenolol</td>
<td>54, 65, 66</td>
</tr>
<tr>
<td>atropine</td>
<td>303, 348, 359</td>
</tr>
<tr>
<td>Bacillus Calmette-Guerin vaccine (BCG)</td>
<td>110, 224, 225, 229, 230</td>
</tr>
<tr>
<td>beclomethasone</td>
<td>271, 272, 309</td>
</tr>
<tr>
<td>benzathine benzylpenicillin</td>
<td>69, 70, 105, 212, 213, 216, 217, 218, 219, 317</td>
</tr>
<tr>
<td>benzoic acid</td>
<td>75</td>
</tr>
<tr>
<td>benzyl benzoate</td>
<td>84, 85, 221</td>
</tr>
<tr>
<td>benzylpenicillin</td>
<td>105, 286</td>
</tr>
<tr>
<td>betamethasone</td>
<td>86, 89, 106, 107</td>
</tr>
<tr>
<td>biguanide</td>
<td>156</td>
</tr>
<tr>
<td>biperiden</td>
<td>260, 261</td>
</tr>
<tr>
<td>bismuth subgallate compound</td>
<td>14, 15</td>
</tr>
<tr>
<td>budesonide</td>
<td>271, 272</td>
</tr>
<tr>
<td>calamine</td>
<td>73, 92, 167, 337</td>
</tr>
<tr>
<td>calcium</td>
<td>101, 103</td>
</tr>
<tr>
<td>calcium channel blocker, long acting</td>
<td>54, 64, 65, 66, 67</td>
</tr>
<tr>
<td>carbamazepine</td>
<td>245, 246</td>
</tr>
<tr>
<td>carvedilol</td>
<td>57, 66</td>
</tr>
<tr>
<td>cefixime</td>
<td>138, 208, 210, 218, 219, 363</td>
</tr>
<tr>
<td>ceftriaxone</td>
<td>19, 27, 29, 42, 98, 111, 137, 207, 211, 307</td>
</tr>
<tr>
<td>Drug Name</td>
<td>Page Numbers</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>cetirizine</td>
<td>219, 234, 250, 251, 279, 285, 288, 300, 364, 377</td>
</tr>
<tr>
<td>chloramphenicol</td>
<td>74, 87, 297, 310</td>
</tr>
<tr>
<td>chlorhexidine</td>
<td>110, 175, 298, 300, 302, 303</td>
</tr>
<tr>
<td>chlorpheniramine</td>
<td>5, 6, 7, 165, 333, 339, 345</td>
</tr>
<tr>
<td>chlorpromazine</td>
<td>74, 87, 89, 91, 92, 93, 167, 191, 298, 309, 329, 337</td>
</tr>
<tr>
<td>choline salicylate/ cetalkonium chloride</td>
<td>259, 260</td>
</tr>
<tr>
<td>cimetidine</td>
<td>9, 187</td>
</tr>
<tr>
<td>ciprofloxacin</td>
<td>26, 136, 137, 138, 207, 209, 210, 211, 212, 213, 251</td>
</tr>
<tr>
<td>clotrimazole</td>
<td>80, 81, 82, 90, 192, 200, 208, 214, 218</td>
</tr>
<tr>
<td>codeine</td>
<td>327</td>
</tr>
<tr>
<td>corticosteroids</td>
<td>26, 106, 271, 275, 309</td>
</tr>
<tr>
<td>cotrimoxazole</td>
<td>186, 188, 192, 200, 286, 289</td>
</tr>
<tr>
<td>dextrose 10%</td>
<td>40, 111, 112, 113, 150, 352, 370</td>
</tr>
<tr>
<td>dextrose 5%</td>
<td>48, 60, 171, 369, 370</td>
</tr>
<tr>
<td>dextrose 5%/sodium chloride</td>
<td>380</td>
</tr>
<tr>
<td>dextrose 50%</td>
<td>40, 50, 60, 113, 150, 370</td>
</tr>
<tr>
<td>diazepam</td>
<td>241, 242, 243, 249, 329, 356, 380, 381</td>
</tr>
<tr>
<td>didanosine</td>
<td>185, 196, 197, 198</td>
</tr>
<tr>
<td>digoxin</td>
<td>57</td>
</tr>
<tr>
<td>diphtheria/tetanus/pertussis vaccine (DTP)</td>
<td>224, 226, 229, 230</td>
</tr>
<tr>
<td>doxycycline</td>
<td>17, 75, 105, 138, 207, 208, 210, 211, 212, 213, 217, 218, 219, 275, 363, 364</td>
</tr>
<tr>
<td>efavirenz</td>
<td>185, 196, 197</td>
</tr>
<tr>
<td>emulsifying ointment (UE)</td>
<td>73, 86</td>
</tr>
<tr>
<td>enalapril</td>
<td>56, 64, 65, 128, 161</td>
</tr>
<tr>
<td>ergometrine</td>
<td>109</td>
</tr>
<tr>
<td>erythromycin</td>
<td>2, 69, 70, 76, 78, 79, 88, 105, 175, 190, 208, 209, 212, 213, 217, 219, 282, 284, 286, 287, 311, 313, 315, 318, 335</td>
</tr>
<tr>
<td>ethambutol</td>
<td>290, 291, 293, 294</td>
</tr>
<tr>
<td>ferrous gluconate</td>
<td>37</td>
</tr>
<tr>
<td>ferrous lactate</td>
<td>37</td>
</tr>
<tr>
<td>ferrous sulphate compound (BPC)</td>
<td>37, 104, 117</td>
</tr>
<tr>
<td>flucloxacillin</td>
<td>76, 78, 79, 88, 311</td>
</tr>
<tr>
<td>fluconazole</td>
<td>82, 187, 191, 202</td>
</tr>
<tr>
<td>fluoxetine</td>
<td>257</td>
</tr>
<tr>
<td>flupenthixol decanoate</td>
<td>260</td>
</tr>
<tr>
<td>fluphenazine decanoate</td>
<td>260</td>
</tr>
<tr>
<td>folic acid</td>
<td>38, 104</td>
</tr>
<tr>
<td>furosemide</td>
<td>56, 59, 67, 129, 131, 133, 374</td>
</tr>
<tr>
<td>gentian violet</td>
<td>4, 165, 201</td>
</tr>
<tr>
<td>glibenclamide</td>
<td>157</td>
</tr>
</tbody>
</table>
gliclazide 157
Haemophilus influenzae type B vaccine (Hib) 224, 227, 229, 230
haloperidol 259, 260, 356
hepatitis B vaccine (HepB) 224, 225, 227, 229, 230
HMGCoA reductase inhibitors (statins) 52, 53, 55, 61, 153
hydrochlorothiazide 56, 64, 65, 66
hydrocortisone 86, 89, 191, 265, 378
hyoscine butylbromide 12
ibuprofen 117, 118, 235, 237, 321, 324, 326, 327, 328, 379
imidazole 80, 81, 82
influenza vaccine 228, 275
insulin, biphasic 148, 158
insulin, intermediate acting 147, 158
insulin, soluble short acting 147, 151
iodine tincture BP 93, 220
ipratropium bromide 265, 275
iron 37
isoniazid 186, 292, 293
isosorbide dinitrate 53, 54, 60, 374
isosorbide mononitrate 54
lactulose 14, 18, 329
lamivudine 185, 196, 197, 365, 366, 367, 368
lamotrigine 247
levonorgestrel 122, 124, 364
levonorgestrel/ethinyl oestradiol 117, 122
lignocaine 14, 15, 108, 337
loperamide 23, 188
lopinavir/ritonavir 185, 197, 198, 368
lorazepam 259, 356, 381
magnesium sulphate 102, 103
measles vaccine 224, 228, 229, 230
mebendazole 32, 37, 43
medroxyprogesterone 119, 121
metformin 156, 157, 158
methyl salicylate 232, 237
methyldopa 63, 66, 102
metoclopramide 13, 328
misoprostol 109
morphine 11, 53, 60, 107, 142, 322, 323, 326, 328, 330, 374
multivitamin 43, 184, 200
naloxone 110, 112, 113, 322, 360
nevirapine 100, 101, 185, 196, 197
nicotinamide 47
nifedipine, short-acting 102, 106, 130, 133
nifedipine, slow release 54, 102
nitrous oxide 107
norethisterone enanthate 121
norgestrel/ethinyl oestradiol 122, 124, 364
NSAID 235, 237, 327
nystatin 4, 201
oestradiol 118, 119
oestrogen, conjugated 118, 119
oral polio vaccine (OPV) 110, 224, 227, 229, 230
oral rehydration solution (ORS) 16, 21, 23, 25, 28
orphenadrine 260, 261
oxygen 53, 59, 60, 102, 111, 130, 132, 248, 264, 265, 276, 278, 279, 284, 289, 343, 347, 358, 359, 373, 374, 380
oxymetazoline 297, 301, 316
oxytocin 98, 108, 109
paracetamol 3, 5, 7, 8, 163, 167, 170, 174, 176, 177, 189, 190, 204, 232, 237, 244, 252, 278, 281, 285, 287, 299, 301, 302, 304, 313, 316, 318, 321, 322, 324, 326, 328, 337, 345, 372, 379
permethrin 83
pethidine 107
petroleum jelly 8, 95, 96, 221
phenobarbitone 245, 246, 381
phenoxymethylpenicillin 69, 70, 317
phenytoin 245, 246, 381
pilocarpine 305
pneumococcal vaccine 224, 275
podophyllin solution 220
podophyllum resin/ salicylic acid 95, 96
polyvalent antivenom (snake) 340, 341
povidone iodine 77, 166, 333, 345
praziquantel 179
prednisone 235, 264, 265, 277, 278
procaine penicillin (depot formulation) 105
promethazine 108, 378
pyrazinamide 293
pyridoxine 47, 186, 290, 292, 293
quine dihydrochloride 171
rabies immunoglobulin 333, 334
rabies vaccine 333, 334
rifampicin 293
rifampicin/isoniazid combination 293, 294, 295
<table>
<thead>
<tr>
<th>Drug Name and Description</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>rifampicin/isoniazid/pyrazinamide combination</td>
<td>293, 295</td>
</tr>
<tr>
<td>rifampicin/isoniazid/pyrazinamide/ ethambutol combination</td>
<td>293, 294</td>
</tr>
<tr>
<td>Ringer–Lactate</td>
<td>16, 21</td>
</tr>
<tr>
<td>salbutamol</td>
<td>108, 264, 265, 269, 271, 272, 275, 276</td>
</tr>
<tr>
<td>selenium sulphide</td>
<td>82, 90</td>
</tr>
<tr>
<td>sennosides A and B</td>
<td>18</td>
</tr>
<tr>
<td>simple linctus</td>
<td>318</td>
</tr>
<tr>
<td>simvastatin</td>
<td>52, 53, 55, 61, 153, 155, 156</td>
</tr>
<tr>
<td>spironolactone</td>
<td>57</td>
</tr>
<tr>
<td>ß2 agonist</td>
<td>269, 271, 272, 275</td>
</tr>
<tr>
<td>ß-blocker</td>
<td>54, 66</td>
</tr>
<tr>
<td>stavudine</td>
<td>185, 196, 197</td>
</tr>
<tr>
<td>streptokinase</td>
<td>60</td>
</tr>
<tr>
<td>streptomycin</td>
<td>291, 294</td>
</tr>
<tr>
<td>sulphonylurea</td>
<td>157, 158</td>
</tr>
<tr>
<td>sulphur</td>
<td>85</td>
</tr>
<tr>
<td>tenofovir</td>
<td>185</td>
</tr>
<tr>
<td>tetanus toxoidvaccine (TT)</td>
<td>225, 228, 229, 230, 334, 340, 345, 372</td>
</tr>
<tr>
<td>tetanus/diphtheria vaccine (Td)</td>
<td>224, 226, 229, 230</td>
</tr>
<tr>
<td>tetracaine</td>
<td>8, 302, 339</td>
</tr>
<tr>
<td>theophylline</td>
<td>273, 275</td>
</tr>
<tr>
<td>thiamine</td>
<td>48, 370</td>
</tr>
<tr>
<td>tramadol</td>
<td>190, 321, 322, 324, 326, 327</td>
</tr>
<tr>
<td>tussi infans</td>
<td>318</td>
</tr>
<tr>
<td>valproate</td>
<td>246</td>
</tr>
<tr>
<td>vitamin A (retinol)</td>
<td>23, 42, 43, 45, 173</td>
</tr>
<tr>
<td>vitamin B complex</td>
<td>46</td>
</tr>
<tr>
<td>vitamin K</td>
<td>110</td>
</tr>
<tr>
<td>xylocaine with adrenaline</td>
<td>3</td>
</tr>
<tr>
<td>xylocaine</td>
<td>3</td>
</tr>
<tr>
<td>zidovudine</td>
<td>100, 101, 185, 196, 197, 198, 365, 366, 367, 368</td>
</tr>
<tr>
<td>zinc and castor oil</td>
<td>90</td>
</tr>
<tr>
<td>zinc</td>
<td>22, 23</td>
</tr>
<tr>
<td>zuclopenthixol acetate</td>
<td>259</td>
</tr>
<tr>
<td>zuclopenthixol decanoate</td>
<td>260</td>
</tr>
<tr>
<td>Condition</td>
<td>Page</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>11</td>
</tr>
<tr>
<td>Abnormal vaginal bleeding during fertile years</td>
<td>116</td>
</tr>
<tr>
<td>Abscess and caries, dental</td>
<td>2</td>
</tr>
<tr>
<td>Abscess, dental</td>
<td>2</td>
</tr>
<tr>
<td>Acne vulgaris</td>
<td>74</td>
</tr>
<tr>
<td>Acute renal failure</td>
<td>130</td>
</tr>
<tr>
<td>Aggressive disruptive behaviour</td>
<td>255</td>
</tr>
<tr>
<td>Allergic rhinitis</td>
<td>309</td>
</tr>
<tr>
<td>Anaemia in pregnancy</td>
<td>103</td>
</tr>
<tr>
<td>Anaemia</td>
<td>35</td>
</tr>
<tr>
<td>Anaemia, iron deficiency</td>
<td>36</td>
</tr>
<tr>
<td>Anaemia, macrocytic or megaloblastic</td>
<td>38</td>
</tr>
<tr>
<td>Anal conditions</td>
<td>14</td>
</tr>
<tr>
<td>Anal fissures</td>
<td>14</td>
</tr>
<tr>
<td>Angina pectoris, stable</td>
<td>54</td>
</tr>
<tr>
<td>Angina pectoris, unstable</td>
<td>53</td>
</tr>
<tr>
<td>Animal and human bites</td>
<td>332</td>
</tr>
<tr>
<td>Antenatal care</td>
<td>100</td>
</tr>
<tr>
<td>Antepartum haemorrhage</td>
<td>99</td>
</tr>
<tr>
<td>Antiretroviral therapy, adults</td>
<td>184</td>
</tr>
<tr>
<td>Antiretroviral therapy, children</td>
<td>196</td>
</tr>
<tr>
<td>Antiseptics and disinfectants</td>
<td>164</td>
</tr>
<tr>
<td>Anxiety and stress related disorders</td>
<td>255</td>
</tr>
<tr>
<td>Aphthous ulcers in HIV infection</td>
<td>187</td>
</tr>
<tr>
<td>Aphthous ulcers</td>
<td>9</td>
</tr>
<tr>
<td>Appendicitis</td>
<td>15</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>232</td>
</tr>
<tr>
<td>Arthritis, rheumatoid</td>
<td>233</td>
</tr>
<tr>
<td>Arthritis, septic</td>
<td>233</td>
</tr>
<tr>
<td>Asthma, chronic</td>
<td>267</td>
</tr>
<tr>
<td>Athlete’s foot – tinea pedis</td>
<td>80</td>
</tr>
<tr>
<td>Bacterial infections of the skin</td>
<td>75</td>
</tr>
<tr>
<td>Balanitis/balanoposthitis (BAL)</td>
<td>214</td>
</tr>
<tr>
<td>Benign prostatic hyperplasia</td>
<td>139</td>
</tr>
<tr>
<td>Bites and stings</td>
<td>332</td>
</tr>
<tr>
<td>Bleeding in pregnancy</td>
<td>98</td>
</tr>
<tr>
<td>Bleeding, post–menopausal</td>
<td>117</td>
</tr>
<tr>
<td>Boil, abscess</td>
<td>75</td>
</tr>
<tr>
<td>Bronchiolitis, acute in children</td>
<td>276</td>
</tr>
<tr>
<td>Bronchitis, acute in adults or adolescents</td>
<td>281</td>
</tr>
<tr>
<td>Bronchospasm, acute associated with asthma and chronic obstructive bronchitis</td>
<td>263</td>
</tr>
<tr>
<td>Bubo</td>
<td>213</td>
</tr>
<tr>
<td>Burns</td>
<td>341</td>
</tr>
<tr>
<td>Medical Condition</td>
<td>Page</td>
</tr>
<tr>
<td>--------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Candida oesophagitis</td>
<td>187</td>
</tr>
<tr>
<td>Candidiasis, oesophageal</td>
<td>202</td>
</tr>
<tr>
<td>Candidiasis, oral (thrush)</td>
<td>4</td>
</tr>
<tr>
<td>Candidiasis, oral (thrush), recurrent</td>
<td>201</td>
</tr>
<tr>
<td>Candidiasis, skin</td>
<td>81</td>
</tr>
<tr>
<td>Cardiac arrest – cardiopulmonary resuscitation</td>
<td>346</td>
</tr>
<tr>
<td>Cardiac arrest, adults</td>
<td>346</td>
</tr>
<tr>
<td>Cardiac failure, congestive (CCF)</td>
<td>55</td>
</tr>
<tr>
<td>Cardiac failure, congestive (CCF), adults</td>
<td>55</td>
</tr>
<tr>
<td>Cardiac failure, congestive (CCF), children</td>
<td>58</td>
</tr>
<tr>
<td>Cardiopulmonary arrest, children</td>
<td>348</td>
</tr>
<tr>
<td>Care of HIV positive pregnant woman</td>
<td>100</td>
</tr>
<tr>
<td>Care of the neonate</td>
<td>110</td>
</tr>
<tr>
<td>Caries, dental</td>
<td>3</td>
</tr>
<tr>
<td>Cellulitis</td>
<td>78</td>
</tr>
<tr>
<td>Chickenpox</td>
<td>166</td>
</tr>
<tr>
<td>Childhood malnutrition, including failure to thrive (FTT)</td>
<td>39</td>
</tr>
<tr>
<td>Cholera</td>
<td>15</td>
</tr>
<tr>
<td>Chronic cancer pain</td>
<td>325</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>126</td>
</tr>
<tr>
<td>Chronic non-cancer pain</td>
<td>323</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease (COPD)</td>
<td>274</td>
</tr>
<tr>
<td>Common cold and influenza</td>
<td>280</td>
</tr>
<tr>
<td>Common warts</td>
<td>95</td>
</tr>
<tr>
<td>Conditions with prominent wheeze</td>
<td>263</td>
</tr>
<tr>
<td>Conjunctivitis of the newborn</td>
<td>299</td>
</tr>
<tr>
<td>Conjunctivitis, allergic</td>
<td>297</td>
</tr>
<tr>
<td>Conjunctivitis, bacterial (excluding conjunctivitis of the newborn)</td>
<td>298</td>
</tr>
<tr>
<td>Conjunctivitis, viral (pink eye)</td>
<td>300</td>
</tr>
<tr>
<td>Conjunctivitis</td>
<td>297</td>
</tr>
<tr>
<td>Constipation</td>
<td>17</td>
</tr>
<tr>
<td>Contraception and HIV and AIDS</td>
<td>123</td>
</tr>
<tr>
<td>Contraception, barrier methods</td>
<td>123</td>
</tr>
<tr>
<td>Contraception, emergency</td>
<td>123</td>
</tr>
<tr>
<td>Contraception, hormonal</td>
<td>121</td>
</tr>
<tr>
<td>Contraception, intrauterine device (IUCD)</td>
<td>122</td>
</tr>
<tr>
<td>Contraception, missed pills</td>
<td>123</td>
</tr>
<tr>
<td>Contraceptive, oral</td>
<td>121</td>
</tr>
<tr>
<td>Contraceptives, injectable</td>
<td>121</td>
</tr>
<tr>
<td>Cracked nipples during breastfeeding</td>
<td>115</td>
</tr>
<tr>
<td>Croup (Laryngotracheobronchitis) in children</td>
<td>277</td>
</tr>
<tr>
<td>Delirium – acutely confused, aggressive patient</td>
<td>255</td>
</tr>
<tr>
<td>Delirium with acute confusion and aggression in adults</td>
<td>355</td>
</tr>
<tr>
<td>Dermatitis, seborrhoeic</td>
<td>89</td>
</tr>
<tr>
<td>Diabetes mellitus type 1, in adults</td>
<td>147</td>
</tr>
<tr>
<td>Diabetes mellitus type 1, in children</td>
<td>145</td>
</tr>
<tr>
<td>Diabetes mellitus type 2, in adolescents</td>
<td>146</td>
</tr>
<tr>
<td>Condition</td>
<td>Page</td>
</tr>
<tr>
<td>-----------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Diabetes mellitus type 2, in adults</td>
<td>153</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>144</td>
</tr>
<tr>
<td>Diabetic emergencies</td>
<td>148</td>
</tr>
<tr>
<td>Diabetic ketoacidosis</td>
<td>150</td>
</tr>
<tr>
<td>Diabetic nephropathy</td>
<td>160</td>
</tr>
<tr>
<td>Diabetic foot</td>
<td>159</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>19</td>
</tr>
<tr>
<td>Diarrhoea, acute in children</td>
<td>19</td>
</tr>
<tr>
<td>Diarrhoea, acute, without blood in adults</td>
<td>23</td>
</tr>
<tr>
<td>Diarrhoea, chronic in adults</td>
<td>24</td>
</tr>
<tr>
<td>Diarrhoea, HIV associated</td>
<td>188</td>
</tr>
<tr>
<td>Diarrhoea, persistent in children</td>
<td>22</td>
</tr>
<tr>
<td>Dosage and administration</td>
<td>224</td>
</tr>
<tr>
<td>Dry skin</td>
<td>73</td>
</tr>
<tr>
<td>Dysentery</td>
<td>24</td>
</tr>
<tr>
<td>Dysentery, amoebic</td>
<td>27</td>
</tr>
<tr>
<td>Dysentery, bacillary</td>
<td>25</td>
</tr>
<tr>
<td>Dysmenorrhoea</td>
<td>118</td>
</tr>
<tr>
<td>Dysentery, heartburn and indigestion</td>
<td>12</td>
</tr>
<tr>
<td>Eczema</td>
<td>85</td>
</tr>
<tr>
<td>Eczema, acute, moist or weeping</td>
<td>88</td>
</tr>
<tr>
<td>Eczema, atopic</td>
<td>85</td>
</tr>
<tr>
<td>Enuresis</td>
<td>140</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>244</td>
</tr>
<tr>
<td>Exposure to poisonous substances</td>
<td>357</td>
</tr>
<tr>
<td>Eye injuries</td>
<td>302</td>
</tr>
<tr>
<td>Eye injury, (blunt or penetrating) foreign body</td>
<td>303</td>
</tr>
<tr>
<td>Eye injury, chemical burn</td>
<td>302</td>
</tr>
<tr>
<td>Failure to thrive or not growing well</td>
<td>43</td>
</tr>
<tr>
<td>Falciparum malaria, severe</td>
<td>171</td>
</tr>
<tr>
<td>Febrile convulsions</td>
<td>242</td>
</tr>
<tr>
<td>Feeding options for HIV positive mothers</td>
<td>115</td>
</tr>
<tr>
<td>Fever</td>
<td>163</td>
</tr>
<tr>
<td>Filiform warts</td>
<td>96</td>
</tr>
<tr>
<td>Fungal infections of the skin</td>
<td>80</td>
</tr>
<tr>
<td>Fungal nail infections</td>
<td>188</td>
</tr>
<tr>
<td>Genital molluscum contagiosum (MC)</td>
<td>220</td>
</tr>
<tr>
<td>Genital ulcer syndrome (GUS)</td>
<td>212</td>
</tr>
<tr>
<td>Genital warts (GW) Condylomata Accuminata</td>
<td>220</td>
</tr>
<tr>
<td>Gingivitis and periodontitis</td>
<td>5</td>
</tr>
<tr>
<td>Gingivitis, uncomplicated</td>
<td>5</td>
</tr>
<tr>
<td>Glaucoma, acute</td>
<td>304</td>
</tr>
<tr>
<td>Glomerular disease – Nephritic syndrome</td>
<td>132</td>
</tr>
<tr>
<td>Glomerular disease – Nephrotic syndrome</td>
<td>134</td>
</tr>
<tr>
<td>Glomerular disease (GN)</td>
<td>131</td>
</tr>
<tr>
<td>Gout</td>
<td>234</td>
</tr>
<tr>
<td>Gout, acute</td>
<td>234</td>
</tr>
</tbody>
</table>
Myocardial infarction, acute (AMI) 59
Nappy rash 90
Nausea and vomiting, non-specific 13
Necrotising peridontitis 6
Neonatal resuscitation 112
Nose bleeds (epistaxis) 373
Occupational post-exposure HIV prophylaxis for healthcare workers (HCW) 366
Opportunistic infections, prophylaxis in adults 186
Opportunistic infections, prophylaxis in children 200
Opportunistic infections, treatment in adults 187
Opportunistic infections, treatment in children 201
Osteoarthritis (osteoarthritis) 237
Otitis externa 310
Otitis media, acute 312
Otitis media, chronic, suppurative 314
Otitis 310
Pain control 320
Painful red eye 305
Papular pruritic eruption 191
Parasitic infections of the skin 83
Pellagra (nicotinic acid deficiency) 46
Penetrative sexual abuse or sexual assault 361
Peridontitis 6
Pityriasis rosea 92
Plane warts 92
Plantar warts 95
Pneumocystis pneumonia in adults 288
Pneumonia in adults with underlying medical conditions or over 65 years 287
Pneumonia in children 283
Pneumonia 282
Pneumonia, severe in adults 288
Pneumonia, uncomplicated in adults 286
Postpartum care 115
Pregnancy, ectopic 116
Preterm labour (PTL) and preterm prelabour rupture of membranes (PPROM) 106
Preterm labour (PTL) 106
Preterm prelabour rupture of membranes (PPROM) 106
Prevention of ischaemic heart disease and atherosclerosis 50
Prostate cancer 140
Prostatitis 138
Psychosis, acute 258
Pubic lice (PL) 221
Pulmonary oedema, acute 373
Pyridoxine (Vitamin B₆) deficiency 47
<table>
<thead>
<tr>
<th>Condition</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Renal calculi</td>
<td>141</td>
</tr>
<tr>
<td>Respiratory infections</td>
<td>280</td>
</tr>
<tr>
<td>Rheumatic fever, acute</td>
<td>69</td>
</tr>
<tr>
<td>Ringworm and other tineas</td>
<td>81</td>
</tr>
<tr>
<td>Rubella (German measles)</td>
<td>177</td>
</tr>
<tr>
<td>Sandworm</td>
<td>91</td>
</tr>
<tr>
<td>Scabies</td>
<td>84</td>
</tr>
<tr>
<td>Schistosomiasis</td>
<td>178</td>
</tr>
<tr>
<td>Scrotal swelling (SSW)</td>
<td>211</td>
</tr>
<tr>
<td>Seizures (convulsions/fits)</td>
<td>241</td>
</tr>
<tr>
<td>Severe malnutrition</td>
<td>39</td>
</tr>
<tr>
<td>Sexually transmitted infections</td>
<td>206</td>
</tr>
<tr>
<td>Shock</td>
<td>375</td>
</tr>
<tr>
<td>Shock, anaphylactic</td>
<td>377</td>
</tr>
<tr>
<td>Sick neonate and neonatal emergencies</td>
<td>110</td>
</tr>
<tr>
<td>Sinusitis, acute, bacterial</td>
<td>314</td>
</tr>
<tr>
<td>Snakebites</td>
<td>338</td>
</tr>
<tr>
<td>Sprains and strains</td>
<td>379</td>
</tr>
<tr>
<td>Status epilepticus</td>
<td>380</td>
</tr>
<tr>
<td>Stroke</td>
<td>240</td>
</tr>
<tr>
<td>Structural abnormalities of the eye</td>
<td>305</td>
</tr>
<tr>
<td>Supportive care</td>
<td>203</td>
</tr>
<tr>
<td>Syphilis in pregnancy</td>
<td>104</td>
</tr>
<tr>
<td>Syphilis serology and treatment</td>
<td>215</td>
</tr>
<tr>
<td>TB chemoprophylaxis</td>
<td>186</td>
</tr>
<tr>
<td>The cold chain</td>
<td>228</td>
</tr>
<tr>
<td>The revised opened multi-dose vial policy</td>
<td>230</td>
</tr>
<tr>
<td>Thiamine deficiency (Wernicke’s encephalopathy and beriberi)</td>
<td>48</td>
</tr>
<tr>
<td>Tonsillitis and pharyngitis</td>
<td>316</td>
</tr>
<tr>
<td>Toxoplasmosis</td>
<td>192</td>
</tr>
<tr>
<td>Treatment of more than one STI syndrome</td>
<td>218</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>289</td>
</tr>
<tr>
<td>Typhoid fever</td>
<td>33</td>
</tr>
<tr>
<td>Upper airways obstruction</td>
<td>277</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>134</td>
</tr>
<tr>
<td>Urticaria</td>
<td>91</td>
</tr>
<tr>
<td>Vaccines for routine administration</td>
<td>225</td>
</tr>
<tr>
<td>Vaginal bleeding</td>
<td>116</td>
</tr>
<tr>
<td>Vaginal discharge syndrome (VDS)</td>
<td>208</td>
</tr>
<tr>
<td>Valvular heart disease and congenital structural heart disease</td>
<td>70</td>
</tr>
<tr>
<td>Visual problems</td>
<td>306</td>
</tr>
<tr>
<td>Vitamin A deficiency</td>
<td>44</td>
</tr>
<tr>
<td>Vitamin B deficiencies</td>
<td>46</td>
</tr>
<tr>
<td>Warts</td>
<td>95</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>ABCD</td>
<td>Airways, Breathing, Circulation, Drip/Doctor/Drugs</td>
</tr>
<tr>
<td>ACE</td>
<td>angiotensin-converting enzyme</td>
</tr>
<tr>
<td>AIDS</td>
<td>acquired immunodeficiency syndrome</td>
</tr>
<tr>
<td>AMI</td>
<td>acute myocardial infarction</td>
</tr>
<tr>
<td>BCG</td>
<td>Bacillus Calmette-Guerin vaccine</td>
</tr>
<tr>
<td>BMI</td>
<td>Body mass index</td>
</tr>
<tr>
<td>BP</td>
<td>blood pressure</td>
</tr>
<tr>
<td>BSA</td>
<td>Body surface area</td>
</tr>
<tr>
<td>C</td>
<td>Celsius</td>
</tr>
<tr>
<td>cap</td>
<td>capsule</td>
</tr>
<tr>
<td>CCF</td>
<td>congestive cardiac failure</td>
</tr>
<tr>
<td>CCMT</td>
<td>Comprehensive care, management and treatment</td>
</tr>
<tr>
<td>CCU</td>
<td>Critical Care Unit</td>
</tr>
<tr>
<td>CD4</td>
<td>cluster designation 4</td>
</tr>
<tr>
<td>CKD</td>
<td>chronic kidney disease</td>
</tr>
<tr>
<td>cm</td>
<td>centimetre</td>
</tr>
<tr>
<td>CNS</td>
<td>central nervous system</td>
</tr>
<tr>
<td>COAD</td>
<td>chronic obstructive airways disease</td>
</tr>
<tr>
<td>COPD</td>
<td>chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td>CPR</td>
<td>cardio-pulmonary resuscitation</td>
</tr>
<tr>
<td>CrCl</td>
<td>creatinine clearance</td>
</tr>
<tr>
<td>CSF</td>
<td>cerebro-spinal fluid</td>
</tr>
<tr>
<td>CVD</td>
<td>cardiovascular disease</td>
</tr>
<tr>
<td>dL</td>
<td>decilitre</td>
</tr>
<tr>
<td>DNA</td>
<td>deoxyribonucleic acid</td>
</tr>
<tr>
<td>DPT</td>
<td>diphtheria, pertussis and tetanus vaccine</td>
</tr>
<tr>
<td>E</td>
<td>ethambutol</td>
</tr>
<tr>
<td>ECG</td>
<td>electrocardiogram</td>
</tr>
<tr>
<td>EDTA</td>
<td>ethylenediamine tetraacetic acid</td>
</tr>
<tr>
<td>ELISA</td>
<td>enzyme-linked immunosorbent assay</td>
</tr>
<tr>
<td>EPI</td>
<td>Expanded Programme on Immunisation</td>
</tr>
<tr>
<td>ET</td>
<td>Endotracheal tube</td>
</tr>
<tr>
<td>FBC</td>
<td>full blood count</td>
</tr>
<tr>
<td>FBG</td>
<td>fasting blood glucose</td>
</tr>
<tr>
<td>FEV1</td>
<td>forced expiratory volume in 1 second</td>
</tr>
<tr>
<td>FTA</td>
<td>Fluorescent Treponemal Antibody</td>
</tr>
<tr>
<td>FTT</td>
<td>failure to thrive</td>
</tr>
<tr>
<td>g</td>
<td>gram</td>
</tr>
<tr>
<td>GFR</td>
<td>glomerular filtration rate</td>
</tr>
<tr>
<td>GIT</td>
<td>gastro intestinal tract</td>
</tr>
<tr>
<td>H</td>
<td>isoniazid</td>
</tr>
<tr>
<td>Hb</td>
<td>haemoglobin</td>
</tr>
<tr>
<td>HbA1c</td>
<td>glycated haemoglobin</td>
</tr>
<tr>
<td>HCW</td>
<td>health care worker</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>HDL</td>
<td>high density lipoprotein</td>
</tr>
<tr>
<td>Hep B</td>
<td>hepatitis B vaccine</td>
</tr>
<tr>
<td>Hib</td>
<td><em>Haemophilus influenzae</em> type B vaccine</td>
</tr>
<tr>
<td>HIV</td>
<td>human immunodeficiency virus</td>
</tr>
<tr>
<td>IDDM</td>
<td>insulin dependent diabetes mellitus</td>
</tr>
<tr>
<td>IM</td>
<td>intramuscular</td>
</tr>
<tr>
<td>IMCI</td>
<td>Integrated management of childhood illness</td>
</tr>
<tr>
<td>IU</td>
<td>international units</td>
</tr>
<tr>
<td>IUCD</td>
<td>intrauterine contraceptive device</td>
</tr>
<tr>
<td>IV</td>
<td>intravenous</td>
</tr>
<tr>
<td>kg</td>
<td>kilogram</td>
</tr>
<tr>
<td>L</td>
<td>litre</td>
</tr>
<tr>
<td>LAP</td>
<td>lower abdominal pain</td>
</tr>
<tr>
<td>LBBB</td>
<td>left bundle branch block</td>
</tr>
<tr>
<td>LDL</td>
<td>low density lipoprotein</td>
</tr>
<tr>
<td>LMP</td>
<td>last menstrual period</td>
</tr>
<tr>
<td>mcg</td>
<td>microgram</td>
</tr>
<tr>
<td>MCV</td>
<td>mean corpuscular volume</td>
</tr>
<tr>
<td>MDR TB</td>
<td>multiple drug resistant tuberculosis</td>
</tr>
<tr>
<td>mg</td>
<td>milligram</td>
</tr>
<tr>
<td>mL</td>
<td>millilitre</td>
</tr>
<tr>
<td>mmHg</td>
<td>millimetres mercury</td>
</tr>
<tr>
<td>mmol</td>
<td>millimol</td>
</tr>
<tr>
<td>MU</td>
<td>million units</td>
</tr>
<tr>
<td>NSAID</td>
<td>non-steroidal anti-inflammatory</td>
</tr>
<tr>
<td>OPV</td>
<td>oral polio vaccine</td>
</tr>
<tr>
<td>ORS</td>
<td>oral rehydration solution</td>
</tr>
<tr>
<td>PCR</td>
<td>polymerase chain reaction</td>
</tr>
<tr>
<td>PEFR</td>
<td>peak expiratory flow rate</td>
</tr>
<tr>
<td>PEP</td>
<td>post exposure prophylaxis</td>
</tr>
<tr>
<td>PHC</td>
<td>primary health care</td>
</tr>
<tr>
<td>PIH</td>
<td>pregnancy induced hypertension</td>
</tr>
<tr>
<td>PTC</td>
<td>Pharmacy and Therapeutics Committee</td>
</tr>
<tr>
<td>R</td>
<td>rifampicin</td>
</tr>
<tr>
<td>RBG</td>
<td>random blood glucose</td>
</tr>
<tr>
<td>Rh</td>
<td>Rhesus</td>
</tr>
<tr>
<td>RH</td>
<td>rifampicin, isoniazid, combination</td>
</tr>
<tr>
<td>RHZ</td>
<td>rifampicin, isoniazid, pyrazinamide combination</td>
</tr>
<tr>
<td>RHZE</td>
<td>rifampicin, isoniazid, pyrazinamide ethambutol, combination</td>
</tr>
<tr>
<td>RIG</td>
<td>human anti-rabies immunoglobin</td>
</tr>
<tr>
<td>RPR/VDRL</td>
<td>rapid plasma reagent test/venereal disease research laboratory test</td>
</tr>
<tr>
<td>RTH</td>
<td>road to health</td>
</tr>
<tr>
<td>S</td>
<td>streptomycin</td>
</tr>
<tr>
<td>SC</td>
<td>subcutaneous</td>
</tr>
<tr>
<td>SSS</td>
<td>sugar and salt solution</td>
</tr>
<tr>
<td>Acronym</td>
<td>Term</td>
</tr>
<tr>
<td>---------</td>
<td>------</td>
</tr>
<tr>
<td>ST</td>
<td>sinus tachycardia</td>
</tr>
<tr>
<td>STI</td>
<td>sexually transmitted infections</td>
</tr>
<tr>
<td>tab</td>
<td>tablet</td>
</tr>
<tr>
<td>TB</td>
<td>tuberculosis</td>
</tr>
<tr>
<td>Td</td>
<td>diphtheria and tetanus vaccine</td>
</tr>
<tr>
<td>TIA</td>
<td>transient ischaemic attack</td>
</tr>
<tr>
<td>TPHA</td>
<td>Treponema pallidum haemagglutination assay</td>
</tr>
<tr>
<td>TT</td>
<td>tetanus vaccine</td>
</tr>
<tr>
<td>UE</td>
<td>emulsifying ointment</td>
</tr>
<tr>
<td>UEA</td>
<td>aqueous cream</td>
</tr>
<tr>
<td>UTI</td>
<td>urinary tract infection</td>
</tr>
<tr>
<td>VVM</td>
<td>vaccine vial monitor</td>
</tr>
<tr>
<td>WFI</td>
<td>water for injection</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organisation</td>
</tr>
<tr>
<td>XDR TB</td>
<td>extreme drug resistant tuberculosis</td>
</tr>
</tbody>
</table>